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Chapter 1
General introduction and outlines of the thesis
A brief history of heart failure
Over the last centuries, many discoveries and developments has contributed to our 
knowledge of heart failure, as shown in Figure 1. The ancient civilizations of China, Egypt, 
Greek, and the Roman Empire were the first to describe manifestations and symptoms 
most likely caused due to heart failure, with the earliest descriptions dating back to 2600 
BC. 1-3 The oldest case identified with heart failure was most likely Nebiri, an Egyptian 
dignitary living during the 18th dynasty Pharaoh Thutmose III (1479 – 1425 BC). After 
discovering his remains, histological examination of the lungs showed signs of pulmonary 
edema, most likely caused by heart failure. 4
The discovery and detailed description of the circulatory system by William Harvey in 
1628 AD was probably the first big step in heart failure research. 5 This discovery led to 
new insights in the hemodynamics of the heart and provided new knowledge on the 
hemodynamic abnormalities associated with heart failure. Additional developments, 
such as the X-ray by Wilhelm Röntgen and the electrocardiogram by Willem Einthoven, 
as well as the introduction of cardiac catheterization and cardiac surgery, improved the 
understanding of heart failure. 6
The treatment of heart failure patients has developed rapidly over the last 200 years. 
In the beginning, bloodletting, bed rest, inactivity, and fluid restrictions were the only 
treatment options available. Later, diuretics and digitalis were used for the therapy 
of heart failure, followed by other pharmacological drugs, such as renin-angiotensin 
system (RAS)-inhibitors (consisting of angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers), beta-blockers and mineral corticoid receptor antagonists 
(MRAs). Since the 1960s, advanced treatment options such as heart transplantation 
and circulatory support using a left ventricular assist device (LVAD) surgery became 
available. 6, 7 Despite all these advances, heart failure management still faces many 
significant challenges that need to be addressed.
Heart Failure
Currently, heart failure is defined as a complex clinical syndrome characterized by 
typical signs and symptoms such as elevated jugular venous pressure, pulmonary 
crackles, peripheral edema, and complaints of breathlessness. These signs and 
symptoms are caused by a structural and/or functional cardiac abnormality resulting 
in reduced cardiac output and/or elevated intracardiac pressures. 8
146122_Veenis,Jesse_BNW-def .indd   12 13-11-2020   14:37
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Chapter 1
Heart failure can be divided based on the left ventricular ejection fraction into heart 
failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection 
fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF), according 
to the most recent 2016 European Society of Cardiology Guidelines for heart failure. 8
Due to an aging population and better survival of cardiovascular diseases, such as 
acute myocardial infarction, more and more patients are diagnosed with heart failure. 
Approximately 1-2% of the European population is diagnosed with heart failure, and 
26 million adults live with heart failure worldwide, and these numbers are expected to 
rise even further. 9, 10 Heart failure remains strongly associated with high morbidity and 
mortality, despite the introduction of new treatment options. 11 The one-year survival 
of heart failure patients is approximately 80%, while only 26% are still alive ten years 
after their initial diagnosis. 12 During this period, heart failure patients are frequently 
hospitalized, and their quality of life is significantly reduced due to limitations in their 
physical and social activities. 9, 13, 14
Heart failure significantly affects the lives of heart failure patients. Additionally, it places 
a significant and increasing burden on hospital and healthcare systems due to the 
rising prevalence of heart failure with high morbidity, mortality, and hospitalization 
rates. Therefore, adequate treatment according to the guidelines based upon clinical 
evidence is crucial to improve patient outcome and wellbeing as well as to reduce 
the economic impact.
Pharmacological treatment of heart failure
Nowadays, many pharmacological treatment options are available in heart failure 
management, and the European Society of Cardiology Guidelines for heart failure 
provides clear treatment recommendations for HFrEF patients. 8 All HFrEF patients 
should be treated with a RAS-inhibitor in combination with a beta-blocker, and an 
MRA should be added if indicated. Additionally, diuretics could be used to reduce signs 
and symptoms of congestion, and newly pharmacological agents such as angiotensin 
receptor neprilysin inhibitors (ARNIs) could be used instead of a RAS-inhibitor. 
Ivabradine could be added to the treatment in HFrEF patients with sinus rhythm and a 
heart rate of 70 beats per minute or higher.
It has been demonstrated that adherence to these guidelines significantly improves the 
prognosis and quality of life of HFrEF patients 8, 15, and reduces the number of heart failure 
related hospitalizations. 16 Therefore, the implementation of the guidelines could be used 
146122_Veenis,Jesse_BNW-def .indd   14 13-11-2020   14:37
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as a benchmark for the quality of care. However, the implementation of these guidelines 
appears to be challenging, with relatively low adherence to the guidelines, as demonstrated 
in recent registries. 14, 17, 18 Additionally, the prescribed dosages are often much lower than 
recommended by the guidelines. 17, 19 However, the optimal up titration strategy is still up for 
debate, and it remains unclear whether the guideline-recommended dose is the ideal dose 
for each patient category. Side-effects, such as symptomatic hypotension and degradation 
of the renal function might be introduced when HF drugs are dosed to high.
Monitoring of the heart failure patient
In addition to adequate treatment, monitoring of heart failure patients is needed to 
detect deterioration leading to hospitalization and improve patient outcomes. Several 
monitoring strategies can be applied, including patient self-care, monitoring during 
outpatient clinic visits, or remote monitoring. 8 Patient self-care is a cornerstone of 
heart failure management. Patients are instructed to use the prescribed medication, 
implement lifestyle recommendations, and regularly monitor themselves for signs 
and symptoms of deterioration of heart failure, such as an increase in weight or 
dyspnea. Unfortunately, these clinical symptoms occur relatively late before heart 
failure decompensation, and hospitalization might not be avertable. 20 Additionally, 
many patients do not perform self-monitoring as frequently as necessary. 21 Another 
monitoring option could be monitoring visits at the outpatient clinic. However, 
this is very time consuming for the patient and places a substantial burden on 
the hospital recourses.
Alternatively, remote monitoring facilitates monitoring of the patient’s status at home. 
Three main remote monitoring strategies are currently used, (1) non-invasive remote 
monitoring using, (2) remote monitoring of implantable cardioverter-defibrillator or 
cardiac resynchronization therapy devices, and (3) remote hemodynamic monitoring 
using implantable devices. 20, 22, 23 Each monitoring strategy has its specific advantages 
and disadvantages, and the optimal remote strategy is still up to debate.
End-stage heart failure
Patients with heart failure can become refractory for pharmacological therapy and 
develop end-stage heart failure. End-stage heart failure is a severe condition, with an 
estimated 1-year survival of 60% and a median survival of 18 months when treated with 
optimal medical therapy. 24 In these patients, advanced treatment options are indicated. 
Heart transplantation is considered to be the gold therapy option in end-stage heart 
failure patients. However, due to a shortage of available heart donors, left ventricular 
1
146122_Veenis,Jesse_BNW-def .indd   15 13-11-2020   14:37
16
Chapter 1
assist device therapy is increasingly used as a bridge to transplantation. 25 Additionally, 
a left ventricular assist device can be used as destination therapy in patients who are 
not eligible for heart transplantation.
An left ventricular assist device is implanted during open-heart surgery. An inflow cannula 
connects the pump with the left ventricle, and an outflow cannula forms the connection 
between the pump and the thoracic aorta. The pump supports the left ventricle by pumping 
blood out of the left ventricle into the aorta and the rest of the circulatory system.
Experience with left ventricular assist device therapy has increased significantly over 
the last years, and essential technological improvements have led to a significant 
improvement in the overall survival of left ventricular assist device patients. 26 However, 
many patients remain affected by left ventricular assist device related complications, 
including right ventricular failure, acute kidney injury, and major bleeding events. 25-28 
Frequent monitoring could aid in improving the overall outcome of left ventricular assist 
device patients. Unfortunately, the left ventricular assist device only provides static 
pump parameters, which can only be monitored during outpatient visits. Additional 
monitoring tools, especially remotely monitoring strategies, are needed to improve the 
left ventricular assist device management. Left ventricular assist device management 
remains very complex and faces many challenges that need to be addressed to improve 
patient outcome further. The effects of patient demographics such as age and sex, 
as well as concomitant procedures, including procedures of the aortic valve, on the 
overall survival remains unclear. Furthermore, iron deficiency is a common comorbidity 
in chronic heart failure patients, associated with reduced survival. However, the 
prevalence of iron deficiency in patients with end-stage heart failure is still unknown.
Aims and outlines of this thesis
As previously described, several significant challenges should be addressed to 
individualize and optimize heart failure management further. Therefore, the purpose 
of this thesis was four-fold: (A) to analyze the current quality of heart failure care 
in The Netherlands and identify patient groups in which heart failure care could be 
optimized; (B) to assess the impact of remote hemodynamic monitoring in chronic heart 
failure patients; (C) to determine the safety and feasibility of remote hemodynamic 
monitoring in left ventricular assist device patients; and (D) to optimize left ventricular 
assist device management.
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A. Assess the current quality of heart failure care in The Netherlands and identify 
patient groups in whom heart failure care could be optimized
In the first part of this thesis, prescription rates and prescribed dosages are investigated 
in chronic heart failure patients as an indication of the quality of heart failure care in 
The Netherlands. The clinical profiles and prescription behavior in different subgroups 
of the Dutch heart failure population were investigated to increase our insight into the 
heart failure treatment in Dutch heart failure outpatient clinics. Additionally, these 
insights might be used to optimize and individualize the heart failure treatment of Dutch 
chronic heart failure patients.
B. Assess the impact of remote hemodynamic monitoring in chronic heart failure 
patients
In the second part, the potential impact of remote hemodynamic monitoring by using 
an implantable device in chronic heart failure patients was investigated. Additionally, 
the daily hemodynamic impact of interventional cardiac procedures, such as MitraClip, 
are investigated, which provides a unique insight into the hemodynamic changes pre- 
and post-valvular procedures.
C. Determine the safety and feasibility of remote hemodynamic monitoring in 
left ventricular assist device patients
In the third part, the safety and feasibility of remote hemodynamic monitoring pre- 
and post-left ventricular assist device surgery was studied to investigate its usefulness 
in preoperative risk prediction as well as preoperative optimization. This concept of 
combining two state of the art techniques, remote hemodynamic monitoring and 
left ventricular assist device therapy, together is completely novel. Furthermore, we 
studied the impact of remote hemodynamic monitoring during the outpatient phase, 
which provides new insights to optimized and individualized ventricular assist device 
management. Remote management in this patient group is still in its infancy.
D. Optimize left ventricular assist device management
The last part of this thesis focused on several challenges that still exist in patients 
requiring left ventricular assist device support to optimize their treatment further. 
Additionally, differences in overall survival and left ventricular assist device-related 
complications according to age, sex, and the usage of implantable cardiac electronic 
devices with a defibrillator was studied. Furthermore, the risks and benefits of 
concomitant aortic valve procedures during left ventricular assist device surgery was 
assessed as well. Finally, the prevalence of iron deficiency was studied.
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Abstract
Background: Elderly patients are underrepresented in clinical trials but comprise the 
majority of heart failure patients. Data on age-specific use of heart failure therapy 
are limited. The European Society of Cardiology heart failure guidelines provide no 
age-specific treatment recommendations. We investigated practice-based heart failure 
management in a large registry at heart failure outpatient clinics.
Design and methods: We studied 8351 heart failure with reduced ejection fraction 
patients at 34 Dutch outpatient clinics between 2013 and 2016. The mean age was 
72.311.8 years and we divided age into three categories: less than 60 years (13.9%); 
60–74 years (36.0%); and 75 years and over (50.2%).
Results: Elderly heart failure with reduced ejection fraction patients (≥75 years) received 
significantly fewer beta-blockers (77.8% vs. 84.2%), renin–angiotensin system inhibitors 
(75.2% vs. 89.7%), mineralocorticoid receptor antagonists (50.6% vs. 59.6%) and 
ivabradine (2.9% vs. 9.3%), but significantly more diuretics (88.1% vs. 72.6%) compared 
to patients aged less than 60 years (Pfor all trends<0.01). Moreover, the prescribed target 
dosages were significantly lower in elderly patients. Also, implantable cardioverter 
defibrillator (18.9% vs. 44.1%) and cardiac resynchronisation therapy device (14.6% vs. 
16.7%) implantation rates were significantly lower in elderly patients. A similar trend in 
drug prescription was observed in patients with heart failure with mid-range ejection 
fraction as in heart failure with reduced ejection fraction.
Conclusion: With increasing age, heart failure with reduced ejection fraction 
patients less often received guideline-recommended medication prescriptions and 
also in a lower dosage. In addition, a lower percentage of implantable cardioverter 
defibrillator and cardiac resynchronisation therapy device implantation in elderly 
patients was observed.
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Introduction
Chronic heart failure (HF) is a major healthcare problem, associated with a poor 
prognosis, high morbidity and mortality.1 Optimising medical and device therapy 
according to the guidelines improves prognosis.2 Therefore, adherence to the guidelines, 
such as the rate of drug prescription and dosage, are often used as benchmarks of 
quality of care. Approximately 1–2% of the global adult population is diagnosed with 
HF.3 Due to an aging population and better survival of underlying heart diseases, these 
numbers are expected to rise even further.4 Elderly patients are a major part of the 
HF population, with approximately 80% older than 65 years, and 40–50% even aged 
75 years or older.2,5
In elderly patients, HF is the leading cause of hospitalization and is associated with high 
morbidity and mortality, resulting in an enormous burden on hospital resources.6 Due 
to the high prevalence of comorbidities in elderly patients, optimising HF management 
remains even more challenging.7 Until now, randomised clinical trials investigating HF 
therapy did not include large number of elderly patients,8 with the exception of the 
SENIORS trial.9 In fact, patients enrolled in these trials were on average 10 years younger 
than in daily clinical practice,3 and elderly patients were clearly underrepresented. 10 A 
few registries have shown a lower prescription rate in the elderly but lack size.8,11 Despite 
the ongoing discussion on optimal therapy in elderly HF patients, there is no European 
Society of Cardiology (ESC) recommended age-specific guidelines for HF treatment,2 
and data in groups of patients with advanced age are scarce.
Therefore, we investigated age-related differences in HF therapy in a large-scale cross-
sectional registry in 34 Dutch HF clinics, reflecting actual practice-based HF care at 
outpatient clinics including large numbers of elderly patients.
Methods
The design and methods of the CHECK–HF (Chronisch Hartfalen ESC – richtlijn 
Cardiologische praktijk Kwaliteitsproject HartFalen) registry have been published in 
detail elsewhere.12,13 Briefly, the CHECK–HF registry consists of 10910 patients with 
chronic HF from a total of 34 participating Dutch centres, participating in the inclusion 
for this cross-sectional observational cohort. Between 2013 and 2016, all centres 
included patients diagnosed with HF according to 2012 ESC guidelines on HF,2 based 
2
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on symptoms and echo parameters, who were seen at the outpatient HF clinic (96%) or 
general cardiology outpatient clinic (4%) if no specific HF clinic was present.
Baseline patient characteristics, aetiology of HF, comorbidities, basic echocardiographic 
and electrocardiographic parameters, laboratory markers, pacemaker, implantable 
cardioverter defibrillator (ICD) and cardiac resynchronisation therapy (CRT) treatment, 
as well as prescription rates of medication (drug name, dosage and frequency and 
total daily dose), were recorded. Furthermore, contraindication and intolerance 
rates were collected.
Ivabradine was only considered indicated on top of optimal treatment with beta-
blockers, angiotensin-converting enzyme inhibitors (ACEIs) (or angiotensin II receptor 
blockers (ARBs)) and mineralocorticoid receptor antagonists (MRAs) (or ARBs), and if 
patients were in sinus rhythm, left ventricular ejection fraction (LVEF) of 35% or less, 
heart rate of 70 beats/minute or greater and were still symptomatic (New York Heart 
Assocation (NYHA) ≥II), or already received ivabradine. Target doses of guideline-
recommended HF therapy are presented in Supplementary Table 1.
Based on echocardiographic results, patients were classified based on LVEF or visual 
assessment of the function of the left ventricle function as heart failure with reduced 
ejection fraction (HFrEF, LVEF <50% (n=8360 (76.6%))), and according to 2016 ESC HF 
guidelines as heart failure with mid-range ejection fraction (HFmrEF) (LVEF 40–49% 
(n=1574 (14.4%))) in those with available measurement of ejection fraction. In addition, 
HFpEF was classified as LVEF of 50% or greater in 2267 (20.8%) patients. In 274 (2.5%) 
patients, recording of the left ventricular function in the database was insufficient to 
classify patients into HF type, in nine patients (0.1%) age was missing in the database, 
and they were excluded from this analysis. In the current analyses, we focus on age-
related treatment differences in guideline recommended HF therapies, including device 
therapy and lifestyle interventions, in HFrEF and HFmEF patients only.
Statistical analysis
Continuous data are expressed as mean value±SD or median and interquartile range, 
depending on the distribution of the data, and compared by the one-way analysis of 
variance (ANOVA) or Mann–Whitney U-test. Categorical data are expressed as counts 
and percentages, and compared by the Pearson chi-square test. In order to investigate 
whether the observed age-related differences were independent of potential clinical 
predictors, univariable and multivariable logistic regression were used. Results of these 
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regression analyses are expressed as odds ratios (ORs) with 95% confidence intervals 
(CIs). A two-sided P value of 0.05 was considered statistically significant.
In model 1, we adjusted for gender only. In model 2, we further adjusted for NYHA and 
LVEF. In model 3, we further included all comorbidities which were significantly related 
to the outcome variable at statistical level P value less than 0.05 using stepwise entry 
method in binary logistic regression. In the specific device therapy-related analysis, 
QRS duration was an additional variable in univariable analysis we included by entry 
method in the models. Age was entered per 10 years into the models.
In a total of 8.9% of all predicting values data were missing. These missing data were 
imputed using multiple imputation. If the missing variables showed a monotone pattern 
of missing values, the monotone method was used, otherwise, an iterative Markov chain 
Monte Carlo method was used with a number of 10 iterations. A total of five imputations 
was performed, and the pooled data were analysed. The imputed data were only used 
for the multivariable analysis. For all reported data of the multivariable analysis, we 
compared crude and imputed P values as well as the ORs and CIs in order to analyse 
whether imputation changed the results, and if no significant changes occurred we only 
presented the imputed values in the main analyses. All analyses were performed with 
SPSS statistical package version 24.0 (SPSS Inc., Chicago, IL, USA).
Results
HFrEF patients (n=8351) were on average 72.3±11.8 years old, with 13.9% less than 60 
years of age, 36.0% between 60 and 74 years, and 50.2% 75 years or older; 63.9% were 
men. Most patients were in NYHA class II and approximately half of the patients had 
an ischaemic cause of their HF (Table 1).
Elderly HFrEF patients had significantly more renal insufficiency, more often atrial 
fibrillation, thyroid disease, chronic obstructive pulmonary disease, diabetes mellitus 
and hypertension and less often obstructive sleep apnoea syndrome when compared 
to younger patients (P<0.01, for all) (Table 1).
2
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Table 1. Patient characteristics in HFrEF patients
HFrEF (n=8351)‡




Age ≥ 75 years
(n=4040)
p-value
Age (years) 51.3 ± 7.1 68.0 ± 4.2 81.8 ± 4.7 <0.01
Male gender 763 (63.6) 2163 (70.0) 2388 (59.3) <0.01
BMI, kg/m2 28.7 ± 6.1 27.9 ± 5.4 26.2 ± 4.4 <0.01
NYHA
I 322 (26.9) 569 (18.5) 421 (10.6)
<0.01
II 667 (55.7) 1845 (60.0) 2176 (54.6)
III 192 (16.0) 618 (20.1) 1295 (32.5)
IV 16 (1.3) 42 (1.4) 91 (2.3)
LVEF, % 30.4 ± 10.4 31.6 ± 10.0 34.2 ± 10.8 <0.01
Cause of HF
Ischemic cause of HF 435 (37.1) 1630 (54.0) 2113 (54.3)
<0.01
Non-ischemic cause of HF 738 (62.9) 1390 (46.0) 1779 (45.7)
Systolic BP, mmHg 123.1 ± 20.0 126.2 ± 20.6 126.0 ± 20.9 <0.01
Diastolic BP, mmHg 74.3 ± 11.5 72.5 ± 11.2 69.3 ± 11.1 <0.01
Heart rate, bpm 72.8 ± 13.8 71.8 ± 14.2 71.9 ± 13.6 0.09
Atrial fibrillation 87 (7.3) 678 (22.1) 1341 (33.6) <0.01
LBBB 156 (12.9) 490 (15.8) 767 (19.0) <0.01
QRS ≥130 ms 289 (27.8) 957 (37.2) 1525 (46.0) <0.01
eGFR, ml/min 79.3 ± 22.8 64.8 ± 23.6 50.8 ± 21.6 <0.01
eGFR
<30 ml/min 23 (3.0) 154 (7.1) 490 (16.5)
<0.0130-59 ml/min 116 (15.2) 774 (35.8) 1552 (52.4)
≥60 ml/min 622 (81.7) 1231 (57.0) 921 (31.1)
Comorbidities
Hypertension 306 (29.1) 1097 (39.4) 1573 (43.2) <0.01
Diabetes Mellitus 252 (23.9) 848 (30.4) 1072 (29.4) <0.01
COPD 118 (11.2) 546 (19.6) 717 (19.7) <0.01
OSAS 95 (9.0) 246 (8.8) 154 (4.2) <0.01
Thyroid disease 57 (5.4) 209 (7.5) 290 (8.0) 0.02
Renal insufficiency† 191 (20.3) 1214 (47.1) 2543 (72.9) <0.01
HFrEF Heart Failure with reduced Ejection Fraction; BMI, Body Mass Index; NYHA, New York Heart 
Association classification; LVEF, Left Ventricular Ejection Fraction; HF, Heart Failure; BP, Blood Pressure; 
LBBB, Left-Bundle Branch Block; eGFR, estimated Glomerular Filtration Rate; COPD, Chronic Obstructive 
Pulmonary Disease; OSAS, Obstructive Sleep Apnea Syndrome.
† Defined as eGFR <60mL/min or a history of renal failure
‡ In nine patients data on age was missing
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Pharmacological therapy in HFrEF
Elderly patients less often received beta-blockers, renin–angiotensin system (RAS) 
inhibitors, MRAs and ivabradine, but significantly more diuretics than younger patients 
(Table 2). These differences gradually increased with age.
Patients received all three of the HF medications (beta-blockers, RAS inhibitors 
and MRAs), if indicated, in 47.8%, 38.7% and 29.6% of the patients in the three age 
groups (<60 years, 60–74 years and ≥75 years, respectively), two out of three were 
prescribed in 39.9%, 45.4% and 47.6%, one out of three was prescribed in 10.2%, 14.0% 
and 19.5%, and none of these medications were prescribed in 2.1%, 1.9% and 3.3%, 
respectively (P<0.01). Supplementary Figure 1 shows the use of RAS inhibitors divided 
into ACEIs and ARBs.
The total reported contraindication or intolerance rates were 3.2% (beta-blockers), 
4.6%, (RAS inhibitors), 4.7% (MRAs) and 1.7% (ivabradine) (Table 3). The reported 
contraindication or intolerance rates in elderly patients were significantly higher for 
beta-blockers, RAS inhibitors and MRAs (P<0.01). However, in a substantial number of 
patients the reason for not receiving RAS inhibitors or MRAs was not specified in the 
patients’ charts.
Elderly patients less often received the recommended target dose of beta-blockers, 
RAS inhibitors and MRAs than the younger patient groups (P<0.01, for all) (Figure 1). 
Fifty per cent or greater of the target dose of all three of the HF medication groups 
(beta-blockers, RAS inhibitors and MRAs) was achieved in 25.4%, 17.7% and 11.0% of 
the patients (<60 years, 60–74 years and ≥75 years, respectively); 50% or greater of the 
target dose of two out of three medications in 38.6%, 40.6% and 35.7%, respectively; 
50% or greater of the target dose of none out of three medication in 27.1%, 32.2% and 
38.3%, respectively. Younger patients more often received 50% or greater of the target 
dose of all three guideline-recommended medications than elderly patients, P<0.01.
2
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Table 3. Reasons for not prescribing HF medication in HFrEF patients 
Contraindicated or intolerance No reason specified
Beta-blocker Total population 262 (3.2) 971 (11.8)
<60 years 21 (1.8) 109 (9.4)
60-74 years 90 (2.9) 300 (9.8)
≥75 years 150 (3.8) 562 (14.1)
RAS-inhibitors Total population 380 (4.6) 1161 (14.1)
<60 years 21 (1.8) 99 (8.5)
60-74 years 105 (3.4) 327 (10.7)
≥75 years 254 (6.4) 735 (18.4)
MRA Total population 387 (4.7) 3479 (42.3)
<60 years 25 (2.2) 445 (38.3)
60-74 years 115 (3.8) 1305 (42.7)
≥75 years 247 (6.2) 1724 (43.2)
Ivabradine* Total population 143 (1.7) 7691 (93.6)
<60 years 12 (1.0) 1038 (89.3)
60-74 years 52 (1.7) 2854 (93.3)
≥75 years 79 (2.0) 3790 (95.0)
HF, heart failure; HFrEF, heart failure with reduced ejection fraction
* If indicated (n=500) 22.6%, 23.5% and 22.2% (<60, 60-74 and ≥75 years, resp.) of patients did not receive 
ivabradine with no specified reason
Figure 1. Percentages of target dose prescribed in heart failure with reduced ejection fraction
2
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After multivariable adjustment, the probability of receiving a beta-blocker, RAS inhibitor, 
MRA and ivabradine decreases for each 10-year increase in age by 10% (MRAs), 12% 
(beta-blockers), 29% (RAS inhibitors) and 21% (ivabradine), whereas the probability of 
receiving diuretics increases by 32% (Table 4). Multiple imputation did not change these 
findings. The age differences in HF therapy, adjusted for the differences in comorbidities, 
are presented in Table 4.
The percentage of fluid and sodium restriction recommendations are presented in 
Supplementary Figure 2.
Device implantation in HFrEF
Elderly patients received significantly more pacemakers, but fewer ICD and CRT 
devices, compared to younger patients (Table 2). After adjustment for multiple clinical 
parameters, the chance of receiving an ICD and CRT device decreases by 39% and 17%, 
respectively, for every 10-year increase in age (Table 4). After multiple imputation, the 
described differences did not change.
General therapy in subgroups of HFmrEF
HFmrEF patients were on average 73.7±11.7 years old, and 58.4% were men. The 
differences in baseline characteristics between HFrEF and HFmrEF patients are shown 
in Supplementary Table 2. Beta-blockers (82.3% vs. 74.7%, P<0.01), RAS inhibitors (88.0% 
vs. 71.9%, P<0.01) and ivabradine (5.9% vs. 2.1%, P=0.02) were less often prescribed 
in patients aged 75 years and older compared to patients less than 60 years, while 
MRAs (35.4% vs. 46.0%, P=0.02) and diuretics (55.4% vs. 86.6%, P<0.01) were more 
often prescribed (Table 2). The inferences of the HFmrEF group are comparable to the 
findings in HFrEF.
Discussion
This large practice-based clinical registry of 8351 HF patients including a relatively large 
group of elderly patients demonstrates that aged HFrEF patients less often receive 
guideline-recommended therapy. Furthermore, the prescribed dosages as a percentage 
of the target dose, especially to elderly patients, are lower than recommended.
Pharmacological therapy
Previous recent large registries demonstrated an age-related decline of ESC HF 
guidelines recommended HF therapy, especially in patients older than 75 years.11,14–17 
2
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However, these registries are older and were not using the ESC HF guidelines of 2012. 
Our results also demonstrate an age-related decline, but in contrast to these earlier 
registries, the decline in our study started already in patients older than 60 years 
of age and seems to be continuous, indicating that the decline is not restricted to 
the very old.
It has been suggested that the higher rate of comorbidities or the different aetiology 
of HF might be an explanation for the age-associated decline in drug prescription. 
16 Although we demonstrated significant differences in comorbidities between age 
groups, these differences were not large enough to explain the observed differences 
in prescription rates as shown in our multivariable analysis. In chronic HF patients, 
chronic obstructive pulmonary disease frequently coexists and symptoms overlap, and 
while getting more prevalent with increasing age, adequate treatment of underlying 
diseases gets even more challenging.18
Frailty in elderly patients is highly prevalent and is associated with a worse prognosis19 
and might explain in some part the lower prescription rate in elderly patients; however, 
this could not be tested in our registry as no information on frailty was available.
Although elderly patients constitute a large part of the general HF population, patients 
aged 75 years of age and older are underrepresented in large randomized clinical 
trials.2,5,11 Thereby the positive effect of the HF medication in the elderly HF population 
is not yet properly investigated. This might be another explanation for the decline in 
prescription rates in elderly patients. However, the decline appears to be not limited 
to the very old, but to be a continuum, starting at a younger age than was previously 
assumed, indicating that the decline cannot be fully explained by lack of evidence in 
the elderly alone.
In contrast to the HF medication, diuretics, fluid and sodium restrictions are more 
often used in elderly patients. However, after adjustment in the multivariable analysis 
for comorbidities, the influence of age is largely reduced, in contrast to the other 
recommendations. This might indicate that the use of diuretics, fluid and sodium 
restrictions can partially be explained by worse renal function in elderly patients.
Despite the fact that elderly patients less often received guideline-recommended 
pharmacological therapy, we still observed an overall high prescription rate in all age 
groups, compared to the CHAMP–HF registry. 20 Importantly, when HF medication is 
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prescribed, the actual dosages are significantly lower in elderly than in younger patients, 
which could potentially lead to a worse outcome. As has been shown, good adherence 
to the guidelines, with prescription of at least 50% of the recommended dosage, is 
associated with better clinical outcomes.21
Despite relative good guideline adherence, there still seems to be room for further 
improvement, especially in the prescribed dosages, and in the elderly population. 
As previously demonstrated, the uptitration of HF medication is possible, even in 
elderly patients.22 However, evidence on the effect of HF therapy in patients aged 75 
years and older is very limited,22,23 and appropriate prospective trials are urgently 
needed to address the important question as to whether treatment should differ 
depending on age.
Device therapy
Elderly patients less often received a ICD or CRT device, and more frequently received 
a pacemaker. These results are in line with recent publications, showing a decline of 
the CRT device and ICD implantation rate in older patients11,14,16 and an increase of the 
pacemaker implantation rate.11
The age differences in implantation rates might be explained by more perceived or 
actual comorbidities or contraindications, including non-HF-related comorbidities such 
as cognitive and mobility impairments.16 It has been shown that elderly HF patients 
have a higher non-cardiac mortality rate compared with younger HF patients.24 This 
might negatively influence the benefits and cost-effectiveness of implanted devices 
in the elderly. However, after multivariable analysis, the age-related differences 
remained. Also, device implantation, such as ICDs, has been shown to be effective 
and even warranted in elderly patients if life expectancy is longer than one year.24 
Still, a recent study in patients with non-ischaemic cardiomyopathy found a strong 
relationship between reduced mortality by ICD and age, with only younger patients 
having any benefit in post-hoc analysis. 25 Furthermore, assumption of a higher risk 
of complications due to the implantation procedure in elderly patients might explain 
the lower implantation rates. However, as recently reported there are no differences 
in the number of complications in elderly patients compared with younger patients.26 
Finally, the perception that quality of life is seen as more important for elderly patients 
than a prolonged survival period might result in the lower implantation rates of a ICD. 
However, the preference of patients to prefer longevity over optimal quality of life was 
found to be surprisingly high and not individually predictable even at a high age.27
2
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The use of a CRT device not only reduces morbidity and mortality, but also symptoms 
and improves quality of life, also in elderly patients.28 In addition, it can lead to a rise 
in blood pressure and protect against bradycardia. 29 These gains may lead to a better 
adherence to recommended HF medication, such as beta-blockers.29 Thus, there is no 
evidence that a CRT device may be less important in HFrEF patients at an older age. As 
elderly patients are more often in need of a pacemaker, as shown in our results, and a 
CRT device holds positive treatment effects for elderly patients, it might be beneficial 
to treat these patients with biventricular CRT pacing instead of right ventricular pacing 
using a pacemaker.
Limitations and strengths
Our study has some limitations. CHECK–HF has a cross-sectional design with no follow-
up data on patient outcomes. In addition, for some important variables data were 
missing, which might influence the results. However, imputation of missing data did 
not influence the results. The strengths of the CHECK–HF registry include the large 
scale, a reflection of the true practice of outpatient HF management in The Netherlands 
representative of western European countries. A further strength is the availability 
of a large number of elderly patients with detailed information on medication 
prescription and dosage.
Conclusion
In this large Dutch registry of a real-world outpatient HF population, HFrEF patients 
in a higher age group less often received guideline-recommended HF drugs, at lower 
dosages and less often ICD and CRT device therapy. The differences cannot be fully 
explained by clinical variables, comorbidities or higher reported contraindications or 
intolerance. Our study indicates the need to focus especially on elderly HF patients, in 
order to optimise their medical therapy, and further uptitrate their dosages or reflect 
on policy and accept lower age-adjusted target doses in elderly patients as they do not 
tolerate higher dosages.
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Supplementary Table 2. Patient characteristics of HF patients according to 2016 ESC HF Guideline 
HFrEF (n=6786) HFmrEF (n=1574) p-value
Age (years) 71.9 ± 11.8 73.7 ± 11.7 p<0.01
Male gender 4403 (65.2) 917 (58.4) p<0.01
BMI, kg/m2 27.2 ± 5.1 27.5 ± 5.4 p<0.01
NYHA
I 1029 (15.3) 284 (18.2)
p<0.01
II 3838 (57.2) 854 (54.8)
III 1716 (25.6) 392 (25.2)
IV 121 (1.8) 28 (1.8)
LVEF, % 29.3 ± 9.0 45.0 ± 5.4 p<0.01
Cause of HF
Ischemic cause of HF 3491 (53.1) 691 (45.4)
p<0.01
Non-ischemic cause of HF 3082 (46.9) 830 (54.6)
Systolic BP, mmHg 124.8 ± 20.4 129.5 ± 21.6 p<0.01
Diastolic BP, mmHg 71.1 ± 11.2 71.8 ± 12.0 p<0.01
Heart rate, bpm 71.9 ± 13.8 72.5 ± 14.3 p=0.03
Atrial fibrillation 1575 (23.5) 534 (34.3) p<0.01
LBBB 1198 (17.7) 216 (13.7) p<0.01
QRS ≥130 ms 2358 (42.0) 416 (31.5) p<0.01
eGFR 60.3 ± 24.7 56.2 ± 23.7 p<0.01
eGFR
<30 534 (10.9) 133 (13.7)
p<0.0130-59 2003 (40.8) 439 (45.1)
≥60 2373 (48.3) 401 (41.2)
Comorbidity
Hypertension 2359 (38.9) 619 (43.7) p<0.01
Diabetes Mellitus 1777 (29.3) 397 (28.0) p=0.10
COPD 1090 (18.0) 291 (20.5) p=0.03
OSAS 379 (6.2) 116 (8.2) p<0.01
Thyroid disease 446 (7.3) 111 (7.8) p=0.40
Renal insufficiency † 3205 (55.4) 745 (60.9) p<0.01
No relevant comorbidity 757 (14.6) 98 (9.0) p<0.01
BMI, Body Mass Index; NYHA, New York Heart Association classification; LVEF, Left Ventricular Ejection 
Fraction; HF, Heart Failure; BP, Blood Pressure; LBBB, Left-Bundle Branch Block; eGFR, estimated 
Glomerular Filtration Rate; NT-proBNP, N-terminal pro Brain Natriuretic Peptide; COPD, Chronic 
Obstructive Pulmonary Disease; OSAS, Obstructive Sleep Apnea Syndrome.
† Defined as eGFR <60mL/min or a history of renal failure
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Supplementary Figure 1. Percentage of RAS-inhibitors prescription in heart failure with reduced 
ejection fraction


















Supplementary Figure 2. Lifestyle therapy in heart failure with reduced ejection fraction
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Abstract
Background: Elderly heart failure (HF) patients are underrepresented in clinical trials, 
though are a large proportion of patients in real-world practice. We investigated 
practice-based, secondary care HF management in a large group of chronic HF patients 
aged ≥ 80 years (octogenarians).
Methods: We analyzed electronic health records of 3490 octogenarians with chronic 
HF at 34 Dutch outpatient clinics in the period between 2013 and 2016 , 49% women. 
Study patients were divided into HFpEF [LVEF ≥ 50%; n = 911 (26.1%)], HFrEF [LVEF < 40%; 
n = 2009 (57.6%)] and HF with mid-range EF [HFmrEF: LVEF 40–49%; n = 570 (16.3%)].
Results: Most HFrEF patients aged ≥ 80 years received a beta blocker and a renin–
angiotensin system (RAS) inhibitor (angiotensin-converting enzyme (ACE) inhibitor or 
angiotensin receptor blocker), i.e. 78.3% and 72.8% respectively, and a mineralocorticoid 
receptor antagonist (MRA) was prescribed in 52.0% of patients. All three of these 
guideline-recommended medications (triple therapy) were given in only 29.9% of 
octogenarians with HFrEF, and at least 50% of target doses of triple therapy, beta 
blockers, RAS inhibitor and MRA, were prescribed in 43.8%, 62.2% and 53.5% of the 
total group of HFrEF patients. Contraindications or intolerance for beta blockers was 
present in 3.5% of the patients, for RAS inhibitors and MRAs in, 7.2% and 6.1%.
Conclusions: The majority of octogenarians with HFrEF received one or more 
guideline-recommended HF medications. However, triple therapy or target doses of the 
medications were prescribed in a minority. Comorbidities and reported contraindications 
and tolerances did not fully explain underuse of recommended HF therapies.
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Introduction
Elderly patients represent a major proportion of the heart failure (HF) population. Most 
of these elderly patients have multiple morbidities. 1–3 This may complicate adherence 
to advocated HF management.
In general, optimizing guideline-recommended HF therapies improves quality of life, 
morbidity and mortality significantly. 4-6 However, randomized clinical trials investigating 
HF therapies did not represent the real-life HF population. The patients enrolled in these 
trials were on average 10 years younger than in real-world practice; elderly patients 
were largely underrepresented and very elderly were even excluded, except for the 
SENIORS-study. 7–10
As such, there are considerable gaps of knowledge in HF treatment effects in 
octogenarians. Practice guidelines do not provide age-specific recommendations for 
implementation and utilization of HF therapies, 4, 5 but several registries reported 
lower prescription rates of evidence-based medication in the elderly. 11–18 High age-
related factors, e.g., frailty, fall risk, cognitive impairment, dementia and disability, 
and also polypharmacy and concerns on drug interaction may interfere with initiation 
and persistence of HF medication, and as such are potential barriers for optimal 
therapy. 5 Importantly, detailed data regarding prescribed HF medication in the very 
elderly are scarce.
In a large-scale real-world registry at Dutch HF outpatient clinics, we investigated 
medical HF therapies and determinants of prescription of individual HF drugs in a 
substantial group of octogenarians, 19, 20 better reflecting contemporary practice-based 
HF in secondary care.
Methods
The design and methods of the CHECK-HF (Chronisch Hartfalen ESC-richtlijn 
Cardiologische praktijk Kwaliteitsproject HartFalen) registry have been published in 
detail earlier. 19 Briefly, the CHECK-HF registry consists of 10,910 patients with chronic 
HF from a total of 34 participating Dutch centers. Between 2013 and 2016, all centers 
included patients diagnosed with HF based on the 2012 ESC Guidelines on HF (i.e., 
based on symptoms and echo parameters) who were seen at the outpatient HF clinic 
(96%) or general cardiology outpatient clinic (4%) if no specific HF clinic was present.
3
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From electronic health records, baseline patient characteristics, etiology of HF, 
comorbidities, basic echocardiographic and electrocardiographic (ECG) parameters, 
laboratory markers, pacemaker, ICD and CRT treatment as well as prescription rates of 
medication (drug name, dosage and frequency and total daily dose) were recorded. The 
target doses of guideline-recommended HF medication are presented in Suppl. Table 
1. Drug doses were calculated compared to the recommended dose and according to 
guidelines as a daily dose or percentage of actual recommended daily dose.
Furthermore, contraindications and intolerance as indicated by the treating 
physician were collected. No predefined rules were applied to determine absolute 
contraindications. CHECK-HF is a cross-sectional observational cohort study and there 
were no outcome data collected.
There were 3601 patients aged ≥ 80 years, comprising 33.1% of the total CHECK- 
HF cohort. In 111 (3.1%) patients, recording of ejection fraction or age in the database 
was insufficient to classify patients; so, these patients were excluded from this analysis. 
In the current analyses of the remaining 3490 patients, aged ≥ 80 years, we focused on 
the prescribed HF medication.
Based on echocardiographic results, octogenarians were divided based on LVEF or visual 
assessment of the function of the left ventricle (LV) according to the contemporary 2016 
ESC HF Guidelines into HFpEF [LVEF ≥ 50%; n = 911 (26.1%)], HFrEF [LVEF < 40%; n = 2009 
(57.6%)] and HF with mid-range EF [HFmrEF: LVEF 40–49%; n = 570 (16.3%)].
This study was approved by the medical ethics committee 2017 at Maastricht University 
Medical Center (Maastricht, the Netherlands). No informed consent of the participants 
in this registry was required.
Statistics
Continuous data are expressed as mean value ± SD or median and interquartile range, 
depending on the distribution of the data, and compared by applying one-way analysis 
of variances (ANOVA) or Mann–Whitney U-test. Categorical data are expressed as counts 
and percentages, and compared by the Pearson Chi-square test. A two-sided p value 
of 0.05 was considered statistically significant.
Multivariable predictors for the use of HF medication were sought, using multivariable 
logistic regression analysis, using the stepwise backward procedure. All predictors of 
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medication use in univariable analysis (data not shown) at a p value of < 0.10 were 
included in the multivariable regression analysis. Results of logistic regression are 
presented as odds ratio (ORs). Some missing data occurred in the variables included 
in the multivariable analyses, which we corrected using multiple imputation. If the 
missing variables showed a monotone pattern of missing values, the monotone method 
was used; otherwise, an iterative Markov chain Monte Carlo method was used with a 
number of 10 iterations. A total of 5 imputations were performed, and the pooled data 
were analyzed. The imputed data were only used for the multivariable analysis. For all 
reported data of the multivariable analysis, we compared crude and imputed p values 
as well as the odds ratios and confidence intervals to analyze whether imputation 
changed the results, and if no significant changes occurred, we present the imputed 
values in the main analyses.
All analyses were performed with SPSS Statistical Package version 24.0 (SPSS Inc, 
Chicago, Illinois).
Results
Baseline characteristics of the 3490 HF patients aged ≥ 80 years are shown in Table 1. 
The median [IQR] age was 84 [82.0–87.0] years and 49% were women. Most patients 
were in NYHA class II and approximately half of the patients had a ischemic cause of their 
HF. Median [IQR] LVEF was 40% [30.0–50.0], one quarter had diabetes mellitus and the 
majority (74%) had an eGFR < 60 ml/min/m2 (Table 1). Several baseline characteristics 
differed significantly between LVEF groups, also when subdividing men and women 
(Suppl. Table 2). HFpEF patients (n = 911) were older and more often women, had a 
higher body mass index, more often had a non-ischemic cause of HF, hypertension, and 
atrial fibrillation in comparison to HFrEF patients (n = 2009). Octogenarians with HFrEF 
more often had a QRS-width ≥ 130 ms and left bundle branch block (LBBB) on their ECG, 
when compared to those with HFpEF, in those with sinus rhythm or atrial fibrillation, 
and not in HF patients with paced or ectopic rhythm (Table 1 and Suppl. Table 3).
3
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Characteristics of HFmrEF patients aged ≥ 80 years (n = 570) did not differ much from those 
with HFrEF except for a higher prevalence of atrial fibrillation and some other relevant 
comorbidities and fewer LBBB on ECG (Table 1). COPD was more prevalent in HFmrEF 
compared to HFrEF patients (22.2% and 18.1%, respectively, p = 0.04). HFpEF patients had 
more often hypertension when compared to both HFrEF and HFmrEF patients (Fig. 1).














































Fig. 1 Comorbidities in octogenarians with heart failure: HFrEF vs. HFmrEF vs. HFpEF (ESC Guidelines 2016). 
HFrEF heart failure with reduced ejection fraction, HFmrEF heart failure with mid-range ejection fraction, 
HFpEF heart failure with preserved ejection fraction, ESC European Society of Cardiology, COPD chronic 
obstructive pulmonary disease, OSAS obstructive sleep apnea syndrome.
Renal insufficiency: defined as eGFR < 60 mL/min or a history of renal failure
Guideline-recommended medical therapy in HFrEF
Following the ESC guidelines 2016, a large proportion of HFrEF patients aged ≥ 80 
years received a beta blocker or a RAS inhibitor [angiotensin-converting enzyme (ACE) 
inhibitor or angiotensin receptor blocker (ARB)], i.e., 78.3% and 72.8%, respectively. An 
MRA was prescribed in 52.0% of patients and diuretics in 90.4%. Women received more 
often a beta blocker and a thiazide diuretic, than men (Table 2).
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The combination of all three HF medication (beta blocker, RAS inhibitor and MRA), were 
prescribed to 29.9% of HFrEF patients aged ≥ 80 years patients, two out of three HF 
medication in 46.5%, one out of three in 20.3%, and none of these medications were 
prescribed in 3.3% of octogenarians with HFrEF. In total, 55 patients (2.7%) received 
ivabradine, which represents 77% of those where ivabradine was indicated.
MRA was less used in patients with more than 2 years of follow-up than in those with 
< 1 year of HF follow-up, 49.0% and 61.5% respectively, p < 0.01 (Suppl. Table 4a).
The percentages of target dose of HF medication prescribed in the 2009 HFrEF patients 
(LVEF < 40%) aged ≥ 80 years are shown in Fig. 2. At least, 50% of target doses of beta 
blockers, RAS inhibitor and MRA were prescribed in 43.8%, 62.2% and 53.5% of HFrEF 
patients, respectively (Fig. 2). A ≥ 50% of target dose of all three of the HF medications 
groups was achieved in 9.5% of the patients; ≥ 50% of the target dose for two out of three 
HF medications in 35.9%; ≥ 50% of the target dose for one out of three HF medications 
in 39.2%; and ≥ 50% of the target dose for none of these HF medications in 15.5%.
Fig. 2 Percentages of target dose of HF medication prescribed in octogenarians with HFrEF (LVEF < 40%). 
HF heart failure, HFrEF heart failure with reduced ejection fraction, RAS renin–angiotensin system, RAS 
inhibitor angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor
The reasons of non-adherence or not prescribing recommended HF medication (ESC 
Guidelines 2016) were reported by the centers and are depicted in Table 3. Contraindications 
or intolerance for beta blockers was present in 3.5% of the patients, for RAS inhibitors, MRAs 
and ivabradine in, respectively, 7.2%, 6.1% and 2.2%. There were no substantial differences 
between men and women (Suppl. Table 5). In a substantial number of patients, the reasons 
for not receiving recommended HF-medication were not specified.
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Table 3. Reasons for not prescribing HF medication in HFrEF patients aged > 80 years
Contraindicated or intolerance No reason specified
Beta-blocker 69 (3.5) 287 (14.4)
RAS-inhibitors 145 (7.2) 396 (19.9)
MRA 121 (6.1) 834 (41.9)
Ivabradinea 43 (2.2) 1891 (95.1)
HF heart failure, HFrEF heart failure with reduced ejection fraction, RAS renin–angiotensin system, RAS 
inhibitor angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), MRA 
mineralocorticoid receptor antagonists
a If indicated (n = 19) 25.7% of patients did not receive ivabradine with no specified reason
Table 4. Multivariable predictors of the use of HF medication in HFrEF patients aged > 80 years
Beta-blocker RAS inhibitor MRA Diuretics
OR OR OR OR
Female gender 1.31 [1.02-1.68] - - -
Age (per 10 y) - 0.63 [0.48-0.83] - -
BMI (kg/m2) - - - 1.06 [1.01-1.12]
Systolic BP (per 10 mmHg) - 1.09 [1.02-1.16] 0.80 [0.75-0.85] -
Diastolic BP (per 10 mmHg) - - - 0.77 [0.63-0.93]
NYHA-class (per class) - - - 2.07 [1.49-2.88]
Heart rate (per 10 bpm) - - - -
QRS-duration (per 10 ms) - 0.97 [0.94-1.00] - -
eGFR (per 10 ml/min) - - - 0.85 [0.76-0.94]
Ischemic etiology - - - -
Hypertension - - - 1.42 [1.04-1.94]
Diabetes mellitus type 2 - - - -
COPD - - - -
Renal failure - 0.73 [0.55-0.98] - 1.93 [1.18-3.16]
HF heart failure, HFrEF heart failure with reduced ejection fraction, RAS renin–angiotensin system, RAS 
inhibitor angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), MRA 
mineralocorticoid receptor antagonists, OR odds ratio, BMI body mass index, BP blood pressure, NYHA New 
York Heart Association classification, eGFR estimated glomerular filtration rate, COPD chronic obstructive 
pulmonary disease, – variable not included in the model 
The results of multivariable analysis on guideline-directed pharmacotherapy in 
octogenarians with HFrEF are presented in Table 4. Lower prescription rates of 
recommended RAS inhibitors were associated with higher age, NYHA class and heart 
rate, wider QRS, and also HFmrEF (versus HFrEF). Higher prescription rates of RAS 
inhibitors and diuretics were related to hypertension. Lower prescription of RAS 
inhibitors but higher use of beta blocker was associated with the presence of renal 
3
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failure. MRA use was not associated with these comorbidities. Prescription rates of 
recommended HF medication were not independently associated with ischemic etiology 
of HF, diabetes mellitus 2 and COPD.
Digoxin was prescribed in one fifth of elderly HFrEF patients (21.4%), amiodarone in 7.7% 
and statins in 69.8%. Polypharmacy including beta blocker, RAS inhibitor, MRA, ivabradine, 
diuretics, statin, digoxin and amiodarone, median 4 of these drugs, was only slightly related 
to prescription of recommended beta blocker, RAS inhibitor and MRA (Suppl. Table 6).
Medical treatment of HFmrEF patients
In the 570 patients with HFmrEF aged ≥ 80 years, beta blockers, RAS inhibitor and MRA 
were prescribed in 72.5%, 67.6% and 49.1% of elderly HFmrEF patients, respectively. 
These proportions did not differ much from those in HFrEF patients (Table 2). Also, the 
percentages of the combined beta blocker, RAS inhibitor and/or MRA use in HFmrEF 
patients, aged ≥ 80 years, were only slightly lower than in HFrEF octogenarians, for men 
and women (Fig. 3). Statins, digoxin and amiodarone were prescribed in 66.3%, 22.0% 
and 5.4% of HFmrEF patients, respectively.
Fig. 3 Percentage of beta blocker, RAS inhibitor and/or MRA use in HFrEF and HFmrEF patients aged ≥ 80 
years for men and women. HFrEF heart failure with reduced ejection fraction, HFmrEF heart failure with 
mid-range ejection fraction, RAS renin–angiotensin system, RAS inhibitor angiotensin-converting enzyme 
(ACE) inhibitor or angiotensin receptor blocker (ARB), MRA mineralocorticoid receptor antagonists, ESC 
European Society of Cardiology
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Medical treatment of HFpEF patients
In the 911 HFpEF patients aged ≥ 80 years, diuretics were used by most frequently 
(91.2%), followed by beta blockers (74.3%), RAS inhibitors (62.0%) and MRAs (44.6%). 
Proportions of beta blockers, RAS inhibitors, MRA and diuretics did not differ much 
from those in HFrEF patients. Digoxin was prescribed in one fifth of elderly HFpEF 
patients (20.4%); and ivabradine and amiodarone in very few patients, 0.5% and 
9.6%, respectively.
The subgroup of HF with supernormal LVEF (LVEF > 65%; HFsnEF) in our CHECK-HF 
octogenarians contained only 58 patients (1.7%), see Suppl. Table 7. This new entity 
compromised too small patients group to make inferences and was not further included 
in the analyses.
Discussion
From our Dutch outpatient registry of chronic HF patients, we demonstrated that most 
octogenarians received recommended HF medication, although at lower percentages 
of target doses than previously reported in the entire group, except for MRAs. 20 Also, 
all three of the HF medications (beta blocker, RAS inhibitor and MRA) were prescribed 
in only about one quarter of octogenarians with HFrEF. Notably, women received more 
often beta blockers and thiazides than men.
The guidelines do not recommend specific HF therapies in patients with HFmrEF and 
HF medication did not differ significantly from HFrEF patients.
In the HFpEF group aged ≥ 80 years, prescription rates of diuretics were higher than 
90%. A substantial proportion received also a beta blocker, RAS inhibitor or MRA, likely 
to be related to the treatment of prevalent comorbidities. Due to clinical referral to 
out-hospital heart failure clinics, irrespective of patients’ age, CHECK-HF contains a 
relatively high percentage of patients with HFrEF (overall 52% and in octogenarians: 
58%) in comparison to the prevalence of HFpEF in Western populations. Although, the 
National Audit for England and Wales also reported that substantially more HFrEF than 
HFpEF patients (66.8% and 33.2%, respectively) were included in their registry (2016–
2017), e.g., after a hospital admission for heart failure. 21
3
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Pharmacological therapy
Elderly patients constitute a large part of the HF population in Western countries, 
1–4 but only few studies addressed HF pharmacologic management of patients aged 
≥ 80 years 11–17. In the Euro Heart Failure Survey (EHFS) II, both mortality rates of 
octogenarians during hospital stay and during follow-up of 12 months were significantly 
higher than in younger patients. 12 Notably, from the consecutive EHFS programs, a 
gradual improvement, though still suboptimal, of medical therapies in octogenarians 
hospitalized for HF was reported. The presence of comorbidities predicted mortality 
and the use of ACE inhibitors and beta blockers were associated with better outcome. 
11, 12 The French OCTOCARDIO study found that even in the absence of comorbidity, in 
elderly patients with HF, ACE inhibitors and beta blockers were prescribed to only 40% 
and 48% of patients, respectively, probably because of their advanced age alone. 13 
Data from a French national observational retrospective cohort of 1825 patients aged 
> 80 years who were for the first time hospitalized for HF demonstrated that only 5% 
of them received an optimal treatment at discharge (combination of RAS inhibitor, 
beta blocker and MRA). 14 During their follow-up period of 2 years, only beta-blocker 
prescription levels (p = 0.02) increased. In the CHECK-HF registry in chronic HF, about 
one third of patients were aged ≥ 80 years, thus resembling contemporary real-world 
practice in civilized countries. We found higher prescription rates of recommended HF 
medication than in these previous registries, which may be related to the delivery of 
specialist outpatient HF care in the vast majority of patients. However, in a substantial 
part of the HFrEF group, the actual dosages were lower than in younger patients. 20
Many factors may play a role in suboptimal therapy in the very old HF patients. In 
CHECK-HF, lower rates of guideline-directed pharmacotherapy in octogenarians with 
HFrEF were associated with NYHA class, LVEF and comorbidities. Lower prescription 
rates and tolerable dosages of recommended HF medication may be attributed to 
several limiting factors, e.g., low blood pressure and renal failure. 27 Also, recent data 
from the CHAMP-HF registry of in total 3518 patients from 150 primary care and 
cardiology practices showed that lower medication utilization or dose was associated 
with older age, lower blood pressure, more severe functional class, renal insufficiency, 
and recent HF hospitalization. 18 Remarkably, a recent post hoc analysis of the BIOSTAT-
CHF study suggested that women with HFrEF might need lower doses of RAS inhibitors 
and beta blockers than men, also adjusted for age. 22
The Swedish Heart Failure Registry reported that 80% of HFrEF patients with age > 
80 years used RAS inhibitors, which was associated with reduced morbidity and 
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mortality in this observational study. 16 Also, the use of beta blockers was associated 
with improved all-cause and CV survival. 17 So, suboptimal use of HF medication may 
lead to worse clinical outcomes. Also, only 40% patients of the total HFrEF cohort of 
that registry (11,215 patients, 27% women; mean age 75 ± 11 years) received a MRA. 
23 Notably, the underuse of MRA was not related to hyperkalaemia, but among other 
factors, to impaired renal function, even in the range of a creatinine clearance 30–59.9 
ml/min, which is not a contraindication for MRA use. Adherence to guideline-directed 
therapy of HFrEF, with prescription of at least 50% of the target dosage, is associated 
with better outcome; 6,24–27 although, this association has not been proven for very 
elderly HF patients. In the QUALIFY international registry, mainly younger patients were 
included and both mean age and age ≥ 74 years did not influence adherence to (ESC 
2012) guideline-directed medical therapy in HFrEF patients.
In addition, other age-related factors, particularly frailty, cognitive impairment and 
polypharmacy may contribute to suboptimal therapy of elderly HF patients. 28. In 
previous randomized clinical trials, patients aged ≥ 75 years were underrepresented. 7-10 
Consequently, there is no conclusive evidence that targeting at high dosages of medical 
therapy is equally beneficial in octogenarians compared with younger HFrEF patients 
and this may be another important reason for a lower uptake of HF medication in 
octogenarians. Awareness and assessment of comorbidities, and adequate management 
of these, may improve tailored HF care of the elderly patients. 29 In addition, reflection 
on optimal management and accepting lower age-adjusted target, tolerable dose of 
HF medication in elderly, may also be advocated. Accordingly, patient preferences and 
caregiver perceptions may influence therapeutic decisions in older HF patients. 30
In HFpEF, there are unmet needs for evidence-based therapies in general and in 
elderly patients in particular, because of the steeply increasing prevalence with age. 
Interestingly, in the Swedish Heart Failure Registry, the use of RAS antagonists and 
beta blockers in HFpEF was associated with lower all-cause mortality. 31, 32 However, 
observational associations in HF have limited potential to make reliable therapeutic 
inferences, because (residual) confounding cannot be excluded. 33
Limitations and strengths
The CHECK-HF registry is a large-scale real-word registry of heart failure outpatient 
clinics in the Netherlands reflective of Western European countries. However, some 
limitations should be mentioned, such as the cross-sectional design and there were 
3
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no outcome data collected. In addition, some missing data exist, which might influence 
results. However, imputation of missing data in multivariable analyses did not influence 
results. The etiology of heart failure was judged by the physician of the participating 
centers. Our registry included only patients seen in secondary, but not in primary 
care, which limits the generalizability of our findings to the primary care setting. Data 
on high age-related factors, e.g., frailty, cognitive impairment, dementia and disability 
were not collected, which may limit the understanding of the reason of not following 
the guidelines. Hardly any information was available for the use of sacubitril/valsartan, 
since it was approved in the Netherlands only in June 2016. Also, the use of oral nitrates 
(isosorbide-dinitrate or isosorbidemononitrate) combined with hydralazine is so low in 
the Netherlands that data was not collected. Strengths of the study are the reflection of 
the true practice of nationwide out-patient HF management and the high percentages 
of elderly patients with detailed information on medication prescription and dosage.
Conclusion
In this Dutch real-world registry of outpatient HF population, the majority of 
octogenarians received evidence-based HF medication, but at lower doses than 
recommended and only a minority received all three of the HF medication (beta blocker, 
RAS inhibitor (ACE inhibitor or ARB) and MRA). Analyses of clinical variables, including 
higher rates of comorbidities and reported contraindications and tolerances, did not 
fully explain the underuse of recommended HF therapies in octogenarians with HFrEF. 
Thus, future research should lead to strategies to improve management of elderly HF 
patients. Both in the HFmrEF group and the HFpEF group, in which evidence-based 
therapies are lacking, prescription rates of diuretics were also high and a substantial 
part of them received a beta blocker, RAS inhibitor and MRA.
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ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; MRA, mineralocorticoid receptor antagonist
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Suppl. Table 3. Heart rate, QRS-duration and LBBB according to heart rhythm
Overall HFrEF (n=2009) HFmrEF (n=570) HFpEF (n=911) p-value
Sinus rhythm (n=1583)
Heart rate 68.0 [61.0-76.0] 68.0 [61.0-76.0] 66.0 [60.0-75.0] 68.0 [60.0-76.0] 0.49
QRS ≥130 ms 468 (35.1) 359 (43.1) 51 (27.3) 58 (18.5) <0.01
LBBB 327 (20.7) 253 (25.7) 34 (15.2) 40 (10.7) <0.01
Atrial fibrillation (n=1371)
Heart rate 75.0 [65.0-85.0] 75.0 [65.0-85.0] 76.0 [65.0-86.0] 75.0 [66.0-85.0] 0.92
QRS ≥130 ms 322 (30.0) 200 (38.8) 64 (29.8) 58 (16.9) <0.01
LBBB 201 (14.7) 130 (19.5) 38 (14.2) 33 (7.6) <0.01
Paced rhythm (n=438)
Heart rate 70.0 [62.0-80.0] 70.0 [63.0-80.0] 72.0 [64.5-80.0] 72.0 [64.5-80.0] 0.33
QRS ≥130 ms 306 (86.2) 203 (88.6) 46 (86.8) 57 (78.1) 0.07
LBBB 53 (12.1) 39 (13.4) 5 (7.7) 9 (11.0) 0.42
Ectopic rhythm (n=53)
Heart rate 72.0 [60.0-87.5] 74.0 [59.5-93.4] 70.0 [62.0-75.5] 71.0 [57.0-80.0] 0.72
QRS ≥130 ms 24 (46.2) 17 (53.1) 3 (33.3) 4 (36.4) 0.44
LBBB 11 (20.8) 9 (27.3) 1 (11.1) 1 (9.1) 0.32
LBBB, Left Bundle Branch Block; HFrEF, Heart Failure with reduced Ejection Fraction; HFmrEF, Heart Failure 
with mid-range Ejection Fraction; HFpEF, Heart Failure with preserved Ejection Fraction.
Suppl. Table 4a.Prescription rates according to duration of HF follow-up in HFrEF patients
HF-medication < 1 year HF
follow-up





Beta-blocker 180 (81.4) 327 (80.5) 1,047 (77.1) 0.16
RAS-inhibitor 158 (71.5) 287 (70.7) 1,001 (73.7) 0.43
MRA 136 (61.5) 230 (56.7) 665 (49.0) <0.01
Ivabradine 7 (3.2) 12 (2.9) 36 (2.6) 0.87
Diuretics 201 (91.0) 369 (90.9) 1,225 (90.2) 0.88
Loop diuretics 198 (89.6) 359 (88.4) 1,196 (88.1) 0.81
Thiazide diuretics 3 (1.4) 12 (3.0) 36 (2.7) 0.46
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Suppl. Table 4b. Prescription rates according to duration of HF follow-up in HFmrEF patients
HF-medication < 1 year HF
follow-up





Beta-blocker 57 (73.1) 92 (73.6) 260 (72.4) 0.97
RAS-inhibitor 50 (64.1) 88 (70.4) 242 (67.4) 0.64
MRA 46 (59.0) 71 (56.8) 160 (44.6) 0.01
Ivabradine 1 (1.3) 4 (3.2) 5 (1.4) 0.39
Diuretics 72 (92.3) 112 (89.6) 323 (90.0) 0.79
Loop diuretics 70 (89.7) 108 (86.4) 317 (88.3) 0.76
Thiazide diuretics 3 (3.8) 4 (3.2) 7 (1.9) 0.53
Suppl. Table 4c. Prescription rates according to duration of HF follow-up in HFpEF patients
HF-medication < 1 year HF
follow-up





Beta-blocker 83 (75.5) 153 (75.7) 426 (73.6) 0.80
RAS-inhibitor 51 (46.4) 127 (62.9) 376 (64.9) <0.01
MRA 67 (60.9) 116 (57.4) 214 (37.0) <0.01
Ivabradine 1 (0.9) 1 (0.5) 3 (0.5) 0.87
Diuretics 107 (97.3) 196 (97.0) 509 (87.9) <0.01
Loop diuretics 107 (97.3) 193 (95.5) 482 (83.2) <0.01
Thiazide diuretics 1 (0.9) 3 (1.5) 29 (5.0) 0.02
HF, Heart Failure; HFrEF, Heart Failure with reduced Ejection Fraction; HFmrEF, Heart Failure with mid-
range Ejection Fraction; HFpEF, Heart Failure with preserved Ejection Fraction; RAS, Renin-Angiotensin 
System; RAS-inhibitor, angiotensin-converting-enzyme (ACE)-inhibitor or angiotensin-receptor-blocker 
(ARB); MRA, Mineralocorticoid Receptor Antagonists.
Suppl. Table 5. Reasons for not prescribing HF medication in HFrEF patients aged > 80 years in men and women
Contraindicated or intolerance No reason specified
Beta-blocker Men 57 (4.0) 234 (16.3)
Women 42 (3.8) 151 (13.7)
RAS-inhibitors Men 124 (8.6) 268 (18.6)
Women 65 (5.9) 263 (23.8)
MRA Men 96 (6.7) 618 (43.0)
Women 62 (5.6) 458 (41.5)
Ivabradine Men 28 (1.9) 1,373 (95.5)
Women 27 (2.4) 1,048 (94.9)
HF, Heart Failure; HFrEF, Heart Failure with reduced Ejection Fraction; RAS, Renin-Angiotensin System; 
RAS-inhibitor, angiotensin-converting-enzyme (ACE)-inhibitor or angiotensin-receptor-blocker (ARB); MRA, 
Mineralocorticoid Receptor Antagonists
3
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Suppl. Table 6. Multivariable predictors of the use of HF medication and polypharmacy in HFrEF patients 
aged > 80 years
Beta-blocker RAS-inhibitor MRA Diuretics
OR OR OR OR
Univariable
Polypharmacy * 1.10 [0.97-1.24] 0.98 [0.88-1.10] 1.04 [0.93-1.16] 1.39 [1.15-1.68]
Multivariable
Polypharmacy * 1.09 [0.96-1.23] 1.07 [0.89-1.14] 1.05 [0.93-1.18] 1.40 [1.15-1.71]
Female gender 1.32 [1.03-1.69] - - -
Age (per 10 y) - 0.63 [0.48-0.84] - -
BMI (kg/m2) - - - 1.06 [1.01-1.12]
Systolic BP (per 10 mmHg) - 1.09 [1.02-1.16] 0.80 [0.75-0.85] -
Diastolic BP (per 10 mmHg) - - - 0.78 [0.64-0.94]
NYHA-class (per class) - - - 2.11 [1.52-2.93]
Heart rate (per 10 bpm) - 0.82 [0.76-0.89] - -
QRS-duration (per 10 ms) - 0.97 [0.94-0.99] - -
eGFR (per 10 ml/min) - - - 0.85 [0.76-0.95]
Ischemic etiology - - - -
Hypertension - - - -
Diabetes mellitus type 2 - - - -
COPD - - - -
Renal failure - 0.73 [0.55-0.98] - 2.01 [1.22-3.32]
* is the number of drugs (beta-blockers, RAS-inhibitors, MRA, ivabradine, diuretics, statine, digoxine or 
amiodarone); exclusive the HF medication in the model (e.q. in the model of beta-blocker, beta-blocker is 
not included in the polypharmacy count.
OR of polypharmacy indicate the OR per extra drug
HF, Heart Failure; HFrEF, Heart Failure with reduced Ejection Fraction; RAS, Renin-Angiotensin System; 
RAS-inhibitor, angiotensin-converting-enzyme (ACE)-inhibitor or angiotensin-receptor-blocker (ARB); MRA, 
Mineralocorticoid Receptor Antagonists; OR, odds ratio; BMI, Body Mass Index; BP, Blood Pressure; NYHA 
New York Heart Association classification; eGFR estimated Glomerular Filtration Rate; COPD, Chronic 
Obstructive Pulmonary Disease
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Impact of sex-specific target 
dose in chronic heart failure 
patients with reduced
ejection fraction
Veenis JF, Brunner-La Rocca HP, Linssen GCM, Erol-Yilmaz A, Pronk ACB, Engelen DJM, 
Van Tooren RM, Koornstra-Wortel HJJ, De Boer RA, Van der Meer P, Hoes AW, Brugts JJ
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Abstract
Aims: A recent study suggested that women with heart failure and heart failure reduced 
ejection fraction might hypothetically need lower doses of angiotensin-converting 
enzyme inhibitors or angiotensin II receptor blockers (= renin-angiotensin-system 
inhibitors) and β-blockers than men to achieve the best outcome.We assessed the 
current medical treatment of heart failure reduced ejection fraction in men and women 
in a large contemporary cohort and address the hypothetical impact of changing 
treatment levels in women.
Methods: This analysis is part of a large contemporary quality of heart failure care 
project which includes 5320 (64%) men and 3003 (36%) women with heart failure 
reduced ejection fraction. Detailed information on heart failure therapy prescription 
and dosage were collected.
Results: Women less often received renin-angiotensin-system inhibitors (79% vs 
83%, p<0.01), but more often b-blockers (82% vs 79%, p<0.01) than men. Differences 
in guideline-recommended target doses between sexes were relatively small. 
Implementing a hypothetical sex-specific dosing schedule (at 50% of the current 
recommended dose in the European Society of Cardiology guidelines in women 
only) would lead to significantly higher levels of women receiving appropriate dosing 
(β-blocker 87% vs 54%, p<0.01; renin-angiotensin-system inhibitor 96% vs 75%, p<0.01). 
Most interestingly, the total number of women with >100% of the new hypothetical 
target dose would be 24% for b-blockers and 52% for renin-angiotensin-system 
inhibitors, which can be considered as relatively overdosed.
Conclusion: In this large contemporary heart failure registry, there were significant but 
relatively small differences in drug dose between men and women with heart failure 
reduced ejection fraction. Implementation of the hypothetical sex-specific target dosing 
schedule would lead to considerably more women adequately treated. In contrast, we 
identified a group of women who might have been relatively overdosed with increased 
risk of side-effects and intolerance.
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Introduction
The overall enrolment of women in clinical trials investigating treatment and outcome 
in heart failure (HF) is generally low and, accordingly, women are underrepresented in 
these trials as compared to the real-world.1 Studies on optimal dose in HF with reduced 
ejection fraction (HFrEF) are scarce and the number of included women was low.2,3 
Likewise, the European Society of Cardiology (ESC) HF guidelines provide no sex-specific 
recommendations.4 Recently, the hypothesis has been suggested that women with 
HFrEF might need lower dose of angiotensin-converting enzyme inhibitors (ACE-is), 
angiotensin II receptor blockers (ARBs) and β-blockers than men, which brings into 
question what the true optimal level of drug therapy is for women.5 Whereas men 
obtained the maximal reduction of mortality and HF hospitalization at the guideline 
recommended target dose of β -blockers, ACE-Is and ARBs. In male HFrEF patients, not 
achieving target dose is equal to not achieving maximum treatment benefit.
In contrast, in women the largest treatment benefit was already observed at 50% 
of recommended target dose, achieving 30% lower overall cardiovascular risk (all-
cause mortality or hospitalization for HF). At higher doses, no additional benefit was 
observed in women, therefore the hypothesis is that maximum benefit can be achieved 
at 50% of target dose at no further expense of intolerance of side-effects.5 The clinical 
impact of this post-hoc analysis can be considerable but should be assessed in large 
contemporary HFrEF cohorts.
The Chronisch Hartfalen ESC-richtlijn Cardiologische praktijk Kwaliteitsproject HartFalen 
(CHECK-HF) registry is a large scale (n=8323) contemporary and well defined Dutch 
cohort of HFrEF patients,6,7 enabling us to assess the impact of adopting the hypothetical 
sex-specific dose schedule in a real-world outpatient setting.
Methods
The design and methods of the CHECK-HF registry have been published in detail earlier.6,7 
Briefly, the CHECK-HF study is a large contemporary crosssectional observational 
cohort, including a total of 10,910 chronic HF patients from 34 participating Dutch 
centres between September 2013–September 2016. All patients were diagnosed 
and treated according to the 2012 ESC HF guidelines,8 and almost all were seen at a 
dedicated outpatient HF clinic (96%). Detailed information on patient characteristics, 
echocardiographic parameters and HF therapy, including HF drug prescription, dose, 
4
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contraindication and intolerance, as well as device therapy were recorded. This study 
was conducted according to the Helsinki Declaration, and was approved by the medical 
ethics committee in 2017 at the Maastricht University Medical Center (Maastricht, the 
Netherlands). Patients were not involved in the research process.
Left ventricular function, assessed during the most recent outpatient clinical visit, was used 
to categorise HF patients. Patients were categorised based on left ventricle ejection fraction 
(LVEF) or visual assessment of left ventricle (LV) function into HFrEF (LVEF<50% (n=8360 
(76.6%)) and HF with preserved ejection fraction (HFpEF) (LVEF≥50% (n=2267 (20.8%)). In 
283 patients, recording of LV function in the database was insufficient to classify patients 
into HF type. In addition, standard baseline demographic data was missing in 37 additional 
HFrEF patients, leaving 8323 HFrEF patients to be included in the analysis.
For a sub-analysis according to the newer 2016 ESC HF guidelines,4 patients with an 
assessed LVEF<50% were categorised into HF with mid-range ejection fraction (HFmrEF) 
(LVEF 40–49% (n=1571 (18.9%)) and HFrEF (LVEF<40% (n=5677 (68.2%), only in those 
patients with a exactly specified LVEF or into patients with only a semi-quantitative 
analysis of LV function (n=1075 (12.9%)).
In order to investigate the impact of the hypothetical sex-specific dose schedule of 
b-blockers and reninangiotensin-system inhibitors (RAS-is) (i.e. ACE-is or ARBs), we 
analysed the prescribed dosages expressed as a percentage of the recommended target 
dose and of the hypothetical target dosage (50% of the guideline recommend target 
dose) in women. Target doses of guideline-recommended HF therapy are presented in 
Supplementary Material Table 1 and in line with the ESC HF guidelines.4
Statistical analysis
Continuous data are expressed as mean value±standard deviation (SD) or median 
and interquartile range, depending on the distribution of the data, and compared by 
one-way analyses of variance (ANOVAs) or Mann-Whitney U-test. Categorical data are 
expressed as counts and percentages, and compared by the Pearson Chi-square test. 
The prescribed dosages are expressed as a percentage of the recommended target 
dose. The differences between the recommended and newly suggested target dose 
were compared by the McNemar test.
Multivariable predictors of HF medication use were assessed using multivariable 
logistic regression analysis. All predictors of medication use in univariable analysis at 
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a p-value of <0.10 were included in a forward step manner in the multivariable logistic 
regression analysis. Results of logistic regression are presented as odds ratio (ORs) with 
95% confidence intervals (CIs).
For variables with missing data in the multivariable analysis, we used multiple 
imputation modelling. If the missing variables showed a monotone pattern of missing 
values, the monotone method was used, otherwise, an iterative Markov chain Monte 
Carlo method was used with a number of 10 iterations. A total of five imputations was 
performed, and the pooled data were analysed. All analyses were performed with SPSS 
Statistical Package version 25.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Baseline characteristics of men and women with HFrEF are presented in Table 1.
Table 1. Patient characteristics in heart failure with reduced ejection fraction (HFrEF) patients.
Men (n=5320) Women (n=3003) p-value
Age (years) (n=8314) 71.6 ± 11.4 73.4 ± 12.4 <0.01
BMI, kg/m2 (n=7638) 27.3 ± 4.8 27.1 ± 5.8 0.32
NYHA (n=8226)
I 913 (17.4) 395 (13.3)
<0.01
II 3000 (57.1) 1671 (56.2)
III 1248 (23.8) 850 (28.6)
IV 90 (1.7) 59 (2.0)
LVEF, % (n=6154) 32.2 ± 10.4 33.5 ± 10.8 <0.01
Cause of HF (n=8058)
Ischemic 3016 (58.5) 1149 (39.6)
<0.01
Non-ischemic 2137 (41.5) 1756 (60.4)
Systolic BP, mmHg (n=8209) 125.3 ± 20.5 126.4 ± 21.0 0.02
Diastolic BP, mmHg (n=8215) 71.5 ± 11.3 70.7 ± 11.4 <0.01
Heart rate, bpm (n=8211) 71.2 ± 13.7 73.5 ± 14.0 <0.01
Atrial fibrillation (n=8216) 1366 (26.0) 734 (24.8) 0.25
LBBB (n=8323) 838 (15.8) 574 (19.1) <0.01
QRS ≥130 ms (n=6908) 1877 (42.5) 887 (35.7) <0.01
eGFR (n=5883) 61.4 ± 24.8 56.6 ± 24.0 <0.01
eGFR (n=5883)
<30 364 (9.8) 303 (14.0)
<0.0130-59 1510 (40.6) 932 (43.0)
≥60 1844 (49.6) 930 (43.0)
4
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Table 1. (continued)
Men (n=5320) Women (n=3003) p-value
Comorbidities (n=7459)
Hypertension 1801 (37.9) 1168 (43.2) <0.01
Diabetes Mellitus 1380 (29.0) 789 (29.2) 0.87
COPD 904 (19.0) 466 (17.2) 0.06
OSAS 401 (8.4) 92 (3.4) <0.01
Thyroid disease 257 (5.4) 300 (11.1) <0.01
BMI: body mass index; BP: blood pressure; COPD: chronic obstructive pulmonary disease; eGFR: estimated 
glomerular filtration rate; HF: heart failure; LBBB: Left Bundle Branch Block; LVEF: left ventricular ejection 
fraction; NYHA: New York Heart Association; OSAS: obstructive sleeping apnoea syndrome.
Pharmacological therapy in HFrEF
Female HFrEF patients significantly less often received a RAS-i (78.9% vs 82.6%, p<0.01) 
and more often β-blockers (82.0% vs 79.1%, p<0.01), ivabradine (5.2% vs 4.2%, p¼0.04) 
and diuretics (85.0% vs 81.6%, p<0.01) compared to male HFrEF patients (Figure 1(a)). 
Of the women that received a RAS-i, a significantly lower percentage received the 
guideline-recommended target dose (74.8% vs 76.1%, p=0.01) as compared to men 
(Figure 1(b)). Triple HF therapy, consisting of β -blocker, RAS-i and mineralocorticoid 
receptor antagonist (MRA) (at indication), as well as triple therapy prescribed at ≥50% 
of the guideline-recommended target dose, were equally prescribed in women and 
men (Figure 1(c) and (d)). No sex-specific significant differences in the number of 
reported contraindications or intolerances were observed, although the numbers 
of contraindications and intolerances were very low in both groups (Supplementary 
Material Table 2).
Predictors of prescription and target dose of HF therapy
In the multivariable regression analysis, lower age and the presence of hypertension 
were significant predictors of prescription of β-blockers; lower age, male gender and 
renal insufficiency were significant predictors of prescription of a RAS-i; and lower 
age, higher New York Heart Association (NYHA)-classification and lower systolic blood 
pressure were significant predictors of prescription of MRAs (Table 2). In multivariate 
analysis, the chance of receiving the guideline-recommended target dose of a RAS-i 
was independently related to male gender, while the chance of receiving the guideline-
recommended target dose of MRA was independently related to female gender (Table 
3). Multiple imputations did not change the results (data not shown).
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Figure 1. (a) Heart failure (HF) therapy usages; (b) prescribed dosages expressed as a percentage of rec-
ommended target dose; (c) triple therapy prescribed; and (d) triple therapy at ≥50% of the recommended 
target dose prescribed in men and women.
RAS-i: renin-angiotensin-system inhibitor; MRA: mineralocorticoid receptor antagonist.
4
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Table 3. Multivariable predictors of receiving guideline-recommended target dose of HF medication in 
HFrEF patients in relation to gender.
β-blocker RAS-i MRA
Univariable Gender 1.03 [0.90-1.17] 0.88 [0.80-0.98] 1.35 [1.19-1.52]
Multivariable
Gender 1.00 [0.83-1.22] 0.87 [0.76-0.99] 1.34 [1.01-1.11]
Age
(per 10 years increase)
0.87 [0.80-0.94] 0.86 [0.81-0.91] -
BMI 1.02 [1.00-1.04] 1.03 [1.02-1.04] 1.03 [1.01-1.12]
LVEF - - -
NYHA classification - 0.81 [0.73-0.90] -
Ischemic etiology HF 0.81 [0.67-0.98] - -
Systolic blood pressure 
(per 10 mmHg increase)
- 1.24 [1.20-1.29] 0.91 [0.88-0.95]
Diastolic blood pressure 
(per 10 mmHg increase)
1.19 [1.09-1.29] - -
Heart rate
(per 10 beats/min 
increase)
- 0.95 [0.91-1.00] 1.06 [1.01-1.11]
QRS duration
(per 10 ms increase)
- - 1.03 [1.01-1.05]
eGFR
(per 10 ml/min increase)
- - -
Hypertension 1.33 [1.10-1.60] 1.38 [1.21-1.58] -
Diabetes mellitus 1.30 [1.06-1.59] - 1.17 [1.00-1.36]
MI: body mass index; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration 
rate; HF: heart failure; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; 
NYHA: New York Heart Association.
This table shows the results from the univariable logistic regression analysis, demonstrating the likelihood 
of prescribing the guideline-recommended target dose of HF drugs in women over men. Additionally, it 
demonstrates the likelihood of prescribing the guideline-recommended target dose of HF drugs in women 
over men adjusted in the full multivariable model. - indicates variable not included in the model.
Clinical impact of new hypothetical sex-specific target dose schedule
Using the hypothetical sex-specific target doses (at 50% of the current recommended dose 
in the ESC guidelines in women only), leads to an considerable increase in the number of 
women who received the target dose for β-blockers (87.2% vs 53.6%, p<0.01) and RAS-is 
(96.0% vs 74.8%, p<0.01) (Figure 2(a)). A large number of women might be relatively 
overdosed, 23.5% of women received >100% of the hypothetical target dose for 
β-blockers and 52.1% for RAS-is, in our study. A significant increase in women receiving 
both HF drugs (with indication) at ≥50% of the new hypothetical target dose (56.3% vs 
29.5%, p<0.01) was observed (Figure 2(b)).
4
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Figure 2. Impact of the newly proposed sex-specific target dose strategy (a) prescribed dosages expressed 
as a percentage of the guideline and newly proposed target dose of β-blockers and renin-angiotensin-sys-
tem inhibitors (RAS-is), and (b) dual therapy at ≥50% of the guideline and newly proposed target dose 
prescribed in women.
>
146122_Veenis,Jesse_BNW-def .indd   80 13-11-2020   14:37
81
Heart failure therapy according to sex
Analysis in patients with HFmrEF according to 2016 ESC guidelines
A sub-analysis studying the different cut-off of HFmrEF and HFrEF according to the ESC 
2016 guidelines does not change the inferences of this analysis (Supplementary Material 
Table 3, Supplementary Material Figure 1). Likewise, the subgroup of semiquantitative 
LV function showed similar differences (Supplementary Material Figure 1).
Discussion
The current analysis shows that HF treatment between men and women differs in this 
large real-world contemporary cohort of HFrEF patients. Women received lower doses 
of HF drugs compared to men. The level of the target dose of HF drugs or maximally 
tolerated levels has been frequently discussed and recently gained more attention 
from a study suggesting that the optimal dose level might be 50% lower in women 
compared with men at maximum sex-specific treatment benefit.5 This hypothesis has 
major implications for HF treatments in general, and we assessed the impact of this 
new hypothetical dose schedule in women.
In this patient sample, doctors were urged to titrate to guideline-recommended 
dosages, and this was successful in some, but not all, patients.
In male patients with HFrEF, the post-hoc analysis from BIOlogy Study to TAilored 
Treatment in Chronic Heart Failure (BIOSTAT-CHF) shows that male patients only achieve 
maximum treatment benefit at the full recommended target dose of HF medication. In 
women, the maximum treatment benefit was observed at 50% of the target dose with 
no further gain in benefit, with only futile risk of intolerance. Naturally, if lower dosages 
were accepted as ‘optimal’ in females, a much larger proportion of the female patients 
would be regarded as being treated optimally when 50% of the recommended dose 
would be regarded as optimal. Notably, this approach identifies a potential subgroup 
of women who are relatively overdosed (>100% dose in females) with an increased risk 
of side effects and intolerance at no incremental benefit of treatment.
Guideline adherence and sex
Women with a (non-ST-segment elevation) myocardial infarction receive the guideline-
recommended therapy less often.9,10 Additionally, sex-specific treatment strategies for 
these conditions have been proposed previously.10,11 Similarly, multiple registries have 
demonstrated sex-related differences in guideline adherence, with women less often 
receiving β-blockers,12 ACE-is,12–14 MRAs12 and more often ARBs15 and diuretics.1,12 The 
4
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current results of our analysis are in line with these previous registries, although sex-
specific differences particularly regarding guideline-recommended target doses were 
relatively small in CHECK-HF. Differences in patient characteristics could influence 
clinicians in their decision-making, but these differences do not fully explain the sex-
related differences in HF drug usage and dosages in our dataset.
Optimal doses of HF therapies in men versus women
Women are underrepresented in clinical trials investigating the efficacy of HF drugs, as 
only 10–40% of the patients included in these trials were women.16 Furthermore, only 
one trial investigated efficacy prospectively stratified by sex,17 while all other studies 
analysed sex-related effects retrospectively and in post-hoc analyses, limiting these 
results. In women, the use of ACE-is leads to a non-significant reduction in all-cause 
mortality and hospitalizations compared to placebo.18 The use of ARBs reduced all-cause 
mortality and hospitalizations in women compared to placebo.19 Women using β-blockers 
had a better clinical outcome compared to women receiving placebo therapy,20–22 and 
similar favourable treatment effects were seen in women using MRAs.23,24 Studies 
investigating the ideal target dose in HFrEF are scarce, especially in women,2,3 therefore 
a one-size-fits-all strategy is recommended in the ESC HF guidelines.4
Several sex-related pharmacological differences can cause differences in the efficacy of 
HF drugs between men and women. So differences in body weight, medication clearance 
rate and the effect of sex hormones contribute to higher plasma concentrations, and 
stronger effects of HF drugs in women.25,26 Additionally, it has been suggested that 
HF drugs might have a larger effect in women compared to men, even if the plasma 
concentrations are similar.27
HF therapy dose and sex
Data on the ideal dosages in women are scarce. Two post-hoc analyses from the 
Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL) and 
Assessment of Treatment with Lisinopril and Survival (ATLAS) trials demonstrated that a 
lower RAS-is dosage in women was equally effective, or even more effective, compared 
to higher dosages.2,28 In contrast, higher dosages of RAS-is were more effective in men. 
These results suggest that using a one-size-fits-all target dose could lead to overdosing 
in women. A sub-analysis from these trials investigating the potential overdosing and 
its effect would be of great interest, especially since a post-hoc analysis from the 
Digitalis Investigation Group (DIG) trial demonstrated that women had a higher serum 
concentration compared to men, although they used a slightly lower dose adjusted for 
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body-mass index.29,30 A similar effect has been seen in the use of β-blockers, with women 
having a higher serum concentration while using a similar dosage.25
New hypothetical target dose levels in women
Recently, a post-hoc analysis from the BIOSTAT-CHF study investigated whether sex-
related differences in the optimal dose of β-blockers and RAS-is for preventing all-
cause mortality and HF-related hospitalization exists in HFrEF patients, and validated 
the results in the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) dataset.5 
This post-hoc analysis demonstrated that in women a 30% risk reduction in all-cause 
mortality and HF-related hospitalizations can be obtained with approximately 50% of 
the recommended target dose of β-blockers and RAS-is, with no further decrease in 
risk at higher dose levels in BIOSTAT-CHF and ASIAN-HF validation cohorts. In contrast, 
in men the largest reduction was observed if 100% of the recommended target dose 
was reached. These results suggest that women with HFrEF might have similar clinical 
outcomes with lower doses of β-blockers and RAS-is than recommended in the ESC 
HF guidelines.4 Naturally, if lower target doses were accepted as optimal in women, a 
larger proportion of women would be regarded as treated optimally, in our registry. 
Additionally, we identified a large group of women who were potentially overdosed, 
possibly without an incremental benefit. It is generally believed that women are more 
often affected by drug-related adverse effects31–33 and differences in target doses could 
be an explanation for this. Unfortunately, we do not have adequate data on side-effects 
to support this statement from our study. In these women, the doses might be lowered, 
improving patient compliance and lowering intolerance rates.
Similar to these findings, specific guideline recommendations or target dosages 
might be warranted for different subgroups as well, for example specific guidelines 
for races or body mass index (BMI) category. However, these should be evaluated 
by additional research.
Limitations and strengths
Our study has some limitations. CHECK-HF has a cross-sectional design with no follow-
up data on patient outcomes. Other prospective studies integrating dose findings of 
HF therapy in women and outcome are needed. Still, our analysis shows the potentially 
large impact of the newly proposed target levels. In addition, for some variables a 
limited number of data were missing, however, after using multiple imputation this 
did not impact the results. Additionally, with changing HF categories based on LVEF in 
4
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the newer guidelines,4 our analysis was limited by a small number of patients where 
LV function was semi-quantitatively analysed with echocardiography. Strengths of the 
CHECK-HF registry include the large scale, contemporary (2016), and a reflection of the 
real-world practice of outpatient HF management in the Netherlands, representative of 
Western European countries. Furthermore, the availability of a large number of women 
with detailed information on medication prescription and dosage is important due to 
the lack of data in this subgroup, as previously noted.
Conclusion
In this large contemporary registry, drug dose significantly differed between men 
and women with HFrEF, although the differences where relatively small. As the first 
large HF study, we demonstrate the clinical impact of a hypothetical adjustment to a 
lower target dose schedule in women, by which more women would be considered 
adequately treated. On top of better adherence, this identifies a considerable large 
subgroup of women who are relatively overdosed in HF medication at no further 
reduction in CV risk but, rather, at higher risk of intolerance when the dose could have 
been further reduced.
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Supplementary Figure 1. HF therapy usages in A HFrEF patients (LVEF <40%) (n=5677), B HFmrEF (LVEF 
40-49%) (n=1571) and C semi-quantitative patients (n=1075) according to the 2016 ESC HF Guidelines in 
men and women
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Abstract
Background: Prescribed dosages of heart failure (HF) therapy in patients with a reduced 
left ventricular ejection fraction remain lower than guideline recommended. It remains 
unclear whether systolic blood pressure (BP) influences prescription of HF drugs to HF 
patients with a reduced left ventricular ejection fraction in a European setting. This 
study aimed to investigate the role of systolic BP on the prescription rate and actual 
dose of guideline-recommended HF therapy.
Methods: A total of 8246 patients with chronic HF with a reduced left ventricular ejection 
fraction from 34 Dutch outpatient HF clinics were included. Detailed information on 
prescription rates and dosages of HF drugs were assessed according to systolic BP 
categories (<95, 95–109, 110–129, and ≥130 mm Hg).
Results: Patients with systolic BP <95 mm Hg receive more often triple therapy 
(β-blocker, renin-angiotensin system inhibitor, and mineralocorticoid receptor 
antagonist; 40.3% versus 30.4% respectively, P<0.001) compared with ≥130 mm Hg. 
Patients with systolic BP <95 mm Hg received significantly more often mineralocorticoid 
receptor antagonists (64.5% versus 43.8%), ivabradine (8.3% versus 3.6%), and diuretics 
(94.2% versus 78.6%) and less often renin-angiotensin system inhibitors (75.4% versus 
82.8%) compared with ≥130 mm Hg (P for all trends, <0.001). The prescribed dosages of 
β-blockers and renin-angiotensin system inhibitors were significantly lower in patients 
with systolic BP <95 mm Hg compared with ≥130 mm Hg (P for all trends, <0.001).
Conclusions: In this large cross-sectional cohort of patients with reduced left ventricular 
ejection fraction, patients with lower systolic BP receive more HF drugs but at lower 
dose relative to the target dose recommended in HF guidelines. Discussion is warranted 
regarding what target BP is acceptable and what should be limiting factors in uptitration 
to adequate levels of HF medication.
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Introduction
The question as to whether treatment should be targeted based on blood pressure (BP) 
levels in chronic heart failure (HF) patients is still open for debate. Both hypotension and 
hypertension are associated with an increased risk of all-cause mortality and HF-related 
hospitalizations in chronic HF patients.1,2 Furthermore, symptomatic hypotension occurs 
more often in chronic HF patients treated with BP-lowering drugs, especially in those 
with initially lower BP.2,3 These results might influence the decision-making of clinicians 
to initiate additional guideline-recommended HF therapy or titrate HF drugs in chronic 
HF patients. Adequate control of BP and inducing minor orthostasis can be a marker 
of achieving the maximally tolerated dose of HF medication, which is recommended 
by the guidelines. However, symptomatic hypotension and side effects may lower 
compliance but might also affect prognosis, beyond identifying a group of patients 
with more advanced HF.
Recently the Change the Management of Patients With Heart Failure (CHAMP-HF) 
investigators demonstrated in a large American registry that <20% of HF patients 
received the guideline-recommended target doses of both β-blockers and renin-
angiotensin system (RAS) inhibitors, even in patients with higher systolic BP.4 
Accordingly, this may imply that low systolic BP hardly influences the prescription 
behavior in a real-world setting, but conformationally data and similar information 
in Europe are lacking. Therefore, it is important to compare the CHAMP-HF data 
with its counterpart in Europe, the Chronisch Hartfalen ESC-richtlijn Cardiologische 
praktijk Kwaliteitsproject HartFalen (CHECK-HF) registry with also large numbers of HF 
patients with reduced ejection fraction (HFrEF) with extensive detailed information on 
prescription rates and dosage of HF medication. The aim of this substudy of CHECK-
HF was to validate and extend the discussion on the role of BP in achieving optimal HF 
medication prescription and dosages.
Methods
The authors declare that all supporting data are available within the article and in 
the Data Supplement. The design and methods of the CHECK-HF registry have been 
published in detail elsewhere.5 Briefly, a total of 10 910 chronic HF patients from 
34 participating Dutch centers between 2013 and 2016 were included in this cross-
sectional observational cohort. All included patients were diagnosed with HF and 
treated according to the 2012 European Society of Cardiology (ESC) HF Guideline6 (Table 
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I in the Data Supplement) and were seen at an outpatient HF clinic (96%). Detailed 
information on patient characteristics, echocardiographic values, and guideline-
recommended HF drug prescription and dosages was recorded. The BP was assessed 
at the arteria brachialis of the upper arm, using an automated, cuffed BP machine 
during the outpatient clinic visit that was used for data entry in the study. The Meta-
Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score was calculated 
and used as an indicator of the severity of HF.7 The study was conducted according to 
the Declaration of Helsinki. Ethical approval was provided for anonymously analyzing 
existing patient data by the Ethical Committee of the Maastricht University Medical 
Center, the Netherlands.
Patients were divided based on left ventricular ejection fraction (LVEF) or visual 
assessment of the left ventricle into HF with reduced LVEF (LVEF <50% [n=8360, 76.6%]) 
and treated according to the 2012 ESC HF guidelines. Two thousand two hundred sixty-
seven patients were diagnosed with HF with preserved ejection fraction (LVEF ≥50% 
[20.8%]) and not included in this analysis. In 283 (2.6%) patients, recording of the left 
ventricular function in the database was insufficient to classify patients into HF type or 
standard baseline demographic data were missing, and they were excluded from this 
analysis. A total of 8246 patients with reduced LVEF were included in this analysis. For a 
subanalysis according to the newer 2016 ESC HF guidelines,8 patients with an assessed 
reduced LVEF <50% according to the 2012 ESC HF guidelines were categorized into HF 
with mid-range ejection fraction (HFmrEF; LVEF, 40%–49% [n=1556, 18.9%]) and HFrEF 
(LVEF <40% [n=5613, 68.1%]), only in those patients with an exactly specified LVEF. Those 
patients with no exact ejection fraction, we present separately as a semiquantitative 
patient group (n=1077 [13.1%]).
We subdivided systolic BP into 4 categories to have more insight in its relationship with 
HF drugs. Patients were divided into those with systolic BP <95 mm Hg (n=313 [3.8%]), 
95 to 109 mm Hg (n=1255 [15.2%]), 110 to 129 mm Hg (n=3252 [39.4%]), and ≥130 mm 
Hg (n=3426 [41.5%]). Additionally, we studied systolic BP in categories of <110 (n=1568 
[19.0%]) and ≥110 mm Hg (6678 [81.0%]) as performed in the CHAMP-HF analysis.4
Statistical Analysis
Continuous data are expressed as mean value±SD or median and interquartile range, 
depending on the distribution of the data and compared by the 1-way ANOVA or 
Mann-Whitney U test. Categorical data are expressed as counts and percentages and 
compared by the Pearson χ2 test.
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To investigate whether the observed differences between BP groups were independent 
of potential clinical predictors, univariable and multivariable logistic regression analyses 
were used, with systolic BP <95 mm Hg set as a reference. The results of these regression 
analyses are expressed as odds ratios with 95% CIs. A 2-sided P of 0.05 was considered 
statistically significant. In model 1, we adjusted for age and sex only. In model 2, we 
further adjusted for New York Heart Association classification and LVEF. In model 3, 
we further included all comorbidities using the forward step method in binary logistic 
regression with a P threshold of <0.10. Missing data occurred in the variables included 
in the multivariable analysis, which were imputed using multiple imputation as has 
been described previously.9 All analyses were performed with SPSS Statistical Package, 
version 25.0 (SPSS, Inc, Chicago, IL).
Results
The baseline characteristics of the 8246 patients with reduced LVEF are shown in Table 
1. The prescription rates of RAS inhibitors were lower in patients with systolic BP <95 
mm Hg (75.4% versus 82.8% respectively, P=0.001), while mineralocorticoid receptor 
antagonist (MRA; 64.5% versus 43.8% respectively, P<0.001), ivabradine (8.3% versus 
3.6% respectively, P<0.001), and diuretics (94.2% versus 78.6% respectively, P<0.001) 
were more often prescribed compared with ≥130 mm Hg (Figure 1A). Patients with 
systolic BP <95 mm Hg less often received the guideline-recommended target dose 
(in those prescribed) of β-blockers (8.3% versus 15.4% respectively, P<0.001) and RAS 
inhibitors (21.2% versus 44.6% respectively, P<0.001) and more often of MRA (39.6% 
versus 21.2% respectively, P<0.001) compared with ≥130 mm Hg (Figure 1B). Triple 
therapy, consisting of β-blocker, RAS inhibitor, and MRA, was prescribed in less than 
half of the overall population. Patients with systolic BP <95 mm Hg received more often 
triple therapy (40.3% versus 30.4% respectively, P<0.001; Figure 1C) but less often triple 
therapy at least at ≥50% of the target dose (9.6% versus 14.7% respectively, P=0.002; 
Figure 1D) compared with ≥130 mm Hg.
An analysis of the number of guideline-recommended HF therapy and the prescribed 
dosage according to combinations of mono, dual, and triple HF therapy in the different 
BP categories is shown in Table 2. In patients with systolic BP <110 mm Hg, patients with 
reduced LVEF more often receive triple therapy but also at lower overall target dose 
levels of β-blockers and RAS inhibitors.
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Age, y (n=8238) 72.3 ± 13.5 71.1 ± 12.5 72.3 ± 11.7 72.7 ± 11.4 0.001
Male gender (n=8209) 205 (65.7) 815 (65.4) 2081 (64.2) 2142 (62.8) 0.32
BMI, kg/m2 (n=7361) 25.8 ± 4.7 26.4 ± 4.8 27.1 ± 4.9 27.7 ± 5.5 <0.001
NYHA (n=8152)
I 22 (7.1) 160 (12.9) 459 (14.3) 653 (19.3)
<0.001
II 138 (44.5) 687 (55.3) 1854 (57.7) 1956 (57.8)
III 121 (39.0) 368 (29.6) 847 (26.4) 741 (21.9)
IV 29 (9.4) 28 (2.3) 52 (1.6) 37 (1.1)
LVEF, % (n=6077) 31.2 ± 12.2 31.0 ± 10.5 31.9 ± 10.5 34.1 ± 10.3 <0.001
Cause of HF (n=7994)
Ischemic 150 (49.7) 650 (53.9) 1642 (51.9) 1683 (50.6)
0.21
Non-ischemic 152 (50.3) 555 (46.1) 1520 (48.1) 1642 (49.4)
Systolic BP, mmHg (n=8246) 88.3 ± 4.7 101.9 ± 3.8 117.9 ± 5.6 145.1 ± 15.0 <0.001
Diastolic BP, mmHg (n=8241) 56.5 ± 7.2 62.8 ± 7.3 69.1 ± 8.5 77.6 ± 11.3 <0.001
Heart rate, bpm (n=8155) 73.9 ± 15.3 72.2 ± 14.4 71.8 ± 13.3 72.0 ± 14.0 0.08
Atrial fibrillation (n=8159) 93 (29.9) 336 (27.0) 839 (26.1) 825 (24.3) 0.05
QRS ≥130ms (n=6884) 118 (46.8) 426 (42.3) 1,089 (40.5) 1,115 (38.0) 0.006
eGFR, ml/min/1.73m2 (n=5835)
<30 44 (18.7) 115 (12.3) 254 (10.5) 245 (10.9)
<0.00130-59 108 (46.0) 373 (39.9) 1024 (42.2) 910 (40.7)
≥60 83 (35.3) 447 (47.8) 1149 (47.3) 1083 (48.4)
Comorbidities (n=7413)
Hypertension 84 (29.4) 332 (30.2) 1022 (35.4) 1513 (48.2) <0.001
Diabetes Mellitus 75 (26.2) 287 (26.1) 866 (30.0) 921 (29.3) 0.07
COPD 63 (22.0) 228 (20.8) 534 (18.5) 542 (17.3) 0.025
OSAS 23 (8.0) 72 (6.6) 188 (6.5) 207 (6.6) 0.80
Thyroid disease 21 (7.3) 76 (6.9) 217 (7.5) 236 (7.5) 0.92
Kidney insufficiency 200 (67.8) 651 (57.0) 1595 (56.1) 1464 (55.1) 0.001
MAGGIC score 28.6 ± 7.4 25.7 ± 7.2 24.4 ± 7.1 22.9 ± 6.8 <0.001
BMI indicates body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; eGFR, 
estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MAGGIC, 
Meta-Analysis Global Group in Chronic Heart Failure; NYHA, New York Heart Association; and OSAS, 
obstructive sleep apnea syndrome.
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Figure 1. Guideline recommended heart failure (HF) therapy according to systolic blood pressure.
A, Prescription rates of guideline-recommended HF therapy. B, Prescribed dosages expressed as a per-
centage of recommended target dose. C, HF combination therapy (β-blocker, renin-angiotensin system 
[RAS] inhibitor, or mineralocorticoid receptor antagonist [MRA]). D, HF combination therapy of at least 
≥50% of the recommended target therapy according to systolic blood pressure (BP).
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Patients with systolic BP <95 mm Hg had higher reported contraindication or intolerance 
rates for RAS inhibitors (41.6% versus 23.0% respectively, P=0.002) and MRA (12.6% 
versus 8.5% respectively, P=0.019) compared with ≥130 mm Hg (Table 3).
Table 3. Reasons for not prescribing HF medication according to systolic blood pressure
Contraindicated or 
intolerance
No reason specified P-value
Beta-blocker
Total population 259 (16.1) 1350 (83.9)
0.73
Systolic BP <95 13 (18.1) 59 (81.9)
Systolic BP 95-109 40 (15.7) 215 (84.3)
Systolic BP 110-129 93 (15.0) 528 (85.0)
Systolic BP ≥130 113 (17.1) 548 (82.9)
RAS-inhibitors
Total population 376 (24.7) 1144 (75.3)
0.002
Systolic BP <95 32 (41.6) 45 (58.4)
Systolic BP 95-109 71 (27.3) 189 (72.7)
Systolic BP 110-129 141 (23.2) 468 (76.8)
Systolic BP ≥130 132 (23.0) 442 (77.0)
MRA
Total population 383 (10.1) 3,427 (89.9)
0.019
Systolic BP <95 14 (12.6) 97 (87.4)
Systolic BP 95-109 45 (10.7) 376 (89.3)
Systolic BP 110-129 164 (11.7) 1239 (88.3)
Systolic BP ≥130 160 (8.5) 1715 (91.5)
BP indicates blood pressure; HF, heart failure; MRA, mineralocorticoid receptor antagonist; and RAS, 
renin-angiotensin system.
After multivariable adjustments, only patients with systolic BP ≥130 mm Hg had a 
lower likelihood to receive an MRA compared with <95 mm Hg (Table II in the Data 
Supplement). Patients with a systolic BP between 110 and 129 and ≥130 mm Hg had a 
significantly lower likelihood of receiving ivabradine. Furthermore, all systolic BP groups 
had a lower likelihood of receiving diuretics, compared with patients with systolic BP 
<95 mm Hg. After multivariable adjustment, the observed difference in prescription 
rates of RAS inhibitors attenuated.
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Figure 2. Guideline recommended heart failure (HF) therapy in the Change the Management of Pa-
tients With Heart Failure (CHAMP-HF) and Chronisch Hartfalen ESC-richtlijn Cardiologische praktijk 
Kwaliteitsproject HartFalen (CHECK-HF) registries according to systolic blood pressure.
A, Prescription rates of guideline-recommended HF therapy. B, Prescribed dosages expressed as a per-
centage of recommended target dose. MRA indicates mineralocorticoid receptor antagonist; and RAS, 
renin-angiotensin system.
≥ ≥
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CHAMP-HF Versus CHECK-HF
In Figure 2A, we compare the prescription rates of β- blockers, RAS, and MRA in the 
American CHAMP-HF registry and CHECK-HF registry according to the BP categories <110 
and >110 systolic BP as used in that subanalysis. The prescription rates and prescribed 
dose of HF drugs in HFrEF were slightly higher in the CHECK-HF registry as compared 
with CHAMP-HF.4 Both registries demonstrated a higher prescription rate for all HF 
drugs in patients with systolic BP <110 mm Hg compared with ≥110 mm Hg, although 
the absolute difference was bigger in the CHECK-HF registry. The prescribed dosages 
of MRA in both BP groups were much higher in the CHECK-HF registry compared with 
the CHAMP-HF registry (Figure 2B). In both registries, a higher prescribed dosage was 
observed in patients with systolic BP ≥110 mm Hg; however, the difference in the CHECK-
HF registry was larger.
Medical Therapy in Subgroups of HFmrEF According to 2016 ESC Guidelines
Treatment did not differ between HFmrEF (LVEF, 49%–50%) and HFrEF (LVEF, <40%) 
in our data set. A subanalysis of only HFmrEF (LVEF, 40%–49%) showed a comparable 
distribution of prescription rates according to BP in HFmrEF patients (mean age, 
73.7±11.7 years; 58.3% were men) and HFrEF patients (Figure I in the Data Supplement). 
Only RAS inhibitors were overall less often prescribed in HFmrEF patients, compared 
with HFrEF patients. Likewise, the subgroup of semiquantitative left ventricular function 
showed similar differences (Figure I in the Data Supplement). There was no significant 
interaction between ejection fraction (HFrEF versus HFmrEF) and systolic BP categories 
(all P=nonsignificant).
Discussion
In this large, cross-sectional Western European registry of patients with a reduced 
LVEF, the prescription rates and dosages of guideline-recommended HF drugs differed 
between categories of systolic BP levels. Most interestingly, the patients with the lowest 
BP received the highest number of triple therapy (β-blocker, RAS inhibitor, and MRA) 
but at lower overall prescribed dosages as compared with higher BP categories. This 
may argue that patients with lower BP have better guidelinerecommended treatment, 
which may have caused lower BP levels. Additionally, this group of patients had more 
advanced HF, indicated by a higher MAGGIC score, with more attention to optimize 
therapy. The number of side effects and intolerance was also reported to be higher. 
Another important finding of this study is that in patients with relatively high BP (≥130 
mm Hg), the prescription of HF drugs is not optimal and also the dose of HF drugs is 
5
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not at target despite the additional room for uptitration with these levels of BP. It is 
generally assumed that low BP limits the uptitration of HF medication. Therefore, in 
patients with BP >130 mm Hg, other factors seem to play a role in the relatively low 
uptake of HF medication, such as less HF symptoms (more New York Heart Association 
class II) or lower MAGGIC score. The discussion becomes even more difficult as it is hard 
to judge on the quality of HF care based on BP alone, as we do not know whether the 
BP is low due to medication or due to the severity of the disease. Still, New York Heart 
Association class II or low MAGGIC score should not be a reason for stopping uptitration 
of HF drugs nor should HF be seen as stable in those patients, one can argue.
CHECK-HF Versus CHAMP-HF
The general conclusion of the comparison of the CHAMP-HF and CHECK-HF registries 
is that with lower BP, patients have a higher percentage of triple therapy as indicated, 
but the actual dose of treatment is higher in the higher BP categories. Although both 
registries showed similar findings, there were some essential differences between them. 
Notable differences of the included populations were a higher percentage of women and 
patients with renal insufficiency in the CHECK-HF registry. As has been demonstrated 
previously, patient characteristics and the presence of comorbidities influence the HF 
drug prescription behavior of clinicians.10,11 Furthermore, the HF care systems differ 
between the 2 countries of the registries. Almost all patients in the CHECK-HF registry 
were treated at specialized HF outpatient clinics, consisting of specialized HF nurses 
and cardiologists. It has been shown that monitoring HF patients in a specialized 
setting, with a coordinating role for HF nurses, leads to better guideline adherence and 
uptitration in chronic HF patients,12,13 which could explain some differences between the 
2 registries. Additionally, healthcare insurance was available for all CHECK-HF patients, 
and all patients had access to a basic level of health care, including reimbursement and 
unrestricted access to medications prescribed including dedicated HF outpatient clinics 
and nurses. In contrast, patients in the CHAMP-HF might have experienced several 
challenges such as the access to HF therapy, different structure and organization of 
HF care, and high costs for HF therapy, which are very relevant public health issues in 
comparing CHECK-HF and CHAMP-HF in general.14
A dose-dependent positive effect has been described for most guideline-recommended 
HF drugs.15–17 Furthermore, it has been demonstrated that β-blockers,18,19 angiotensin-
receptor blocker,20 angiotensin repector neprilysin inhibitor,2,21 and ivabradine22 reduce 
mortality and HF-related hospitalization rates independent of baseline systolic BP. 
This indicates the importance of drug uptitration. Recently, the propensity-matched 
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Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With 
Heart Failure (OPTIMIZE-HF) study demonstrated that HFrEF patients discharged with 
a systolic BP <130 mm Hg were at a greater risk of mortality compared with patients 
with a systolic BP ≥130 mm Hg.23 These findings are in line with earlier reports from 
observational cohorts and post hoc analysis from randomized controlled trials, 
indicating that patients with lower systolic BP are at a greater risk of all-cause mortality 
and HF-related hospitalization,1,2,19,20,22–25 and could also be sicker patients as reflected 
in the MAGGIC score. However, the HFrEF medication that lower systolic BP, are also 
associated with a lower mortality and hospitalization rates, and are an indicator of the 
level of quality of HF care.8 So, these contradictions cause that it still remains unclear 
what the ideal systolic BP target in HFrEF patients should be and whether low BP is a 
marker of successful HF treatment with drugs at target level or a marker of elevated 
risk with likewise sicker patients. Therefore, new studies investigating the ideal systolic 
BP targets are needed. Additionally, the best uptitration strategy has not yet been 
properly studied and is, therefore, still under debate. In particular, it is largely unknown 
whether the BP response to therapy should influence the uptitration scheme to improve 
outcomes. A predefined BP level may be targeted during uptitration, making sure the 
BP does not drop too low. Another strategy may be to uptitrate HF medication close to 
orthostatic hypotension allowing to achieve the maximal dose. However, clinicians might 
be reluctant to adopt this latter strategy in fear of inducing symptomatic hypotension 
and significant side effects. Still, uptitrating HF medication in patients with low systolic 
BP is possible in most patients by using a slow and closely monitored titration strategy.3 
However, implementing these kinds of strategies into a real-world practice can be 
challenging, which may result in patients with low systolic BP levels receiving less often 
HF drugs at the recommended dose, as shown in our registry. Furthermore, only a 
minority of patients received triple HF therapy at the recommended dose, even in 
patients with higher systolic BP. In addition, other factors, often unclear, influence the 
uptitration decision as well. Further understanding of the decision-making process in 
uptitration is urgently needed to optimize this process.
Recently, the use of dapagliflozin has been investigated in HFrEF patients. In these 
patients, most likely the natriuretic effect of dapagliflozin influenced BP significantly.26 
We believe that dapagliflozin will be a very useful addition in the treatment of HFrEF 
patients; however, the exact place of these new drugs in relation to BP levels in 
adequately treated HFrEF patients or undertreated patients with still elevated BP is 
still to be determined.
5
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Limitations and Strengths
Strengths of this registry are the large sample size, the contemporary recent data, 
and real-world practice-based HF registry, with detailed information on HF medication 
prescription and dosages. This registry has some limitations. Most importantly, due 
to its cross-sectional design, there are no data on clinical events and longitudinal 
patient outcomes. Additionally, with changing HF categories based on LVEF in the 
newer guidelines, our analysis was limited by a small number of patients where 
left ventricle function was semiquantitatively analyzed with echocardiography— a 
practice not following guidelines. The registry is a quality of HF care project to study 
the determinants of guideline-recommended HF therapy in the Netherlands; however, 
the systolic blood pressure could be lowered due to HFrEF medication, which has been 
associated with a lower mortality and hospitalization rates, and are an indicator of the 
level of quality of HF care.
Conclusions
In this large study of patients with reduced LVEF, we observe that the highest level of HF 
drug triple therapy (β-blocker, RAS inhibitor, and MRA) is prescribed in those patients 
with the lowest systolic BP, but this is limited by lower levels of prescribed dose as 
compared with higher BP levels and higher levels of intolerance. Systolic BP appears to 
be one of the limiting factors in the uptitration of the dose of guideline-recommended 
HF therapy. Debate is warranted whether the optimal level of HF drugs should be based 
on the level of the BP, the severity of the disease, the tolerated level by the patient, or 
the guideline-recommended dose as advocated.
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ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; MRA, mineralocorticoid receptor antagonist
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Supplementary Figure 1 – Prescription rates of guideline-recommended HF therapy in A HFrEF patient 
(EF <40%) (n=5,613), B HFmrEF patient (EF 40-49%) (n=1,556) and C semi-quantitative patients (n=1,077) 
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Atrial fibrillation in chronic 
heart failure patients with 
reduced ejection fraction: the 
CHECK-HF registry
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Abstract
Background: Atrial fibrillation (AF) is common in chronic heart failure (HF) patients and 
influences the choice and effects of drug and device therapy. In this large real-world HF 
registry, we studied whether the presence of AF affects the prescription of guideline-
recommended HF therapy.
Methods: We analyzed 8253 patients with chronic HF with reduced ejection fraction 
(HFrEF) from 34 Dutch out-patient clinics included in the period between 2013 and 2016 
treated according to the 2012 ESC guidelines.
Results: 2109 (25.6%) of these patients were in AF (mean age 76.8 ± 9.2 years, 65.0% were 
men) and 6.144 (74.4%) had no AF (mean age 70.7 ± 12.2 years, 63.6% were men). Patients 
with AF more often received beta-blockers (81.7% vs. 79.7%, p = 0.04), MRAs (57.1% vs. 
51.7%, p < 0.01), diuretics (89.7% vs. 80.6%, pb0.01) and digoxin (40.1% vs. 9.3%, p < 0.01) 
compared to patients without AF, whereas they less often receive renin-angiotensin-
system (RAS)-inhibitors (76.1% vs. 83.1%, p < 0.01). The number of patients who received 
beta-blockers, RAS-inhibitor and MRA at ≥ 50% of the recommended target dose was 
comparable between those with and without AF (16.6% vs. 15.2%, p = 0.07).
Conclusion: In this large cohort of chronic HFrEF patients, the prevalence of AF was high 
and we observed significant differences in prescription of both guideline-recommended 
HF between patients with and without AF.
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Introduction
Atrial fibrillation (AF) is a common comorbidity in chronic heart failure (HF) patients,with 
a prevalence that has been reported from 10% up to 50–60%, depending on age and 
severity of HF 1–3. Pathophysiological changes in HF can lead to AF and vice versa 2,4. HF 
induces elevated filling pressures in the atria, leading to interstitial fibrosis of the left 
atrium, eventually leading to AF. Furthermore, calcium handling is altered in HF patients, 
and due to alterations in the electric properties of the atrial tissue in HF patients, AF 
can be induced. Otherwise, AF affects the left ventricular function due to loss of atrial 
contraction, irregular ventricular heart rhythm, and often rapid ventricular response, 
leading to and sustaining HF.
Multiple studies have shown that incident AF in chronic HF patients is associatedwith 
an increased risk of all-causemortality, cardiovascular mortality, stroke and transient 
ischemic attack 1,5. Moreover, concomitant AF may influence the choice of HF therapy, as 
the effects of therapies may differ in HF patients with AF 6. There are European Society 
of Cardiology (ESC) guidelines for both HF and AF, providing clear recommendations 
for the treatment of both conditions 7,8. Information on the ESC HF guideline adherence 
in patients with and without AF is relatively scarce.
Therefore, the aimof this studywas to (1) investigate the adherence to the HF ESC 
guidelines in HF patients with reduced ejection fraction (HFrEF) depending on the 
existence of underlying AF as well as to (2) provide insight in the prescription of 
antiarrhythmic drugs and anticoagulation therapy in HFrEF patients with AF in a 
practice-based registry.
Methods
The design and methods of the CHECK-HF (Chronisch Hartfalen ESCrichtlijn 
Cardiologische praktijk Kwaliteitsproject HartFalen) registry have been reported in 
detail earlier 9. Briefly, the CHECK-HF registry consists of 10,910 patientswith chronic HF 
froma total of 34 participating Dutch centers, participating in the inclusion of this cross-
sectional observational cohort. Between 2013 and 2016, all centers included patients 
diagnosed with HF-based on symptoms, signs, ECG, biomarkers and echocardiography 
according to the 2012 ESC Guideline on HF 10,whowere seen at the outpatient HF clinic 
(96%) or general cardiology outpatient clinic (4%) if no specific HF clinic was present. No 
NTproBNP threshold levels were used as inclusion criteria in this registry. The study was 
6
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conducted according to the Declaration of Helsinki. Ethical approval was provided for 
anonymously analyzing existing patient data by the Ethical Committee of theMaastricht 
UniversityMedical Center, the Netherlands.
A dedicated database was used to register all available records of the included 
patients, including baseline characteristics, laboratorymarkers, device implantation 
rates, aswell as prescription and dosages ofmedication. Furthermore, information 
on contraindications and drug intolerance were collected. For HF medical therapy, 
sotalol was analyzed separately from other beta-blockers. Target doses of guideline 
recommended HF therapy are presented in Supplementary Table 1.
Patients were classified based on left ventricular ejection fraction (LVEF) or visual 
assessment of the left ventricle (LV) function into HFrEF (LVEF b50% (n= 8360 (76.6%)) 
and HF with preserved ejection fraction (HFpEF) (LVEF≥50% (n = 2267 (20.8%) according 
to 2012 ESC HF guidelines 10. In 283 (2.6%) patients data on LV functionwas insufficient 
to classify patients, these patients, and all HFpEF patients, were excluded from this 
analysis. Based on a 12-lead ECG, performed during the most recent out-patient clinic 
visit, HFrEF patients were divided into those with documented AF (or a documented 
history of AF), sinus rhythmor other cardiac rhythms, in 107 (1.3%) patients data on 
cardiac rhythm wasmissing, and these patients were excluded fromthis analysis. Thus, 
a total of 8253 HFrEF patientswith AF orwithout AF (including sinus, pacemaker, and 
ectopic rhythm) was included.
Statistical analysis
Continuous data are expressed as mean value ± standard deviation (SD) or median 
and interquartile range, depending on the distribution of the data, and compared by 
the unpaired t-test or Mann-Whitney U test when appropriate. Categorical data are 
expressed as counts and percentages, and compared by the Pearson Chi-square test. In 
order to investigate whether the observed differences according to AF were independent 
of potential confounders, such as age and sex, univariable and multivariable logistic 
regression were used. The results of these regression analyses are expressed as 
odds ratios (ORs) and 95% confidence intervals (CIs). A two-sided p-value of 0.05 was 
considered statistically significant.
In model 1, we adjusted for heart rate (per 10 beats/min). In model 2,we further 
adjusted for age, sex, New York Heart Association (NYHA) classification, and LVEF. In 
model 3, we further included all comorbidities which were significantly related to the 
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outcome variable at statistical level p-value <0.05 using the enter method in a binary 
logistic regression model.
For some of these potential confounders, data were missing and were imputed using 
multiple imputation. If the missing variables showed a monotone pattern of missing 
values, the monotone method was used. Otherwise, an iterative Markov chain Monte 
Carlo method was used with a number of 10 iterations. A total of 5 imputations were 
performed, and the pooled data were analyzed. The imputed data was only used 
for the multivariable analysis. For all reported data of the multivariable analysis, we 
compared crude and imputed p-values as well as the ORs and CIs in order to analyze 
whether imputation changed the results, and if no significant changes occurred,we only 
presented the imputed values in the main analyses.
A sensitivity analysis was conducted for patients with documented AF (n= 2109) and 
documented sinus rhythm (n= 4901).
For a sub-analysis according to the newer 2016 ESC HF guidelines, patients with an 
assessed LVEF <50% were categorized into HF with mid-range ejection fraction (HFmrEF) 
(LVEF 40–49% (n = 1559 (18.9%)) and HFrEF (LVEF<40% (n = 5625 (68.2%), only in those 
patients with a exactly specified LVEF or into patients with only a semiquantitative 
analysis of the LV function (n= 1069 (13.0%)). For a subanalysis according to type of AF, 
patients diagnosed with AF were categorized into those with paroxysmal, persistent, 
permanent AF or AF of unknown type. All analyses were performed with SPSS Statistical 
Package version 25.0 (SPSS Inc., Chicago, Illinois).
Results
Baseline characteristics
Of all HFrEF patients, 2109 (25.6%) patients had AF on the entry-ECG at themost recent 
out-patient clinic visit or had a documented history of AF, 4901 (59.4%) had sinus rhythm, 
1141 (13.8%) had pacemaker rhythm and 102 (1.2) had an ectopic rhythm (in total 6144 
(74.4%) had no AF). The prevalence of AF increased in higher NYHA-classifications (NYHA 
I 18.0%, NYHA II 24.8%, NYHA III 31.2% and NYHA IV 30.8%, p b 0.01). Patients with AF 
were significantly older compared to patients without AF (76.8 ± 9.2 vs. 70.7 ± 12.2 
years resp., p < 0.01), were more often in NYHA III/IV (33.4% vs. 25.2% resp., p < 0.01), 
and had more comorbidities compared to patients without AF as shown in Table 1.
6
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Table 1. Patient characteristics of HFrEF patients according to AF
Overall population 
(n=8253)
Patients with AF 
(n=2109)
Patients without AF 
(n=6144)
p-value
Age (years) (n=8244) 72.3±11.8 76.8±9.2 70.7±12.2 <0.01
Male gender (n=8216) 5258 (64.0) 1366 (65.0) 3892 (63.6) 0.25
BMI, kg/m2 (n=7599) 27.2±5.2 27.1±5.1 27.2±5.2 0.48
NYHA (n=8160)
I 1291 (15.8) 232 (11.1) 1059 (17.4)
<0.01
II 4644 (56.9) 1154 (55.5) 3490 (57.4)
III 2079 (25.5) 648 (31.2) 1431 (23.5)
IV 146 (1.8) 45 (2.2) 101 (1.7)
LVEF, % (n=6097) 32.7±10.6 35.3±10.9 31.8±10.3 <0.01
Cause of HF (n=7998)
Ischemic cause of HF 4122 (51.5) 850 (41.6) 3272 (54.9)
<0.01
Non-ischemic cause of HF 3876 (48.5) 1192 (58.4) 2684 (45.1)
Systolic BP, mmHg (n=8159) 125.7±20.7 124.4±20.2 126.1±20.8 <0.01
Diastolic BP, mmHg (n=8164) 71.2±11.4 71.6±12.0 71.0±11.1 0.04
Heart rate, bpm (n=8199) 72.0±13.9 77.0±16.7 70.3±12.3 <0.01
LBBB (n=8253) 1411 (17.1) 324 (15.4) 1087 (17.7) 0.01
QRS ≥130 ms (n=6899) 2757 (40.0) 549 (32.4) 2208 (42.4) <0.01
eGFR (n=5813) 59.7±24.6 57.6±24.2 60.4±24.7 <0.01
eGFR (n=5813)
<30 655 (11.3) 180 (12.1) 475 (11.0)
<0.0130-59 2410 (41.5) 671 (45.2) 1739 (40.2)
≥60 2748 (47.3) 632 (42.6) 2116 (48.9)
Comorbidity (n=7399)
Hypertension 2949 (39.9) 843 (44.3) 2106 (38.3) <0.01
Diabetes Mellitus 2148 (29.0) 589 (31.0) 1559 (28.4) 0.03
COPD 1372 (18.5) 358 (18.8) 1014 (18.4) 0.72
OSAS 491 (6.6) 120 (6.3) 371 (6.7) 0.51
Thyroid disease 551 (7.4) 160 (8.4) 391 (7.1) 0.06
Renal insufficiency a 3901 (56.3) 1156 (63.3) 2745 (53.8) <0.01
No relevant comorbidity 840 (13.6) 158 (9.6) 682 (15.0) <0.01
Previous interventions 
(n=6529)
PCI 1658 (25.4) 310 (18.6) 1348 (27.7) <0.01
CABG 1450 (22.2) 363 (21.8) 1087 (22.4) 0.63
Valve intervention 523 (8.0) 173 (10.4) 350 (7.2) <0.01
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Table 1.  (continued)
Overall population 
(n=8253)
Patients with AF 
(n=2109)




Sinus rhythm 4901 (59.4) - 4901 (79.8)
-
Ectopic rhythm 102 (1.2) - 102 (1.7)
Pacemaker rhythm 1141 (13.8) - 1141 (18.6)
Paroxysmal AF 305 (3.7) 305 (14.5) -
Persisted AF 370 (4.5) 370 (17.5) -
Permanent AF 1116 (13.5) 1116 (52.9) -
AF of unknown type 318 (3.9) 318 (15.1) -
AF, Atrial Fibrillation; BMI, Body Mass Index; NYHA, New York Heart Association classification; LVEF, Left 
Ventricular Ejection Fraction; HF, Heart Failure; BP, Blood Pressure; LBBB, Left-Bundle Branch Block; 
eGFR, estimated Glomerular Filtration Rate; COPD, Chronic Obstructive Pulmonary Disease; OSAS, 
Obstructive Sleep Apnea Syndrome; PCI, Percutaneous Coronary Intervention; CABG, Coronary Artery 
Bypass Graft.
a Defined as eGFR <60mL/min or a history of renal failure
Pharmacological therapy
Patients with AF significantly more often received beta-blockers (81.7% vs. 79.7%, 
p = 0.04), mineralocorticoid receptor antagonists (MRAs) (57.1% vs. 51.7%, p < 0.01), 
diuretics (89.7% vs. 80.6%, p < 0.01), digoxin (40.1% vs. 9.3%, p < 0.01), oral anticoagulation 
(OACs) (82.4% vs. 41.7%, p < 0.01) and non-vitamin K antagonist oral anticoagulant 
(NOACs) (7.3% vs. 3.6%, p < 0.01), and less often RAS-inhibitors (76.1% vs. 83.1%, p < 0.01), 
amiodarone (12.9% vs. 15.2%, p = 0.04), and sotalol (2.7% vs. 5.6%, p < 0.01) compared 
to patients without AF, as shown in Fig. 1A. 89.7% of the patients with AF receive (N)OAC 
therapy as compared to 45.4% of those without AF (p < 0.01). Reasons for prescription 
of anticoagulation in patients without AF were artificial valves, severe LV dysfunction or 
LV thrombus. As shown in Fig. 1C, there were no significant differences in the number 
of patients who received triple HF therapy, consisting of beta-blocker, RAS-inhibitor, 
and MRA. Additionally, patients with sinus rhythm had more often an implantable 
cardioverter defibrillator (29.0% vs. 15.4%, p < 0.01) or a cardiac resynchronization 
therapy device (9.9% vs. 7.3, p < 0.01) compared to patients with AF.
The prescribed dosages of beta-blocker, RAS-inhibitors, and MRA are presented in Fig. 1B. 
Patients with AF significantly more often received beta-blocker at target dose as compared 
to patients without AF, and there were no significant differences in the prescribed dosages 
of RAS-inhibitors and MRAs. As shown in Fig. 1D, there was no significant difference in 
the number of patients who received triple HF therapy at ≥50% at the target dose.
6
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Fig. 1. A Prescription rates of HF therapy, antiarrhythmic drugs and anticoagulation therapy, B prescribed 
dosages of HF therapy expressed as percentage of recommended target dose, C combination of be-
ta-blocker, RAS-inhibitor and MRA, D and combination of beta-blocker, RAS-inhibitor and MRA at least 
≥50% of target dose prescribed, between patients with and without atrial fibrillation.
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A sensitivity analysis excluding patients with pacemaker rhythm and ectopic rhythm 
produced qualitatively similar results with the exception of beta-blockers, which 
difference was no longer significant (Supplementary Fig. 1).
As shown in Table 2, after adjusting for heart rate, patients with AF had still higher 
odds of receiving beta-blockers, MRAs, diuretics, digoxin, OACs and NOACs, and lower 
odds of receiving RAS-inhibitors and sotalol. After additional adjustment for other 
potential confounders, patients with AF had higher odds of receiving beta-blockers, 
MRAs, diuretics, digoxin, OACs and NOACs and lower odds of receiving sotalol compared 
to patients without AF. Multiple imputation did not change the results.
Medical therapy in patients with HFmrEF according to 2016 ESC guidelines
Medical therapy did not differ between patients with HF with mid-range ejection 
fraction (HFmrEF) and HFrEF in this registry according to the latest HF guidelines. 
Baseline parameters are shown in Supplementary Table 2. A sub-analysis of only 
HFmrEF patients showed a similar medical therapy pattern between patients with and 
without AF as in HFrEF patients (Supplementary Fig. 2).
Baseline characteristics and medical therapy according AF type
Several significant differences in baseline characteristic were observed between the 
different AF type cohorts, as shown in Supplementary Table 3. Additionally, patients 
diagnosed with paroxysmal AF and HF received less often HF medical therapy compared 
to the other AF types, while sotalol and amiodarone were more often prescribed 
(Supplementary Table 3).
6
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Discussion
In this large practice-based outpatient registry, one-quarter of the HFrEF patients had 
documented AF. Patients with AF were significantly older and had more symptomatic 
HF. The differences in the prescription rates of antiarrhythmic drugs, anticoagulation 
and guideline-recommended HF therapy according to AF, could not be fully explained 
by heart rate, age or other patient characteristics. These results provide more 
insight into the clinical profile of HF patients with AF and the guideline adherence 
in these patients.
Pharmacological therapy
The efficacy of beta-blockers in chronic HF patients in sinus rhythm has clearly been 
demonstrated 8, and is reflected in high prescription rates in recent large HF registries 
11–13, as well as in this registry. However, the efficacy of beta-blockers in HF patients with 
AF remains unclear. Several explanations for a different efficacy of beta-blockers in HF 
patients with AF have been proposed. Studies investigating the relationship between 
heart rate and mortality outcomes in HF patients reported inconsistent results. Sub-
analysis from randomized controlled trials did not show an association between 
mortality and heart rate 14, while observational cohorts did, although these cohorts are 
at risk for selection bias 15. A recent meta-analysis demonstrated that a higher heart rate 
was not associated with a higher mortality rate in HF patients having AF 16. Furthermore, 
differences in structural or cellular function in patients with AF could lead to a difference 
in the efficacy of beta-blockers in these patients 17. A higher heart rate could compensate 
for the loss of the atrial kick in AF patients, and thus reducing the effect of beta-blockers 
18. Moreover, irregularity might be less with a higher heart rate.
In a meta-analysis based on individual patient data of basically all major randomized 
controlled trials, Rienstra et al. demonstrated that the beta-blockers did not reduce the 
risk of mortality in HF patients with AF, in contrast to HF patients with sinus rhythm 
19. However, this analysis was published after 2016 and could, therefore, not influence 
the prescription pattern in CHECK-HF. Additional registries are required to see if this 
individual patient data basedmeta-analysis influenced the prescription pattern of beta-
blockers in HFrEF patients with AF. Multiple other meta-analyses have investigated 
this relationship with mixed results 6,20. Several important factors might contribute 
to the observed differences. Importantly, studies demonstrating a reduction in all-
cause mortality in HF patients with AF using beta-blockers were all cohort studies 
6. The risk of inclusion and prescription bias limited the results of these studies. 
6
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Furthermore, patients included in the randomized controlled trials were on average 
more symptomatic patients compared with patients included in the cohort studies. It 
could be that these less symptomatic patients could tolerate beta-blockers better, and 
in a higher dose, and therefore benefit more from beta-blockers, although this clearly is 
not the case in patients with sinus rhythm. In a non-randomized cohort study, a dose-
dependent effect of beta-blockers in HF patients with AF has been demonstrated, with 
the largest reduction of events in patients up titrated to the recommended dosage 21.
RAS-inhibitors are a cornerstone in chronic HF treatment 8, and could be used to 
prevent the occurrence of new paroxysmal AF episodes in HF patients 22,23. As shown 
in our registry, the prescription rate of RAS-inhibitors in both HF patients with and 
without AF was high, and the observed difference between the groups was explained 
by significant confounders.
Two studies have compared the efficacy of MRAs in chronic HF patients with and without 
AF, demonstrating similar effects in the prevention of cardiovascular deaths and HF-
related hospitalizations 24,25. Moreover, MRAs reduced the risk of any future AF event in 
HF patients, although this was only investigated in a post-hoc analysis 25. We found that 
patientswith AFmore often receive MRAs, even after adjustment for several significant 
confounders. However, prescription rates were relatively low in both groups. Recent 
registries, investigating the guideline adherence o fMRA in chronic HF patients without 
AF, showed similar prescription rates between 40 and 60% 13,26. HF patients with AF 
might be considered to be sicker and were more often symptomatic, indicated by the 
higher prevalence of AF in more symptomatic HF patients.
Antiarrhythmic drugs
In chronic HF patients, rhythm control for AF has not been shown to be superior over 
rate control 27, and adequate rate control prevented unfavorable ventricular remodeling 
in HF patients 28. Moreover, in the ESC AF guidelines, it is recommended (Class IA 
indication) that rate control should be the initial approach in elderly patients with 
minor AF-related symptoms 7. Additionally, the ESC HF guidelines recommend reserving 
rhythm control for HF patients with a reversible cause of AF, or those who do not 
tolerate AF 8. This could explain the relatively low prescription rates of amiodarone and 
sotalol in our registry. Sotalol is considered to be contraindicated in HFrEF, explaining 
the low prescription rate. However, a substantial portion of HF patients without AF did 
receive amiodarone and sotalol. These drugs might be prescribed due to ventricular 
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tachycardia and premature ventricular complexes in patients without AF. Unfortunately, 
we cannot determine the prescription indication of these medications from our data.
In low dosages, digoxin exerts mainly neurohormonal effects, which could be beneficial 
primarily for reducing hospitalizations in chronic HF patients without AF 29. The effect 
of digoxin in HF patients without AF has been investigated in only one randomized 
controlled trial 30, and showed a neutral effect on mortality, but a beneficial effect on 
hospitalizations. Since then, post-hoc analyses fromobservational cohorts demonstrated 
higher mortality in HF patients without AF treated with digoxin. However, these results 
are at great risk for prescription bias, with sicker HF patients receiving more often 
digoxin. Additionally, the use of digoxin in patients with AF without HF is controversial as 
well, as a meta-analysis demonstrated an association between digoxin use in AF patients 
and an increased risk of all-cause and cardiovascular mortality 31. However, these results 
are based on post-hoc analyses from observational cohorts which are at great risk 
for prescription bias, with sicker patients more likely to receive digoxin. Therefore, it 
remains unclear whether it is safe to use digoxin in patientswith both AF and HF. The 
upcoming DECISION trial (NCT03783429), a multicenter randomized controlled trial, will 
provide more insight into the effect of digoxin in HF patients with AF.
Anticoagulation therapy
The importance of adequate anticoagulation therapy, in order to prevent stroke, 
systemic embolism but also excess of bleedings in HF patients with AF, is well known 
32. However, the PINNACLE-AF registry and the EuroHeart survey demonstrated that 
only approximately 60–70% of HFrEF patients received anticoagulation therapy 33,34. In 
contrast, the prescription rates in CHECK-HF were higher, which might be explained by 
the close monitoring of the Dutch thrombosis service, reducing the risk of potential 
bleedings. Recently, two meta-analyses showed the efficacy and safety of NOACs in 
chronic HF patients with AF 35,36. The prescription rates of NOACs in our registry were 
very low, reflecting the period of 2013 up to 2016, in which NOACs were just introduced 
in Dutch clinical practice.We expect that the prescription rates also in HF patients have 
risen significantly since then. In contrast, the prescription rates of oral anticoagulation 
therapy were very high in patients with AF.
Limitations and strengths
This practice-based registry has some limitations that should be noted. Due to the 
cross-sectional design of the registry, no follow-up data on patient outcomes is 
6
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available. Also, some data was missing in our study,which could have caused some 
bias, althoughmultiple imputation did not influence the results. Furthermore, patients 
were divided based on a 12-lead ECG, performed during the most recent out-patient 
clinic visit, or a documented history of AF. The history of AF might have been incomplete, 
and paroxysmal AF patients could have been missed. Additionally, no details on the 
indication for OAC/NOAC or anti-arrhythmic therapy, such as a history of ventricular 
arrhythmias, was available. Furthermore, in the newer guidelines 8, HF categories based 
on LVEF have been changes, our analysis was limited by a small number of patients 
where LV function was semi-quantitatively analyzed with echocardiography, and some 
newer treatment strategies, such as the uptake sacubitril/valsartan (substitution for 
ACE-i/ARB) or NOACs were only in small numbers used in this time period. Still, NOACs 
improbably influences the already high us of anticoagulation in AF and the use of RAS-
inhibitors was high in both patients with and without AF. Therefore, it is unlikely that 
the conclusions from CHECK-HF are influenced by the focus on the period between 
2012 and 2016. The major strengths of this study are the large sample size and the 
reflection of true clinical practice of the nationwide outpatient HF management, with 
detailed information on HF medication prescription rate and prescribed dosages.
Conclusion
In this national registry, consisting of 8253 chronic HFrEF patients, significant differences 
exist in prescription rates of guideline-recommended HF therapy between patients 
with and without AF. These results show the need for a better understanding of the 
efficacy and adherence of guideline-recommended HF therapy in patients with AF.
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ACE, angiotensin-conver ting enzyme; 
ARB, angiotensin II receptor blocker; MRA, 
mineralocorticoid receptor antagonist
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Supplementary Table 3. Patient characteristics of patients with, paroxysmal, persistent, permanent AF 











Age (years) 76.0±9.6 76.7±8.9 77.6±8.7 75.1±10.2 <0.01
Male gender 200 (65.8) 242 (65.6) 704 (63.5) 220 (69.2) 0.30
BMI, kg/m2 26.9±5.5 57.5±5.1 27.1±5.0 26.9±5.1 0.34
NYHA
I 35 (11.6) 20 (5.6) 74 (6.7) 103 (32.5)
<0.01
II 164 (54.3) 223 (61.9) 631 (57.4) 136 (42.9)
III 90 (29.8) 111 (30.8) 374 (34.0) 73 (23.0)
IV 13 (4.3) 6 (1.7) 21 (1.9) 5 (1.6)
LVEF, % 32.7±10.7 33.2±8.1 36.0±11.3 35.9±10.1 <0.01
Cause of HF
Ischemic 162 (54.4) 149 (41.6) 410 (38.4) 129 (40.6)
<0.01
Non-ischemic 136 (45.6) 209 (58.4) 658 (61.6) 189 (59.4)
Systolic BP, mmHg 125.5±20.5 125.2±21.9 121.4±18.5 133.0±21.1 <0.01
Diastolic BP, mmHg 71.2±11.8 71.5±12.9 70.2±10.3 77.2±15.0 <0.01
Heart rate, bpm 73.2±16.1 76.3±17.7 77.1±15.7 81.4±18.6 <0.01
QRS ≥130 ms 80 (33.5) 109 (31.7) 270 (33.8) 90 (28.7) 0.41
eGFR 61.9±27.2 55.2±21.5 57.4±24.2 51.8±17.3 <0.01
eGFR
<30 31 (12.2) 28 (12.1) 114 (12.3) 7 (10.1)
0.0630-59 99 (38.8) 109 (47.0) 421 (45.4) 42 (60.9)
≥60 125 (49.0) 95 (40.9) 392 (42.3) 20 (29.0)
Comorbidity
Hypertension 115 (40.1) 150 (43.4) 459 (47.4) 119 (39.7) 0.04
Diabetes Mellitus 88 (30.7) 109 (31.5) 319 (32.9) 73 (24.3) 0.05
COPD 46 (16.0) 66 (19.1) 202 (20.8) 44 (14.7) 0.06
OSAS 15 (5.2) 26 (7.5) 57 (5.9) 22 (7.3) 0.52
Thyroid disease 29 (10.1) 9 (2.6) 83 (8.6) 39 (13.0) <0.01
Renal insufficiency † 192 (63.2) 217 (59.5) 698 (64.2) 49 (70.0) 0.25
No relevant 
comorbidity
26 (9.1) 46 (13.3) 86 (8.9) 0 (0.0) 0.01
Previous interventions
PCI 66 (24.7) 40 (11.4) 151 (16.2) 53 (45.3) <0.01
CABG 69 (25.8) 64 (18.2) 171 (18.4) 59 (50.4) <0.01
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Valve intervention 27 (10.1) 23 (6.6) 90 (9.7) 33 (28.2) <0.01
Therapy
Beta-blocker 233 (76.6) 316 (85.4) 904 (81.1) 255 (84.7) 0.01
RAS-inhibitor 223 (73.4) 291 (78.6) 834 (74.8) 243 (80.7) 0.07
MRA 164 (53.9) 250 (67.6) 686 (61.5) 94 (31.2) <0.01
Diuretics 265 (87.5) 334 (90.3) 1,025 (92.0) 248 (82.4) <0.01
Amiodarone 49 (20.8) 18 (18.6) 72 (7.7) 28 (100.0) <0.01
Digoxin 79 (26.0) 157 (42.4) 464 (41.6) 138 (45.8) <0.01
Sotalol 21 (6.9) 4 (1.1) 28 (2.5) 4 (1.3) <0.01
OAC 207 (71.4) 317 (92.4) 924 (83.4) 217 (77.5) <0.01
NOAC 36 (12.4) 14 (4.1) 92 (8.3) 6 (2.1) <0.01
ICD 54 (20.2) 29 (8.3) 116 (12.2) 56 (67.5) <0.01
CRT 25 (9.4) 9 (2.6) 47 (4.9) 39 (47.0) <0.01
HFrEF, Heart Failure with reduced Ejection Fraction; HFmrEF, Heart Failure with mid-range Ejection Fraction; 
AF, Atrial Fibrillation; BMI, Body Mass Index; NYHA, New York Heart Association classification; LVEF, Left 
Ventricular Ejection Fraction; HF, Heart Failure; BP, Blood Pressure; LBBB, eGFR, estimated Glomerular 
Filtration Rate; COPD, Chronic Obstructive Pulmonary Disease; OSAS, Obstructive Sleep Apnea Syndrome; 
PCI, Percutaneous Coronary Intervention; CABG, Coronary Artery Bypass Graft.
† Defined as eGFR <60mL/min or a history of renal failure
6
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Supplementary Figure 1 – A Prescription rates of HF therapy, antiarrhythmic drugs and anticoagulation 
therapy, B prescribed dosages of HF therapy expressed as percentage of recommended target dose, C 
combination of beta-blocker, RAS-inhibitor and MRA, D and combination of beta-blocker, RAS-inhibitor 
and MRA at least ≥50% of target dose prescribed, between patients with atrial fibrillation (n=2,109) and 
sinus rhythm (n=4,901)
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Supplementary Figure 2 – A Prescription rates of HF therapy, antiarrhythmic drug and anticoagulation 
therapy in HFrEF (LVEF<40%) (n=5,625), B HFmrEF (LVEF 40-49%) (n=1,559) and C semi-quantitative patients 
(n=1,069) according to the 2016 ESC guidelines
6
146122_Veenis,Jesse_BNW-def .indd   139 13-11-2020   14:37
7
146122_Veenis,Jesse_BNW-def .indd   140 13-11-2020   14:37
7
Submitted
Diabetes and contemporary 
treatment for chronic heart 
failure in a large real-world 
heart failure population
Veenis JF, Radhoe SP, Brunner-La Rocca HP, Linssen GCM, Van der Lee C, 
Eurlings LWM, Kragten H, Al-Windy NYY, Van der Spank A, Koudstaal S, Brugts JJ
146122_Veenis,Jesse_BNW-def .indd   141 13-11-2020   14:37
Under embargo
8
146122_Veenis,Jesse_BNW-def .indd   164 13-11-2020   14:38
8
Neth Heart J, 2020 Jun; 28(6):334-344.
Differences in guideline-
recommended heart failure 
medication between Dutch 
heart failure clinics: an analysis 
of the CHECK-HF registry
Veenis JF*, Linssen GCM*, Brunner-La Rocca HP, Van Pol PEJ, Engelen DJM, 
Van Tooren RM, Koornstra-Wortel HJJ, Hoes AW, Brugts JJ 
* Equal contributions
146122_Veenis,Jesse_BNW-def .indd   165 13-11-2020   14:38
166
Part A | Chapter 8
Abstract
Background: Heart failure (HF) is associated with poor prognosis, high morbidity and 
mortality. The prognosis can be optimised by guideline adherence, which also can 
be used as a benchmark of quality of care. The purpose of this study was to evaluate 
differences in use of HF medication between Dutch HF clinics.
Methods: The current analysis was part of a crosssectional registry of 10,910 chronic 
HF patients at 34 Dutch outpatient clinics in the period of 2013 until 2016 (CHECK-HF), 
and focused on the differences in prescription rates between the participating clinics 
in patients with heart failure with reduced ejection fraction (HFrEF).
Results: A total of 8,360 HFrEF patients were included with a mean age of 72.3± 11.8 
years (ranging between 69.1± 11.9 and 76.6± 10.0 between the clinics), 63.9% were men 
(ranging between 54.3 and 78.1%), 27.3% were in New York Heart Association (NYHA) 
class III/IV (ranging between 8.8 and 62.1%) and the average estimated glomerular 
filtration rate (eGFR) was 59.6± 24.6ml/min (ranging between 45.7± 23.5 and 97.1± 16.5). 
The prescription rates ranged from 58.9–97.4% for beta blockers (p< 0.01), 61.9–97.1% 
for renin-angiotensin system(RAS) inhibitors (p< 0.01), 29.9–86.8% for mineralocorticoid 
receptor antagonists (MRAs) (p< 0.01), 0.0–31.3% for ivabradine (p< 0.01) and 64.9–
100.0% for diuretics (p< 0.01). Also, the percentage of patients who received the target 
dose differed significantly, 5.9–29.1% for beta blockers (p< 0.01), 18.4–56.1% for RAS 
inhibitors (p< 0.01) and 13.2–60.6% for MRAs (p< 0.01).
Conclusions: The prescription rates and prescribed dosages of guideline-recommended 
medication differed significantly between HF outpatient clinics in the Netherlands, not 
fully explained by differences in patient profiles.
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Introduction
Heart failure (HF) is associated with a high symptom burden, morbidity and mortality 
1–3. Optimising guideline-recommended HF therapies improve health-related quality of 
life and prognosis 4–6. However, in real-world practice, implementation and adherence 
to recommended treatment, a benchmark of quality of care, are suboptimal. A recent 
analysis of medication profiles of 22,476 unselected patients with a diagnosis of HF at 
hospital discharge between 2001 and 2015 derived from the Dutch PHARMO Database 
Network showed only partial improvement of prescribed HF medication over time 7. The 
percentage of patients prescribed the combination of a beta blocker and an angiotensin-
converting-enzyme (ACE) inhibitor or angiotensin receptor blocker increased from 24 to 
approximately 45% within this 15-year period. The percentage of patients who also used 
a mineralocorticoid receptor antagonist (MRA) reached approximately 20%. Notably, 
the probability of being prescribed these combinations decreased with increasing age 
and there was no significant increase in MRA prescriptions. Moreover, recent real-
world registries demonstrated underuse of HF therapies despite clear evidence-based 
recommendations 8–10.
In fact, randomised clinical trials and surveys did not represent real-life HF 
populations 11–13. Moreover, the distribution of recommended HF treatment and 
considerable practice variation between regions and hospitals are largely unexplained, 
but also unexplored.
In a large-scale real-world registry at Dutch HF outpatient clinics, we therefore 
investigated the differences in medical HF therapies and determinants of prescription 
of individual, recommended HF drugs in HFrEF patients 14, 15 among 34 HF clinics 
in the Netherlands.
Methods
The design and methods of the CHECK-HF (Chronic Heart failure ESC guideline-based 
Cardiology practice Quality project) registry have been published in detail earlier 14. 
Briefly, the CHECK-HF registry consists of 10,910 patients with chronic HF froma total 
of 34 participating centres (40% of the 86 centres in the Netherlands of which 60 have 
an outpatient HF unit) (Fig. 1). Patients were included cross-sectionally based on the 
available records of these patients. Between 2013 and 2016, all participating centres 
included patients diagnosed with HF based on the 2012 ESC guidelines on HF (i.e. based 
8
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on symptoms and echo parameters) who were seen at the outpatient HF clinic (96%) or 
general cardiology outpatient clinic (4%) if no specific HF clinic was present.
Fig. 1 Geographical distribution of the 34 participating clinics of the CHECK-HF registry in the Netherlands
Baseline patient characteristics, aetiology of HF, comorbidities, basic echocardiographic 
and electrocardiographic (ECG) parameters, laboratory markers, pacemaker, 
implantable cardioverter-defibrillator treatment and cardiac resynchronisation 
therapy as well as prescription rates of medication (drug name, dosage and frequency 
and total daily dose) were recorded. The target doses of guideline-recommended HF 
medication are presented in Suppl. Table 1. Drug doses were calculated compared with 
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the recommended dose and according to guidelines as a daily dose or %, percentage 
of actual recommended daily dose.
Furthermore, contraindications and intolerance as indicated by the treating physician were 
collected. No predefined rules were applied to determine absolute contraindications.
In 283 (2.6%) patients, recording of ejection fraction in the database was insufficient to 
classify patients, so these patients were excluded from this analysis.
Based on echocardiographic results, the remaining 10,627 patients were divided based 
on left ventricular ejection fraction (LVEF) or visual assessment of the function of the left 
ventricle into HF with preserved ejection fraction (HFpEF) (LVEF ≥50%, n= 2,267 (21%)) 
and HF with reduced ejection fraction (HFrEF: LVEF <50%, n= 8,360 (79%)), according 
to the 2012 ESC HF guidelines 4.
For a sub-analysis according to the newer 2016 ESC HF guidelines, patients with an 
assessed LVEF <50% were categorised into HF with mid-range ejection fraction (HFmrEF) 
(LVEF 40–49%, n= 1,574 (19%)), HFrEF (LVEF <40%, n= 5,701 (68%)), and into HF with a 
semi-quantitative analysis of the systolic left ventricular function only (n= 1,085 (13%)). 
In the current analyses, we focused on the prescribed HF medication in HFrEF patients 
(LVEF <50%).
The Medical Research Ethics Committee of the Maastricht University Medical Center, 
the Netherlands, provided ethical approval for anonymously analysing existing patient 
data. No informed consent of the participants in this registry was required.
Statistics
Continuous data are expressed as mean value± standard deviation (SD) or median 
and interquartile range, depending on the distribution of the data, and compared by 
applying one-way analysis of variances (ANOVA) or Mann-Whitney U test as appropriate. 
Categorical data are expressed as counts and percentages, and compared by the 
Pearson chi-squared test. A two-sided p-value of 0.05 was considered statistically 
significant. Multivariable predictors for the use of HF medication associated with 
the hospital-ranked prescription of HF medication (beta blocker, renin-angiotensin 
system [RAS] inhibitor, MRA, ivabradine and diuretics, respectively) were sought, using 
multivariable logistic regression analysis, using the stepwise forward procedure. All 
predictors of medication use in univariable analysis at a p-value of <0.10 were included 
8
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in the multivariable regression analysis. Results of logistic regression are presented as 
odds ratios (ORs) and confidence intervals (CIs).
All analyses were performed with SPSS Statistical Package version 25.0 (SPSS Inc, 
Chicago, Illinois).
Results
Baseline characteristics of the total group of 8,360 HFrEF patients are shown in Table 
1. Mean age was 72.3± 11.8 years (ranging between 69.1± 11.9 and 76.6± 10.0 between
the clinics), 63.9% were men (ranging between 54.3 and 78.1%), 27.3% were in New York 
Heart Association (NYHA) class III/IV (ranging between 8.8 and 62.1%) and the average
estimated glomerular filtration rate (eGFR) was 59.6± 24.6ml/min (ranging between
45.7± 23.5 and 97.1± 16.5). Between centres, a wide range of prevalence rates with
regard to ischaemic aetiology of HF, atrial fibrillation and comorbidities were found,
as presented in Table 1. When subdividing HF patients in LVEF groups according to
ESC guidelines 2016, HFmrEF patients (n= 1,574) were more often female, had less
often ischaemic aetiology, less wide QRS complex and more often atrial fibrillation,
hypertension and chronic obstructive pulmonary disease (COPD), all compared with
HFrEF patients (n= 5,701). However, in both groups, there was a wide variation of all
baseline characteristics between centres (Suppl. Tables 2 and 3).
Table 1. Baseline characteristics of HFrEF patients (LVEF<50%) and range between centers
Overall population Range
Number of patients 8,360 32; 1,549
Age (years) (n=8,351) 72.27±11.8 69.1±11.9; 76.6±10.0
Male gender (n=8,323) 5,320 (63.9) 54.3; 78.1
BMI, kg/m2 (n=7,671) 27.2±5.2 26.2±4.7; 28.4±5.1
NYHA (n=8,262)
I 1,313 (15.9) 0.0; 45.5
II 4,692 (56.8) 35.0; 88.1
III 2,108 (25.5) 8.8; 60.0
IV 149 (1.8) 0.0; 9.6
LVEF, % (n=6,179) 32.6±10.5 28.4±10.5; 44.2±16.0
Cause of HF (n=8,094)
Ischemic cause of HF 4,182 (51.7) 34.9; 63.4
Non-ischemic cause of HF 3,912 (48.3) 36.6; 65.1
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Table 1. (continued)
Overall population Range
Systolic BP, mmHg (n=8,246) 125.7±20.7 113.8±19.6; 135.4±22.7
Diastolic BP, mmHg (n=8,252) 71.2±11.4 64.9±10.4; 75.1±12.9
Heart rate, bpm (n=8,248) 72.0±13.9 64.7±8.0; 76.7±17.1
Atrial fibrillation (n=8,253) 2,109 (25.6) 12.2; 50.0
LBBB (n=8,360) 1,414 (16.9) 0.0; 30.2
QRS ≥130 ms (n=6,936) 2,774 (40.0) 0.0; 53.5
eGFR (n=5,883) 59.6±24.6 45.7±23.5; 97.1±16.5
eGFR (n=5,883)
<30 667 (11.3) 0.0; 27.3
30-59 2,442 (41.5) 0.0; 54.5
≥60 2,774 (47.2) 18.2; 100.0
Comorbidity (n=7,488)
Hypertension 2,978 (39.8) 7.8; 75.5
Diabetes Mellitus 2,174 (29.0) 16.7; 51.0
COPD 1,381 (18.4) 9.5; 29.9
OSAS 495 (6.6) 0.0; 14.1
Thyroid disease 557 (7.4) 0.6; 11.8
Renal insufficiency a 3,950 (56.3) 30.5; 78.9
No relevant comorbidity 855 (13.6) 0.0; 28.3
a Defined as eGFR <60ml/min or a history of renal failure
BMI body mass index, NYHA New York Heart Association classification, LVEF left ventricular ejection fraction, 
HF heart failure, HFrEF HF with reduced ejection fraction, HFmrEF HF with mid-range ejection fraction, HFpEF 
HF with preserved ejection fraction, BP blood pressure, LBBB left bundle branch block, eGFR estimated 
glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, COPD chronic obstructive 
pulmonary disease, OSAS obstructive sleep apnoea syndrome
Guideline-recommended medical therapy in HFrEF
The prescription rates ranged between centres from 58.9–97.4% for beta blocker 
according to ESC guidelines 2012 (p< 0.01), 61.9–97.1% for renin-angiotensin system 
(RAS) inhibitors (p< 0.01), 29.9–86.8% for MRA (p< 0.01), 0.0–31.3% for ivabradine (p< 
0.01) and 64.9–100.0% for diuretics (p< 0.01), see Table 2 and Fig. 2. In symptomatic HF 
patients (NYHA class II–IV), guideline-recommended medication only slightly differed 
from the total HFrEF group (Suppl. Table 4).
8
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Fig. 2 Prescription rates and prescribed dosages of HFmedication in HFrEF patients (LVEF <50%) per par-
ticipating clinic (n= 34) (The left panels show the order of hospitals on the x-axis based on the percentage 
of prescription rate of each drug. The red bar is the overall presciption rate (%) and the green bars are the 
prescription rates (%) in each clinic. The same order is shown in the panels on the right.) (HF heart failure, 
HFrEF heart failure with reduced ejection fraction, LVEF left ventricular ejection fraction, RAS renin-angio-
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Dual therapy (beta blocker and RAS inhibitor) was prescribed in average 66.3% (min. 
47.7 to max. 80.5) of HFrEF patients, one out of two in 28.7% (15.6–43.7) and none in 
5.0% (0.9–13.5) respectively. Triple therapy (beta blocker, RAS inhibitor and MRA) was 
prescribed in average 35.6% (16.1–68.4) of HFrEF patients, two out of three in 45.7% 
(28.9–58.9), one out of three in 16.1% (0.0–24.7) and none in 2.6% (0.0–6.9) respectively. 
Also, the percentage of patients who received the target dose differed significantly, 
5.9–29.1% for beta blocker (p< 0.01), 18.4–56.1% for RAS inhibitor (p< 0.01) and 13.2–
60.6% for MRA (p< 0.01).
HFrEF patients seen at HF clinics received more often beta blockers, MRA, ivabradine 
and diuretics in comparison with those seen in general cardiology outpatient clinics, 
although rates of prescribed of RAS inhibitors were similar (Suppl. Table 5). Women with 
HFrEF less often received RAS inhibitors (79% vs 83%), but more often beta blockers 
(82% vs 79%) as compared with men. MRA were given in 53% of patients, both men 
and women (Suppl. Table 6).
Multivariable analysis of hospitals showed that the differences in prescribed HF 
medication between centres cannot be explained by clinical variables (Table 3, see 
Suppl. Table 7 for univariable analysis).
According to ESC guidelines 2016, the prescription rates inHF patients with LVEF <40%, 
both overall and ranges between centres of prescription rates of HF medication, were 
not different in a clinically meaningful way from HF with LVEF <50%.
Medical treatment of HFmrEF and semi-quantitative patients
The distribution of beta blockers, RAS inhibitors and MRA in HFmrEF and semi-
quantitative patients are shown in Table 2. Both overall prescription rates and ranges 
between centres did not differ in a clinically meaningful way from those in HFrEF 
patients. Also, in all LVEF groups, there was a wide range of prescribed dosages of HF 
medication percentages between centres (Suppl. Fig. 1, 2 and 3).
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Discussion
From our outpatient HF registry in a representative number of centres in the 
Netherlands, we demonstrated that demography, HF characteristics and comorbidities 
in HFrEF patients widely varied between those centres. Also, the prescription rates 
and prescribed dosages of guideline-recommended HF medication varied significantly, 
both for HFrEF and HFmrEF patients. Those variations between hospitals could not be 
explained by differences in baseline characteristics of participating HF patients.
Overall, we found higher prescription rates of recommended HF medication than in 
previous registries, which may be related to the delivery of specialist outpatient HF 
care in the vast majority of patients 10.
Variation in prescribed heart failure medication
Remarkably, a wide distribution of prescribed medication between centres was 
observed. Many factors may play a role both in suboptimal therapy in the HF patients 
and in substantial variations between centres. Previously we reported from CHECK-
HF that lower rates of guideline-directed pharmacotherapy in HFrEF patients were 
associated with increasing age, but much less influenced by comorbidities 10. Recorded 
contraindications and intolerabilities did not explain the underuse of RAS inhibitors, 
beta blockers and MRA. Further analyses demonstrated that elderly heart failure 
patients with reduced ejection fraction (≥75 years) were prescribed significantly fewer 
beta blockers (77.8% vs 84.2%), RAS inhibitors (75.2% vs 89.7%), MRAs (50.6% vs 
59.6%) and ivabradine (2.9% vs 9.3%), but significantly more diuretics (88.1% vs 72.6%) 
compared with patients aged less than 60 (P for all trends <0.01) 16. In addition, the 
prescribed target dosages were significantly lower in elderly patients. Notably, patients 
with HFmrEF showed a similar trend in use of medication as in patients with HFrEF.
Also, recently reported data from the CHAMP-HF registry with 3,518 participating 
patients from 150 primary care and cardiology practices, demonstrated that lower 
medication utilisation or dose, was associated with older age, lower blood pressure, 
more severe functional class, renal insufficiency, and recent HF hospitalisation 9.
Notably, only 40% of the total HFrEF cohort of the Swedish Heart Failure Registry (11,215 
patients, 27% women; mean age 75± 11 years) received an MRA 17. Underuse of MRA 
was not related to hyperkalaemia, but it was, among other factors, related to impaired 
renal function (even moderately impaired), which is not a contraindication for MRA 
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use. An explanation for the underuse ofMRA might be the reluctance of prescribing 
an MRA to a vulnerable group of HF patients, already treated with an RAS inhibitor, 
beta blocker and in the majority of cases also a diuretic 18, 19. Remarkably, age of 
patients in the present analysis had no impact on the differences in prescription of HF 
medication between centres.
Therefore, perceived polypharmacy, presence of comorbidities and overestimation of 
side-effects may influence use and dosing of evidence-based medication. In addition, 
patient preferences and family caregiver perceptions may influence therapeutic 
decisions 20. Furthermore, an analysis by the BIOSTAT-CHF study group suggested that 
women with HFrEF might need lower doses of RAS inhibitors and beta blockers than 
men, also adjusted for age 21.
However, it is unclear why not only new medication, e.g. ivabradine and more recently 
sacubitril/valsartan, but also long-standing, established, disease-modifying therapies 
are not widely adopted nor fully prescribed. Therefore, it is important to gain detailed 
insights in reasons for not adopting recommended therapies both at a hospital 
level and at an individual patient level. Assessing information on real motivation of 
medical decisions and perceived barriers would contribute to effective improvement 
of HF care.
Importantly, suboptimal use of HF medication may have detrimental effects on clinical 
outcomes. Adherence to guideline-directed therapy of HFrEF, with prescription of at 
least 50% of the target dosage is associated with better outcome 6, 22, at least in younger 
patients with little comorbidities 23.
Optimising heart failure management
Although nonadherence to guideline-directed HF therapies is not fully understood, 
several practical recommendations to improve HF management can be made 
(Suppl. Table 8).
Obviously, being informed on performance of health care professionals involved in 
HF management, will contribute to improving delivery of care. Therefore, the CHECK-
HF centres received individual feedback and in national meetings possible solutions 
to optimise HF care were shared. Furthermore, a nationwide, structured HF registry 
is being launched.
8
146122_Veenis,Jesse_BNW-def .indd   177 13-11-2020   14:38
178
Part A | Chapter 8
Acknowledging that HF care should be delivered seamless to patients, the Netherlands 
Society of Cardiology, started the CONNECT Heart Failure programme, in which concepts 
of integrated collaboration were translated towards detailed protocols by joint health 
care professionals in geographic regions 24. These collaborations also provide strategies 
for optimising diagnostic pathways and HF therapies, accompanied by educational 
activities for professional teams. The initiated national registry will provide information 
on the effectiveness of incorporating these strategies.
At a patient level, clinical judgment of the heart failure syndrome, management of 
comorbidities, in concert with optimally implemented disease-modifying therapies are 
of pivotal importance 25–27. In addition, blood pressure, renal function and hyperkalaemia 
may limit up-titration of all recommended drugs 28. Thismay be evenmore complicated 
by the fact that the number of drug classes shown to improve outcome in HFrEF is 
increasing 29. Among potential solutions are start-low and go-slow dosing strategies, 
close monitoring of vital parameters and side-effects, the use of new potassium binders 
and angiotensin receptor/neprilysin inhibition. Critical appraisal and reduction of co-
medication may also be beneficial. In addition, pharmacy care improves adherence to 
HF medications and quality of life, which was recently demonstrated by the PHARM-
CHF investigators 30.
In concert with dedicated efforts of professional HF teams, well-informed patients 
and family caregivers may empower their participation in medical decisionmaking 
and contributes to earlier access of new therapies 5, 24. Informed treatment choices 
are of particular relevance in guidance of decisions during advanced and palliative 
stages of care.
Limitations and strenghts
The CHECK-HF registry is a large-scale real-world registry of HF outpatient clinics in 
the Netherlands reflective of Western European countries. However, some limitations 
should be mentioned, such as the crosssectional design limiting follow-up data on 
patient outcomes. Some missing data exists, which might influence results. Our registry 
included only patients seen in secondary, but not in primary care, which limits the 
generalisability of our findings to the primary care setting. Information on actual 
protocols of diagnostic workup and medical decision-making strategies in centres was 
not collected. Notably, the CHECK-HF inclusion period was from 2013 till end of 2016, in 
which the CONNECT programme for Heart failure regional care had been in the initial 
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phase of implementation in regions. Therefore, we have not collected data on adoption 
of the CONNECT Heart Failure programme in the centres. Strengths of the study are 
the reflection of the true practice of large scale nationwide outpatient HF management 
with detailed information on medication prescription and dosage.
Conclusion
In this Dutch real-world registry of outpatient HF population, wide between-clinic 
ranges of demography, severity of heart failure and comorbidities of HF patients 
were observed. Also the prescription rates and prescribed dosages of guideline-
recommended HF medication differed significantly, not fully explained by differences 
in the patient profiles. Thus, future research should lead to strategies to improve 
management of HF patients including reduction of practice variation.
8
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ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, MRA mineralocorticoid receptor 
antagonist, HFrEF heart failure with reduced ejection fraction
Suppl. Table 2. Baseline characteristics in HFrEF patients (LVEF<40%) and range between centres
Overall population Range
Number of patients 5,701 25; 785
Age (years) (n=5,694) 71.4±11.8 66.9±11.8; 75.8±10.3
Male gender (n=5,677) 3,767 (66.4) 57.5; 82.9
BMI, kg/m2 (n=5,276) 27.2±5.1 25.9±3.7; 29.1±6.9
NYHA (n=5,643)
I 839 (14.9) 0.0; 46.2
II 3,244 (57.5) 33.3; 87.5
III 1,449 (25.7) 7.7; 62.7
IV 111 (2.0) 0.0; 8.9
LVEF, % (n=4,880) 29.3±9.0 26.7±8.5; 38.1±16.5
Cause of HF (n=5,505)
Ischaemic cause of HF 2,945 (53.5) 35.1; 69.3
Non-ischaemic cause of HF 2,560 (46.5) 30.7; 64.9
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Suppl. Table 2. (continued)
Overall population Range
Systolic BP, mmHg (n=5,613) 124.4±20.2 111.5±18.3; 133.6±22.7
Diastolic BP, mmHg (n=5,615) 71.2±11.2 64.3±10.6; 75.8±12.9
Heart rate, bpm (n=5,624) 71.9±13.8 64.8±8.0; 77.6±16.8
Atrial fibrillation (n=5,625) 1,258 (22.4) 12.2; 56.0
LBBB (n=5,701) 1,050 (18.4) 0.0; 32.4
QRS ≥130 ms (n=4,824) 2,080 (43.1) 0.0; 58.1
eGFR (n=4,178) 61.2±24.9 48.5±26.2; 97.5±16.7
eGFR (n=4,178)
<30 430 (10.3) 0.0; 19.5
30-59 1,676 (40.1) 0.0; 63.6
≥60 2,072 (49.6) 18.2; 100.0
Comorbidity (n=5,073)
Hypertension 1,944 (38.3) 5.6; 76.7
Diabetes Mellitus 1,481 (29.2) 17.6; 51.4
COPD 900 (17.7) 6.7; 33.3
OSAS 320 (6.3) 0.0; 16.7
Thyroid disease 368 (7.3) 0.0; 12.2
Renal insufficiency † 2,741 (54.8) 28.6; 84.0
No relevant comorbidity 671 (15.0) 0.0; 33.3
† Defined as eGFR <60ml/min or a history of renal failure
BMI body mass index, NYHA New York Heart Association classification, LVEF left ventricular ejection fraction, 
HF heart failure, HFrEF HF with reduced ejection fraction; BP blood pressure, LBBB left bundle branch 
block, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, COPD 
chronic obstructive pulmonary disease, OSAS obstructive sleep apnoea syndrome
Suppl. Table 3. Baseline characteristics in HFmrEF patients (LVEF 40-49%) and range between centres
Overall population Range
Number of patients 1,574 3; 415
Age (years) (n=1,573) 73.7±11.7 68.1±12.8; 80.9±6.8
Male gender (n=1,571) 917 (58.4) 34.5; 100.0
BMI, kg/m2 (n=1,462) 27.5±5.4 24.0±7.0; 30.5±4.4
NYHA (n=1,558)
I 284 (18.2) 0.0; 50.0
II 854 (54.8) 22.2; 90.0
III 392 (25.2) 5.5; 66.7
IV 28 (1.8) 0.0; 11.6
LVEF, % (n=1,299) 45.0±5.4 46.2±5.3; 48.8±9.0
8
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Suppl. Table 3. (continued)
Overall population Range
Cause of HF (n=1,521)
Ischaemic cause of HF 691 (45.4) 11.1; 70.0
Non-ischaemic cause of HF 830 (54.6) 30.0; 88.9
Systolic BP, mmHg (n=1,556) 129.5±21.6 113.5±17.5; 138.7±21.9
Diastolic BP, mmHg (n=1,560) 71.8±12.0 58.3±13.9; 77.2±8.6
Heart rate, bpm (n=1,554) 72.5±14.3 63.2±10.0; 79.3±17.9
Atrial fibrillation (n=1,559) 534 (34.3) 9.5; 71.4
LBBB (n=1,574) 216 (13.7) 0.0; 66.7
QRS ≥130 ms (n=1,320) 416 (31.5) 0.0; 100.0
eGFR (n=973) 56.2±23.7 35.8±3.0; 96.4±9.9
eGFR (n=973)
<30 133 (13.7) 0.0; 45.5
30-59 439 (45.1) 0.0; 100.0
≥60 401 (41.2) 0.0; 100.0
Comorbidity (n=1,417)
Hypertension 619 (43.7) 0.0; 81.8
Diabetes Mellitus 397 (28.0) 0.0; 66.7
COPD 291 (20.5) 0.0; 44.4
OSAS 116 (8.2) 0.0; 28.6
Thyroid disease 111 (7.8) 0.0; 33.3
Renal insufficiency † 745 (60.9) 0.0; 100.0
No relevant comorbidity 98 (9.0) 0.0; 38.9
† Defined as eGFR <60mL/min or a history of renal failure
BMI body mass index, NYHA New York Heart Association classification, LVEF left ventricular ejection fraction, 
HF heart failure, HFmrEF HF with mid-range ejection fraction; BP blood pressure, LBBB left bundle branch 
block, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, COPD 
chronic obstructive pulmonary disease, OSAS obstructive sleep apnoea syndrome
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Suppl. Table 8. Practical recommendations for optimal use of guideline-directed heart failure therapies
At hospital level, providing:
Multidisciplinary team (MDT) care programme
Trained allied professionals (e.g. nurse-specialists and physician assistants)
Life-long learning programme for health-care professionals
Transmural collaboration
Up-to-date diagnostic and therapeutic protocols
Nurse-directed or pharmacist-directed optimisation of recommended medication
Advanced and palliative care programme
e-Health solutions, telemonitoring facilities
Benchmarking and adopting best practices
Monitoring of adherence, clinical outcomes and patient reported outcomes
Periodic review of performance, improving heart failure care accordingly
At patient level, aimed at:
MDT is fully informed regarding medical history and social context
Assessing current condition and therapies
Management of comorbidities
Awareness of cognitive impairment and frailty
Matching patient profile and therapeutic options
Initiation, up-titration and maintenance of evidence-based therapies
Tailored dosing regimens and monitoring of blood pressure and heart rate
Addressing intolerabilities and side effects
Critical appraisal of polypharmacy
Patient education and counselling
Promoting self-management
Home-based monitoring, with implantable devices if applicable
In select patients: implantable pulmonary artery pressure monitoring
Addressing patient preferences and barriers
Involvement of family caregivers
Tailored end-of-life choices
Holistic approach preferably
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Suppl. Fig. 1. Prescription rates (%) and prescribed dosages (%) of HF medication in HFrEF patients (LVEF 
<40%) per participating clinic (n = 34) (The left panels show the order of hospitals on the x-axis based on 
the percentage of prescription rate of each drug. The red bar is the overall prescription rate (%) and the 
green bars are the prescription rates (%) in each clinic. The same order is shown in the panels on the right). 
(HF heart failure, HFrEF heart failure with reduced ejection fraction, LVEF left ventricular ejection fraction, 
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Suppl. Fig. 2. Prescription rates (%) and prescribed dosages (%) of HF medication in HFmrEF patients (LVEF 
40–49%) per participating clinic (n = 34) (The left panels show the order of hospitals on the x-axis based 
on the percentage of prescription rate of each drug. The red bar is the overall prescription rate (%) and 
the green bars are the prescription rates (%) in each clinic. The same order is shown in the panels on the 
right). (HF heart failure, HFmrEF heart failure with mid-range ejection fraction, LVEF left ventricular ejection 
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Suppl. Fig. 3. Prescription rates and prescribed dosages of HF medication in HF patients with semiquan-
titatively measured LV function per participating clinic (n = 27) (The left panels show the order of hos-
pitals on the x-axis based on the percentage of prescription rate of each drug. The red bar is the overall 
prescription rate (%) and the green bars are the prescription rates (%) in each clinic. The same order is 
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Abstract
Exacerbations of chronic heart failure (HF) with the necessity for hospitalisation 
impact hospital resources significantly. Despite all of the achievements in medical 
management and non-pharmacological therapy that improve the outcome in HF, 
new strategies are needed to prevent HF-related hospitalisations by keeping stable 
HF patients out of the hospital and focusing resources on unstable HF patients. 
Remote monitoring of these patients could provide the physicians with an additional 
tool to intervene adequately and promptly. Results of telemonitoring to date are 
inconsistent, especially those of telemonitoring with traditional non-haemodynamic 
parameters. Recently, the CardioMEMS device (Abbott Inc., Atlanta, GA, USA), an 
implantable haemodynamic remote monitoring sensor, has shown promising results 
in preventing HF-related hospitalisations in chronic HF patients hospitalised in the 
previous year and in New York Heart Association functional class III in the United States. 
This review provides an overview of the available evidence on remote monitoring in 
chronic HF patients and future perspectives for the efficacy and cost-effectiveness of 
these strategies.
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Introduction
The management of patients with chronic heart failure (HF) places a high burden on 
health care resources due to the frequent follow-up visits combined with recurrent 
hospitalisations due to cardiac decompensation. 1 Early detection of HF deterioration 
is crucial to prevent HF-related hospitalisations, potentially improve overall survival 
and quality of life and lower the burden on health care resources. Remote monitoring 
of chronic HF patients can aid in the detection of HF deterioration; therefore several 
remote monitoring strategies have been developed. In this review, we provide an 
overview of available evidence on remote monitoring of chronic HF patients and provide 
further perspectives of anticipated developments in the remote care of HF.
Non-haemodynamic remote monitoring
Over the last few decades, several studies have investigated the use of non-
haemodynamic remote monitoring. However, the results have been largely inconsistent. 
A recently updated Cochrane review included 41 randomised controlled trials (RCTs) 
investigating the use of structured telephone support (25 studies, 9332 patients) or 
non-invasive telemonitoring (18 studies, 3860 patients) compared with standard HF 
care. 2 This review showed a modest beneficial effect of remote monitoring on all-
cause mortality and HF-related hospitalisations, although no effect on the overall 
hospitalisation rates was observed. However, the quality of the evidence of this review 
is limited by the many different inclusion and exclusion criteria for patients included 
in the studies and considerably heterogeneity of compared data. Also, the studies 
included used different intervention therapies, ranging from telephone calls only, 
weight monitoring to complex multiple-variable telemonitoring strategies making it 
difficult to conclude which component drives the effect. Additionally, the majority of 
selected individual studies (more than twenty) were neutral.
Multiple large multi-centre prospective clinical studies and RCTs have investigated 
multiple noninvasive remote monitoring strategies, ranging from symptom and body 
weight monitoring to complex and intensive strategies including body weight, blood 
pressure, electrocardiography and peripheral capillary oxygen saturation. The landmark 
studies of high quality design and well specified intervention show no consistent 
beneficial effect of non-haemodynamic remote monitoring in HF patients (Tab. 1). 3–11 
Of specific note and most promising are the recent results of TIM-HF2 trial showing a 
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benefit on all-cause mortality and cardiovascular hospitalizations of a well-structured 
but labour intensive 24/7 telemonitoring strategy, but remarkably showed no effect 
on quality of life. 6 Also, ‘real-world’ data, such as those from the Medicare database, 
did not show consistent benefits of non-haemodynamic remote monitoring strategies 
on mortality or hospitalisation rates. 12 Our conclusion is that although results are 
inconsistent for non-invasive telemonitoring, the simplicity makes it potentially useful 
for larger groups of HF patients at relatively lower risk or less symptomatic, where 
invasive telemonitoring may have more impact in sicker patients.
Remote monitoring using pacemaker/ICD devices
Multiple studies have investigated the remote monitoring abilities of implantable 
cardioverter defibrillator/cardiac resynchronisation therapy (ICD/CRT) devices in chronic 
HF patients to improve HF-related hospitalisation rates (Tab. 2). The MORE-CARE multi-
centre RCT showed that remote monitoring of advanced diagnostics via CRT-D did not 
reduce mortality or hospitalisation rates, although the health care resource utilisation 
was reduced due to a reduction in outpatient follow-up visits. 13 Additionally, the DOT-
HF, OptiLink and REM-HF trials investigated the use of remote monitoring using ICD/CRT 
devices, but all failed to show a reduction in HF-related hospitalization rates. 14–16 The 
DOT-HF trial even showed an increase in the number of HF hospitalisations in the remotely 
monitored groups. 16 The EFFECT study, a multi-centrer clinical trial, showed that remote 
monitoring of ICD in HF patients reduced mortality and cardiovascular hospitalisations, 
17 and the COMMIT-HF trial showed that remote monitoring of ICD/CRT HF patients 
significantly reduces long-term mortality but not HF-related hospitalisations. 18
Other patient outcomes have been investigated as well, with mixed results. The IN-
TIME RCT showed that using the remote monitoring abilities of the ICD and CRT devices 
leads to a reduction of a combined endpoint of all-cause death, overnight HF-related 
hospitalisation, change in New York Heart Association (NYHA) class, and change in 
patient global self-assessment. 19 However, other trials found no significant effect on 
patient outcomes. 20, 21 The effect of remote monitoring using ICD/CRT devices has 
recently been investigated in a meta-analysis, including 11 RCTs (5702 patients). This 
meta-analysis showed a reduction in the number of outpatient visits in remotely 
monitored patients, although remote monitoring with an ICD/CRT device had no effect 
on mortality or HF-related hospitalisations rates in these patients. 22
10
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The MultiSENSE algorithm aims to predict the individualized risk for worsening of HF 
based on first and third heart sounds, thoracic impedance, respiration rate, the ratio 
of respiration rate to tidal volume, heart rate and patient activity. This could aid in 
the timely detection of HF worsening with the threshold retrospectively calculated by 
the algorithm. However, the overall sensitivity is only 70%. 23 Another algorithm with 
a similar aim is the HeartLogic algorithm. 24 To date, no clinical endpoint data or trial 
data are available and the technique is limited to certain ICD types and brands only.
The shift in remote HF care: haemodynamic (invasive) 
remote monitoring
In HF patients cardiac filling pressures rise weeks before an exacerbation of HF 
leading to a related hospitalisation. Symptoms of clinical congestion such as gain 
in body weight will occur about 2 weeks later, usually shortly before hospitalisation 
(Fig. 1). 25 Monitoring of cardiac filling pressures can be an effective strategy to detect 
upcoming HF decompensation, as it might provide a window of opportunity to intervene 
adequately and promptly, which is not possible with previous remote monitoring 
strategies. Therefore multiple implantable haemodynamic monitoring devices have 
been developed over the last few years. The ePAD (Medtronic, Dublin, Irland) device, 
an estimate pulmonary artery (PA) end-diastolic pressure device, can be implanted in 
the right ventricle and has been investigated in the COMPASS-HF trial. In this trial, NYHA 
class III/IV chronic HF patients were included and investigated as to whether remote 
haemodynamic monitoring using the ePAD could reduce HF-related hospitalisation, 
emergency or urgent care visits requiring intravenous therapy. This study did not find 
significant differences in its endpoint, although it was underpowered due to a lower 
inclusion rate. Furthermore, clinicians did not receive guidance on how to react to 
pressure changes. 26
Left atrium pressures (LAP) can be directly measured using a LAP device. The tip 
of this device is implanted transvenously into the atrial septum oriented towards 
the left atrium, enabling remote LAP monitoring. This device was used only in the 
LAPTOP-HF trial, which aimed to investigate the safety and effectiveness of this sensor. 
However, the enrollment was stopped early due to a perceived excess of procedure-
related complications. This is an important issue as the procedure needs an interatrial 
septum puncture and is placed in the left side of the heart with the risk of arterial 
side complications. However, in the patients already included in this trial, and followed 
for 12 months, a 41% reduction of HF-related hospitalisations was observed in the 
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patients with a LAP device. 27 Currently, the V-LAP™Left Atrium Monitoring systEm for 
Patients With Chronic sysTOlic and Diastolic Congestive heaRt Failure (VECTOR-HF) trial 
is investigating a new LAP device (V-LAP; Vectorious Medical Technologies Ltd., Tel Aviv, 
Israel) to assess the safety, performance and usability of this device in NYHA class III 
HF patients (NCT03775161).
Fig. 1 Pathophysiology of decompensated heart failure. (Reprinted from 54, with permission)
Off all the remote monitoring strategies currently available, remote haemodynamic 
monitoring using the CardioMEMS HF system device (Abbott Inc., Atlanta, GA, USA) 
(Fig. 2) appears to be the most promising with respect to safety, durability and ability 
to prevent HF-related hospitalisations. The CardioMEMS is implanted into the PA and 
enables daily pulmonary artery pressure (PAP) readings. Treating physicians can react to 
these changes in PA trend data to maintain normal PAP levels, as a sign of a stable clinical 
status. Furthermore, these daily PAP readings can be used as a feedback mechanism 
after treatment changes, providing feedback on whether the treatment changes led to 
a sufficient decline of PAPs. These strategies can lead to individualised HF therapy.
The CardioMEMS consists of a coil combined with a pressure-sensitive capacitor sealed 
in a capsule, forming an electrical circuit that resonates at a specific frequency when it 
is electromagnetically coupled with an external antenna. 28 This antenna provides the 
power for the device, so the device is completely free from batteries or leads. At both 
sides of the capsule, a loop is placed to ensure that the CardioMEMS remains at the 
implanted position until the endothelialisation is complete, approximately 3–4 weeks 
after implantation. When pressure is applied, the resonant frequency changes via a 
characteristic pattern and is received by the external antenna. The antenna converts 
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this signal into a pressure waveform and sends it to a secure website, where it can be 
monitored. The device is implanted during a right heart catheterisation, with access via 
the femoral vein. An appropriate target location, based on vessel size and location, is 
identified on a pulmonary arteriogram. The CardioMEMS delivery system is advanced 
to the target location over a guidewire, where the CardioMEMS is released. After 
implantation, the device is calibrated using PAP obtained with a Swan Ganz catheter.
ba
Fig. 2 CardioMEMS HF system, consisting of the pulmonary artery pressure sensor (a) and the patient 
electronics system (b) used to take daily pressure readings. (Courtesy of Abbott, Inc.)
Two studies have validated the PAP measured by the CardioMEMS, with cardiac filling 
pressures measured by Swan-Ganz catheterisation or echocardiography directly after 
implantation and after 6 months of follow-up. 29, 30 Swan-Ganz measurements showed a 
good correlation with mean PAP assessed by CardioMEMS (r2= 0.90at implantation and 
r2=0.94at follow-up, p< 0.01). 30 Furthermore, a good correlation (r2= 0.80 at implantation 
and r2= 0.75, both p<0.01at follow-up) was found between PAP measurements by the 
CardioMEMS and estimated pressure measurements by echocardiography. 29
Safety
The safety of the CardioMEMS has been investigated in the CHAMPION trial. A total of 
15 serious adverse events occurred during all implantation attempts in the CHAMPION 
trial. 31 In total, 1% (n= 8) of patients developed a device-related adverse event, and 
1% (n= 7) developed a procedure-related adverse event. The following events were 
reported: four bleeding events, three anticoagulation-related hospitalisations, two pre-
existing atrial dysrhythmia exacerbations during implantation, two febrile illnesses, one 
pulmonary in situ thrombus during implantation that was treated with anticoagulation, 
one cardiogenic shock, one case of atypical chest pain, and one delivery-system failure 
requiring a snare to remove the delivery system. 32 An analysis of the post-marketing 
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data of more than 5500 CardioMEMS implantations showed that 2.8% of all CardioMEMS 
patients experienced an adverse event. 33 Most adverse events were a recalibration of 
the system (n= 35) or access-site-related bleeding (n= 15). The reported adverse event 
rates are comparable with those of a standard right heart catheterisation, which is 
considered a safe procedure. 34 The recent US Post Approval Study (PAS) reported a 
device- or system-related complication in 0.3% of all patients, and a sensor failure in 
only 0.1% of all patients, which confirms the safety and durability of this technique.
Clinical efficacy
The CardioMEMS was investigated for the first time in the CHAMPION trial. 32 In this 
trial, 550 patients with NYHA class III HF and at least one hospitalization in the last 
year received a CardioMEMS and were randomised. Of the patients in the intervention 
group, the haemodynamic information was available to the treating physicians, and 
the physicians were instructed to react on pressure changes. In the control group, the 
CardioMEMS readings were not available to the physicians, and these patients received 
only the standard care. Using the haemodynamic feedback in the intervention group 
led to a significantly higher number of medication changes, especially diuretics and 
vasodilator changes, compared to the control group. 35 Furthermore, remote monitoring 
with the CardioMEMS device led to a significant reduction in mean PAP 32, 36; similar 
results were observed in a real-world setting. 37
The effectiveness of the CardioMEMS in preventing HF-related hospitalisations has been 
investigated in multiple studies (Fig. 3). 32, 36, 38, 39 During the first 6 months of remote 
monitoring of HF patients, the HF hospitalisation rates declined by approximately 
30% 32, 38 compared with standard care. During the long-term follow-up, the sustained 
reduction was approximately 33%. 31, 38, 39 Also, all-cause hospitalisation rates were 
reduced: 45% at 6 months 38 and 16% at 18 months of follow-up. 31 None of these studies 
were powered to observe mortality differences; however, the CHAMPION trial showed 
a strong trend towards survival benefit in HF and reduced ejection fraction (HFrEF) 
patients monitored with the CardioMEMS system (p= 0.06). 40
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Fig. 3 Cumulative heart-failure-related hospitalisations during the entire period of randomised single-blind 
follow-up (a), and freedom from first heart-failure-related hospitalisation or mortality (b) in the CHAMPION 
trial. (Reprinted from 32, with permission)
The recently presented PAS results confirm the consistent treatment benefit with 
CardioMEMS in chronic HF patients, reducing the number of HF hospitalisations in 
a more contemporary setting. The PAS study showed a 58% reduction in HF-related 
hospitalization in the first year after CardioMEMS implantation compared with 1 year 
before implantation. Furthermore, a reduction in HF hospitalisations, mortality and 
all-cause mortality was observed after CardioMEMS implantation. However, patients 
included in the PAS study were their own historical controls and there has been no 
randomised comparison to standard care without PA monitoring.
CardioMEMS and evidence in HFpEF patients
In a real-world setting, remote monitoring using the CardioMEMS leads to a similar 
reduction in mean PAP in both HFrEF and HFpEF patients. 37 Interestingly, in the 
CHAMPION trial, a larger reduction of HF-related hospitalisations in HFpEF patients 
compared with HFrEF patients was observed after at least 6 months of remote 
monitoring. 40, 41 Besides the alleged benefit of spironolactone in the United States (US) 
and European participants of the TOPCAT trial 42 with spironolactone, this is the first 
evidence of a treatment or tool to improve the outcome in HFpEF patients.
10
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Standard care in chronic HF
Recently two large HF registries have been published, the CHAMP-HF registry 43 from 
the USA and the CHECK-HF Registry 44 from The Netherlands. These two registries 
showed the differences in standard care between the USA and Western Europe. The 
prescription rates of RAS inhibitors (82.3% vs 59.9%), beta-blockers (80.6% vs 66.8%) and 
mineralocorticoid receptor antagonist (MRA) (54.8% vs 33.1%) in HFrEF patients were 
much higher in the CHECK-HF registry compared to the CHAMP-HF registry (Fig. 4a). 
Furthermore, the prescribed dosages differed between the two registries, with higher 
prescribed dosages for RAS inhibitors in the CHECK-HF registry and higher dosages for 
MRA in the CHAMP-HF registry (Fig. 4b) Differences in the HF readmission rates were 
observed between the USA and Europe. 45, 46 The generalizability of the US findings 
in terms of clinical effectiveness when using the CardioMEMS device in addition to 
standard care is therefore limited, and additional costs cannot be directly extrapolated 
between the two different health care structures. Additional research is needed in the 
European setting. In Germany, the CardioMEMS European Monitoring Study for Heart 
Failure (MEMS-HF) study was set up as a post-marketing study to test the safety and 
clinical effectiveness in a European setting but lacks a control group. 47
Cost-effectiveness of CardioMEMS
The cost-effectiveness of remote monitoring using the CardioMEMS is highly relevant. 
Using the US CHAMPION trial data the incremental cost-effective ratio (ICER, cost per 
quality-adjusted life-year) for the US setting has been calculated. 32, 48–50 These studies 
estimated an increase in the quality-adjusted life-years in the CardioMEMS group of 
between 0.28 and 0.58, with incremental costs between $4282 and $20,079, compared 
with standard care patients. This results in an estimated ICER in the USA of between 
$13,379 and $71,462, which are additional costs in order to gain one quality-adjusted 
life-year in patients monitored with the CardioMEMS device. Sensitivity analyses 
demonstrated that the cost-effectiveness of the CardioMEMS is highly influenced by 
device costs, costs of routine outpatient care, hospitalisation rates, mortality rates and 
duration of remote monitoring using the CardioMEMS.
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Fig. 4 Differences between the United States and the Netherlands in the use of (a) and dosing of (b) 
guideline-recommended medication in patients with heart failure and reduced ejection fraction in the 
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There are no patient-level data for cost-effectiveness analyses in Western Europe. With 
assumptions and estimations based on extrapolating data from the CHAMPION trial 
and despite the large differences in standard care and financial systems, Cowie et al. 51 
calculated the ICER in the European setting, which was approximately between €22,555 
(for the Netherlands) and €23,814 (for Germany). However, all these analyses used data on 
the reduction of HF hospitalization from the CHAMPION trial and used different estimated 
mortality rates from population-based cohorts for the cost-effectiveness analyses.
Health care utilisation
Two studies investigated the potential reduction of health care utilisation achieved by 
using the CardioMEMS. 38, 52 In a real-world Medicare database, 1-year remote monitoring 
with the CardioMEMS led to an $11,260 cost reduction for HF hospitalisations compared 
with 1 year before the CardioMEMS implantation. 38 Based on the effects reported in the 
CHAMPION trial, and the expected prevalence and hospitalisation costs in Germany, 
remote monitoring with the CardioMEMS could lead to an overall cost reduction of 
106,000,000 in Germany in 2021. 52
As shown above, remote monitoring of PAP with the CardioMEMS in chronic HF patients 
leads to more medication changes and a larger reduction of PAP compared with patients 
receiving standard care, indicating that these patients receive more individualized HF 
care. In the US, this strategy was effective in reducing the number of HF-related and 
all-cause hospitalisations. It was suggested that this strategy could improve mortality 
rates and has been shown to be cost-effective. However, as discussed earlier, some 
important differences in HF care exist between the USA and Europe.
Recommendation of ESC 2016 guidelines on remote 
monitoring
The 2016 ESC guidelines report on the lack of consistent evidence for non-
haemodynamic telemonitoring or remote monitoring in HF patients. The guidelines 
state that remote monitoring may be considered in selected patients to improve HF 
outcome with individual approaches such as CardioMEMS to reduce the risk of HF 
admissions and multi-parameter monitoring with ICD (in-time approach) to improve 
outcome in HFrEF patients with a level IIb class B recommendation. 53
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Conclusion
In recent years, many remote monitoring strategies have been developed, and development 
continues at a rapid rate. Non-invasive remote monitoring of symptoms and signs, as well 
as weight, has not been proven to be effective in improving outcome measurements. Also, 
the monitoring of biomarkers or thoracic impedance has not been shown to be beneficial. 
Invasive or haemodynamic measures of remote monitoring are developed with right-sided 
(CardioMEMS) and left-sided (LA devices) sensors. The LAPTOP-HF trial with LA devices 
was stopped early for safety reasons. The CardioMEMS is the most promising (invasive) 
remotemonitoring tool currently available. The haemodynamic information allows for 
a window of timely and adequate intervention based upon raised PAP, preventing an 
upcoming HF decompensation. Additionally, its safety and durability have been tested 
and confirmed in post-marketing studies. However, important information on the effect 
on the quality of life and cost-effectiveness is still lacking in a Western European setting, 
which is currently being investigated in the MONITOR-HF study.
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Abstract
Background: Assessing haemodynamic congestion based on filling pressures instead 
of clinical congestion can be a way to further improve quality of life (QoL) and clinical 
outcome by intervening before symptoms or weight gain occur in heart failure (HF) 
patients. The clinical efficacy of remote monitoring of pulmonary artery (PA) pressures 
(CardioMEMS; Abbott Inc., Atlanta, GA, USA) has been demonstrated in the USA. 
Currently, the PA sensor is not reimbursed in the European Union as its benefit when 
applied in addition to standard HF care is unknown in Western European countries, 
including the Netherlands.
Aims: To demonstrate the efficacy and cost-effectiveness of haemodynamic PA 
monitoring in addition to contemporary standard HF care in a high-quality Western 
European health care system.
Methods: The current study is a prospective, multicentre, randomised clinical trial 
in 340 patients with chronic HF (New York Heart Association functional class III) 
randomised to HF care including remote monitoring with the CardioMEMS PA sensor 
or standard HF care alone. Eligible patients have at least one hospitalisation for HF in 
12 months before enrolment and will be randomised in a 1:1 ratio. Minimum follow- up 
will be 1 year. The primary endpoint is the change in QoL as measured by the Kansas 
City Cardiomyopathy Questionnaire (KCCQ). Secondary endpoints are the number of HF 
hospital admissions and changes in health status assessed by EQ-5D-5L questionnaire 
including health care utilisation and formal cost-effectiveness analysis.
Conclusion: The MONITOR HF trial will evaluate the efficacy and cost-effectiveness of 
haemodynamic monitoring by CardioMEMS in addition to standard HF care in patients 
with chronic HF.
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Introduction
In Western European countries such as the Netherlands, chronic heart failure (HF) is 
estimated to occur in 1.5–2.0% of the population. 1, 2 In the Netherlands, the prevalence 
was 227,000 patients in 2017, and the number of HF hospital admissions is high at 
29,011 admissions per year with an average hospital stay of 9 days. 1, 2 The overall 
hospital burden from HF hospitalisations will rise rapidly in the coming decade due 
to aging of the population and better survival following myocardial infarctions. The 
main public and personal burden of HF is clustered in patients with New York Health 
Association (NYHA) functional class III and IV, who most often need to be hospitalised. 
Approximately 25% of all Dutch HF patients are in NYHA class III based on the latest 
CHECK HF registry findings. 3 Contemporary treatment of chronic HF shows a reasonably 
high adherence to European guidelines for the recommended drugs, when compared 
to US data in the CHAMP-HF registry. 4, 5 Still, both registries show considerable room 
for improvement in HF therapy considering target or optimal dosing of medication. 4, 
5 So clearly, despite optimal medical treatment, there is a considerable residual risk, 
especially for patients in NYHA class III. The main problem for care givers and patients 
is timely recognition of a daunting cardiac decompensation and, if recognised, to react 
adequately and promptly.
Remote monitoring and telemonitoring initiatives have received wide attention for their 
promise in detecting early signs of decompensation and guiding HF therapy. Proactive 
guided treatment could optimize treatment further and prevent clinical deterioration. 
Such an approach could reduce HF hospitalisations and relieve the large burden of 
chronic HF exacerbations for the current health care systems. However, numerous 
telemonitoring programmes which were based on remote signs of clinical congestion 
such as weight or symptoms or impedance measurements through pacemakers 
have been largely disappointing. 6–15 From a physiological point of view, weight gain 
and symptoms of HF are late signs of an exacerbation of HF. New management 
strategies should focus on markers preceding the exacerbation of HF. It has been 
recognised that a period of decompensation starts with a rise in (intracardiac) filling 
pressures. A chain of events from haemodynamic (asymptomatic) congestion transits 
to clinical congestion.
CardioMEMS (Abbott Inc., Atlanta, GA, USA) is a small sensor capable of measuring 
pressures in the pulmonary artery (PA) on a daily basis. PA pressures can be used as an 
invasive haemodynamic surrogate marker of filling pressures, which has been shown 
11
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to precede a period of decompensation for several weeks. This time window would 
allow the physician to intervene before clinical symptoms arise and act in a proactive 
way to avert an exacerbation of HF by adjusting the dose of diuretics or vasodilators. 
In line with this hypothesis, the CHAMPION trial in the USA demonstrated a significant 
37% reduction in HF hospitalisations with PA monitoring applied in addition to standard 
care in patients with chronic HF. 16, 17 Observations in post-marketing studies (with 
historical controls) were consistent and confirm the low-risk and safe procedure as 
well as the durability of the device. 17–20 Despite the innovation in patient management, 
several profound differences exist in the organisation of HF care (HF outpatient clinic 
and HF nurses), level of standard care, as well as financial structure of the health care 
systems in Europe and the USA, which mean that the results of this one trial cannot be 
translated directly. Additionally, individual trial data in a European setting are lacking 
and clinical and financial data can only be extrapolated from US data, 21, 22 in the 
knowledge that the costs and setup of the US health care system are not comparable 
to the European situation. We therefore designed the MONITOR HF randomised clinical 




The MONITOR HF trial is an investigator-initiated, multicentre, randomised clinical trial 
enrolling 340 patients with chronic HF NYHA class III and at least one HF hospitalisation 
in the previous 12 months. In total, 20 Dutch hospitals, distributed over the country, 
agreed to participate (Fig. 1; Electronic Supplementary Material, Appendix Tab. 1). Sites 
without previous experience with CardioMEMS will go through a learning curve of two 
patients for sensor implantation and pressure management, who do not participate in 
the main trial but are followed according to study protocol. Alternatively, added centres 
can proctor two patients in an experienced centre. The MONITOR HF trial aims to test 
the effect of PA monitoring in addition to standard HF care on quality of life (QoL), the 
number of HF hospitalisations and cost-effectiveness in a Dutch health care system. 
Four populations for analysis are defined in the MONITOR HF trial: intention-to-treat, 
as-treated and per-protocol (time until implant after randomisation (maximum 3 weeks 
per protocol)) and safety analysis. The principal analysis for the primary effectiveness 
endpoint will be performed in the intention-to-treat population.
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Fig. 1 Participating centres in the Netherlands
The MONITOR HF trial is sponsored by the Dutch Ministry of Health and National Health 
Care Institute (Zorginstituut, Nederland) as part of a conditional coverage programme 
in the Netherlands for the health-care-related costs. The study and data management 
are performed by the CRO Erasmus MC University Medical Centre (Sponsor).
Type of patients
Patients with chronic HF (≥3 months) in NYHA functional class III and at least one 
hospitalisation for HF (or emergency ward visit resulting in intravenous diuretic therapy) 
in the 12 months prior to enrolment are eligible for the trial. The diagnosis of HF is 
made according to the criteria set out in the 2016 European Society of Cardiology (ESC) 
11
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guidelines for the treatment of HF. 23 Patients with HF and reduced ejection fraction 
(HFrEF), mid-range (HFmrEF) or preserved ejection fraction (HFpEF) are eligible for the 
trial. The inclusion and exclusion criteria are presented in Tab. 1 and 2.
Table 1. Inclusion criteria. In order to be eligible to participate in this study, a subject must meet all of 
the following criteria
1 Written informed consent obtained from subject aged ≥18 years
2 Diagnosis of chronic heart failurea (≥3 months) in NYHA functional class III with 1 HF hospitalisation 
within 12 months (defined as an admission for HF longer than 6h and/or use of i.v. diuretics) or 
emergency ward visit for HF resulting in i.v. diuretic therapy (independent of EF %)
3 HF subjects with reduced EF (HFrEF) should be treated according to national and international 
(ESC) guidelines for optimal or maximum tolerated doses of HF medication and evaluated for ICD 
or CRT-D therapy, if indicated
4 Subjects with a BMI≤ 35. Subjects with BMI> 35 will require their chest circumference to be measured 
at the axillary level<65 inches or 165 centimetre (related to distance of the sensor to the pillow)
5 Subjects willing and able to comply with the follow-up requirements of the study and able to 
comply with the daily readings
a According to the definition given in the 2016 ESC guidelines for heart failure. 10 In line with good clinical 
practice, a patient cannot participate in any other interventional study or active telemonitoring programme 
(on HF parameters) during the study
NYHA New York Heart Association, HF heart failure, EF ejection fraction, ESC European Society of Cardiology, 
ICD implantable cardioverter-defibrillator, CRT-D cardiac resynchronization therapy defibrillator, BMI body 
mass index
Table 2. Inclusion criteria
1 Subjects with an active infection
2 Subjects with a history of recurrent (>1) pulmonary embolism or deep vein thrombosis
3 Subjects who have had a major cardiovascular event (e.g. myocardial infarction, open heart 
surgery, stroke) within the past 2 months
4 Subjects with a CRT implanted <3 months prior to enrolment and implantation of the sensor (in 
order to avoid manipulation of lead)
5 Subjects with an estimated GFR< 25ml/min (obtained within 2 weeks of the baseline visit), 
refractory to diuretic therapy, or on chronic renal dialysis
6 Subjects with complex congenital heart disease or mechanical right heart valve(s)
7 Subjects with known pulmonary arterial hypertension (WHO category 1 or 4/5) in whom PA 
pressure is most likely not responsive to cardiac treatment
8 Subjects scheduled for or likely to undergo heart transplantation or receive a ventricular assist 
device within 6 months of baseline visit
9 Subjects with known coagulation disorders or allergy to acetylsalicylic acid and/or clopidogrel
CRT cardiac resynchronisation device, GFR glomerular filtration rate, PA pulmonary artery
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Randomisation
At the baseline visit, patients will be randomised in a 1:1 ratio for standard care plus 
CardioMEMS PA monitoring versus standard HF care with written and signed informed 
consent. Crossover is not allowed per study protocol and leads to termination of the 
patient’s participation in the study. After randomisation, the sensor is to be implanted 
within 3 weeks per protocol in those randomised to CardioMEMS and a second informed 
consent form will be signed for use of the Merlin.net website.
CardioMEMS system
The CardioMEMS HF system includes an implantable wireless sensor with delivery 
catheter, a patient and hospital electronics system and a patient database (Integrated 
Merlin.net website for patient data management). 16 The sensor measures PA pressure 
using MEMS (micro-electromechanical systems) technology and requires neither 
battery nor leads (wireless). The sensor is implanted in a branch of the left PA via 
a transvenous catheter inserted through the femoral vein. The sensor is 15mm in 
length, 3.4mm in width and 2mm thick. The sensor remains in the PA as a permanent 
implant which endothelialises completely (Fig. 2). A 4-week course of acetylsalicylic 
acid and clopidogrel is recommended in those patients without anticoagulation or 
platelet inhibition. 16 Clinicians are informed about the daily CardioMEMS derived PA 
and PA trends over time via Merlin.net (diagnostic tool in disease management). A study 
operating procedure will be available for clinicians to help them guide HF therapy, most 
importantly based on a significant rise in PA pressure over time, aiming for normal 
PA pressures avoiding progressive clinical congestion, or additionally, a significant fall 
in PA pressure over time avoiding chronic hypovolaemic triggers. The device is FDA 
approved and CE marked for use in chronic HF patients in NYHA class III and with one 
HF hospitalisation in the previous year (NYHA classes, Tab. 3).
Fig. 2 a The CardioMEMS sensor (with permission of Abbott Inc.). b The CardioMEMS HF system patient 
unit including antenna (with permission of Abbott Inc.). c Location of the CardioMEMS sensor in the left 
pulmonary artery (with permission of Abbott Inc.)
11
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Table 3. New York Health Association classification of heart failure symptoms
NYHA class I Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. 
no shortness of breath when walking, climbing stairs etc
NYHA class II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during 
ordinary activity
NYHA class III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, 
e.g. walking short distances (20–100m). Comfortable only at rest
NYHA class IV Severe limitations. Experiences symptoms even while at rest.
Mostly bedbound patients
Standard care
In patients with HFrEF, standard care is defined as treatment according to the 
recommendations in the national and ESC guidelines for HF with up-titrating 
recommended HF therapies to maximum tolerated or optimal dosages and to evaluate 
the patient for an ICD/CRT-D when indicated. 23 For HFpEF (and HFmrEF) treatment 
recommendations are lacking, but in accordance with the 2016 ESC guidelines it is 
advised to focus on optimal management of comorbidities and cardiovascular risk 
factors such as hypertension and atrial fibrillation. 23 All Dutch hospitals have a 
structured HF outpatient clinic with specialized HF nurses who are supervised by a 
cardiologist with experience or specific interest in HF treatment. At these outpatient 
clinics, patients are seen for the uptitration of HF drug therapies at frequent intervals 
to reach optimal or maximum tolerated dosages of evidence-based medication. 
Treatment choices are at the discretion of the physician. Further, patients are 
counselled, e.g. about the aetiology of their HF, diet, fluid and salt restrictions, as well 
as the importance of treatment compliance and of abstaining from tobacco use and 
minimising alcohol consumption. Patients are instructed when to contact the outpatient 
clinic in case of alarming symptoms or abnormal weight gain. After hospital discharge, 
patients are generally seen by the HF nurse within 2 weeks, and we estimate that 
patients visit these outpatient clinics on average 3 times/year to see the nurse and 
at least 2 times/year to see the cardiologist depending on their clinical need and 
ongoing therapeutic decisions.
Hypothesis
We hypothesise that the CardioMEMS HF system applied in addition to standard care 
will improve QoL and reduce HF hospitalisations in patients with chronic HF.
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Clinical study
Inclusion window/enrolment
The planned inclusion phase is 24 months. Twenty centres have initially been selected 
to start including patients in this study. In anticipation of a stable inclusion rate, we 
calculate a mean inclusion rate of 0.7 patients per centre per month to reach a sample 
size of 340 patients in 2 years. Patient inclusions are competitive between centres. If, 
at 6 months, the inclusion rate is lower than 50% of that expected, the number of sites 
can be increased, if necessary.
Duration of follow-up
All patients will be followed for at least 12 months, resulting in a minimum follow-up of 
12 months (for the last patient included) and a maximum follow-up of 36 months (for the 
first patient included) according to the above-mentioned enrolment schedule. The follow-
up visits are scheduled at 3, 6, and 12 months and every 6 months thereafter (Fig. 3).
Fig. 3 The MONITOR HF trial follow-up scheme. Randomisation at baseline visit
Patient visits
At baseline demographics, medical history and medication use are evaluated. An 
echocardiogram is part of the baseline visit (type of HF) as well as a detailed laboratory 
assessment, QoL questionnaires (Kansas City Cardiomyopathy Questionnaire 
(KCCQ) and EQ-5D-5L) and a 6-min walk test (6MWT). 24, 25 During follow-up visits, an 
electrocardiogram (ECG) is recorded in all patients, NYHA class is established, and a 
physical examination is performed, including vital parameters and standard laboratory 
assessments, which will consist of renal function and natriuretic peptides (NTproBNP or 
BNP). Serum samples are stored at regular intervals for a biobank at Durrer Center for 
Cardiovascular Research. A 6MWT is performed at baseline, 6 and 12 months of follow-
up. Serial echocardiography is performed at baseline, 12 months and 24 months of 
follow-up. The KCCQ is performed at baseline, 3, 6 and 12 months, EQ-5D-5L at baseline, 
11
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3, 6, 12 and 24 months of follow-up. An iMTA Medical Consumption Questionnaire 
(iMCQ) for health care utilization and health technology assessment (HTA) analyses is 
performed prospectively at 3, 6 and 12 months. 26 Changes in medication and reasons for 
change are recorded in a detailed logbook. In another detailed logbook, information on 
patient contacts is recorded, including the reason for contact, direction of contact and 
location (telephone, general practitioner, outpatient clinic, emergency ward, clinic).
Outcome measures
Primary endpoint: Change in QoL as assessed with the KCCQ HF questionnaire
The KCCQ questionnaire is conducted at baseline (t= 0), and at follow-up intervals of 3, 6 
and 12months’ follow-up after randomisation in both treatment arms. Primary analysis is 
based on change in KCCQ scores at 12 months (Tab. 4). The KCCQ questionnaire assesses 
QoL in HF patients and has undergone extensive validation in HF populations. 27, 28
Table 4. Study endpoints
Primary endpoint Quality of life as measured by the KCCQ HF questionnaire
at 12 months’ follow-up
Secondary endpoint The number of HF hospitalisations during follow-up
Health status as measured by the EQ-5D-5L questionnaire
KCCQ Kansas City Cardiomyopathy Questionnaire, HF heart failure
Secondary endpoints
· The number of HF hospitalisations during followup, defined as an unscheduled
admission for HF longer than 6h and/or the need for intravenous diuretics for
decongestion of the patient.
· Change in health status as assessedwith the EQ-5D-5L questionnaire.
Other endpoints will be all-cause mortality; all-cause hospitalisations; scheduled HF 
hospitalisations, composite of all-cause mortality and cumulative HF hospitalisations; 
cardiovascular mortality; days alive outside of the hospital; days in hospital; emergency 
ward visits (or equivalent), composite of HF hospitalisations and emergency ward visits 
for HF, change in NYHA class, health care utilisation, number of patient contacts, change 
in baseline PA pressure; number ofmedication changes.
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Statistical analysis
Sample size
The conditional coverage agencies requested 90% power on QoL endpoints and at least 
85% for the secondary endpoint HF admissions in order to have adequate estimates of 
effect sizes for cost-effectiveness analyses (which are dependent on this set of variables). 
We decided to aim for 90% statistical power to detect an at least 6-point difference in 
KCCQ overall summary (KCCQ-OS) score between randomised treatment groups 27; 
we calculated, at an alpha level of 0.05 and standard deviation (SD) of 15, group sizes 
of N1 133 and N2 133 patients (total sample size 266 patients). With an anticipated 
10% withdrawal rate, we will need to include 292 patients in total. For the secondary 
endpoint of HF admissions, we used two assumptions of estimated treatment effect 
size and estimated event rates of HF hospitalisations in the Netherlands. The long-term 
results of the CHAMPION trial, more comparable to our follow-up length, showed a 
reduction of 33% in HF hospitalisations compared to controls (182 HF hospitalisations vs 
279 HF hospitalisations, in 270 and 280 patients treated with CardioMEMS vs standard 
care, respectively; average follow-up 18 months) and the Dutch COACH trial provided 
an event rate of 2.03% per month in a comparable but slightly less sick cohort of chronic 
HF patients. 16, 17, 29 Under these assumptions, at least 85% statistical power at an alpha 
level of 0.05, and a treatment effect size of CardioMEMS of 33% and event rate of 2.0% 
per month in the control group, when N1 164 and N2 164 patients, a total of 328 patients 
is to be included. For the secondary endpoint, EQ-5D-5L improvement in health status, 
90% statistical power to detect a significant difference of 0.06at an alpha level of 0.05 
and SD 0.18, a sample size of N1 155 and N2 155 totalling 310 patients is needed, and 
by including a 10% early withdrawal rate a total sample size of 340 patients is to be 
included. Therefore, the total sample size of the trial required to adequately answer 
the research questions is 340 patients.
Data analysis
Data will be summarised using univariate statistics (number, mean, standard deviation, 
median) or frequency (number, percentage). For baseline characteristics, between-
group comparisons will be performed with the χ2 test for categorical variables and 
two-sample t-tests for continuous variables. The primary time-point for effectiveness 
analyses on improvement of QoL is 12 months. Change in the KCCQ-OS from baseline 
to 12 months will be compared between the intervention and standard care groups. 
Additionally, a linear mixed-effects model will be used to compare change in the KCCQ-
OS over time between the randomly allocated treatment groups to account for missing 
data and longitudinal trends. The effect of CardioMEMS in comparison to standard care 
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in changes of KCCQ clinical summary and KCCQ-OS scores is compared using repeated 
measurement analysis of covariance adjusted for baseline KCCQ score. EQ-5D-5L scores 
will be analysed in a comparable manner. The secondary endpoint in the study is the 
number of HF hospitalisations during follow-up. A Cox proportional hazard regression 
model with Anderson-Gill method for recurrent events will be used for analysis of 
clinical events (HF hospitalisations, mortality rates). Additionally, Cox proportional 
hazard models are implemented to analyse time to first events, including mortality 
and hospitalisation. Hospitalisation rates and mortality rates are estimated using the 
Kaplan-Meier method, and p-values are computed using the log-rank test. All reported 
analyses are performed using the intention-to-treat principle. All statistical tests will 
be 2-sided with a significance level of 0.05.
Cost-effectiveness analysis
The cost-effectiveness analyses will be conducted in accordance with the Dutch 
guidelines for HTA and will calculate incremental-cost-effectiveness ratio (ICER) per 
quality-adjusted-life-year (QALY) gained both from a societal as well as health care 
perspective. For cost-effectiveness analyses, the EQ-5D-5L is the required standard 
tool to use. In addition, iMCQ, a generic instrument for measuring medical costs 26, will 
be used together with costs from the Dutch costing manual. 28 Cost-effectiveness will 
be evaluated by use of a decision analytical model, e.g. a Markov cohort simulation, 
developed to capture the clinical events and costs for the current and a (hypothetical) 
cohort of patients. The number of states (e.g. alive or dead; NYHA class; hospitalised; 
after a cardiovascular event) and transitions between these states distinguished in the 
cost-effectiveness model will be chosen based upon the available evidence regarding 
the natural history of disease and treatment pathways. Survival probabilities beyond 
the trial period can be estimated by fitting a parametric survival model to the trial data. 
For patients who are alive, the period of survival can be weighted by patients’ utility 
measured with the EQ-5D-5L. Similarly, the out-of-hospital period will be weighted by 
patient utility EQ-5D-5L. Missing data in the EQ-5D-5L questionnaires can be adjusted 
for using linear effect models or multiple imputations. Costs evaluated in the model 
included those for sensor implantation and device, care, HF hospitalisation, medication 
changes, number of visits, and end-of-life support for those who died. To extrapolate 
costs beyond follow-up, we will make use of standardised estimates of health-care 
spending from the Netherlands. 30 Total costs and QALYs will be modelled according 
to the time (in intervals) patients spent in each health state. The ICER will be evaluated 
against the appropriate severity-weighted threshold for cost-effectiveness.
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Trial structure, registration and organisation
The MONITOR HF trial is designed, implemented and overseen by an independent 
executive board and steering committee. The study was evaluated by scientific 
committees (ZonMW) and councils of the National Health Care Institute and patient 
councils. Site and data management is performed by the CRO Erasmus MC trial 
organisation. An independent data safety monitoring board (DSMB) has been 
established and will review safety data on an ongoing basis during the trial in accordance 
with the DSMB charter. An independent clinical endpoint committee (CEC) has been 
established, blinded to study group assignment, and will review and adjudicate all 
deaths and hospitalisations using prospectively defined criteria in the CEC charter. 
The adjudicated data are used for outcomes regarding hospitalisations and deaths. 
The DSMB and CEC are organised and led by an external independent organisation 
(Cardialysis, Clinical Trial Research Centre). The clinical trial is structurally monitored 
by independent monitors from the research trial organisation. The study complies 
with good clinical practice in accordance with the Declaration of Helsinki and the laws 
and regulations applicable in the Netherlands, including the European Union General 
Data Protection Regulations, as the clinical trial has been approved by the appropriate 
medical ethics committee and review board (Erasmus MC, MEC 2018-1563). The clinical 
trial was registered under the number NL7430 (NTR7672, clinical trial registration 
number) on 12 December 2018. The study started enrolment on 1 April 2019.
Discussion
This multicentre, randomised clinical trial (MONITOR HF) will evaluate the efficacy and 
cost-effectiveness of remote PA monitoring with CardioMEMS applied in addition to 
standard care in patients with chronic HF, from a European perspective. The benefits 
of remote monitoring with CardioMEMS were demonstrated in the CHAMPION trial of 
550 participants in the US, who were studied between 2007 and 2009 14, and have been 
confirmed in several large-scale post-marketing registries. 15–17. The MONITOR HF trial 
will provide contemporary trial data on the effectiveness of CardioMEMS in a highly 
organised European health care system where HF patients are routinely followed in 
dedicated HF outpatient clinics after an HF admission. The recently published CHAMP-HF 
and CHECK-HF registries highlight the differences in guideline adherences between the 
Netherlands and the USA. 3–5 Additionally, profound differences exist between Europe 
and the USA as regards the organisation of health care as well as financial structures. 
The current study will provide the individual data necessary to perform calculations on 
cost-effectiveness of remote monitoring from a European health care perspective.
11
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In the CHAMPION trial, QoL was not a primary endpoint and data are only available on 
small subsets of patients with a short follow-up. 16 The current trial has QoL as a primary 
endpoint, which is a novel aspect in telemonitoring but is emerging as a relevant clinical 
endpoint in HF trials. Additionally, QoL might hypothetically be valued most by the patient, 
as living longer in poor health might not be the main focus of choice. For the secondary 
endpoint, the number of HF hospitalisations, it is most likely that rehospitalisation rates 
differ between the USA and Europe, and we expect a lower event rate in the Dutch health 
care system with dedicated HF nurses and HF outpatient clinics as the organisation 
of standard care differs. 29 Dedicated HF outpatient clinics and structured HF care 
after HF admissions are emerging throughout Europe as standard HF care, including 
multidisciplinary team approaches, heart teams, and cardiac rehabilitation programmes 
as advocated in the 2016 ESC guidelines. 23 The recently published US Post Approval 
Study (PAS) confirms the consistent treatment benefit with CardioMEMS in chronic HF 
patients, reducing the number of HF hospitalisations in a more contemporary setting. 20 
However, the patients included in the PAS study were their own historical controls and 
no randomised comparison to standard care without PA monitoring was made. However, 
the main inference of the PAS is the consistent safety of the implantation procedure and 
the durability of the sensor without sensor failures. 20
From a financial point of view, a cost-effectiveness analysis using the US CHAMPION 
trial data calculated an ICER for costs per QALYs of $29,593 for CardioMEMS based on 
US health care data. 21 Extrapolating the US data to European health care systems, 
such as those in the UK, the Netherlands and Germany, showed that PA-pressure-
guided HF therapy is anticipated to be cost-effective, but the intervention increases 
costs compared with usual care by £10,916 over a time horizon of 10 years while the 
ICER is estimated to be £19,274 with a reduction in admissions. 22 The analysis did 
not include staff time, due to a lack of data concerning this variable. Running the 
model with estimated staff time included resulted in an increased ICER of between 
£22,342 and £25,464 per QALY gained. 22 No individual data from European systems 
are currently available.
Other forms of telemonitoring and available evidence
Several studies have been performed using non-haemodynamic parameters of remote 
monitoring such as signs and symptoms of HF, blood pressure or daily weights. These 
studies have shown no effect on HF hospitalisations. 6–15 Clearly, simple markers such as 
weight or blood pressure are inadequate for monitoring fluid status and if the variation 
in weight is caused by decompensation, treatment comes too late and cannot prevent 
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a hospitalisation. Additionally, some studies have investigated natriuretic peptides to 
guide HF therapy, but these were not successful in reducing HF hospitalisations. 10 
Other studies with non-haemodynamic parameters of remote monitoring have focused 
on information from ICD devices using intrathoracic impedance or other specific 
combinations of parameters in algorithms. 13–15 None of these studies have shown any 
actual benefit in reducing the number of hospitalisations. Most recently, the TIM-HF 
2 trial was one of the first studies to show a small benefit of remote monitoring in HF 
patients with regard to length of hospital stay, despite its labour intensity (fully staffed 
telemedicine centre).11
The 2016 ESC guidelines report on the lack of consistent evidence for non-
haemodynamic telemonitoring or remote monitoring in HF patients. The guidelines 
state that remote monitoring may be considered in selected patients to improve HF 
outcome with individual approaches such as CardioMEMS to reduce the risk of HF 
admissions and multi-parameter monitoring with ICD (in-time approach) to improve 
outcome in HFrEF with a level IIb class B recommendation. 23
Future developments and potential impact
The most essential concept remains the shift from remote monitoring with (late) 
signs of clinical congestion to parameters of (early) haemodynamic congestion, which 
precede all above non-haemodynamic parameters by several weeks and provides a 
window of proactive intervention in order to prevent further exacerbation of HF. In this 
way, it makes sense that nonhaemodynamic parameters have not made a significant 
impact in remote monitoring of HF patients to date despite their simplicity and the 
relatively low effort involved, for instance in monitoring weight. The current trial sets 
out to evaluate the benefit of CardioMEMS remote monitoring versus standard care in 
relation to QoL and HF hospitalisations as well as cost-effectiveness in the Netherlands. 
If proven effective, this has important implications for countries with similar health care 
structures and levels of HF care in Western Europe. The field of remote monitoring is 
most likely to develop further with additional tools for patient control and pressure 
feedback with more sophisticated monitoring websites or tools and patient self-
management. The HF path of care will evolve into a more structured approach 
integrating remote monitoring to achieve a proactive, preventive approach to patient 
care instead of passive, symptom-driven care delivery. Remote monitoring has the 
potential to lower the overall hospital burden (number of outpatient visits, admissions 
and resources used) of HF in an attempt to keep the stable patient out of hospital and 
the unstable patient in hospital only if refractory to remote interventions at home.
11
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Strengths and limitations
The current trial is important as it is the first randomised clinical trial in Europe 
comparing haemodynamic remote monitoring by CardioMEMS with a control group 
in chronic HF. The trial is adequately powered to test the efficacy of CardioMEMS 
(in addition to standard care) in improving QoL and reducing HF hospitalisations as 
compared to standard care. Additionally, this trial will provide further contemporary 
data with CardioMEMS in addition to the CHAMPION trial and post-marketing registries. 
As randomisation is essential in efficacy studies (but lacking in post-marketing studies), 
the current European trial is the first with a control group of standard HF care after 
the US CHAMPION trial. This MONITOR HF trial will not have a sham procedure 
in consultation with the MEC and patient councils for a variety of reasons. A sham 
procedure and sham measurements every day during 3 years of follow-up was deemed 
unethical with a futile risk, patient efforts and costs. Furthermore, we argue that daily 
sham measurements (with the sensor turned off, but with its costs) are not a part of 
current standard care and would impact the true comparison with standard care as it 
is actually delivered. We recognise that the lack of a sham procedure may introduce a 
potential bias in the standard care arm. However, this effect can be of any magnitude, 
direction and degree for each individual patient, either positive or negative (as the 
technique is most likely not suited for all), and therefore it will be complex to completely 
quantify the placebo effect (and directions). We will keep precise track of medication 
changes in response to abnormal readings of PA pressure and HF admissions as well as 
detailed records of health care utilization rates, to provide objective proof of subjective 
improvements. Finally, despite the mentioned limitations, proactive monitoring and 
interventions based upon pre-symptomatic pressure shifts are needed to achieve 
any actual sustained benefit of the device. The design of the current trial and the 
involvement of HTA experts from the start of the project ensures high-quality data for 
future cost-effectiveness analyses and modelling from a Western European perspective, 
including detailed health care utilisation data.
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Conclusions
The MONITOR HF randomised clinical trial compares haemodynamic remote monitoring 
with the CardioMEMS PA sensor in addition to contemporary standard care versus 
standard care in improving QoL and reducing HF hospitalisation in patients with chronic 
HF in NYHA class III independent of left ventricular function. In addition, the study will 
evaluate health care utilisation and cost-effectiveness in Western Europe from a societal 
and health care perspective.
11
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In chronic heart failure (HF) patients, functional mitral valve regurgitation (FMR) is a 
common finding and is associated with worse outcome. The position of the MitraClip™ 
(Abbott Vascular, Santa Clara, CA, USA) as a therapeutic option is still debated after the 
publication of the MITRA-FR and COAPT trials, showing conflicting results.
A 51-year-old male, with a history of severely dilated, non-ischaemic cardiomyopathy, 
severe FMR, actively on the heart transplant (HTx) waiting list, remotely monitored with 
the CardioMEMS™ sensor (Abbott Vascular), developed persistent elevated pulmonary 
artery pressires (PAPs) (mean 42 mmHg), despite high-dose diuretics, which were limited 
by prerenal insufficiency. Swan-Ganz measurement demonstrated no reversibility of 
pulmonary hypertension (PH) (mean PAP [mPAP] 42 to 35 mmHg), wedge pressure (23 to 22 
mmHg) or transpulmonary gradient (TPG) (19 to 13 mmHg) after intravenous administration 
of nitroglycerine at maximal tolerated dosage (due to a significant drop in systemic blood 
pressure). The Heart Team judged that the patient was not a good candidate for an HTx at 
this stage due to the high pressures.
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Figure 1. pre- and post-MitraClip daily PAP readings
In this setting, it was unclear how much the severe FMR contributed to the PH. The Heart 
Team decision was made for a MitraClip implantation. On the day of implantation, mPAP 
was 45 mmHg. After successful implantation of two MitraClips, FMR was reduced to 
mild on echocardiography, and mPAP dropped to 32 mmHg. In the following days, mPAP 
dropped to 23 mmHg (Figure 1). NT-proBNP decreased from 579 pmol/L (normal <14 
pmol/L) pre implantation to 165 pmol/L four days post implantation. Kidney function 
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(estimated glomerular filtration rate [eGFR]) improved from 62 ml/min to 72 ml/min 
and, based on the normalised PAPs, the diuretic dosage was decreased, and the patient 
was discharged in a good clinical condition. During follow-up, the CardioMEMS showed 
a gradual rise of PAP, on which the diuretic dosage could be titrated again to maintain 
normal PAP at the normal home setting. A Swan-Ganz measurement was repeated 
approximately 1.5 months after MitraClip implantation (mPAP 19 mmHg, wedge 
pressure 12 mmHg, TPG 7 mmHg), confirming the CardioMEMS readings. Subsequently, 
the patient returned to active status on the HTx waiting list.
The CardioMEMS offers valuable and unprecedented information to the treating 
physician to monitor the effects of therapy modifications, such as medication 
or dosage changes1, or valvular interventions such as a MitraClip implantation. 
This unique “at home” haemodynamic feedback for the treating clinicians allows 
further therapy optimisation.
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Abstract
Left ventricular assist devices (LVAD) are frequently used in the treatment of end-stage 
heart failure (HF), and due to the shortage of heart donors and destination programs, 
it is likely to keep on growing. Still, LVAD therapy is not without complications and 
morbidity and rehospitalization rates are high. New ways to improve LVAD care both 
from the side of the patient and the physician are warranted. Remote monitoring could 
be a tool to tailor treatment in these patients, as no feedback exists at all about patient 
functioning on top of the static pump parameters. We aim to provide an overview and 
evaluation of the novel remote monitoring strategies to optimize LVAD management and 
elaborate on the opportunities of remote hemodynamic monitoring with CardioMEMS, 
at home in these patients as the next step to improve care.
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Introduction
Epidemiological data on end-stage heart failure (HF) is scarce. Estimations performed 
by the America Heart Association suggest that < 1% of all HF patients are in end-stage 
HF. 1 Other studies estimated that approximately 5–10% of the HF population develop at 
some moment in life advanced HF despite optimal medical treatment. 2 These patients 
become refractory for medical therapy and are frequently hospitalized and have high 
mortality rates, leaving heart transplantation or left ventricular assist device (LVAD) 
implantation as the only treatment options. Due to shortness in available heart donors, 
LVAD implantation rates continue to rise. 3, 4
Despite new LVAD designs and technological improvements, LVAD care remains very 
complex and associated with high mortality and with many rehospitalization and 
outpatient contacts. 3, 5, 6 The main reason for hospitalization is gastrointestinal (GI) 
bleeding or LVAD-related (driveline) infection, followed by decompensated HF and 
arrhythmia. 7, 8 Due to the growing number of patients treated with a LVAD, combined 
with the high hospitalization and complication rates, LVAD care places a high burden on 
hospital resources, with many logistical challenges with available hospital beds, as many 
other departments are not familiar with LVAD devices, so LVAD patients preferably are 
admitted at a cardiology ward despite non-cardiac admission indications.
It is difficult for pump optimization to be available in a short time at the outpatient clinic 
and so it is only based on echocardiographic images and static pump parameters.
Patient self-management and remote monitoring is an important part of chronic HF care, to 
prevent admission. Due to the complexity of LVAD care, remote monitoring has the potential 
to provide valuable information to help the physician in structured decision making. It 
has been suggested that remote monitoring of pump parameters, combined with remote 
monitoring of blood pressure, pacemaker-related parameters, coagulation values, and 
driveline exit parameters could improve LVAD care. 9 However, many of these investigations 
are still unexplored, and not yet tested in large populations. We aim to provide an overview 
of these new technological advances for the remote monitoring of LVAD patients.
The LVAD and hemodynamics
Different LVAD designs, pump mechanisms (axial or centrifugal), and implantation 
techniques are used. The two most common used LVADs are the HeartMate 3 (HM3, 
14
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Abbott Inc, Atlanta, GA, USA) and the HVAD (Medtronic Inc, Framingham, MA, USA) 
(Fig. 1. Both are centrifugal pumps, placed in the pericardial space. The HM3 uses a 
fully magnetic levitated pump rotor, whereas the HVAD uses passive magnetic and 
hydrodynamic thrust bearings. 10–12
Fig. 1 Schematic presentation of the HeartMate 3 (a) and HeartWare LVAD (c), and close-ups of the pump 
house and inner work (b, d, resp) Courtesy of Abbott, Inc. and Medtronic, Inc. to provide the illustrations
Common LVAD-related complications
LVAD care can be lifesaving, however, it is also associated with several LVAD-related 
complications, such as right ventricular (RV) failure, LVAD-related infection, cardiac 
arrhythmia, hemolysis and thrombosis, GI bleeding due to angiodysplasia and renal 
dysfunction. 13 An overview of the incidence rates of common LVAD complications in 
HM3 and HVAD LVADs is presented in Table 1.
RV failure is a serious hemodynamic complication, occurring in up to 20–30% of the 
LVAD patients. 14–17 Signs of RV failure are elevated central venous pressure (CVP) and 
manifestations of elevated CVP, such as edema, ascites or increasing renal dysfunction. 18
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Tamponade, which can develop shortly after LVAD implantation, is a feared complication, 
occurring in up to 20% of the LVAD patients. 19 Symptoms usually occur in a late stage, 
and common hemodynamic signs, such as tachycardia, shock or pulsus paradoxus 
can be masked by the LVAD pump. 20 Late tamponade can be hard to visualize on 
echocardiography until the patient is in shock, and the first sign might be a drop in 
pump parameters. 21, 22
GI bleeding is a common complication in LVAD patients, affecting up to 20–30% of 
the patients. 14–17, 23–25 GI bleeding has different presenting symptoms, 50% of patients 
present with melena, 25% with unexplained anemia, 15% with hematochezia and 10% 
with hematemesis. 26
LVAD-related infections occur in 10–25% of the LVAD patients in the first 3 months after 
LVAD implantation. 14–16, 23–25, 27 Presenting symptoms are fever, erythema at the driveline 
site, or purulent fluids from the driveline exit site.
Pump thrombosis affects approximately 15% of axial-flow LVAD, and 1% of centrifugal-
flow LVADs. 14–16, 23, 25 Pump thrombosis is characterized by signs of worsening HF in the 
patients, which cannot be explained otherwise, abnormal pump parameters and signs 
of hemolysis in laboratory results, such as elevated LDH. 28, 29
Quality of life
All the above-mentioned LVAD-related complications affect the mortality and morbidity 
of LVAD patients. However, the complications and the hospitalizations due to these 
complications also affect the quality of life of LVAD patients. Especially in patients with 
an LVAD as the destination therapy, quality of life should be the main focus. 30 Remote 
monitoring of LVAD patients could aid in improving the quality of life of LVAD patients. 
By earlier detection of LVAD-related complications, earlier intervention is possible, 
potentially reducing the number of rehospitalizations. Additionally, LVAD settings and 
the patient’s status could be better monitored, allowing for better optimization of the 
pump settings, improving the pump function. 31
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Monitoring strategies
Non-invasive remote monitoring
An overview of remote monitoring strategies in LVAD patients is showed in Table 2. One 
of the keystones in traditional ambulant HF management is the active participation 
of patients with their medical care team. The use of noninvasive remote monitoring, 
or structured telephone monitoring in HF patients, has been investigated in multiple 
trials showing different results. 32 A recent Cochrane review showed that the use of 
non-invasive and structured telephone remote monitoring reduced mortality and HF-
related hospitalizations. 32
At this moment, there is one study that investigated the use of a structured telephone 
remote monitoring system in LVAD patients. 33 This retrospective study investigated 
96 LVAD patients, among who 25 received bi-weekly telephone calls, consisting of an 
inquiry about LVAD parameters, alarms, blood pressure, INR, body weight, temperature, 
driveline exit status, symptoms and presence of edema. They found after 2 years a 
better overall survival in the intervention group (89% vs. 57%, p = 0.027), however, there 
was no effect on time free of readmission between the groups.





Schloglhöfer, et al. 96
At 2 year of follow-up, using bi-weekly telephone 
calls (consisting of an inquiry about LVAD 
parameters, alarms, blood pressure, INR, body 
weight, temperature, driveline exit-status, 
symptoms and presence of edema) the overall 
survival was significantly better compared to 
standard care (89% vs. 57%, p=0.027); but no 






Moderate correlation between INR measured 
using a POC device and in a central 
laboratory(correlation coefficient of 0.83)
34
Joshi, et al. 41 samples
Good correlation between INR measured 
by a POC device and in a central 
laboratory(correlation coefficient of 0.96)
35
14
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Bishop, et al. 11
Using a POC INR measurement device at 
home leads patients to be more often within 
therapeutic range compared with regular INR 
measurements at a central laboratory (44% vs. 
31%, p=0.026)
36
Gavalas, et al. 956 samples
The statistical performance of positive urine 
hemoglobin to predict LDH ≥600IU/L is: 




Pektok, et al. 5
Demonstrates the feasibility of remote pump 
parameter monitoring, providing additional 
information to the treating clinicians
41
Kawahito
Adding a vibration sensor to an LVAD could 
adequately detect pieces of silicone, acting like 
thrombi, at the four most common thrombus 
locations
43
Bishop, et al. 6
In patients with no or minimal AoV regurgitation, 




Bartoli, et al. 1
Demonstrates the potential utility of 
intrathoracic impedance measurements in 
a patient with an LVAD, with an increased 
intrathoracic impedance preceded intravascular 
volume depletion and dangerous LVAD 
dysfunction
49
Implantable hemodynamic monitoring devices
Feldman, et al. 27
Using remote monitored PAP, by the CardioMEMS, 
leads to a large reduction of PAP and an optimized 
timing of LVAD-implantation compared to those 
receiving standard care
54
Hubert, et al. 4
Significant correlation between left atrial pressure 
sensor, and pump speed, LV and LA size and 
pulmonary capillary wedge pressure (r=0.92-0.99, 
p<0.05)
55
POC point-of-care, LDH lactate dehydrogenase, PPV positive predicting value, NPV negative predicting 
value, AoV aortic valve, LVAD left ventricular assist device, PAP pulmonary artery pressure, LV left ventricle, 
LA left atrial
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Remote antithrombotic monitoring
LVAD care is associated with thromboembolic complications, such as pump thrombosis, 
which could be a lifethreatening complication, thus showing the need for adequate 
chronic anticoagulation. 7 However, LVADs are also associated with bleeding events, 
particularly GI bleeding, thus requiring a small target window of chronic anticoagulation 
to minimize the risk of bleeding events. 7, 34 The development of accurate point-of-
care (POC) INR monitors made patient self-testing possible. In patients with other 
indications for anticoagulation therapy, self-testing led to a higher percentage of 
time in the therapeutic range. 35 Two studies showed a moderate to good correlation 
between the INR measured by the POC system and laboratory results. 36, 37 Bishop et al. 
38 compared 11 LVAD patients using a POC-INR monitoring system or regular laboratory 
INR monitoring in the outpatient setting. Patients using a POC system were significantly 
more frequently tested (7.4 vs. 21.4 days, p < 0.01), and were more often within the 
therapeutic range (44% vs. 31%, p = 0.03). Furthermore, they investigated the potential 
differences in the number of bleeding or thromboembolic events, however, due to the 
small sample size, no significant difference was found. Self-testing in LVAD patients has 
the potential to increase the frequency of INR monitoring. By doing so, dosage changes 
can be made more often, leading to a higher percentage of “time in therapeutic INR 
range”. This could contribute to reducing the number of thromboembolic and bleeding 
events in LVAD patients, but has not been shown yet.
The diagnosis of pump thrombosis is complex, consisting of an evaluation of symptoms 
of HF, pump parameters, echocardiographic analysis and serum lactate dehydrogenase 
(LDH). LDH is a sign of hemolysis, and probably one of the most reliable markers of 
pump thrombosis. 39, 40 LDH monitoring is usually only performed during regular 
outpatient clinic follow-up visits, leading to potential delays in pump thrombosis 
detection of weeks. Gavalas et al. 41 demonstrated a good correlation between a simple 
dipstick urine analysis for urine hemoglobin and serum-measured LDH. Absent of urine 
hemoglobin had a negative predicting value for LDH ≥ 600 IU/L (significant hemolysis) of 
> 90%, thus indicating the potential use for easy remote monitoring at home of pump 
thrombosis in LVAD patients.
Remote pump monitoring
Although experience with remote monitoring especially in ICDs and CRTs is growing 
42, experience with a remote monitoring function within an LVAD system is limited. 
However, the first experiences with remote monitoring of pump parameters 
have been described. 43, 44 The HeartAssist 5 and aVAD LVADs have these remote 
14
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monitoring functions, allowing to transmit pump parameters, such as pump speed, 
rounds per minute (rpm) and pump flow, as well as errors, to a website accessible 
to the care team. This new information can be used in earlier detection of pump 
complications. Hypovolemia and LVAD thrombosis could be detected by a downward 
LVAD flow trend. 44
Furthermore, new technologies and algorithms are developed which use the LVAD 
parameters and help with troubleshooting, and patient monitoring. Detection of 
vibrations as a sign of mechanical failure is widely used in the biomechanical industry, 
however, it is not yet used in LVAD management. Kawahito 45 investigated the use of 
a vibration sensor in combination with an LVAD detect pump thrombosis. This study 
investigated vibration signals caused by pieces of silicon, acting like actual thrombi, 
attached at the four most common locations for thrombus in an LVAD: the total area of 
the bottom of the impeller, an eccentric shape on the bottom of the impeller, a circular 
shape around the shaft top and an eccentric shape on the top of the impeller. Thrombi 
at these specific locations can be detected by specific vibration signals, indicating the 
potential use for early detection of pump thrombosis in LVAD patients.
The aortic valve opening rate is an important aspect of LVAD care. When the aortic valve 
is not opening the risk of adverse cerebrovascular events increases 46 and commissural 
fusion can occur, one of the causes of aortic valve regurgitation. 47 Bishop et al. 48 
described a novel algorithm to analyze in patients with no or minimal aortic valve 
regurgitation whether the aortic valve is opening or not. This algorithm uses the electric 
current waveforms provided by the HeartMate-II LVAD and analyzes this data using a 
modified Karhunen–Loève transformation. The algorithm could accurately predict aortic 
valve opening and closing. This algorithm can also be used in an automatic regulation 
program which can automatically change the rpm settings of the LVAD based on this 
physiological feedback to maintain a predefined aortic valve opening rate.
Intrathoracic impedance
Remote intrathoracic impedance monitoring is possible in the newer ICD and CRT 
devices. A drop in intrathoracic impedance is seen during pulmonary congestion, as an 
early sign of HF decompensation. Due to the remote monitoring function of newer ICD 
and CRT devices, the intrathoracic impedance can be used to detect HF decompensation 
at an earlier stage. Multiple studies investigated whether remote monitoring of 
intrathoracic impedance could lead to a better outcome in chronic HF patients. A recent 
systematic review 49 showed that intrathoracic impedance was associated with lower 
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health care costs due to a reduction in planned hospital visits, despite a slight increase 
in unplanned visits. However, the use of remote impedance monitoring did not affect 
all-cause or cardiac mortality.
At this moment, there is only one case report 50 describing the use and potential 
benefits of remote monitoring of intrathoracic impedance in LVAD patients. This 
patient experienced shortly after LVAD implantation an increase in the impedance 
as a sign of intravascular fluid depletion. The patient was admitted and treated with 
fluid repletion and the impedance was increased. This case showed that intrathoracic 
impedance measurements in LVAD patients might provide some information on their 
fluid status. However, the use of remote monitoring of impedance in chronic HF holds 
limited additional value, and it is unclear whether this will be better in LVAD patients.
Implantable hemodynamic monitor devices
Due to the failure of simple non-invasive and intrathoracic impedance remote 
monitoring strategies to improve the outcome of chronic HF patients, new, wireless 
implantable hemodynamic monitor systems were developed. These systems measure 
filling pressures, and work according to the hypothesis that filling pressures will 
increase before other signs of decompensated HF occur, as shown in Fig. 2. As has 
been shown, intracardiac pressures will rise weeks before patients are hospitalized 
due to decompensated HF. 51 Recently, Abraham provided an overview of multiple 
implantable hemodynamic monitor devices, which were developed in recent years. 
52 In chronic HF patients, one of the most promising techniques is the CardioMEMS 
system (Abbott Inc, Atlanta, GA, USA) (Fig. 3). This device is implanted in the pulmonary 
artery during right-heart catheterization, and consists of a pressure-sensitive capacitor 
combined with a coil and can be powered by coupling this electrical circuit with an 
external antenna. When powered, the capacitor resonates, which is received by the 
external antenna. When pressure by the pulmonary artery pressure (PAP), is applied, 
the frequency of resonated energy changes via a characteristic pattern and can be 
converted into a pressure wave. This system has been shown in clinical trials as well 
as in real-world clinical practice to be effective in reducing HF hospitalization rates by 
maintaining normal PAP. 53, 54
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Fig. 2 Hypotheses of pressure monitored and guided heart failure management Reprinted from Abraham 
52, 2017, with permission from Elsevier
Fig. 3 CardioMEMS HF system, consisting of the pulmonary artery pressure sensor (a) and the patient elec-
tronics system (b) used to take daily pressure readings Courtesy of Abbott, Inc. to provide the illustrations
A subgroup analysis of the CHAMPION trial, the initial clinical trial investigating the 
CardioMEMS, consisting of 27 chronic HF patients, who received an LVAD, showed that 
patients who received an LVAD were sicker, and had a higher PAP when compared to the 
group who did not receive an LVAD. 55 The intervention group received more medical 
changes, based on the hemodynamic feedback provided by the CardioMEMS compared 
to the control group. However, the PAP did not decrease significantly in the patients who 
received an LVAD, indicating that a lack of decrease of PAP can be a sign of refractory 
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HF, and thus providing useful information in the timing of an LVAD implantation. Post-
LVAD implantation, the PAP dropped in both groups, however, using the hemodynamic 
feedback in the intervention group, the PAP dropped even lower. This indicates that the 
use of the PAP provided by the CardioMEMS leads to a better and more optimal LVAD 
management, leading to a better pump function.
Hubbert et al. 56 investigated in four LVAD patients an implantable left atrial pressure 
(LAP) monitor, the Titan LAP monitoring system (ISS Inc. Ypsilanti, MI). They showed 
a significant correlation between LAP and pump speed, LV and left atrial size and the 
pulmonary capillary wedge pressure, thus indicating the potential use of pressures 
obtained by an implantable hemodynamic monitor for optimization of the pump 
settings during a ramped speed test.
Potential impact of implantable hemodynamic monitoring
We believe that the implantable hemodynamic monitors hold more potential in LVAD 
patients than currently shown. Using the daily pressure readings, which provide real-
time insight into patients’ fluid status, the clinicians could optimize patients shortly 
prior to the LVAD implantation, thereby improving patients’ status and their clinical 
outcome. Also, this hemodynamic information provides direct feedback on medical 
changes made. We believe that using this hemodynamic feedback will lead to better 
optimization, thus improving patients’ status and potentially improving their clinical 
outcome. 57 Furthermore, optimizing patients will lead to a better decongestion and 
thereby better unloading of the RV, thus, reducing the impact of the LVAD implantation 
on the RV and reducing the risk of RV failure.
Changes in filling pressures post-LVAD implantation might indicate potential 
postoperative complications. An increase in filling pressures might indicate a 
tamponade, since the venous return reduces due to inflow obstruction due to elevated 
pressures in the pericardium. An earlier detection and thereby earlier intervention 
might prevent late-stage tamponade and more severe complications.
Multiple complications, such as pump thrombosis, hemodynamic important 
arrhythmias or aortic valve regurgitation, will lead to congestion. Similar to chronic HF 
patients, in LVAD patients filling pressures will rise as a result of congestion. 58 A rise in 
filling pressures might indicate one of these complications is occurring. Hospitalization 
and the worsening outcome can potentially be prevented by acting on rising filling 
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pressures. Furthermore, investigating the waveforms and rhythm could provide insight 
into potential arrhythmias.
A drop in filling pressures might indicate a loss of circulating volume, which might point 
to a GI bleeding.
LVAD therapy will increase cardiac output, and thereby increase the renal perfusion 
and resolve the congestion, lowering the renal venous pressure and thereby improving 
the renal function. 59 Filling pressures might aid in optimizing LVAD therapy, and thus 
improve the renal function even further.
Fixed pulmonary hypertension is an absolute contraindication for heart transplantation. 
In these patients, the by ischemic stunned right ventricle will be unable to overcome 
the elevated afterload and is most likely to fail immediately after heart transplantation. 
In patients with fixed pulmonary hypertension, LVAD therapy can be used as a bridge 
to candidacy for heart transplantation, since LVAD therapy is more effective in treating 
fixed pulmonary hypertension, compared to medical therapy alone. 60 Pulmonary 
hypertension should be evaluated periodically using a right-heart catheterization, as 
recommended by the ISHLT guidelines to evaluate whether the patient has become 
eligible for heart transplantation. 61 However, remote hemodynamic monitoring could 
replace these periodically right-heart catheterizations, and provide daily feedback on 
hemodynamic changes. Providing continues insight when a patient could be considered 
eligible for heart transplantation.
Recently, it has been shown that preforming hemodynamically guided ramp 
testing could reduce the number of LVAD-related complications and the number of 
hospitalizations. 31, 62, 63 However, this technique is limited by the need for frequent 
Swan-Ganz measurements, which increases the risk of bleeding events. Using the 
hemodynamic information provided by the CardioMEMS, this limitation could be 
overcome and allowing for easy hemodynamic optimizing of LVAD pump settings.
Future perspectives: design of the HEMO-VAD study to 
guide LVAD management by hemodynamic feedback
To investigate the potential impact of an implantable hemodynamic monitor in LVAD 
patients, we designed the HEMOVAD pilot study. 64 In this study, we will investigate ten 
consecutive end-stage HF patients, who are accepted for LVAD implantation. These 
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patients will receive prior to LVAD implantation a CardioMEMS device, which will be used 
for daily hemodynamic monitoring to optimize patients prior to LVAD implantation and 
monitoring of complications and patient status after LVAD implantation.
Conclusion
Many remote monitoring strategies are currently investigated and developed for LVAD 
patients, ranging from non-invasive telephone monitoring programs to implantable 
hemodynamic monitoring systems. Based on results from trials investigating the use 
of remote monitoring of regular heart failure, it is warranted to study these devices 
in LVAD patients. This technique holds the potential to provide additional information 
for determining the optimal LVAD implantation window, optimizing the patients prior 
to and post-LVAD implantation, and monitoring for LVAD-related complications to 
identify the patients most likely to benefit from such therapy and for early discovery 
of its complications.
14
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Abstract
Pulmonary hypertension (PH) type II (classified by the World Health Organization) is 
a common complication in chronic left-sided heart failure. In advanced heart failure 
therapy, fixed PH is an absolute contraindication for heart transplantation after 
which a left ventricular assist device (LVAD) is the only remaining option. With remote 
monitoring, we can now continuously evaluate the pulmonary artery pressures during 
long-term LV unloading by the LVAD. In this case, we demonstrate that fixed PH can be 
reversed with LVAD implantation, whereby previous thoughts of this concept should 
be redefined in the era of assist devices.




In patients with chronic left-sided heart failure (HF), pulmonary hypertension (PH) 
(classified by the World Health Organization as group 2) is a common complication.1 
PH occurs in up to 60% of the patients with severe left ventricular systolic dysfunction, 
and up to 70% in patients with HF with preserved ejection fraction.2 HF causes chronic 
pulmonary congestion, resulting in elevated pulmonary capillary wedge pressure 
(PCWP). The right ventricle (RV) adapts slowly over time in order to overcome the 
increasing PCWP, leading to increasing pulmonary artery pressures (PAPs). Over time, 
this process results in pulmonary capillary and arterial remodelling. The vascular wall 
stiffens and loses its elasticity and ability to compensate for the higher pressures, 
resulting in elevated pulmonary vascular resistance (PVR). Additionally, several 
pulmonary diseases affect the PVR and cause PH. At screening for candidacy for heart 
transplantation (HTx), the standard procedure is to perform a right heart catheterization 
(RHC) to study these aspects in detail. If at the Swan–Ganz measurement the patient 
has PH, we perform a vasodilator test to evaluate the reversibility of PH and PVR. 
Reversibility is crucial in potential HTx candidates. Because the RV of the donor heart 
will not be capable to build up PAPs to overcome the fixed high PVR, after a period of 
stunning by ischemia, the RV is most likely to fail immediately. Left ventricular assist 
device (LVAD) therapy can be successful in lowering PAPs by unloading the left ventricle, 
which will aid in the treatment of PH caused by left-sided heart disease.3 However, 
limited data are available on the topic whether fixed PH can be reversed as well. The 
acute and chronic effects of LVAD therapy on PH have not been clearly investigated. 
The recently introduced CardioMEMS sensor offers the possibility to study this concept, 
because it allows for remote daily monitoring of PAPs, even in LVAD patients,4 as we 
have shown in our case.
Case report
A 53-year-old man with a history of severe dilated cardiomyopathy was admitted with 
progressive HF, despite maximal tolerated medical therapy. During the admission, 
the patient was screened for both HTx and LVAD implantation. The RHC revealed a 
cardiac output of 3.8 L/min, PAP 61/31 mmHg (mean 43), PCWP 28 mmHg, and PVR 
316 dynes/s/cm5 (3.9 Woods). During the vasodilator test of reversibility, intravenous 
nitroglycerin was up-titrated to maximum tolerated dosage (100 μg/min) without 
inducing systemic hypotension; PAP [47/23 mmHg (34)], PCWP (20 mmHg), and the 
PVR (295 dynes/s/cm5 , 3.7 Woods) remained elevated, confirming the diagnosis of 
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fixed PH. In the multidisciplinary heart team, the patient was rejected as candidate 
for HTx owing to irreversible PH and was accepted for LVAD (HeartMate 3, Abbott Inc, 
Atlanta, GA, USA) as bridge to transplant or destination therapy. A CardioMEMS device 
was implanted, followed by LVAD implantation 2 weeks later. Post-operatively, the 
LVAD support provided additional room for further up-titration of the medical therapy. 
Echocardiography and PAPs were used to uptitrate renin–angiotensin system inhibition, 
mineralocorticoid receptor antagonist, and diuretics and the LVAD speed settings. The 
patient recovered well with an uncomplicated course and was discharged home.
In the outpatient setting, haemodynamic feedback provided by the CardioMEMS was 
used for further treatment optimization. A combination of hydralazine/isosorbide 
dinitrate was started and slowly up-titrated resulting in a small decline in PAP. However, 
this was limited owing to complaints of dizziness.
Approximately 160 days after LVAD implantation, the patient was admitted owing to 
dehydration and hypotension due to insufficient intake, which was identified by the 
sudden drop in PAPs. During admission, antihypertensive medication and diuretics 
had to be lowered or stopped, allowing the renal function to recover. After discharge, 
medication was up-titrated again to maximum tolerated dosage, limited once more by 
complaints of dizziness. Even though further up-titration of medication was not possible, 
the mean PAP (mPAP) continued to decline gradually and then finally normalized. 
Approximately 290 days post-LVAD implantation, a consistent mPAP < 25 mmHg 
was reached. During follow-up, the patient regularly underwent echocardiography, 
demonstrating a stable RV function and only a minor tricuspid valve regurgitation, 
suggesting that the decline in mPAP was caused by reversibility of the ‘fixed’ PH and 
was not due to a decline in RV function. Currently, the candidacy for HTx is re-evaluated, 
and likely no cardiac issues will be raised for acceptance on the waiting list.
Discussion
This case report demonstrates for the first time the continuous follow-up of PAP data 
in a LVAD patient with fixed PH, for up to 300 days post-LVAD implantation. This case 
demonstrates that LVAD therapy is a successful treatment for lowering PAP in patients 
with fixed PH, additional to optimal medical treatment. The reversibility of PH and 
candidacy for HTx thereby become a more dynamic state, which changes views on 
these programmes in light of expanding LVAD programmes.
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Monitoring pulmonary pressures
The increase of left ventricular filling pressure leads to an increase in post-capillary 
pressure and elevated PCWP in the pulmonary circulation. This leads to endothelial 
dysfunction, making the vascular walls less flexible owing to smooth muscle cell 
hypertrophy and hyperplasia, increasing the PVR. Thereby, PH arises, followed by 
remodelling of the arterial wall. This is characterized by medial hypertrophy and 
intimal fibrosis. Longstanding PH can grow to a state of fixed PH. Current data are 
conflicting about the reversibility of severe or fixed PH, with some data suggesting 
that LVAD therapy can reverse fixed PH. However, it remains unclear whether this is 
caused by remodelling of the pulmonary vascular wall or LV unloading and remodelling. 
Furthermore, the cut-off between fixed and reversible PH is unclear, and there is no 
agreement on the time needed to reach irreversibility.5
Continuous-flow LVADs unload the left ventricle and lower the cardiac filling pressures. 
As has been shown previously, LVAD therapy is more effective in treating ‘fixed’ PH than 
is maximal medical therapy.3,5 The CardioMEMS device allows for daily PAP readings 
(Figure 1) and was used to observe the haemodynamic changes after medication 
changes. As shown in this case, up-titrating the medical therapy to maximal tolerated 
dosage did not lead to a normalization of the PAPs. However, as shown, during the 
longer-term follow-up, the PAPs slowly declined, and after 0.5 to 1 year of LVAD 
support, the PAPs normalized with an mPAP < 25 mmHg. These results show the natural 
decline of PAP while on LVAD support besides the haemodynamic effects of maximal 
tolerated medical therapy.










































Figure 1 Daily pulmonary artery pressure readings and medication changes. LVAD, left ventricular assist 
device; MRA, mineralocorticoid receptor antagonist; PA, pulmonary artery; RAS, renin–angiotensin system.
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Previous studies investigating the reversibility of fixed PH were limited to repeated 
invasively measured PAP readings, instead of continuous PAP readings. So the timing 
of reversibility of fixed PH is still unclear.
Mikus et al. investigated the reversibility of PH during LVAD support at 6, 12, and 18 
months of follow-up and concluded that the biggest reduction in PAP will occur within 
the first 6 months post-LVAD implantation.5 In contrast, our case shows a slow decline 
in PAP over time in which the PAP of our patient normalized only after 300 days on 
LVAD support. This result suggests that the decline of PAP can occur past the 6 months 
suggested in the previous study.
Reversibility of fixed PH is very important because fixed PH is a contraindication for 
HTx. When HTx is performed in a patient with fixed PH, the stunned RV of the donor 
could not overcome the high afterload and fails owing to elevated PVR. RV failure is a 
major cause of both mortality and morbidity after LVAD implantation as well (20–50% of 
patients).6 By lowering PAP, there is more potential to improve or maintain RV function 
at long-term LVAD support, which is essential, especially in destination therapy. This 
could help in the longterm survival of LVAD patients who depend on a good working 
RV for a proper functioning LVAD. This case demonstrates that the haemodynamic 
feedback, provided by the CardioMEMS, can be used to optimize medical therapy also 
in LVAD patients. And this provides feedback on haemodynamic changes, which could 
help to detect problems such as dehydration or decompensation in earlier stages.
Conclusions
Continuous-flow LVAD can reverse fixed PH, even after a period of 6 months on LVAD 
support. The CardioMEMS sensor enables to monitor and guide the treatment of PH in 
patients with an LVAD and severe PH.
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Abstract
Aims: We aim to study the feasibility and clinical value of pulmonary artery pressure 
monitoring with the CardioMEMS™ device in order to optimize and guide treatment in 
patients with a HeartMate 3 left ventricular assist device (LVAD).
Methods and results: In this single-centre, prospective pilot study, we will include 10 
consecutive patients with New York Heart Association Class IIIb or IV with Interagency 
Registry for Mechanically Assisted Circulatory Support Classes 2–5 scheduled for 
implantation of a HeartMate 3 LVAD. Prior to LVAD implantation, patients will receive 
a CardioMEMS sensor, for daily pulmonary pressure readings. The haemodynamic 
information provided by the CardioMEMS will be used to improve haemodynamic 
status prior to LVAD surgery and optimize the timing of LVAD implantation. Post-
LVAD implantation, the haemodynamic changes will be assessed for additive value in 
detecting potential complications in an earlier stage (bleeding and tamponade). During 
the outpatient clinic phase, we will assess whether the haemodynamic feedback can 
optimize pump settings, detect potential complications, and further tailor the clinical 
management of these patients.
Conclusions: The HEMO-VAD study is the first prospective pilot study to explore the 
safety and feasibility of using CardioMEMS for optimization of LVAD therapy with 
additional (remote) haemodynamic information.
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Introduction
As the prevalence and incidence of heart failure (HF) keeps increasing, more and more 
patients develop end-stage HF despite improved medical management.1–3 About 10–15% 
of the HF patients develop advanced HF every 3 years and become refractory to drug 
therapy, leaving heart transplantation or haemodynamic support by left ventricular 
assist device (LVAD) implantation as the only therapy option.1
Experience with LVADs is rapidly growing worldwide; however, mortality and morbidity 
of this advanced therapy remains high. LVAD therapy is life-saving but remains an 
intensive complex treatment with high rehospitalization rates and outpatient clinic 
contacts.4 Recently, novel LVAD designs have improved post-operative outcomes with 
a marked reduction in pump thrombosis and cerebrovascular accidents,5 but bleeding, 
driveline infections, and long-term right ventricle (RV) failure continue to impair the 
long-term efficacy of this intervention.6–8 Patients with long-term LVAD therapy remain 
particularly vulnerable for RV failure, with up to 20–40% of the patients developing 
early RV failure 5,9,10 and 15% late RV failure.11 Severe RV dysfunction remains the leading 
cause of death in the first month after LVAD implantation.12,13 There is a growing clinical 
demand for physicians to have better ways to predict response to treatment as well as 
tailor clinical management in these patients. Currently, the pump controller only reflects 
a fixed number of rotations per minute (rpm) and notifications of a calculated pump 
flow and pulse index of the device itself but no actual haemodynamic feedback.
The CardioMEMS™ pulmonary artery (PA) sensor allows frequent remote monitoring of 
haemodynamic information, with proven effectiveness in reducing HF hospitalizations 
by maintaining normal pulmonary artery pressure (PAP) as surrogate markers of 
filling pressures (which rise in eminent decompensation) in chronic HF patients.14,15 An 
innovation would be to combine two state-of-the-art strategies such as LVAD therapy 
and guidance by PA monitoring in order to improve the outcome in this complex patient 
category and reduce the high burden of complications by early detection of pressure 
shifts. New insights will be provided by such haemodynamic feedback in order to tailor 
therapy in this patient group as well as to learn more on RV dynamics and pulmonary 
hypertension during long-term treatment with daily haemodynamic data. In order 
to study the feasibility and clinical value of the hybrid construction of CardioMEMS 
and HeartMate 3 (HM-3), we present the pilot study design to address this hypothesis 
in LVAD patients.
16
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Study design
This is an investigator-initiated, single-centre, prospective pilot study enrolling 10 
consecutive patients who undergo a scheduled semi-elective or elective implantation of 
an HM-3 LVAD. The decision for LVAD therapy will be established by heart team consensus. 
Before LVAD implantation, all patients will receive a Swan–Ganz right heart catheterization, 
and a CardioMEMS PA sensor will be implanted to measure PAP. This study has been 
approved by the ethics committee (MEC no. 2017-342), and the study will be conducted 
according to the Helsinki declaration, with all patients providing informed consent prior to 
participation. The study is registered at clinicaltrails.gov under NTR 2017-6804.
Study population
The HEMO-VAD pilot study involves 10 patients with New York Heart Association 
functional Class IIIb or IV with Interagency Registry for Mechanically Assisted Circulatory 
Support (INTERMACS) Classes 2–5, who undergo a scheduled implantation of an HM-3 
LVAD at the Erasmus MC Thoraxcentre, Rotterdam, The Netherlands. Inclusion criteria 
are presented in Table 1, and exclusion criteria are presented in Table 2.
Table 1. Inclusion criteria
- Age ≥ 18 years
- LVEF < 25%
- NYHA Class IIIb or NYHA Class IV with INTERMACS classes 2-5
- Scheduled for LVAD implantation within 1 month after heart team consensus
- Life expectancy > 1 year
- Body surface area ≥ 1.2 m2 and chest circumference, at the axillary level, of less than 65 inches 
if BMI >35kg/m2
- Signed informed consent form
BMI, body mass index; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; 
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; NYHA, New York Heart 
Association.
Table 2. Exclusion criteria 
- No signed informed consent form
- INTERMACS 1 emergency LVAD implantations
- Patients with a known coagulation disorder or hypersensitivity to aspirin
- Intolerance to anticoagulant or antiplatelet therapies
- Patients with contra-indications for the PAP sensor device, which will include active infection, a 
history of deep vein thrombosis or recurrent pulmonary embolism, mechanic right heart valve, 
or unable to tolerate Swan ganz.
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Table 2. (continued)
- History of pulmonary embolism within 30 days prior to enrollment or history of recurrent 
  (>1 episode) pulmonary embolism and/or deep vein thrombosis
- History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with 
  significant (>80%) uncorrected carotid stenosis
- Serum creatinine ≥ 221 umol/L or CKD-EPI eGFR < 25 ml/min not related to cardiac condition or the 
  need for chronic renal replacement therapy
- Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely 
  to impair compliance with the study protocol and LVAD management
CKD-EPI, Chronic Kidney Disease–Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; 
INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular 
assist device; PAP, pulmonary artery pressure.
Objectives and endpoints
The objectives of this study are as follows:
• to investigate the feasibility and safety of using haemodynamic guidance by the 
CardioMEMS PA sensor in LVAD HM-3 patients,
• to investigate the information provided by haemodynamic data of CardioMEMS PA 
sensor in relation to incident LVAD complications prospectively, and
• to study haemodynamics (PAP) preoperatively and post-operatively of LVAD surgery.
The proposed impact and goals of haemodynamic guidance in LVAD patients are further 
shown in Table 3. All study endpoints are shown in Table 4.
Table 3. Proposed impact and goals of CardioMEMS in LVAD
Phase A: 
Pre-LVAD optimization phase
· Improve patient selection pre-LVAD implantation
· Evaluate timing of LVAD implantation
· Optimizing clinical patient status towards surgery, 
  INTERMACS class pre-LVAD implantation
Phase B: 
Clinical phase
Guide post cardiac surgery treatment






Guide LVAD therapy remotely
Evaluate further improvement of PA guided LVAD pump settings
Decrease the high rate of HF related hospitalizations (70% first year)
Early discovery of late complications of LVAD
Evaluate pulmonary hypertension on LVAD therapy
HF, heart failure; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory; LVAD, left 
ventricular assist device; PA, pulmonary artery; RV; right ventricle.
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Table 4. Study endpoints
Primary end points
- Safety of the hybrid construction of CardioMEMS and LVAD
- Feasibility of the hybrid construction of CardioMEMS and LVAD
- Clinical endpoints, defined as:
• Number of HF-related hospitalizations
• Number of LVAD related complications (such as tamponade, RV failure, GI bleeding, infection,
pump thrombosis and hemolysis)
Secondary endpoints
- The number of improvements in INTERMACS classes during pre-operative optimization phase
- Clinical endpoints, defined as:
• Number of HF-related hospitalizations
• Number of LVAD related complications
- Time to reach optimal condition for surgery in the pre-operative phase (days)
- Predictive value of PAP during follow-up in out-patient clinic LVAD patients of risk of RV failure, GI 
bleeding, suboptimal fluid balance and development of long-term aortic valve insufficiency
- Monitoring of PAP and pulmonary hypertension, and reversibility of pulmonary hypertension 
in LVAD patients
- Detection of arrhythmia and heart rate monitoring with CardioMEMS in LVAD
- Feasibility of pump optimization using CardioMEMS during rpm test, and number of pump changes
- Changes in quality of life (KCCQ, EQ-5D-5L, PHQ-9)
- 6MHWD post HM-III implantation and changes during out-patient clinic phase
- HF medication changes (counts and TDD) during pre-LVAD implantation phase, post-LVAD 
implantation phase and out-patient clinical phase
- Iron deficiency before and after LVAD treatment, incidence of GI bleeding and the relationship 
with PAP and early discovery of occult blood loss
- Change in renal function in relation to PAP and diuretic medication dosage
- LDH, PAP and the incidence of pump thrombosis and hemolysis in LVAD patients
- Number of days hospitalized, number of days requiring inotropic support, and number of physical 
contact in the out-patient clinic
- Percentage of days PAP in goal range, changes in PAP from baseline and analysis of PAP waveforms 
in LVAD
GI, gastrointestinal; HF, heart failure; HM-3; Heart Mate 3; INTERMACS, Interagency Registry for 
Mechanically Assisted Circulatory Support; KCCQ, Kansas City Cardiomyopathy Questionnaire; LDH, lactate 
dehydrogenase; LVAD, left ventricle assist device; PAP, pulmonary artery pressure; PHQ-9, Patient Health 
Questionnaire 9; rpm, rotations per minute; RV, right ventricle; TDD, total daily dose; 6MHWD, 6 min hall 
walk distance.
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Study overview: CardioMEMS allocation and patient flow
The study can be divided into three phases (A–C), as is shown in Figure 1. The different 
phases are described below.
Figure 1 Study overview. LVAD, left ventricular assist device.
Phase A: Pre-left ventricular assist device optimization phase (1 week)
Every consecutive patient, who is accepted by the heart team for scheduled LVAD 
implantation (both destination therapy and bridge to transplant), is screened for 
eligibility to participate in the HEMO-VAD study. After the heart team decision has been 
taken to plan an LVAD implantation, the CardioMEMS sensor is implanted as soon as 
possible, that is, at 0–1 day. LVAD implantation is to be scheduled with the aim within 
1 week in semi-elective to elective patients, with minimum 1 day and maximum within 
4 weeks after heart team consensus.
After enrolment and informed consent, but prior to HM-3 implantation, subjects will 
be implanted with the CardioMEMS HF system. The baseline visit (t = 0) includes the 
day of the right heart catheterization (Swan–Ganz) occurring in all patients and the 
implantation of the CardioMEMS PA sensor in the left lower lobe PA. PAP data will 
be utilized to guide adjustments of medical therapy (e.g. diuretics, vasodilators, and 
inotropes or phosphodiesterase inhibitors) for optimization of the haemodynamic 
status prior to HM-3 implantation, with the aim to improve the pre-LVAD INTERMACS 
class, which is one of the best parameters of outcome. The main objective is to ensure 
optimal status to decompress venous congestion (unloading) of the RV and mean PAP 
(mPAP) below 25 mmHg. Recommendations for these adjustments will be provided 
with options for the physician as deemed clinically appropriate.
In this PAP-guided phase prior to LVAD implantation, the physician will use the PAP 
obtained by the sensor to optimize the patient condition and fluid status proceeding 
towards LVAD surgery. This contains optimal fluid status (euvolemia) and lowered 
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right heart pressures (unloading the RV) to optimal capacity as judged by the treating 
clinician, laboratory values, and echocardiographic parameters. The clinician normally 
uses a treatment course of phosphodiesterase inhibitors or inotropes and titrates 
diuretics, angiotensin-converting enzyme inhibitors, and nitrates dosages. Another 
aspect of the pre-LVAD optimization phase is to learn more on optimal timing window 
of LVAD surgery. When optimal timing window to proceed to LVAD surgery is reached, 
the HM-3 implantation follows. Based on clinical judgement or clinical urgency, this 
timing can be adjusted.
Phase B: Clinical phase
After LVAD implantation, the patients will be admitted to the intensive care unit (ICU), 
where patients will receive regular care. At the ICU, potential interference between the 
implanted PAP sensor, LVAD controller, and potential other equipment will be tested, 
as an important part of the feasibility and safety of this novel hybrid construction. 
In addition to the regular care, daily pressure readings provided by the CardioMEMS 
system will be used to guide HF treatment, according to the predefined goals: diastolic 
PAP will be targeted and maintained between 8 and 15 mmHg as well as mPAP below 
25 mmHg. Furthermore, PAP changes might indicate the presence of complications 
such as RV failure, infection, or cardiac tamponade, on top of echocardiography in an 
earlier stage. At the moment, haemodynamic recordings after LVAD implantation are 
very limited in the current literature to provide insights in these mechanisms. Recently, 
a retrospective sub-analysis of the CHAMPION trial provided some information of 
PAP changes after LVAD implantation, suggesting that additional haemodynamic 
information has the potential to improve LVAD management.16 However, information 
during the hospitalization for LVAD implantation and during potential LVAD-related 
complications is still lacking.
When clinically stable, patients will be transferred to the HF department. Patients will 
receive the usual care, and at least once a day, pressure readings will be continued. 
Haemodynamic feedback will be used for optimizing HF medication titration, leading 
to tailored therapy (maintain normal PAP), and evaluating haemodynamic changes 
during potential complications. During admission, LVAD care echocardiography will 
be performed to optimize pump settings (rpm testing), as is standard care, only with 
additional pressure feedback for the CardioMEMS system, which will be analysed 
separately. Furthermore, patients will be trained in using the LVAD device, controller, 
and exchange batteries as well as operating the home monitoring unit and instructed 
to take daily PAP measurements.
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Phase C: Outpatient monitoring phase (long-term follow-up)
Throughout the long-term follow-up period and subsequent hospitalizations, the 
pressure data upload will be performed at least daily using the home monitoring system 
and the Merlin.net website. Pressures will be reviewed remotely at least once a week 
and more frequently when pressures are outside the target range, on the Merlin.net 
website, with anticipation of treatment alterations based on maintaining normal PAP. 
Patients will be followed during regular outpatient clinic visits, approximately at 1, 2, and 
4 weeks and 3, 6, 9, and 12 months. During these visits, patients will receive standard 
care, expanded with specific blood, urinary, and echocardiography parameters, as well 
as questionnaires on quality of life, and the performance status will be assessed.
Parameters of interest
Primary study parameter(s) of CardioMEMS device
Daily PAP measurements will be performed in the preoperative period towards LVAD 
implantation, direct post-operative period on ICU, clinical department, and the regular 
outpatient clinic setting. Measurements record systolic PAP, diastolic PAP, mPAP, mean 
trend, and heart rate.
Our study protocol will further study PAP in relation to the following:
• serial lactate dehydrogenase levels, international normalized ratio values, and pump 
thrombosis;
• serial creatinine clearance, urinary samples, and kidney dysfunction;
• serial iron status and gastrointestinal bleeding incidence; and
• serial measurements of quality of life at 3, 6, and 12 months.
Other parameters of interest
Baseline Swan–Ganz measurements (including cardiac index, systolic PAP, diastolic 
PAP, mPAP, wedge pressures, RV pressures, right atrial pressures, and PA pulsatility 
index) are recorded at baseline during CardioMEMS implantation (protocol describing 
the Swan–Ganz procedure and CardioMEMS implantation is described in detail in Table 
5). Vasoreactivity is tested during the LVAD screening, using continuous administration 
of an i.v. vasodilating agent, such as nitroglycerin, in increased dosage. During the 
entire study, at regular intervals, clinical parameters (such as heart rate, blood 
pressure, weight, and symptoms of congestion), laboratory results (including standard 
routine care laboratory results, renal function, haemolysis parameters, iron status, 
and biomarkers), urine analysis (proteinuria), LVAD parameters log file (rpm, flow, 
pulse index, power, pulsatility index events, and suction events), echocardiography 
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parameters (such as ventricle dimensions, valve patency, ventricle and vena cava 
dimensions, tricuspid annular plane systolic excursion, and rpm measurements), 
electrocardiogram, performance status (New York Heart Association and INTERMACS 
classification, and 6 min hall walk test), and quality of life questionnaires (EQ-5D-5L, 
Kansas City Cardiomyopathy Questionnaire, and Patient Health Questionnaire 9) 
will be assessed.
Table 5. Swan-Ganz and CardioMEMS implantation protocol:
1. Insert, using ultrasound guidance, a 7F balloon-tipped Swan-Ganz pulmonary artery catheter through 
the femoral vein
2. Obtain standard Swan Ganz right heart catheterization pressure reading at RA, RV, PA and pulmonary 
capillary wedge pressure. Preferably right pulmonary artery.
3. Obtain the cardiac output using thermodilution (using 10 ml NaCl 0.9% per measurement), calculated 
as the average of at least three adequate measurements
4. Introduce the adequate pigtail shaped into the venous sheath and localize the pigtail with fluoroscopy 
into the left lower pulmonary artery. And perform a standard pulmonary artery angiogram of the 
left lower pulmonary artery
5. Perform standard measurements of vessel size and re-assure maximum vessel size diameter and 
anatomical requirements (inner vessel diameter must be > 7 mm) suited for CardioMEMS
6. Insert the CardioMEMS catheter in the left lower pulmonary artery targeted vessel site, and confirm 
adequate positioning by fluoroscopy
7. Turn the catheter switch button to release the wires of the CardioMEMS sensor which fixes itself 
in the pulmonary artery. Confirm adequate positioning of the device by the radiopaque markers 
with fluoroscopy
8. Re-introduce the Swan Ganz catheter and position the catheter in the right pulmonary artery. Start 
calibrating and equilibrate the CardioMEMS pressure readings with the simultaneous Swan Ganz 
pressure readings (nulling of the sensor). Perform baseline measurements and calibration three 
times and confirm measurements and baseline recordings are identical
9. Remove Swan Ganz catheter. Remove the venous sheath from the femoral vein. At preference of 
the operator, use a closure device for the femoral vein, manual compression or pressure bandage 
at the venous puncture site
PA, pulmonary artery; RA, right atrium; RV, right ventricle.
Device description and implantation procedure
The device description and implantation procedure of the CardioMEMS HF sensor 
system (Abbott Inc., Atlanta, GA, USA)17 and of the HM-3 LVAD (Abbott Inc., Pleasanton, 
CA, USA) have been published previously.18
Statistical analysis
For the purpose of this study, all data will be recorded on a case report form and 
introduced into the study database environment. All patient data will be collected by a 
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dedicated research fellow or PhD student. Baseline quantitative data will be presented 
with mean ± standard deviation or median with interquartile range when appropriate. In 
general, statistical analyses in this pilot study will be descriptive in nature. The data will 
be summarized using descriptive statistics (e.g. N, mean, standard deviation, median, 
minimum, and maximum) or frequency (e.g. N, %) as appropriate. Changes in PAP will be 
measured as area under the curve of PAP relative to the baseline. Changes in quality of 
life (assessed using EQ-5D-5L, Kansas City Cardiomyopathy Questionnaire, and Patient 
Health Questionnaire 9) will be analysed. The primary time point for safety analyses is 
6 months post-enrolment. The time point for analyses of feasibility and haemodynamic 
performance is at 6 and 12 months post-enrolment.
Discussion
The HEMO-VAD pilot study is the first prospective study investigating haemodynamic 
guided management of HM-3 LVAD patients with an implantable pressure sensor 
(CardioMEMS). The primary goal is to assess the safety and feasibility of this hybrid 
construction and evaluate its additive value in optimizing treatment in LVAD patients. 
Reaching and maintaining optimal fluid status and maximizing optimal medical 
treatment and timing of surgery towards LVAD therapy (preoperative and post-operative 
stages) are the main focus. Additionally, this study will evaluate the use of frequent 
remote measurement of PAP to discover early and late complications of LVAD therapy 
during hospitalization. Finally, we evaluate whether direct haemodynamic feedback 
can influence outpatient clinical management and optimize pump settings on top of 
current standard care.
Left ventricular assist device therapy is a complex entity with high risk of mortality and 
morbidity without clear tools to predict outcome or complications during treatment. 
9,19–23 From a haemodynamic point of view, RV failure is the most common serious 
complication after LVAD implantation. RV failure after LVAD implantation can be divided 
into early or late RV failure (<4 weeks and >4 weeks after implantation, respectively). 
Early RV failure occurs in as much as 20–40% 5,9 and late RV failure in 15% of LVAD 
patients.11 Preoperative assessment of RV function is essential in LVAD screening but 
dependent on filling status and right heart pressures. Prolonged elevated PAP is a 
major cause of RV failure, but pulmonary hypertension alone is not a contraindication 
for LVAD implantation, unless there is already severe RV failure pre-LVAD. One of the 
caveats is that RV failure after LVAD implantation is highly unpredictable.5,12 Current risk 
assessment scores have limited predictive value and clinical usefulness for predicting 
16
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LVAD-related complications, especially RV failure. 9,10,24 Recently, the EUROMACS-RHF risk 
score has been developed and aims to predict early RV failure and associated mortality 
after LVAD implantation.10 At the moment, the best predictive variable for RV failure 
post-LVAD implantation is RV function prior to surgery as assessed by echocardiography, 
which largely depends on fluid status, vascular resistance, degree to which pulmonary 
pressures are elevated, and severity of tricuspid valve regurgitation. Echocardiography 
can be used to evaluate RV function but correlated poorly with the development of 
RV failure. Right heart catheterization is the gold standard to assess RV workload and 
function; however, this is an invasive procedure, performed at one moment in time, 
and greatly depends on loading conditions at that moment. More tools are needed to 
adequately predict and assess the risk of post-LVAD RV failure.
We hypothesize that PAP is key in the preoperative stage to deliver the patient to the 
surgeon in optimal decongested state to lower the impact of the surgery on the RV. 
After implantation, we hypothesize that PAP can be used as a marker of treatment 
success of left ventricular (LV) unloading by the LVAD with insight into residual fixed 
vascular resistance, which may be a target for therapies with the goal of protecting RV 
function by reducing afterload. Additionally, PAP information may predict potential 
complications of LVADs such as occult bleeding, haemolysis, or pump thrombosis in 
association with the fixed measurement from the pump. Better prediction of upcoming 
RV dysfunction, directed by measuring PAP combined with optimization of therapy 
based on haemodynamic feedback, might lead to a better LV unloading, lowering the 
PAP and lowering chances of RV failure.
As described previously, pulmonary hypertension alone is not a contraindication for 
LVAD implantation. Often PAP and pulmonary vascular resistance normalize several 
months after LVAD implantation, which cannot be matched by any medical therapy. 
Furthermore, LVAD implantation appears to be the best tool for reversal of ‘fixed’ 
pulmonary hypertension.12 However, continuous data of PAP after LVAD implantation 
are not available at this moment. This study will provide novel insights of changes in 
PAP data during LVAD therapy.
Despite existing risk scores,21,25–27 an adequate measuring tool for determining the ideal 
LVAD implantation timing is still missing. Multiple studies 13,21,26,27 demonstrated that 
sicker and more instable patients, indicated by a lower INTERMACS profile, had worse 
survival outcome than less sick patients, indicated by a higher INTERMACS profile.
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It has been shown that an improvement in risk score shortly before LVAD implantation 
lead to a better outcome after LVAD implantation.25 We hypothesize that the 
haemodynamic feedback, provided by the implantable haemodynamic monitoring, 
will lead to a tailor made, optimized medical therapy pre-LVAD. By doing so, we think 
that the patient will get in an optimal clinical condition, potentially rising the INTERMACS 
class from 2 to 3, or 3 to 4. Furthermore, we hypothesize that haemodynamic feedback 
provides additional information in order to determine the optimal timing of LVAD 
implantation. We hypothesize that optimizing the patients’ clinical condition and the 
timing of LVAD implantation will lead to a better clinical outcome.
Other research areas of interest
Pulmonary artery pressure data provided by the CardioMEMS during LVAD therapy 
provide a unique opportunity of a wealth of novel haemodynamic data.
In the post-operative period, one of the major complications of LVAD is bleeding 
(40%) or tamponade requiring surgical intervention (20%).20,22 The clinical diagnosis 
of tamponade is often missed in this complex patient group, as the pump keeps on 
providing flow even in the late stages of tamponade.20 In case of tamponade, we expect 
to detect a decrease in PAP if the pericardial fluid impairs the filling of the right side of 
the heart; at the left side, located pockets could also impair pump function and increase 
PAP. CardioMEMS might be a valuable tool to detect the changes in a much earlier stage. 
In contrary, a major post-operative bleeding might lead to a drop in PAP due to loss of 
circulating volume. Additionally, in the outpatient clinical phase, the haemodynamic 
data could provide important feedback on development of frequent complications 
such as gastrointestinal bleeding (20–40%),19,28 pump thrombosis (8–10%),23 or renal 
dysfunction (12%) 21 at an earlier stage.
As described previously,29 filling pressures will rise as a result of congestion. Congestion 
can be a sign of development of aortic valve regurgitation and pump dysfunction 
(kinking outflow graft or bent relief), resulting in higher PAP. For example pump 
thrombosis leads to LVAD dysfunction and impaired LV unloading. This will lead to 
signs and symptoms of HF and pulmonary congestion.23,30
Additionally, considering renal function,8 lowering PAP by better unloading LV and 
providing better cardiac output will improve renal function. However, when kidney 
failure occurs and patients’ urine production declines, PAP might rise. We will study 
these issues with separate research subthemes within the HEMO-VAD pilot study.
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Limitations
The design of our study has some limitations. Due to the pilot study design we include 
only a small number of patients, with the aim to test the feasibility of this hybrid 
construction. Also, we have not included a control group in the study design, because 
of the observational nature. Still, the current study is the first prospective study 
investigating this new hybrid combination of CardioMEMS with an LVAD providing a 
wealth of novel haemodynamic data. After feasibility is demonstrated, we need to test 
the clinical value of this concept in a large-scale randomized clinical trial in patients 
scheduled for LVAD therapy as is currently anticipated.
Conclusions
The HEMO-VAD study will test the safety and feasibility of the hybrid construction 
of PAP measurements by the CardioMEMS device and LVAD therapy during 6 and 12 
months of follow-up.
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Abstract
Aims: Left ventricular assist device (LVAD) therapy remains to be affected by several 
severe LVAD-related complications. Additional tools to optimize and identify high-risk 
patients for adverse clinical outcomes are needed. We aimed to assess the safety, 
feasibility, and effectiveness of a hybrid construction of using CardioMEMS monitoring in 
patients before LVAD surgery and during LVAD therapy to optimize patient management 
as a proof of concept.
Methods and results: Ten patients (NYHA≥III; INTERMACS 2-5) accepted for (semi-) 
elective LVAD surgery were included and received a CardioMEMS ≤2 weeks before 
surgery. The aim was to optimize filling pressure to decongest the kidney and unload 
the right ventricle (RV) using hemodynamic data on top of physical examination and 
blood biomarkers. Patients were categorized whether hemodynamic optimization was 
achieved (mean pulmonary artery pressure (mPAP)≤25mmHg (n=4) vs. mPAP>25mmHg 
(n=6)) pre-LVAD surgery. Primary endpoints were CardioMEMS device safety and 
a combined endpoint of all-cause mortality, acute kidney injury, renal replacement 
therapy, and/or right ventricle failure at 3 months follow-up.
No device or system-related complications, or sensor failure of CardioMEMS, and no 
interference with the LVAD occurred during measurements. The combined end-point 
occurred most often in non-optimized CardioMEMS patients compared to hemodynamic 
optimized CardioMEMS patients (83%, 0%, p=0.007).
Conclusions: This pilot study demonstrates that combining CardioMEMS monitoring 
with LVAD therapy is safe and generates the hypothesis that using continuous 
hemodynamic data pre-LVAD surgery can improve patient outcome post-LVAD surgery. 
Patients with an mPAP>25mmHg pre-LVAD surgery, despite medical management, 
identify a very high-risk group for adverse clinical outcomes.
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Introduction
Chronic heart failure (HF) is a complex clinical syndrome with increasing prevalence 
and incidence worldwide1. If HF progresses, patients can become refractory to medical 
therapy, leaving heart transplantation or left ventricular assist device (LVAD) surgery 
as advanced HF treatment options. Due to a shortage of available heart donors, LVAD 
therapy is increasingly used2. Despite growing experience with LVAD and technical 
improvements, overall survival remains affected by several severe LVAD-related 
complications, such as right ventricular (RV)-failure, acute kidney injury (AKI), LVAD-
related infections, and major bleeding events3-6. The short term (≤3 months) mortality 
rate remains high, at approximately 10%2. Improving patient status shortly pre-LVAD 
surgery can improve post-LVAD surgery outcomes7.
Identifying the ideal patients, as well as the timing of LVAD surgery, is essential 
in advanced HF management. Physical examination, laboratory results, and 
echocardiography are parameters that can be used pre-operatively but have limited 
predictive value for the outcome post-surgery. Many risk-scores are developed and 
provide some guidance in determining high-risk patients, but do not provide tools 
to optimize the patient pre-LVAD surgery3, 8-11. Congestion of the kidneys, indicated 
by an elevated central venous pressure (CVP), is associated with a higher risk of 
AKI and mortality12. Additional tools to optimize and assess the ideal LVAD surgery 
window are needed.
Recently, remote monitoring using the CardioMEMS device, an implantable pulmonary 
artery pressure (PAP) sensor, has shown to be safe and effective in preventing HF-
related hospitalization in chronic HF patients13, 14. This technique could also be used as 
an additional tool to optimize patients during the work-up for LVAD surgery, allowing 
for hemodynamic optimization of patients going for surgery, unloading the RV, and 
decongestion of the kidney. This approach might improve the timing of surgery 
and might identify patients at high-risk for worse outcomes, e.g., RV-failure, where 
additional assistance (RV back-up) is necessary during, and shortly after surgery. Post-
LVAD surgery, hemodynamic data could be used to remotely monitor patients as a 
hybrid construction with the static pump measurements provided by the LVAD at the 
out-patient clinic and at home.
The HEMO-VAD (HEMOdynamic guidance with CardioMEMS in patients with a left 
Ventricular Assist Device) pilot study assessed the safety and feasibility of combining 
17
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CardioMEMS with LVAD therapy. Furthermore, the study tests the hypothesis that 
combining the hemodynamic data provided by CardioMEMS in the pre-operative 
period towards LVAD surgery can improve patient selection, timing window, and 
overall surgical outcome. This is the first study evaluating this concept in a structured 
manner pre- and post-operatively to study this promising combination of techniques 
to optimize patient management.
Methods
The design and methods of the HEMO-VAD pilot study, an investigator-initiated, 
prospective pilot study, has been published in detail elsewhere 15. In brief, all consecutive 
patients accepted by the heart team for LVAD surgery (HeartMate 3, HM3), both as 
destination therapy (DT) and bridge to transplantation (BTT), in the Erasmus MC Thorax 
Center, Rotterdam, between November 2017 and March 2019 were screened for study 
eligibility. In total, ten chronic HF patients with New-York Heart Association (NYHA) 
functional Class ≥III and Interagency Registry for Mechanically Assisted Circulatory 
Support (INTERMACS) Class 2-5, scheduled for (semi-) elective LVAD implantation were 
enrolled (Figure 1). Patients with significant RV dysfunction, indicated by a tricuspid 
annular plane systolic excursion (TAPSE) measurement ≤13 mm 16, were excluded from 
participation in this study. All patients provided informed consent, the local medical 
ethics committee approved the study (MEC nr. 2017-342), and the study complies with 
the Declaration of Helsinki.
CardioMEMS patients
All enrolled patients underwent CardioMEMS implantation at baseline (moment of 
acceptance within one day, per protocol), allowing for daily PAP monitoring in the 
pre-operative period towards LVAD surgery. The daily hemodynamic information, on 
top of standard care, was used to guide the adjustments in the medical treatment to 
hemodynamically optimize the patients prior to LVAD surgery. During the optimization 
phase, the central aim was to adjust the diuretic dosage to reach euvolemia and 
vasodilator therapy to aim for a normal mean PAP (mPAP) ≤25 mmHg. The timing of 
surgery was determined by normalized PAP, the urgency of surgery at the discretion of 
the physician, no responding pressure trend to medical changes, or a maximum period 
of two weeks. Post-LVAD surgery, the PAP readings were used in addition to regular care 
on the intensive care unit (ICU) and clinical ward, as well as at the out-patient clinic, to 
HF treatment and fluid (substitution) therapy and to optimize pump settings, targeting 
for a diastolic PAP between 8 and 15 mmHg as well as an mPAP ≤25 mmHg.
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Figure 1. Optimization phase (pre-LVAD implantation): mPAP and number of medication changes from Car-
dioMEMS implantation up to LVAD surgery according to hemodynamically optimized status pre-LVAD surgery
Colored area indicates ±1SE
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Safety endpoints
The endpoints of the safety analysis were freedom of sensor failures at 3 months, 
freedom of device-related complications at 3 months, and the presence of signal 
malfunction or interference with the CardioMEMS device and HM3.
Clinical endpoints
The primary clinical endpoint of this analysis was the 3 months outcome after LVAD 
surgery, assessed as a composite endpoint of all-cause mortality, AKI and/or renal 
replacement therapy (RRT), and RV-failure. Secondary endpoints were all-cause 
mortality, AKI and/or RRT, RV-failure, as well as all-cause hospitalization-free survival, 
changes of mPAP pre- and post-LVAD surgery, the number of medication changes pre- 
and post-LVAD surgery, and changes in laboratory results (NT-proBNP, eGFR, bilirubin), 
quality of life (assessed using the EQ-5D-5L, Kansas City Cardiomyopathy Questionnaire 
(KCCQ) and Patient Health Questionnaire-9 (PHQ-9) questionnaires) and functional 
performance defined as 6-minute walking distance.
AKI was defined as a minimal 1.5 times increase of baseline serum creatinine during 
the first seven days post-LVAD implantation, according to the kidney disease improving 
global outcome criteria 17. RV-failure was defined as continuous inotropic support for 
≥14 days, or nitric oxide ventilation for ≥48 hours 18.
Statistical analysis
Continuous data are expressed as median and interquartile range and compared by 
the Mann-Whitney U-test. Categorical data are expressed as counts and percentages 
and compared by the two-sided Fishers’ exact test. The probability of survival/
combined endpoint was calculated using the Kaplan-Meier method and compared 
using the log-rank test (time-to-first event analysis). Changes in quality of life 
between baseline and 6 months of follow-up within and between patient groups were 
analyzed using the repeated ANOVA test. A two-sided P value of 0.05 or lower was 
considered statistically significant.
The CardioMEMS patients were stratified based on mPAP provided by the CardioMEMS, 
into two groups: patients who could be hemodynamically optimized, defined as a pre-
LVAD surgery mPAP≤25mmHg and those who could not be hemodynamically optimized, 
defined as a pre-LVAD surgery mPAP>25mmHg.
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All statistical analyses were performed using Statistical Package for Social Sciences, 
version 25.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of all patients are presented in Table 1. In the entire cohort, 
the median age was 60 [52-63] years, 70% of patients were men, and the median left 
ventricular ejection fraction was 19% [13-24]. At baseline, the patients had a median TAPSE 
of 16 [15-20]mm, and a median systolic, diastolic, and mean PAP of 45 [39-50], 25 [21-30] 
and 33 [28-36]mmHg, respectively, at baseline. The median pulmonary capillary wedge 
pressure (PCWP) was 14 [11-29]mmHg, and the cardiac output was 3.9 [3.5-5.3]L/min.










Age (years) 60.1 [52.4-63.0] 60.3 [51.6-66.3] 58.7 [53.4-61.9] 0.670
Male gender (%) 7 (70.0) 4 (66.7) 3 (75.0) 1.000
BMI (kg/m2) 27.2 [23.1-28.6] 27.2 [23.5-29.2] 24.8 [21.5-30.6] 0.670
Systolic BP (mmHg) 98.5 [89.0-108.5] 101.5 [88.8-115.3] 95.5 [89.3-102.5] 0.593
Diastolic BP (mmHg) 66.5 [57.0-72.8] 65.5 [50.3-81.3] 66.5 [60.8-70.0] 0.915
Heart rate (/min) 70.0 [67.5-78.0] 70.0 [64.3-84.0] 71.5 [68.5-75.3] 0.829
History
Myocardial infarction 4 (40.0) 4 (66.7) 0 (0.0) 0.076
CABG 2 (20.0) 2 (33.3) 0 (0.0) 0.467
PCI 0 (0.0) 0 (0.0) 0 (0.0) -
Atrial fibrillation 4 (40.0) 3 (50.0) 1 (25.0) 0.571
Diabetes Mellitus 4 (40.0) 2 (33.3) 2 (50.0) 1.000
Renal insufficiency 8 (80.0) 5 (83.3) 3 (75.0) 1.000
TIA/CVA 2 (20.0) 1 (16.7) 1 (25.0) 1.000
Laboratory values
Creatinine (µmol/L) 159.5 [124.5-191.0] 174.5 [156.5-206.0] 121.0 [109.5-152.0] 0.032
e-GFR (mL/min) 38.5 [31.5-47.5] 33.5 [27.8-39.0] 50.0 [40.5-63.3] 0.019
NT-proBNP (pmol/L) 476.5 [297.8-565.0] 531.5 [328.8-655.0] 372.0 [263.3-544.5] 0.522




19.0 [13.0-24.0] 19.0 [12.0-27.5] 17.5 [15.0-20.0] 1.000
TAPSE 16.0 [15.0-20.3] 18.0 [15.0-21.0] 16.0 [15.3-19.8] 0.826
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RA pressure (mmHg) 5.5 [3.0-10.5] 5.0 [3.0-11.0] 5.0 [2.5-7.5] 0.392
Systolic PAP (mmHg) 44.5 [38.8-49.8] 46.5 [42.3-58.8] 39.5 [26.0-47.0] 0.165
Diastolic PAP (mmHg) 25.0 [20.8-29.5] 27.5 [24.0-34.0] 22.0 [13.3-24.8] 0.042
Mean PAP (mmHg) 32.5 [27.8-36.0] 33.5 [31.3-42.5] 28.5 [17.3-34.5] 0.238
PAP index 3.28 [1.76-6.50] 3.05 [1.27-8.17] 4.58 [2.20-6.00] 0.831
PCWP (mmHg) 13.5 [10.5-29.0] 19.5 [7.5-38.8] 13.0 [11.3-16.3] 0.670
Cardiac output (L/min) 3.89 [3.48-5.25] 3.69 [3.33-6.75] 4.10 [3.83-4.68] 0.522
HF therapy at baseline
Loop diuretics 100 (100.0) 6 (100.0) 4 (100.0) -
Beta-blocker 9 (90.0) 5 (83.3) 4 (100.0) 1.000
Vasodilators 7 (70.0) 4 (66.7) 3 (75.0) 1.000
MRA 7 (70.0) 4 (66.7) 3 (75.0) 1.000
Anticoagulation 10 (100.0) 6 (100.0) 4 (100.0) -
ICD therapy 10 (100.0) 6 (100.0) 4 (100.0) -
CRT-D 7 (70.0) 4 (66.7) 3 (75.0) 1.000
BMI, Body Mass Index; BP, Blood Pressure; CABG, Coronary Artery Bypass Graft; COPD, Chronic Obstructive 
Pulmonary Disease; TIA, Transit Ischemic Attack; CVA, Cerebrovascular Accident; e-GFR, estimated 
Glomerular Filtration Rate; TAPSE, Tricuspid Annular Plane Systolic Excursion; RA, Right Atrial; PAP, 
Pulmonary Artery Pressure; PCWP, Pulmonary Capillary Wedge Pressure; MRA, Mineralocorticoid Receptor 
Antagonist; ICD, Implantable Cardioverter Defibrillator; CRT, Cardiac Resynchronization Therapy
Safety & feasibility
The freedom of device or system-related complications of CardioMEMS was 100%, and 
the freedom of sensor failures of CardioMEMS was 100%, including no interference with 
the LVAD HM3 during measurements. In all patients, a clinically useful daily PA signal 
was achieved pre- and post LVAD surgery at the ICU, ward, and at home.
Pulmonary artery pressure
The median duration of the optimization phase before the planned elective LVAD 
surgery was 9 [6-12] days in patients who were not hemodynamically optimized (n=6) 
and 6 [5-10] days in patients who were hemodynamically optimized (n=4). Despite a 
lower number of medication changes during the optimization period, the decline in 
mPAP was larger in the patients who were hemodynamically optimized compared with 
those not hemodynamically optimized, as shown in Figure 1. In all patients who could 
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not be hemodynamically optimized, a combination of diuretics, as well as Enoximone, 
was used in an attempt to optimize these patients. During the optimization phase, three 
out of four hemodynamically optimized patients had an improvement in INTERMACS 
class (1.00 [0.25-1.75]). In contrast, one not hemodynamically optimized patient had an 
improvement, three patients remained in a similar INTERMACS class, and two patients 
had a worsening INTERMACS class (0.00 [-1.00-0.25]. Of the hemodynamically optimized 
patients, all proceeded towards LVAD-surgery because optimal mPAP were achieved. 
In the not hemodynamically optimized patients, three patients proceeded towards 
LVAD-surgery because the mPAP did not respond to changes, two patients because they 
excided the two weeks threshold and one patient at the discretion of the physician.
After LVAD surgery, in both patient groups, an initial increase in mPAP was observed, 
most likely by the fluid substitution at the ICU period, followed by a decline in both 
patient groups, as shown in Figure 2. Patients who were not hemodynamically 
optimized had more medication changes compared with the patients who 
were hemodynamically optimized.
Clinical outcome and LVAD-related adverse events
The combined endpoint of all-cause mortality, AKI/RRT, or RV-failure occurred 83.3% of 
the CardioMEMS patients who were not hemodynamically optimized. In comparison, 
no events occurred in the CardioMEMS patients who were hemodynamically optimized 
(0.0%), p=0.017 (Figure 3A). All-cause mortality occurred in 16.7% of the CardioMEMS 
patients who were not hemodynamic optimized, while no deaths occurred in the 
CardioMEMS patients who were hemodynamically optimized (0.0%) (p=0.414, Figure 
3B). Both AKI and/or RRT, as well as RV-failure, occurred the least in the CardioMEMS 
patients who were hemodynamically optimized (0.0% and 0.0%, respectively) compared 
CardioMEMS patients who were not hemodynamically optimized (83.3% and 66.7%, 
respectively) (p=0.017 and p=0.054, respectively, Figure 3C and 3D).
All-cause hospitalization-free survival
The all-cause hospitalization-free survival did not significantly differ between the 
patient groups during the first 3 months post-LVAD surgery (p=0.665), as shown in 
Supplementary Figure 1. The all-cause hospitalization-free survival was 75.0% in the 
CardioMEMS patients who were hemodynamically optimized, and 60% in those who 
were not hemodynamically optimized.
17
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Figure 2. Out-patient monitoring phase: Mean mPAP and mean number of medication changes up to 
90 days post-LVAD surgery according to hemodynamically optimized status pre-LVAD surgery
Colored area indicates ±1SE
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Figure 4. Changes in quality of life between baseline and 3 months post-LVAD surgery: A Index value (EQ-
5D-5L) B Self-reported quality of life (EQ-5D-5L), C KCCQ overall summary score, D KCCQ clinical summary 
score and E PHQ-9 depression score
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Lab values
The renal function, as well as the serum levels of NT-proBNP values and total bilirubin, 
improved in both patient groups, as shown in Supplementary Figure 2. The increase 
in serum creatinine levels increased the most in the CardioMEMS patients who were 
not hemodynamically optimized, and the least in the hemodynamically optimized 
CardioMEMS patients, as shown in Supplementary Figure 3.
Quality of life and functional performance
The self-reported quality of life in the CardioMEMS cohort improved during the first 3 
months post-LVAD surgery for both patient groups, in all quality of life questionnaires 
(Figure 4A-E). In both CardioMEMS groups, a trend towards an improvement in the 
functional performance, measured by the 6-minute walking distance, between baseline 



















































Figure 5. Changes in 6-minute walking distance at baseline, discharge and 3 months of follow-up in 
CardioMEMS patients
Discussion
The current pilot study showed that the concept of combining CardioMEMS before 
LVAD surgery is safe, feasible, and might improve patient management and outcome 
of LVAD patients. The hemodynamic feedback provided by CardioMEMS could be 
clinically useful and intuitive to identify a high-risk group of worse LVAD outcomes 
with no adequate response of PAP. The ability to adjust PAP before surgery with a 
17
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decongestion of the kidney and RV might identify a group with a good prognosis after 
elective LVAD surgery.
Using the hemodynamic feedback provided by the CardioMEMS pre-LVAD surgery leads 
to a tailored approach and true hemodynamic optimization of LVAD recipients. The 
current hybrid approach might serve as an important new risk marker or guide of 
therapy where the physician can be alerted to start RRT earlier or provide RV support 
at an early stage in anticipation of worse outcomes.
The overall survival of chronic HF patients supported with a continuous-flow LVAD has 
been extensively reported, with a 30-day survival rate between 89 and 98%19, 20, and a 
one-year survival rate between 75 and 85%19, 21-23. Despite technological improvements, 
the short-term outcome is effected due to LVAD-related complications, such as RV-
failure, renal failure, and post-operative bleedings22. Several risk factors for post-
operative complications have been identified, including a higher age, LVAD surgery as 
DT, a worse kidney function, and a lower INTERMACS profile2, 21-24. Although it has been 
shown that improving the INTERMACS profile shortly prior to LVAD surgery improves 
outcomes7, strategies to optimize the patient clinical status prior to LVAD surgery are 
still lacking. As our results demonstrate, using the hemodynamic feedback provided by 
the CardioMEMS device to hemodynamically optimize patients prior to LVAD surgery is 
safe, feasible and might improve the outcome of LVAD patients.
Patient selection, risk assessment, and timing of LVAD surgery remain significant 
challenges for treating physicians. In a small subgroup analysis of the CHAMPION 
trial and a small retrospective study, patients who received a CardioMEMS device and 
(naturally) progressed to end-stage HF needing LVAD showed a gradual increase in PAP 
till the moment of surgery25, 26. By using the hemodynamic information, clinicians could 
better identify chronic HF patients who did not respond to pharmacological therapies 
on top of standard care and could identify patients in need for LVAD surgery at an earlier 
stage25. However, both studies had a retrospective design, including a case series of 
studied patients already on LVAD therapy without a structured pre-operative approach 
using the sensor information going into surgery.
Based on physical examination and blood biomarkers, all patients included in 
the CardioMEMS cohort were deemed to be in an optimal state for surgery before 
CardioMEMS implantation. However, as indicated by the elevated PCWP at baseline, 
many patients were still in a hypervolemic state. Adding daily PAP monitoring on top 
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of standard care could help the HF-specialist to decongest the RV and kidneys truly, 
and achieve a better pre-operative condition. Normalization of the mPAP shortly 
prior to LVAD surgery might indicate an ideal optimization and could aid in improving 
the timing of LVAD surgery. Eventually, this might result in a lower incidence of AKI, 
RRT, and RV-failure post-LVAD surgery. Additionally, a very high-risk population for 
LVAD-related complications might be identified by the inability to normalize the mPAP 
pre-LVAD surgery.
Additionally, we observed a small increase in PAP in the first days after LVAD surgery, 
which could be caused by significant fluid infusion during surgery and at the ICU that 
may stress and impair the already vulnerable RV and kidney function in this period. 
PAP guidance could help to prevent aggressive fluid management, allowing relative 
hypotension in LVAD patients during the first days post-operatively (preventing 
unnecessarily stretching the RV). These findings are hypothesis-generating due to the 
small patient size, but clinically plausible.
Minimizing the risk of RV-failure and AKI post-LVAD
LVAD implantation affects the RV in multiple ways. LVAD support results in higher cardiac 
preload to the RV, resulting in a bigger venous return to the RV, potentially overloading 
the RV27. Also, LVAD support can cause an intraventricular septum shift, impairing the 
RV contraction28. These hemodynamic factors could contribute to the development 
of immediate RV-failure, that may occur in more than 20% of all LVAD implantations2, 
12. Many risk factors for RV-failure post-LVAD surgery have been identified, including 
several patient characteristics, echocardiographic parameters and hemodynamic 
information, including higher PAP12. An elevated PAP might be used as an indicator of 
elevated preload and/or afterload of the RV, in addition to existing markers.
Recently, it has been proposed that concomitant implantation of a temporary 
transcutaneous RV assist device with LVAD surgery could improve LVAD patient’s 
short term outcome 29. However, identifying the appropriate patients remains 
challenging. Hemodynamic monitoring pre-LVAD surgery using the CardioMEMS 
could aid in identifying patients at high risk for RV-failure post-LVAD surgery. In these 
patients, concomitant implantation of a temporary transcutaneous RV assist device 
might be indicated.
A wide variation of the incidence of AKI post-LVAD surgery has been reported, ranging 
from 10-50%30. Additionally, AKI is strongly associated with a higher risk of mortality in 
17
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LVAD patients31. One of the risk factors for the development of AKI post-LVAD surgery 
venous congestion of the kidneys, indicated by an elevated CVP12.
Hemodynamically guided medical optimization pre-LVAD surgery could result in a 
lower PAP prior to LVAD surgery. As a result of this, the RV afterload will be reduced, 
reducing the stress on the RV during and shortly after the LVAD implantation, and 
decongesting the kidneys, and hypothetically lowering the chance of RV-failure and 
AKI shortly after LVAD surgery.
Limitations
We acknowledge the small sample size of our pilot study, thereby limiting the results 
as hypothesis-generating in a pilot study. Additionally, the expected event rate in the 
hemodynamically optimized patients was very low, so observed differences might 
have been caused due to the small sample size. However, the results are clinically 
meaningful and promising, considering its shown significant findings and clinical 
plausibility/intuitiveness of the hybrid construction. Pilot studies need to be followed 
by a large scale pivotal study, which has currently started as a separate study in the 
US (NCT03247829). Much more hybrid construction can be tested in the near future of 
combining daily hemodynamic info with, for example CRT-D response and optimization, 
or diuretic management pre- and post-procedural of valvular interventions e.g., 
Mitraclip in a similar approach 32-34.
Conclusion
Remote monitoring using the CardioMEMS sensor in end-stage chronic HF patients 
pre- and post-LVAD surgery is a safe and feasible strategy positively testing the 
hypothesis that patient management and the outcome can be further improved when 
patients are hemodynamically optimized before surgery with the central concept of 
“better in, better out”. This novel combination of these two state-of-the-art techniques 
with direct hemodynamic feedback in LVAD patients warrants a large randomized 
controlled pivotal study.
146122_Veenis,Jesse_BNW-def .indd   334 13-11-2020   14:38
335
Hemodynamic optimization pre- and post-LVAD surgery
References
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola 
VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, 
Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M, Document R. 2016 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the 
diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology 
(ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur 
J Heart Fail 2016;18(8):891-975.
2. Goldstein DJ, Meyns B, Xie R, Cowger J, Pettit S, Nakatani T, Netuka I, Shaw S, Yanase M, Kirklin JK. Third 
Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison 
of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 
2019;38(4):352-363.
3. Loforte A, Grigioni F, Marinelli G. The risk of right ventricular failure with current continuous-flow left 
ventricular assist devices. Expert Rev Med Devices 2017:1-15.
4. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC, Jr., Colombo PC, Walsh MN, Milano CA, Patel 
CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long 
JW, Salerno C, Investigators M. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart 
Failure. N Engl J Med 2017;376(5):440-450.
5. Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, Pagani FD, Aaronson KD, Maltais S. 
Adverse events in contemporary continuous-flow left ventricular assist devices: A multi-institutional 
comparison shows significant differences. J Thorac Cardiovasc Surg 2016;151(1):177-89.
6. Verma S, Bassily E, Leighton S, Mhaskar R, Sunjic I, Martin A, Rihana N, Jarmi T, Bassil C. Renal Function 
and Outcomes With Use of Left Ventricular Assist Device Implantation and Inotropes in End-Stage 
Heart Failure: A Retrospective Single Center Study. J Clin Med Res 2017;9(7):596-604.
7. Amione-Guerra J, Cruz-Solbes AS, Gonzalez Bonilla H, Estep JD, Guha A, Bhimaraj A, Suarez EE, 
Bruckner BA, Torre-Amione G, Park MH, Trachtenberg BH. Melding a High-Risk Patient for Continuous 
Flow Left Ventricular Assist Device into a Low-Risk Patient. ASAIO J 2017.
8. Soliman OI, Akin S, Muslem R, Boersma E, Manintveld OC, Krabatsch T, Gummert JF, de By T, Bogers A, 
Zijlstra F, Mohacsi P, Caliskan K, investigators E. Derivation and Validation of a Novel Right-Sided Heart 
Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices:The EUROMACS 
(European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk 
Score. Circulation 2017.
9. Kang G, Ha R, Banerjee D. Pulmonary artery pulsatility index predicts right ventricular failure after 
left ventricular assist device implantation. J Heart Lung Transplant 2016;35(1):67-73.
10. Morine KJ, Kiernan MS, Pham DT, Paruchuri V, Denofrio D, Kapur NK. Pulmonary Artery Pulsatility 
Index Is Associated With Right Ventricular Failure After Left Ventricular Assist Device Surgery. J Card 
Fail 2016;22(2):110-6.
11. Tchantchaleishvili V, Maltais S, Sharma S, Haglund NA, Davis ME, Cowger J, Shah P, Desai SS, Aaronson 
KD, Pagani FD, Dunlay SM, Stulak JM. A novel, highly discriminatory risk model predicting acute severe 
right ventricular failure in patients undergoing continuous-flow left ventricular assist device implant. 
Artif Organs 2019;43(7):624-632.
12. Bellavia D, Iacovoni A, Scardulla C, Moja L, Pilato M, Kushwaha SS, Senni M, Clemenza F, Agnese V, 
Falletta C, Romano G, Maalouf J, Dandel M. Prediction of right ventricular failure after ventricular 
assist device implant: systematic review and meta-analysis of observational studies. Eur J Heart Fail 
2017;19(7):926-946.
17
146122_Veenis,Jesse_BNW-def .indd   335 13-11-2020   14:38
336
Part C | Chapter 17
13. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, Group CTS. Sustained 
efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete 
follow-up results from the CHAMPION randomised trial. Lancet 2016;387(10017):453-61.
14. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru 
S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS, Group CTS. Wireless pulmonary 
artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet
2011;377(9766):658-66.
15. Veenis JF, Manintveld OC, Constantinescu AA, Caliskan K, Birim O, Bekkers JA, van Mieghem NM, den 
Uil CA, Boersma E, Lenzen MJ, Zijlstra F, Abraham WT, Adamson PB, Brugts JJ. Design and rationale
of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the
HEMO-VAD pilot study. ESC Heart Fail 2019;6(1):194-201.
16. Raymer DS, Moreno JD, Sintek MA, Nassif ME, Sparrow CT, Adamo L, Novak EL, LaRue SJ, Vader JM. The
Combination of Tricuspid Annular Plane Systolic Excursion and HeartMate Risk Score Predicts Right 
Ventricular Failure After Left Ventricular Assist Device Implantation. Asaio J 2019;65(3):247-251.
17. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. Incidence
and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 
2006;17(4):1135-42.
18. Holman WL, Acharya D, Siric F, Loyaga-Rendon RY. Assessment and management of right ventricular 
failure in left ventricular assist device patients. Circ J 2015;79(3):478-86.
19. Hanke JS, Dogan G, Zoch A, Ricklefs M, Wert L, Feldmann C, Bara C, Shrestha M, Tillmanns J, Kempf T, 
Bauersachs J, Haverich A, Schmitto JD. One-year outcomes with the HeartMate 3 left ventricular assist 
device. J Thorac Cardiovasc Surg 2018;156(2):662-669.
20. Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf 
F, Damme L, Schmitto JD. Fully Magnetically Levitated Left Ventricular Assist System for Treating
Advanced HF: A Multicenter Study. J Am Coll Cardiol 2015;66(23):2579-2589.
21. Braun OO, Nilsson J, Gustafsson F, Dellgren G, Fiane AE, Lemstrom K, Hubbert L, Hellgren L, Lund LH.
Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. Scand 
Cardiovasc J 2019;53(1):14-20.
22. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, 
Naftel DC. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. 
J Heart Lung Transplant 2017;36(10):1080-1086.
23. Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik 
J, Atluri P, Grady KL, Kirklin JK. The Society of Thoracic Surgeons Intermacs database annual report:
Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant 2019;38(2):114-126.
24. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, Hong KN, Teuteberg JJ. Clinical 
outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative 
INTERMACS classification. J Heart Lung Transplant 2011;30(4):402-7.
25. Feldman DS, Moazami N, Adamson PB, Vierecke J, Raval N, Shreenivas S, Cabuay BM, Jimenez J,
Abraham WT, O’Connell JB, Naka Y. The Utility of a Wireless Implantable Hemodynamic Monitoring
System in Patients Requiring Mechanical Circulatory Support. Asaio J 2018;64(3):301-308.
26. Kilic A, Katz JN, Joseph SM, Brisco-Bacik MA, Uriel N, Lima B, Agarwal R, Bharmi R, Farrar DJ, Lee S,
Evolving Mechanical Support Research Group I. Changes in pulmonary artery pressure before and
after left ventricular assist device implantation in patients utilizing remote haemodynamic monitoring. 
ESC Heart Fail 2019;6(1):138-145.
146122_Veenis,Jesse_BNW-def .indd   336 13-11-2020   14:38
337
Hemodynamic optimization pre- and post-LVAD surgery
27. Alnsasra H, Asleh R, Schettle SD, Pereira NL, Frantz RP, Edwards BS, Clavell AL, Maltais S, Daly RC, 
Stulak JM, Rosenbaum AN, Behfar A, Kushwaha SS. Diastolic Pulmonary Gradient as a Predictor 
of Right Ventricular Failure After Left Ventricular Assist Device Implantation. J Am Heart Assoc 
2019;8(16):e012073.
28. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, 
part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 
2008;117(11):1436-48.
29. Schmack B, Weymann A, Popov AF, Patil NP, Sabashnikov A, Kremer J, Farag M, Brcic A, Lichtenstern 
C, Karck M, Ruhparwar A. Concurrent Left Ventricular Assist Device (LVAD) Implantation and 
Percutaneous Temporary RVAD Support via CardiacAssist Protek-Duo TandemHeart to Preempt Right 
Heart Failure. Med Sci Monit Basic Res 2016;22:53-7.
30. Patel AM, Adeseun GA, Ahmed I, Mitter N, Rame JE, Rudnick MR. Renal failure in patients with left 
ventricular assist devices. Clin J Am Soc Nephrol 2013;8(3):484-96.
31. Muslem R, Caliskan K, Akin S, Sharma K, Gilotra NA, Constantinescu AA, Houston B, Whitman G, 
Tedford RJ, Hesselink DA, Bogers A, Russell SD, Manintveld OC. Acute kidney injury and 1-year mortality 
after left ventricular assist device implantation. J Heart Lung Transplant 2018;37(1):116-123.
32. Veenis JF, Birim O, Brugts JJ. Pulmonary artery pressure telemonitoring by CardioMEMS in a patient 
pre- and post-left ventricular assist device implantation. Eur J Cardiothorac Surg 2019.
33. Veenis JF, Van Mieghem NM, Caliskan K, Manintveld OC, Brugts JJ. Monitoring pulmonary artery 
pressure in chronic heart failure patients and evaluating the treatment effect of MitraClip implantation 
for functional mitral regurgitation. EuroIntervention 2019;15(5):418-419.
34. Brugts JJ, Manintveld OC, van Mieghem N. Remote monitoring of pulmonary artery pressures 
with CardioMEMS in patients with chronic heart failure and NYHA class III: first experiences in the 
Netherlands. Neth Heart J 2018;26(2):55-57.
17
146122_Veenis,Jesse_BNW-def .indd   337 13-11-2020   14:38
338
Part C | Chapter 17
Supplementary data
Supplementary Figure 1. Kaplan-Meier time event-free survival: freedom from all-cause hospitalization survival
Colored area indicates ±1SE
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Supplementary Figure 2. Changes in laboratory results in CardioMEMS patients and historical controls: 
A changes in renal function (eGFR), B changes in NT-proBNP, C changes in total bilirubin
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Supplementary Figure 3. Changes in serum creatinine levels shortly pre- and lost-LVAD surgery
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Abstract
Aims: To compare characteristics of left ventricular assist device (LVAD) recipients 
receiving a cardiac implantable electronic device (CIED) with a defibrillator component 
(implantable cardioverter-defibrillator and cardiac resynchronization therapy with 
defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a 
device contiguously with an LVAD is associated with outcomes.
Methods and results: Overall, 448 patients were analysed (mean age 52±13 years, 82% 
male) in the multicentre European PCHF-VAD registry. To account for all active CIED-Ds 
during ongoing LVAD treatment, outcome analyses were performed by a time-varying 
analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time 
of LVAD implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD 
support was 1.1 years (interquartile range 0.5–2.0 years). A reduction of 36% in the risk 
of all-cause mortality was observed in patients with an active CIED-D [hazard ratio 
(HR) 0.64, 95% confidence interval (CI) 0.46–0.91; P = 0.012), increasing to 41% after 
adjustment for baseline covariates (HR 0.59, 95% CI 0.40–0.87; P = 0.008) and 39% after 
propensity score adjustment (HR 0.61, 95% CI 0.39–0.94; P = 0.027). Other than CIED-D, 
age, LVAD implant as redo surgery, number of ventricular arrhythmia episodes and use 
of vasopressors pre-LVAD were remaining significant risk factors of all-cause mortality. 
Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased 
risk of all-cause and cardiovascular death, respectively; carrying an active CIED-D 
remained associated with a 47% and 43% reduction in these events, respectively.
Conclusions: In an analysis accounting for all active CIED-Ds, including those implanted 
during LVAD support, carrying such a device was associated with significantly better 
survival during LVAD support.
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Introduction
It is estimated that patients with advanced heart failure (HF) comprise 1–10% of 
the entire population of patients with HF, with increasing prevalence paralleling the 
growth of the HF population and the improvements in available treatments, prolonging 
survival.1 Advances in long-term mechanical circulatory support with left ventricular 
assist devices (LVADs) have significantly improved outcomes in this rapidly expanding 
population.2,3 However, several challenges in the clinical management of LVAD recipients 
remain and several opportunities exist to further optimize patient benefits,4–6 including 
combined device therapy with cardiac implantable electronic devices (CIEDs).
Therapies for advanced HF are indicated with progression of the disease beyond 
adequate symptom management or adequate preservation of end-organ function, 
despite ongoing and optimized guideline-directed medical and device therapies.1 For 
patients with HF with reduced ejection fraction (HFrEF), the guidelines mandate the 
use of implantable cardioverter-defibrillators (ICD) and, in selected patients, cardiac 
resynchronization therapy (CRT) devices.7 Given the progressive nature of the disease, 
a certain amount of overlap of device-based treatment modalities is encountered – 
according to the INTERMACS database, 80% of LVAD recipients already have an ICD 
device in situ.8 On the other hand, patients may receive an LVAD without having a CIED 
when the LVAD is indicated for an acute HF episode. Although the existing literature on 
patient outcomes with combined device therapy is growing, the results are conflicting; 
the majority of the studies were conducted in single-centre patient populations, with 
few exceptions.8–15 Importantly, a perspective on the European landscape of combined 
device therapy in advanced HF is still lacking. The current International Society for Heart 
and Lung Transplantation (ISHLT) guidelines for mechanical circulatory support provide 
a class I recommendation for the reactivation of an ICD after LVAD surgery and a class 
IIa recommendation for ICD placement after LVAD for those without one.16 However, 
more conservative strategies have recently been advocated.17
We compared characteristics among patients receiving a CIED with a defibrillator 
component (ICD and CRT-D devices) and those without one in a multicentre European 
registry of LVAD recipients to assess whether carrying a defibrillator component 
contiguously with an LVAD, including CIEDs implanted post-LVAD, was associated 
with improved outcomes.
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Methods
Study population
This observational study enrolled patients through a network of 12 European HF tertiary 
referral centres, stemming from participants and alumni of the Postgraduate Course 
in Heart Failure (PCHF) of the Heart Failure Association of the European Society of 
Cardiology and the European Heart Academy, forming the PCHF-VAD registry. Each 
participating centre acquired the approval of their local institutional/ethics review board 
for the study protocol and retrospective acquisition of patient data, predominantly with 
a waiver of informed consent.
Currently, the registry consists of 488 patients who underwent durable ventricular 
assist device (VAD) implantation for advanced HF and are in regular follow-up by 
the participating centres. The variables collected in the registry include baseline 
demographic patient information, baseline device (VAD, ICD, CRT) information, patient 
physical status and functional class, electrocardiographic and echocardiography data, 
laboratory findings, right heart catheterisation data, data on medications and therapies 
as well as VAD and CIED parameters – except for baseline data, all other variables 
were collected at three time points: prior to VAD implantation, at discharge from VAD 
implantation, and 6 months after the last device implantation. In order to represent 
the currently most utilised form of durable mechanical circulatory support and to 
retain homogeneity of the studied cohort, data were analysed for patients implanted 
with a continuous-flow LVAD (cf-LVAD) – patients with pulsatile LVADs, right VADs 
and biventricular assist devices, as well as those with missing ICD/CRT carrier status 
(including missing implantation/potential inactivation dates) were excluded from the 
analysis. All cf-LVADs were implanted between 1 December 2006 and 15 April 2018. 
All-cause death was defined as the primary outcome. The secondary outcomes were 
cardiovascular mortality, hospitalisation for HF, the occurrence of clinically significant 
ventricular arrhythmias (VAs) after LVAD implantation (defined as symptomatic 
arrhythmias and/or arrhythmias leading to CIED therapy delivery, and/or arrhythmias 
requiring medical intervention), device-related (both LVAD and CIED) infections 
requiring antibiotic treatment, intracranial bleeding and non-cerebral bleeding events. 
The adjudication of outcomes was performed by the teams of the registry centres.
The patient data were collected and managed using REDCap (Research Electronic Data 
Capture) electronic data capture tools – a secure, web-based application,18 hosted at the 
University of Zagreb, School of Medicine, which served as the data coordinating centre.
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Statistical analysis
Baseline characteristics are expressed as counts and percentages for categorical 
variables or as mean±standard deviation [alternatively, median (25th–75th percentile) 
for those non-normally distributed] for continuous variables. At baseline, the inter-
group differences were based on CIED with an active defibrillator component (CIED-D) 
carrier status before LVAD implantation and were assessed using the chi-square test 
or ANOVA (or Kruskal–Wallis test for non-normally distributed variables) for categorical 
and continuous variables, respectively.
Outcome analyses were performed using the primary endpoint of all-cause death as 
well as the secondary outcomes. For survival analyses, the time of LVAD implantation 
was considered as the index date; the time of follow-up was defined as time to last 
contact, heart transplant, weaning from LVAD or death (whichever came first). In order 
to include in the analysis all active ICD and CRT-D devices during the time of ongoing 
LVAD treatment (including those implanted and excluding those inactivated during 
LVAD support), outcome analyses were performed by a time-varying analysis with 
active CIED-D carrier status following LVAD implantation as the time-varying covariate 
to assess the association between active CIED-D carrier status post-LVAD and the 
occurrence and time course of the primary outcome. The incidence rate was estimated 
for the primary and secondary endpoints based on the time-varying covariate (active 
CIED-D carrier post-LVAD), and the hazard ratios (HR) were estimated using the Cox 
proportional hazards model with the group of patients with no active CIED-D post-LVAD 
serving as the referent group. A Cox regression model based on a forward stepwise 
selection process with a significance level of 0.05 and 0.10 for entry and removal 
thresholds, respectively, was used to test the association of active CIED-D carrier 
status with 25 baseline covariates (online supplementary Methods S1) that significantly 
differed between the two patient groups at baseline and had less than 30% missing 
data: age, gender, CIED-D status, heart rate, LVAD type, LVAD intention, INTERMACS 
class, aetiology of HF, known history of: chronic kidney disease, atrial fibrillation/flutter, 
VAs; significant VAs pre-LVAD, prior cardiac surgery, concomitant procedure with LVAD 
implant, type of life support prior to LVAD, diuretic use, beta-blocker use, ivabradine 
use, mineralocorticoid receptor antagonist use, vasopressor use, ultrafiltration, type 
of mechanical ventilation, creatinine values, left ventricular internal dimension at end-
diastole, and LVAD implant date quartile (Table 1).
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Age, years 52±13 50±14 54±12 <0.001
Female sex 81 (18.1) 46 (22.1) 35 (14.6) 0.039
Geographical area








Southeast Europe (Croatia, Poland, 






Quartiles of date of LVAD implant
1st quartile
(6 Dec 2006 – 2 Jan 2012)
112 (25) 72 (34.6) 40 (16.7)
<0.001
2nd quartile
(3 Jan 2012 – 8 Dec 2014)
112 (25) 62 (29.8) 50 (20.8)
3rd quartile
(9 Dec 2014 – 20 Jul 2016)
113 (25.2) 48 (23.1) 65 (27.1)
4th quartile
(21 Jul 2016 – 04 Apr 2018)
111 (24.8) 26 (12.5) 85 (35.4)
ICD status
No ICD 238 (53.1) 188 (90.4) 50 (20.8)
<0.001Primary prevention 153 (34.2) 15 (7.2) 138 (57.5)
Secundary prevention 57 (12.7) 5 (2.4) 52 (21.7)
CRT status
No CRT 345 (77.0) 188 (90.4) 157 (65.4)
<0.001CRT-P carrier 16 (3.6) 16 (7.7) 0 (0.0)
CRT-D carrier 87 (19.4) 4 (1.9) 83 (34.6)
Heart rate, b.p.m. 85±20 93±21 80±17 <0.001
SBP, mmHg 100±15 101±16 100±14 0.71
DBP, mmHg 65±11 65±12 65±10 0.91
BMI, kg/m2 25.8±4.6 25.3±4.4 26.2±4.8 0.050
NYHA class
II 15 (3.8) 5 (2.9) 10 (4.5)
0.06
IIIa 132 (33.4) 58 (33.3) 74 (33.5)
IIIb 105 (26.6) 37 (21.3) 68 (30.8)
IV 143 (36.2) 74 (42.5) 69 (31.2)
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Heart Mate II 246 (54.9) 144 (69.2) 102 (42.5)
<0.001
HeartWare HVAD 94 (21.0) 36 (17.3) 58 (24.2)
Heart Mate 3 87 (19.4) 22 (10.6) 65 (27.1)
Other 21 (4.7) 6 (2.9) 15 (6.2)
LVAD Intention
BTT 305 (71.1) 137 (68.8) 168 (73.0)
<0.001BTD 68 (15.9) 47 (23.6) 21 (9.1)
DT 56 (13.1) 15 (7.5) 41 (17.8)
INTERMACS class
1 73 (16.7) 55 (27.4) 18 (7.6)
<0.001
2 121 (27.7) 63 (31.3) 58 (24.6)
3 139 (31.8) 47 (23.4) 92 (39.0)
4-7 104 (23.8) 36 (17.9) 68 (28.8)
Aetiology of heart failure
Dilated cardiomyopathy 190 (42.4) 68 (32.7) 122 (50.8)
<0.001Ischaemic cardiomyopathy 206 (46.0) 104 (50.0) 102 (42.5)
Other 52 (11.6) 36 (17.3) 16 (6.7)
Co-morbidities
Arterial hypertension 102 (22.8) 47 (22.6) 55 (22.9) 0.94
Diabetes mellitus 90 (20.1) 37 (17.8) 53 (22.1) 0.26
Chronic kidney disease 102 (22.8) 31 (14.9) 71 (29.6) <0.001
Coronary artery disease 111 (24.8) 52 (25.0) 59 (24.6) 0.92
Prior MI 168 (37.5) 87 (41.8) 81 (33.8) 0.08
Prior coronary revascularization 132 (29.5) 66 (31.7) 66 (27.5) 0.33
COPD 42 (9.4) 14 (6.7) 28 (11.7) 0.07
Atrial fibrillation/flutter 128 (28.6) 31 (14.9) 97 (40.4) <0.001
Ventricular arrhythmias 102 (22.8) 30 (14.4) 72 (30.0) <0.001
Cerebrovascular events 33 (7.4) 12 (5.8) 21 (8.8) 0.23
Significant ventricular arrhythmias prior to 
LVAD implant
None 245 (66.9) 120 (83.3) 125 (56.3)
<0.001
1 episode 58 (15.8) 14 (9.7) 44 (19.8)
2 episodes 25 (6.8) 5 (3.5) 20 (9.0)
3 episodes 21 (5.7) 2 (1.4) 19 (8.6)
≥4 episodes 17 (4.6) 3 (2.1) 14 (6.3)
Prior cardiac surgery 55 (12.3) 33 (15.9) 22 (9.2) 0.031
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Concomitant procedure with LVAD implant 79 (17.6) 50 (24.0) 29 (12.1) <0.001
Life support prior to LVAD implant
None 318 (73.6) 112 (56.0) 206 (88.8)
<0.001
ECMO 35 (8.1) 30 (15.0) 5 (2.2)
Temporary LVAD 4 (0.9) 4 (2.0) 0 (0.0)
Temporary BiVAD 1 (0.2) 1 (0.5) 0 (0.0)
IABP 55 (12.7) 35 (17.5) 20 (8.6)
Other 19 (4.4) 18 (9.0) 1 (0.4)
Medications
Diuretic 349 (90.6) 130 (79.3) 219 (99.1) <0.001
Beta blocker 230 (64.1) 64 (43.5) 166 (78.3) <0.001
ACEI/ARB 183 (49.5) 78 (49.7) 105 (49.3) 0.94
MRA 243 (72.8) 76 (55.9) 167 (84.3) <0.001
Ivabradine 36 (11.6) 9 (7.1) 27 (14.7) 0.042
Inotrope 232 (65.5) 104 (68.9) 128 (63.1) 0.25
Vasopressor 36 (10.8) 23 (16.8) 13 (6.6) 0.003
Ultradiltration 12 (3.6) 10 (7.4) 2 (1.0) 0.003
Mechanical ventilation
None 310 (92.3) 116 (84.1) 194 (98.0)
<0.001NIV/cPAP 2 (0.6) 2 (1.4) 0 (0.0)
Intubation 24 (7.1) 20 (14.5) 4 (2.0)
Laboratory valuese
Creatinine, umol/L 126±57 117±57 133±56 0.004
Bilirubin, umol/l 19.0 (12.0-30.8) 19.8 (12.0-34.0) 18.8 (12.0-28.0) 0.019
Echocardiographic data
LVIDd, mm 70.4±12.8 67.4±13.1 72.5±12.2 <0.001
LVEF, % 19±7 19±8 20±7 0.46
Values expressed as mean±standard deviation, number (%), or median (interquartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BiVAD, biventricular 
assist device; BMI, body mass index; BTD, bridge to decision; BTT, bridge to transplantation; CIED-D, 
cardiac implantable electronic device with a defibrillator component; COPD, chronic obstructive pulmonary 
disease; cPAP, continuous positive airway pressure; CRT, cardiac resynchronization therapy; CRT-D, cardiac 
resynchronization therapy with a defibrillator component; CRT-P, cardiac resynchronization therapy with 
a pacemaker component; DBP, diastolic blood pressure; DT, destination therapy; ECMO, extracorporeal 
membrane oxygenation; FAC, fractional area change; IABP, intra-aortic balloon pump; ICD, implantable 
cardioverter-defibrillator; LVEF, left ventricular ejection fraction; LVIDd, left ventricular intraventricular 
dimension in end-diastole;MI,myocardial infarction;MRA,mineralocorticoid receptor antagonist;NIV, non-
invasive ventilation;NYHA, New York Heart Association; RVIDd, right ventricular intraventricular dimension 
in end-diastole; SBP, systolic blood pressure; VAD, ventricular assist device.
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Additional sensitivity analyses were performed to determine the consistency of the 
results. A multiple imputation was performed whereby missing data were managed 
using multiple imputation by chained equations (STATA mi impute chained). Imputation 
was performed for each variable with 1–30% of missing data; it was based on linear 
regression using 20 baseline clinical variables and 18 predictor variables and estimated 
over 30 imputations.19 Furthermore, in order to additionally adjust for the differences 
between the patients grouped by CIED-D carrier status prior to LVAD implantation 
(Table 1), we created a propensity score to determine the possibility of having a 
CIED-D pre-LVAD. The propensity score was calculated using a multivariable logistic 
regression model including the following variables: ICD/CRT carrier status, age, gender, 
previous history of hypertension, diabetes, chronic kidney disease, coronary artery 
disease, myocardial infarction, cerebrovascular accident, atrial fibrillation and VAs; 
type of LVAD, intention of LVAD treatment, INTERMACS score, LVAD implant as redo 
surgery and concomitant surgical procedures. This was followed by a propensity score 
adjusted analysis to assess the relation of CIED-D carrier status and the occurrence of 
the primary and secondary outcomes. Finally, to control for immediate perioperative 
deaths, we have utilised the time-varying coefficient to test the interaction between 
the duration of follow-up and the CIED-D treatment effect at 30 and 90 days 
following LVAD implantation.
A P-value of <0.05 was considered statistically significant. The statistical analyses were 
performed in Stata version 14 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics
After excluding data from 14 patients with pulsatile LVADs and biventricular assist 
devices, as well as 26 patients with missing ICD/CRT carrier status (including missing 
implantation and potential inactivation dates), the analysed population consisted of 
448 patients (Figure 1). The baseline clinical characteristics were collected prior to LVAD 
implantation; the patients were thus divided into two groups according to CIED-D status 
before LVAD implantation: 240 patients (54%) were an CIED-D carrier pre-LVAD, while 
the remaining 208 patients (46%) did not carry any of these devices pre-LVAD (of note, 
the discrepancies such as the 20 ICD patients in the non-CIED-D group are those that 
cross-over during the course of LVAD treatment) (Figure 1). Baseline characteristics of 
the patient population according to CIED-D status pre-LVAD are provided in Table 1 and 
in the online supplementary Table S1. CIED-D carriers were older and more frequently 
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male compared to those without CIED-D pre-LVAD. Of the patients receiving a CIED-D 
pre-LVAD, the majority were those implanted with an LVAD in the last quartile of LVAD 
implantation dates, i.e. from 21 July 2016 onwards (online supplementary Figure S1). 
The predominant disease aetiology was dilated cardiomyopathy in those with CIED-D, 
while ischaemic cardiomyopathy was more common in the other group. While chronic 
kidney disease was more represented in CIED-D carriers, other co-morbidities such as 
hypertension, diabetesmellitus, coronary artery disease, chronic obstructive pulmonary 
disease and prior cerebrovascular accident did not differ significantly between the 
two groups. Known atrial fibrillation and previous VAs (defined as those requiring ICD 
therapy or external defibrillation prior to LVAD implantation verified in ICD memory or 
during patient monitoring) were more frequent in the CIED-D pre-LVAD group. Although 
left ventricular ejection fraction did not differ significantly between groups, patients 
with CIED-D pre-LVAD had larger left ventricles. Haemodynamic measurements did 
not reveal a significant difference between groups, nor did their blood pressure values. 
However, heart rate was significantly higher in those without CIED-D pre-LVAD.
Figure 1. (Left) Selection of the study population from the PCHF-VAD registry. (Right) Patient flow during 
the follow-up period in respect to a cardiac implantable electronic device (CIED) with a defibrillator com-
ponent (CIED-D). BiVAD, biventricular assist device; cfLVAD, continuous-flow left ventricular assist device; 
LVAD, left ventricular assist device.
The distribution of LVAD types differed significantly: those with CIED-D were more 
frequently carriers of HeartWare HVAD and HeartMate 3 devices than patients in the 
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other subgroup, where HeartMate II was more common. The proportion with an LVAD 
as a bridge to decision was higher in those without a CIED-D; these patients were also 
more frequently in INTERMACS classes 1 and 2, while no significant difference in New 
York Heart Association (NYHA) class was noted. The proportion of patients on diuretics, 
beta-blockers and mineralocorticoid receptor antagonists was higher in those with 
a CIED-D pre-LVAD. A higher proportion of patients without a CIED-D pre-LVAD was 
treated with vasopressor medications (but not inotropes) and was on life support, 
predominantly intra-aortic balloon pump and extracorporeal membrane oxygenation. 
LVAD implantation as redo surgery as well as concomitant surgical procedures were 
more frequent in this group as well. In the group with CIED-D pre-LVAD, 58% of the 
patients carrying an ICD received it for primary prevention; 44% of the patients without 
a CIED-D pre-LVAD and 34% of those with such a device were transplanted (39% of 
the entire cohort).
Twenty patients received a CIED-D post-LVAD (9.6% of those without a CIED-D pre-VAD), 
at a median time to CIED-D implant of 57 days [interquartile range (IQR) 29.5–243.5 
days, range 0–1068 days]. Forty-five patients (19% of those with a CIED-D pre-VAD) 
had their ICD or CRT-D device deactivated post-LVAD at a median time of deactivation 
of 252 days (IQR 77–379 days, range 0–981 days). Of these deactivations, 11 occurred 
during active LVAD support (median time to deactivation 40 days; IQR 0–368 days, 
range 0–664 days), while in the remaining 34 patients the deactivation occurred 
due to heart transplantation, i.e. on the day of transplantation (Figure 1 and online 
supplementary Figure S2).
All-cause mortality and active CIED-D carrier status following left ven-
tricular assist device implantation
The median time on LVAD support was 1.1 years (IQR 0.5–2.0 years) starting at the time 
of LVAD implantation (online supplementary Figure S3), which was similar in those with 
active CIED-D carrier status during LVAD support and those without one (median 1.1 
years, IQR 0.5–2.0 years; and 1.1 years, IQR 0.4–2.0 years, respectively). At the time of 
LVAD implantation, 213 patients (48%) did not have a CIED-D and 235 patients (52%) 
had such a CIED in situ and activated (Figure 1). The primary outcome of all-cause death 
occurred in a total of 134 patients (30% of the overall study population). A total of 68 
patients remained in the non-CIED-D group and 55 remained in the CIED-D group and 
suffered from all-cause death. Five patients had the CIED-D deactivated and six entered 
the CIED-D group before the event. The incidence rates for all-cause death were 28 
events per 100 patient-years [95% confidence interval (CI) 22–36 events] and 18 events 
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per 100 patient-years (95% CI 14–23 events) for those without and with a CIED-D after 
LVAD implant, respectively (Table 2). One-year survival in the overall cohort was 80.1%. 
The rate of all-cause death was the greatest in the first 30 days post-LVAD implant 
(event rate 7.3% per month; 95% CI 5.2–10.4%), declined between 30 and 90 days (event 
rate 3.0% per month; 95% CI 2.0–4.5%) and between 90 days and 1 year (event rate 
1.3% per month; 95% CI 0.9–1.8%), remaining stable after 1 year (event rate 1.4% per 
month; 95% CI 1.0–1.9%). In a time-varying analysis, the unadjusted HR demonstrated 
a 36% reduction in the risk of all-cause mortality in patients with an active CIED-D 
following LVAD implantation (HR 0.64; 95% CI 0.46–0.91, P = 0.012) (Figure 2 and Table 
2). No significant alteration in the treatment effect after 30 or 90 days following LVAD 
implantation was found (interaction P =0.68 and P =0.07, respectively).
Table 2. Incidence rates and hazard ratios for the primary endpoint (all-cause death), cardiovascular 
mortality, heart failure hospitalisation, ventricular arrhythmias post-left ventricular assist device (LVAD), 
device-related infection requiring systemic antibiotics, non-cerebral and intracranial bleeding by time-
updated CIED-D carrier status following LVAD implantation















































































The incidence rates are presented as number of events per 100 patient-years (95% CI).
CI, confidence interval; CIED-D, cardiac implantable electronic device with a defibrillator component; HR, 
hazard ratio.
aAdjusted for age, number of ventricular arrhythmia episodes before LVAD implantation, use of 
vasopressors prior to LVAD implantation, LVAD type and LVAD implant as a redo surgical procedure.
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Figure 2. Kaplan–Meier plot of time to all-cause mortality, according to CIED-D carrier status following 
left ventricular assist device (LVAD) implantation. The analysis time begins at the time of LVAD implanta-
tion. CIED-D status 0 stands for no CIED-D present post-LVAD, CIED-D status 1 stands for CIED-D present 
post-LVAD. CIED-D, cardiac implantable electronic device with a defibrillator component; HR, hazard ratio.
Using stepwise regression, CIED-D carrier status, age, number of VA episodes before 
LVAD implantation, use of vasopressors prior to LVAD implantation, LVAD type and LVAD 
implant as a redo surgical procedure were identified as independently significant of 
all-cause mortality. After adjustment for these variables, the HR for CIED-D post-LVAD 
status remained significant (0.59, 95% CI 0.40–0.87; P = 0.008). Age, LVAD implant as 
redo surgery, number of VA episodes pre-LVAD and vasopressor use were the remaining 
significant predictors of the primary outcome (Table 3). Active CIED-D carrier status 
after LVAD implant remained significant after adding active CRT with a pacemaker 
component (CRT-P) carrier status post-LVAD implant to the model (HR 0.57, 95% CI 
0.38–0.84; P = 0.005) (Table 3). Furthermore, the benefit of CIED-D treatment on all-
cause mortality remained significant even after excluding patients with a CIED-D placed 
or deactivated/removed following LVAD implantation, both in unadjusted (HR 0.71, 95% 
CI 0.50–1.00; P = 0.048) and adjusted analysis (HR 0.63, 95% CI 0.41–0.96; P = 0.030). In 
a subgroup analysis, the effect of treatment with a CIED-D following LVAD implantation 
was consistent across various categorical subgroups at baseline (Figure 3). Of note, 
exposure to ultrafiltration at baseline was associated with a significant interaction 
P-value (0.0044), suggesting a possible interaction effect: CIED-D therapy post-LVAD 
was associated with a larger benefit in those not undergoing ultrafiltration pre-LVAD 
implant (HR 0.63, 95% CI 0.42–0.94) compared to those undergoing ultrafiltration (HR 
7.76, 95% CI 1.07–56.0), however only five patients in the latter subgroup died during 
follow-up (hence not shown in the forest plot).
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Table 3. Multivariate Cox regression models of risk factors for all-cause death by time-updated CIED-D 
carrier status following left ventricular assist device implantation
Variable HR (95% CI) P-value
CIED-D post-LVAD 0.59 (0.40-0.87) 0.008
Age 1.03 (1.02-1.05) <0.0001
LVAD implant as redo surgery 1.69 (1.09-2.61) 0.019
LVAD type
Heart Mate II Referent
0.35
Heart Ware 1.28 (0.81-2.02)
Heart Mate 3 0.73 (0.39-1.36)
Other 0.76 (0.33-1.72)












CIED-D post-LVAD 0.57 (0.38-0.84) 0.005
CRT-P post-LVAD 0.62 (0.25-1.59) 0.322
Age 1.03 (1.01-1.05) <0.0001
LVAD implant as redo surgery 1.74 (1.12-2.71) 0.014
LVAD type
Heart Mate II Referent
0.349
Heart Ware 1.27 (0.80-2.00)
Heart Mate 3 0.73 (0.39-1.36)
Other 0.73 (0.32-1.66)












CI, confidence interval; CIED-D, cardiac implantable electronic device with a defibrillator component; CRT-P, 
cardiac resynchronization therapy with a pacemaker component; HR, hazard ratio; LVAD, left ventricular 
assist device; VA, ventricular arrhythmia; VAD, ventricular assist device.
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Figure 3. The effect of treatment with a cardiac implantable electronic device with a defibrillator compo-
nent following left ventricular assist device (LVAD) implantation on all all-cause mortality for individual 
patient subgroups. 0 stands for absent, 1 for present. AF, atrial fibrillation; BTD, bridge to decision; BTT, 
bridge to transplant; CKD, chronic kidney disease; DT, destination therapy; VA, ventricular arrhythmia.
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Secondary outcomes and active ICD/CRT-D carrier status following left 
ventricular assist device implantation
The occurrence of one or more episodes of symptomatic VAs or those requiring 
intervention was noted in 24% of the entire cohort (107 patients): 30 patients remained 
in the non-CIED-D group and 73 remained in the CIED-D group and suffered from new-
onset VAs, while two patients transitioned from the CIED-D group and two entered 
the CIED-D group before their event (the incidence rates are provided in Table 2). In 
patients with a CIED-D, a VA episode requiring anti-tachycardia pacing (ATP) occurred 
in 25 patients (median time to first ATP 231 days; IQR 25–495 days), while 42 patients 
received a shock (median time to first shock 121 days; IQR 7–231 days); 29% of the 
CIED-D cohort received at least one of these therapies. None of these patients died on 
the day of therapy delivery. Patients with a CIED-D post-LVAD had a nominally significant 
crude increased risk of post-LVAD VAs which was no longer significant after adjusting 
for the relevant baseline characteristics (HR 1.57, 95% CI 0.98–2.52, P = 0.06, adjusted by 
variable selection for the primary outcome; Table 2 and online supplementary Tables S2 
and S3). We further used stepwise regression to detect variables that are independently 
significant of the occurrence of VAs post-LVAD. After additional adjustment for these 
variables, active CIED-D post-LVAD status remained unrelated to the occurrence of 
this secondary endpoint (online supplementary Table S2). An additional analysis of 
incident VAs post-LVAD as a time-varying covariate demonstrated that the occurrence 
of such arrhythmias portended a 2.4-fold increased risk of all-cause death and a 2.6-
fold increased risk of cardiovascular death, while carrying an active CIED-D remained 
associated with a significant 47% reduction in all-cause death and 43% reduction in 
cardiovascular death. LVAD implant as redo surgery, vasopressor use prior to LVAD 
implant and increasing patient age were significantly associated with both of these 
outcomes, while the occurrence of VAs pre-LVAD was identified as an additional risk 
factor for all-cause death (online supplementary Table S4).
The incidence rates for cardiovascular mortality, HF hospitalisation, device-related 
infection requiring systemic antibiotics, as well as extracranial and intracranial bleeding 
events are presented in Table 2. Cardiovascular death occurred in 83 patients: 40 
remained in the non-CIED-D group and 36 remained in the CIED-D group and suffered 
from cardiovascular death, while three patients transitioned from the CIED-D group and 
four entered the CIED-D group before death from cardiovascular cause. The crude risk 
for cardiovascular mortality was not modified by CIED-D status, while in the adjusted 
analysis there was a trend towards a reduction in the risk of cardiovascular death with 
active CIED-D status (HR 0.65, 95% CI 0.39–1.07; P = 0.09) (online supplementary Tables 
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S3 and S4). Both the crude and adjusted risks for the remaining outcomes were not 
significantly modified by CIED-D post-LVAD (Table 2 and online supplementary Table 
S3; the full results of the multivariable regression models for the remaining outcomes 
are provided in the online supplementary Tables S5 and S6).
Sensitivity analyses
In addition to a forward variable selection procedure, we have also performed a 
backwards selection, according to which CIED-D carrier status, age, disease aetiology, 
number of VA episodes before LVAD, LVAD type, intention of LVAD therapy, use of 
vasopressors, use of beta-blockers, type of mechanical ventilation implantation and 
intention of LVAD therapy were identified as independently significant of all-cause 
mortality. After adjustment for these variables, the results remained consistent with 
the primary analysis (HR 0.61, 95% CI 0.40–0.94; P = 0.024); the remaining significant 
predictors of the primary outcome were age (HR per 1 year change in age: 1.04, 95% 
CI 1.02–1.06; P <0.0001), vasopressor use pre-LVAD (P = 0.0007), type of mechanical 
ventilation pre-LVAD (P = 0.025) and number of episodes of VAs pre-LVAD (P = 0.028) 
(online supplementary Table S7).
Given the significant differences in the baseline characteristics between the two patient 
groups, we have additionally performed a propensity score adjustment, following 
which the relative risk of all-cause death remained significantly reduced in the CIED-D 
carriers (HR 0.60, 95% CI 0.39–0.94; P = 0.024), while the propensity score itself was 
not significantly related to all-cause death. Strong predictors of CIED-D carrier status 
included having a history of atrial fibrillation [odds ratio (OR) 2.9] or VAs (OR 2.0), while 
having a prior myocardial infarction and a concomitant procedure with LVAD implant 
reduced the odds of carrying a CIED-D (OR 0.5 and 0.4, respectively). LVAD type, LVAD 
intention and INTERMACS class were additional predictors of CIED-D carrier status (all 
P <0.05) (online supplementary Table S8).
In order to account for missing data, additional sensitivity analyses were performed 
by multiple imputation of missing values. The results were consistent with the original 
analyses – when adjusting by variable selection for the primary outcome, time-
updated active CIED-D carrier status, patient age and LVAD implantation as a redo 
surgical procedure remained the only significant predictors of all-cause mortality 
(online supplementary Table S9). In an additional stepwise multiple regression model 
obtained from the multiple imputation dataset, age and LVAD implantation as redo 
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surgery remained additional predictors of all-cause mortality, in addition to active 
CIED-D status post-LVAD (online supplementary Table S10).
In an additional analysis of ICD-only carriers (excluding those with a CRT-D device) 
contiguously with an LVAD, the crude HR showed a trend towards a reduction in all-
cause mortality (HR 0.73, 95% CI 0.51–1.04; P = 0.077). However, in adjusted analysis, 
carrying an ICD-only reached a significant reduction in all-cause mortality (HR 0.60, 
95% CI 0.39–0.92; P = 0.019, online supplementary Table S11). After multiple imputation, 
the adjusted HR remained consistent, suggesting a 35% reduction in all-cause death 
in active ICD-only carriers during LVAD support (online supplementary Table S11).
Discussion
In this analysis of the PCHF-VAD registry, we have described the baseline characteristics 
and outcomes of 448 cf-LVAD carriers from 12 European academic centres in relation to 
carrying a CIED with an active defibrillator component (either in an ICD or CRT-D device) 
during the course of LVAD support. In patients enrolled in the registry, carrying an active 
defibrillator component during LVAD support was associated with a reduced crude 
and adjusted risk of all-cause mortality, compared to the patients without an active 
defibrillator component. This finding was consistent in several sensitivity analyses, 
including a propensity score adjusted analysis. Higher patient age, LVAD implantation 
as a redo surgical procedure, number of clinically significant VA episodes pre-LVAD and 
use of vasopressors recognized as other significant predictors of all-cause mortality.
The prevalence of either ICD or CRT-D carriers prior to LVAD implantation of 54% in 
this cohort is notably lower than that of >80% of LVAD carriers with an ICD in recent 
analyses of the INTERMACS and UNOS registries,8,9 while it is more comparable to 
the EUROMACS population in which 58% carry an ICD.20 This points out an important 
difference between LVAD carriers in Europe and the United States, while the currently 
available data predominantly originate from US centres. The source of this discrepancy 
is unclear but might be reflective of nearly four-fold higher ICD implantation rates in 
the United States, compared to Europe.21 The clinical profile of CIED-D carriers pre-
LVAD in our registry suggests a more chronic course of HF prior to the initiation of 
LVAD support – these patients were in higher INTERMACS classes with less need for 
life support therapies (vasopressors, ultrafiltration or mechanical ventilation) prior to 
LVAD; they had more remodelled left ventricles and a higher use of guideline-mandated 
HF therapies, including beta-blockers that may supress ventricular ectopy, compared 
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to patients without an CIED-D pre-LVAD. A more chronic profile corresponds to ICD 
carriers described in other LVAD cohorts.10,11,13–15 However, compared to several other 
analyses, the use of LVADs as bridge to transplantation was much more frequent in our 
cohort.9,10 Furthermore, patients implanted with an LVADmore recently were more likely 
to have received an CIED-D, as well as those with a higher number of VAs pre-LVAD.
While the survival benefit of ICDs is well established in symptomatic HFrEF patients,7 the 
data on the utility of defibrillators in LVAD carriers are still conflicting. Traditionally, LVAD 
patients are considered to tolerate life-threatening VAs,22 possibly due to the Fontan-like 
circulation that occurs when the fibrillating right ventricle becomes a passive conduit.17 
Conversely, in some patients VAs may cause progressive right ventricular failure or lead 
to more gradual HF and death. ‘Routine’ implantation of ICDs post-LVAD is still debated 
and predominantly hindered by increased risk of bleeding and infection in this high-
risk population.23–25 Notwithstanding this, the replacement of exhausted generators of 
defibrillators implanted prior to onset of LVAD therapy is increasingly supported.16,17
While a meta-analysis of six observational studies assessing the impact of ICDs on 
survival of LVAD patients reported a significant reduction in mortality associated with 
ICD use, this finding was not significant when confined to the cf-LVAD population.22 The 
results of one of these studies suggested that only patients who suffered potentially 
life-threatening VAs prior to LVAD implantation had recurring arrhythmias after LVAD 
implantation, thus benefiting from ICD therapy.10 However, the rate of all-cause death 
in our multicentre cohort, and in particular the subgroup without CIED-D post-LVAD, 
was notably higher in comparison to this single-centre study, yet lower than reported 
from the EUROMACS data, and similar to the INTERMACS report.8,10,26 In an analysis 
of the UNOS registry, the presence of ICDs at listing in durable LVAD recipients was 
not associated with lower waitlist mortality; however, numerically fewer arrhythmic 
deaths were noted in the ICD group.27 As mentioned, the penetration of ICDs in this 
cohort is notably greater than in our European cohort which may portend differences 
among the populations. In the largest currently available analysis from the INTERMACS 
database, no survival benefit was associated with ICD in VAD carriers: in the primary 
analysis, ICD implantation was associated with increased mortality of unexpected 
death, which had not met significance levels in additional sensitivity analyses.8 While 
we can only speculate on the aggregate causes of the discrepant results between our 
and the INTERMACS registry, several features clearly differ between these cohorts: the 
INTERMACS cohort was dominated by patients in NYHA class IV (around 83% of patients 
in the propensity score-matched cohort, as opposed to 36% of our cohort), a much 
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larger proportion of destination therapy patients (40%, as opposed to only 13% of our 
population) and those with prior cardiac surgery (68% in INTERMACS compared to 12% 
in PCHF-VAD). Despite the fact that both studies identify clear differences in outcomes 
between those with and without an ICD, it is unclear whether the patient characteristics 
more typical for the INTERMACS registry portended potentially harmful effects of 
ICD therapy in that cohort. Importantly, in addition to a much larger penetration of 
ICDs within the LVAD population compared to our European registry, the INTERMACS 
analysis excluded patients with de-novo ICDs after LVAD implantation. As such, possible 
‘crossover’, i.e. initiation and/or termination of CIED therapy during active LVAD support 
warrants to be accounted for.
We have thus utilised a time-varying analysis that has provided consistent results: in 
an unadjusted analysis, carrying an active CIED with a defibrillator component was 
associated with a 36% reduction in all-cause death, which remained significant and 
comparable after adjustment for the relevant baseline covariates (41% reduction in all-
cause death), after propensity score adjustment (40% reduction), after adjustment for 
the occurrence of VAs post-LVAD (47% reduction) and by utilising multiple imputation to 
compensate for the missing data (37% reduction). Our analysis was expanded to carriers 
of both ICD and CRT-D devices to include the effect of the defibrillator component in 
either type of CIED. After additional adjustment for CRT-P carrier status, the reduction 
in the risk of all cause-death remained significant and reached 43%. Furthermore, 
in a sub-analysis of the ICD-only subgroup, the crude HR suggested a trend towards 
reduced all-cause death, while the adjusted analysis confirmed a 40% reduction in 
all-cause death in active ICD-only carriers during LVAD support. The benefit of active 
CIED-D therapy with an LVAD remained consistent in subgroup analyses as well as with 
additional sensitivity analyses.
Ventricular arrhythmias post-LVAD occurred in 24% of our cohort, which is within 
the reported range of 22–52%.8 In the MOMENTUM 3 trial, sustained ventricular 
tachyarrhythmias occurred relatively frequently (18% in centrifugal-flow VADs, 20% in 
axial-flow VADs), but rarely resulted in death.3 While our data suggested a nominally 
increased crude risk of developing clinically significant VAs post-LVAD in CIED-D carriers 
(Table 2), this did not remain significant in adjusted analyses and was likely an effect of 
enhanced arrhythmia monitoring provided by the CIED. While we cannot infer causality 
between the delivery of defibrillator-driven therapies and reduction in mortality, we 
have noted that nearly one third of the CIED-D carriers received at least one of these 
therapies on at least one occasion, with a median time to first ATP or shock well beyond 
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the arrhythmically fragile early post-surgical period. Moreover, in an analysis of incident 
VAs post-LVAD as a time-varying covariate, the occurrence of the arrhythmia was a 
strong predictor of all-cause and cardiovascular mortality as was increasing patient age, 
LVAD implant as redo surgery and vasopressor use prior to LVAD, while the presence 
of an active CIED-D device remained associated with a reduction in the risk of all-
cause death. Whether the optimal timing of CIED-D implantation is before or after LVAD 
remains to be explored.
Limitations
Our analysis was limited by typical features of retrospective registry studies: 
incompleteness of the dataset which we aimed to account for by multiple imputation 
methods, possible selection bias and misclassification of events. Furthermore, the 
study was limited by lack of data on arrhythmic events in non-CIED-D carriers. We 
acknowledge the limited possibility of determining causality with a retrospective 
analysis, as well as the ability to adequately adjudicate the endpoints which also limits 
the possibility of determining the mitigation of risk of arrhythmic deaths by a CIED-D. 
Finally, this type of study design does not allow optimal control for multiple potential 
confounders, however extensive adjustments have confirmed the robustness of our 
results in terms of reduced all-cause mortality with CIED-D post-LVAD, whereby all 
adjusted models for all-cause death show a stronger treatment effect of CIED-D. 
However, only a randomised prospective trial, which we believe is warranted, would 
be able to adequately address this clinically relevant topic.
Conclusion
In an LVAD cohort with granularly described baseline data stemming from a multicentre 
European registry, we report a significant reduction in the crude and adjusted risk 
of all-cause death in patients carrying a CIED with an active defibrillator component 
during LVAD support, which was consistent across sensitivity analyses. Higher 
patient age, number of clinically significant VAs pre-LVAD, use of vasopressors and 
LVAD implantation as redo surgery were recognized as other significant predictors of 
all-cause mortality.
Finally, an analysis of incident VAs post-LVAD confirmed its occurrence as a strong 
predictor of all-cause and cardiovascular mortality, while in this analysis the presence 
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of an active CIED-D remained associated with a reduction in the risk of all-cause 
and cardiovascular death.
Unambiguous disparities in CIED-D usage in LVAD recipients as well as its impact on 
outcomes exist between European and US cohorts. Further insight in the comparison of 
these populations should improve the understanding of (non-)response to CIEDs, while 
evidence from a randomised controlled trial would be anticipated to inform decisions 
on contiguous device usage in this growing patient population.
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Supplementary content
Supplemental methods:
We have used 25 variables for the current stepwise selection process; the data were 
complete for 11 of these variables. The forward stepwise procedure considered only 
complete cases and was ultimately based on 333 subjects – for categorical variables 
with >5% of unreported values, we treated the unreported values as an additional 
category which increased the number of subjects from 249 to the final 333 subjects. 
In order to address the issue with missingness from an additional approach, we have 
also performed a multiple imputation analysis which has provided comparable results 
(adjusted analysis for the primary outcome: HR 0.59, 95% CI: 0.40-0.87; p=0.008, 
adjusted analysis for the primary outcome including multiple imputation: HR 0.63, 95% 
CI 0.43-0.93, p=0.019).
Supplemental Figure 1. The dates of LVAD implantation.
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Supplemental Figure 2: Left panel: Kaplan-Meier plot of time to CIED-D implantation following LVAD 
implantation (during active LVAD support). Right panel: Kaplan-Meier plot of time to CIED-D deactivation 
following LVAD implantation (during active LVAD support).
Supplemental Figure 3. The duration of follow-up. The median time on LVAD support was 1.1 years (IQR 
0.5-2.0 years) starting at the time of LVAD implantation.
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Supplemental Table 1. Baseline characteristics of the studied patients by CIED-D carrier status prior to 










ARNI 3 (1.0) 1 (0.8) 2 (1.1) 0.80
Calcium channel blocker 1 (0.3) 1 (0.8) 0 (0.0) 0.23
Laboratory values


















RVIDd, mm 42.3±8.2 40.8±7.8 43.4±8.4 0.15
FAC, % 28±10 28±9 28±10 0.97
Right heart catheterization data
sPAP, mmHg 51±17 52±17 51±18 0.41
mPAP, mmHg 34±12 35±11 34±13 0.38
dPAP, mmHg 27±11 29±10 27±11 0.13
CVP, mmHg 10 (6-14) 11 (7-15) 10 (5-14) 0.037
PCWP, mmHg 24.7±8.9 25.9±8.5 24.1±9.0 0.08
TPG, mmHg 11.7±6.7 11.2±7.1 12.1±6.4 0.40
PVR, Wood Units 3.0 (2.0-4.5) 3.0 (2.2-4.9) 3.0 (1.9-4.3) 0.32
CO, L/min 3.8±1.1 3.7±1.0 3.8±1.1 0.25
CI, L/min/m2 1.9±0.5 1.9±0.5 2.0±0.6 0.22
Values expressed as mean ± standard deviation or median (interquartile range).
ARNI – angiotensin receptor-neprilysin inhibitor; BNP – B-type natriuretic peptide; NT-proBNP – N-terminal 
pro hormone BNP; RVIDd - right ventricular intraventricular dimension in end-diastole; FAC – fractional 
area change; TAPSE - tricuspid annular plane systolic excursion; sPAP – systolic pulmonary artery pressure; 
mPAP – mean pulmonary artery pressure; dPAP – diastolic pulmonary artery pressure; CVP – central 
venous pressure; PCWP – pulmonary capillary wedge pressure; TPG – transpulmonary gradient; PVR – 
pulmonary vascular resistance; CO – cardiac output; CI – cardiac index.
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Supplemental table 2a. Multivariate Cox regression model of risk factors for the secondary outcome of 
the occurrence of ventricular arrhythmias post-LVAD implantation from the stepwise selection process 
by time-updated CIED-D carrier status following LVAD implantation, adjusted by variable selection per 
the primary outcome
Variable HR 95% CI P value
CIED-D post-LVAD 1.57 0.98-2.52 0.06
Age 0.99 0.98-1.01 0.30
LVAD implant as redo surgery 0.74 0.35-1.54 0.42
LVAD type
Heart Mate II Referent
0.80
Heart Ware 0.90 0.54-1.50
Heart Mate 3 1.03 0.61-1.74
Other 0.64 0.24-1.69
Number of VA episodes pre-VAD












Supplemental table 2b. Multivariate Cox regression model of risk factors for the secondary outcome of the 
occurrence of ventricular arrhythmias post-LVAD implantation from the stepwise selection process by time-
updated CIED-D carrier status following LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
CIED-D post-LVAD 1.52 0.94-2.46 0.09
Female gender 0.38 0.18-0.80 0.011
Age 0.98 0.97-1.00 0.055
Aetiology
Nonischaemic cardiomyopathy Referent
0.02Ischaemic cardiomyopathy 1.78 1.15-2.76
Other 0.96 0.44-2.11
Number of VA episodes pre-VAD
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Supplemental table 2b. (Continued)















Supplemental Table 3. Unadjusted and adjusted hazard ratios for the primary endpoint (all-cause death) 





Adjusted by variable 
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Adjusted by variable 





















* Adjusted for age, number of ventricular arrhythmia episodes before LVAD implantation, use of
vasopressors prior to LVAD implantation, LVAD type and LVAD implant as a redo surgical procedure.
† Adjusted for: LVAD type and LVAD implant as a redo surgical procedure.
‡ Adjusted for: LVAD type, number of VA episodes pre LVAD.
§ Adjusted for: gender, age, aetiology, number of VA episodes pre LVAD, use of vasopressors, beta-blockers 
and type of mechanical ventilation pre-LVAD.
‖ Adjusted for: age, LVAD type, number of VA episodes pre LVAD, use of ivabradine and beta-blockers
and pre-LVAD.
¶ Adjusted for: aetiology, quartile of date of LVAD implant.
# Adjusted for: LVAD type.
Supplemental table 4a. Multivariate Cox regression model of risk factors for the primary outcome of 
all-cause death, using post-LVAD VAs as a time-varying covariate.
Variable HR 95% CI P value
CIED-D post-LVAD 0.53 0.36-0.79 0.002
Incident VA post-LVAD 2.42 1.58-3.69 <0.0001
LVAD implant as redo surgery 1.75 1.12-2.73 0.013
Age 1.03 1.02-1.05 <0.0001
LVAD type
Heart Mate II Referent
0.29
Heart Ware 1.34 0.85-2.13
Heart Mate 3 0.72 0.39-1.34
Other 0.82 0.36-1.88
Number of VA episodes pre-VAD











146122_Veenis,Jesse_BNW-def .indd   396 13-11-2020   14:38
397
CIED with a defibrillator component in LVAD carriers
Supplemental table 4b. Multivariate Cox regression model of risk factors for the secondary outcome of 
cardiovascular death, using post-LVAD VAs as a time-varying covariate.
Variable HR 95% CI P value
CIED-D post-LVAD 0.57 0.34-0.95 0.031
Incident VA post-LVAD 2.60 1.53-4.43 <0.0001
LVAD implant as redo surgery 2.29 1.32-3.97 0.003
Age 1.03 1.01-1.05 0.01
LVAD type
Heart Mate II Referent
0.23
Heart Ware 1.41 0.80-2.49
Heart Mate 3 0.74 0.35-1.58
Other 0.47 0.13-1.62
Number of VA episodes pre-VAD











Supplemental Table 5a. Multivariate Cox regression model of risk factors for secondary outcome of 
cardiovascular death. from the stepwise selection process by time-updated CIED-D carrier status following 
LVAD implantation, adjusted by variable selection per the primary outcome
Variable HR 95% CI P value
CIED-D post-LVAD 0.65 0.39-1.07 0.09
Age 1.03 1.00-1.05 0.018
LVAD as redo surgery 2.14 1.25-3.67 0.006
LVAD type
Heart Mate II Referent
0.30
Heart Ware 1.32 0.75-2.31
Heart Mate 3 0.76 0.36-1.61
Other 0.46 0.13-1.55
Number of VA episodes pre-VAD
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Supplemental Table 5a. (Continued)
Variable HR 95% CI P value











Supplemental table 5b. Multivariate Cox regression model of risk factors for secondary outcome of 
cardiovascular death. from the stepwise selection process by time-updated CIED-D carrier status following 
LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
CIED-D post-LVAD 0.79 0.50-1.24 0.30
LVAD implant as redo surgery 2.16 1.27-3.66 0.004
LVAD type
Heart Mate II Referent
0.41
Heart Ware 1.26 0.75-2.13
Heart Mate 3 0.76 0.36-1.58
Other 0.54 0.17-1.76
Supplemental Table 6a. Multivariate Cox regression model of risk factors for secondary outcome of 
heart failure hospitalisation from the stepwise selection process by time-updated CIED-D carrier status 
following LVAD implantation, adjusted by variable selection per the primary outcome
Variable HR 95% CI P value
CIED-D post-LVAD 0.92 0.56-1.51 0.74
Age 1.01 0.99-1.03 0.60
LVAD as redo surgery 0.88 0.40-1.96 0.76
LVAD type
Heart Mate II Referent
0.0009
Heart Ware 3.02 1.74-5.24
Heart Mate 3 2.23 1.20-4.14
Other 1.33 0.49-3.59
Number of VA episodes pre-VAD
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Supplemental Table 6a. (Continued)
Variable HR 95% CI P value











Supplemental table 6b. Multivariate Cox regression model of risk factors for secondary outcome of 
heart failure hospitalisation from the stepwise selection process by time-updated CIED-D carrier status 
following LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
CIED-D post-LVAD 0.93 0.57-1.51 0.76
LVAD type
Heart Mate 2 Referent
0.0005
Heart Ware 3.05 1.79-5.21
Heart Mate 3 2.25 1.23-4.13
Other 1.39 0.53-3.62
Number of VA episodes pre-VAD
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Supplemental Table 6c. Multivariate Cox regression model of risk factors for secondary outcome of device-
related infection requiring systemic antibiotics from the stepwise selection process by time-updated CIED-D 
carrier status following LVAD implantation, adjusted by variable selection per the primary outcome
Variable HR 95% CI P value
CIED-D post-LVAD 0.96 0.66-1.40 0.84
Age 1.00 0.98-1.01 0.64
LVAD as redo surgery 1.50 0.95-2.39 0.09
LVAD type
Heart Mate II Referent
0.0008
Heart Ware 1.72 1.16-2.55
Heart Mate 3 0.57 0.32-1.03
Other 0.47 0.17-1.33
Number of VA episodes pre-VAD











Supplemental table 6d. Multivariate Cox regression model of risk factors for secondary outcome of device-
related infection requiring systemic antibiotics from the stepwise selection process by time-updated CIED-D 
carrier status following LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
CIED-D post-LVAD 0.96 0.65-1.41 0.82
Age 1.00 0.99-1.01 0.89
LVAD type
Heart Mate II Referent
0.0005
Heart Ware 1.88 1.25-2.83
Heart Mate 3 0.59 0.33-1.07
Other 0.57 0.20-1.62
Number of VA episodes pre-VAD
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Supplemental table 6d. (Continued)








Supplemental Table 6e. Multivariate Cox regression model of risk factors for secondary outcome of non-
cerebral bleeding from the stepwise selection process by time-updated CIED-D carrier status following 
LVAD implantation, adjusted by variable selection per the primary outcome
Variable HR 95% CI P value
CIED-D post-LVAD 0.64 0.40-1.03 0.07
Age 1.02 1.00-1.04 0.07
LVAD as redo surgery 1.42 0.77-2.61 0.26
LVAD type
Heart Mate II Referent
0.90
Heart Ware 1.03 0.58-1.83
Heart Mate 3 0.81 0.43-1.54
Other 0.85 0.37-1.96
Number of VA episodes pre-VAD
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Supplemental table 6f. Multivariate Cox regression model of risk factors for secondary outcome of non-
cerebral bleeding from the stepwise selection process by time-updated CIED-D carrier status following 
LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
CIED-D post-LVAD 0.82 0.52-1.28 0.37
Aetiology
Nonischaemic cardiomyopathy Referent
0.10Ischaemic cardiomyopathy 1.23 0.77-1.94
Other 2.02 1.06-3.86






Supplemental Table 6g. Multivariate Cox regression model of risk factors for secondary outcome of 
intracranial bleeding from the stepwise selection process by time-updated CIED-D carrier status following 
LVAD implantation, adjusted by variable selection per the primary outcome
Variable HR 95% CI P value
CIED-D post-LVAD 0.55 0.24-1.26 0.16
Age 1.05 1.01-1.09 0.01
LVAD as redo surgery 1.11 0.38-3.21 0.85
LVAD type
Heart Mate II Referent
0.18
Heart Ware 2.63 1.07-6.47
Heart Mate 3 1.20 0.36-4.01
Other 0.98 0.20-4.76
Number of VA episodes pre-VAD
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Supplemental table 6h. Multivariate Cox regression model of risk factors for secondary outcome of 
intracranial bleeding from the stepwise selection process by time-updated CIED-D carrier status following 
LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
CIED-D post-LVAD 0.70 0.34-1.46 0.34
LVAD type
Heart Mate II Referent
0.35
Heart Ware 2.07 0.92-4.65
Heart Mate 3 1.09 0.35-3.43
Other 1.33 0.30-5.88
Supplemental Table 7. Multivariate Cox regression model of risk factors for all-cause death based on a 
backward variable selection model, by time-updated CIED-D carrier status following LVAD implantation.
Variable HR 95% CI P value
CIED-D post-LVAD 0.61 0.40-0.94 0.024






Heart Mate II Referent
0.43
Heart Ware 1.19 0.74-1.92
Heart Mate 3 0.70 0.37-1.34
Other 0.70 0.26-1.89
LVAD intention
Bridge to transplantation (BTT) Referent
0.43Bridge to decision (BTD) 1.13 0.66-1.92















Number of VA episodes pre-VAD
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Supplemental Table 7. (Continued).
Variable HR 95% CI P value







Supplemental table 8. Results of the propensity score model assessing the possibility of having a 
CIED-D pre-LVAD.
Variable OR 95% CI P value
Age 1.02 1.00-1.04 0.07
Female gender 0.76 0.40-1.45 0.41
Arterial hypertension 1.12 0.62-2.02 0.72
Diabetes mellitus 0.94 0.50-1.77 0.85
Chronic kidney disease 1.62 0.89-2.96 0.12
Coronary artery disease 0.69 0.35-1.38 0.30
Prior MI 0.45 0.21-0.96 0.04
Prior coronary revascularization 1.56 0.72-3.37 0.26
Cerebrovascular events 1.68 0.68-4.15 0.26
Atrial fibrillation/flutter 2.90 1.63-5.15 <0.0001
Ventricular arrhythmias 2.03 1.12-3.68 0.020
LVAD as redo surgery 0.59 0.28-1.23 0.16
Concomitant procedure with LVAD implant 0.39 0.21-0.73 0.003
LVAD type
Heart Mate II Referent
<0.0001
Heart Ware 3.24 1.63-6.45
Heart Mate 3 5.88 2.90-11.91
Other 3.91 1.04-14.75
LVAD intention
Bridge to transplantation Referent
0.0008Bridge to decision 0.24 0.11-0.50






4 or higher 4.31 1.94-10.11
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Supplemental table 9a. Sensitivity analyses performed through additional multivariate Cox regression 
models of risk factors for all-cause death by time-updated CIED-D carrier status following LVAD 
implantation estimated by multiple imputation procedures.
Variable HR 95% CI P value
CIED-D post-LVAD 0.63 0.43-0.93 0.019
Age 1.03 1.02-1.05 <0.0001
LVAD as redo surgery 1.72 1.11-2.66 0.015
LVAD type
Heart Mate II Referent
0.36
Heart Ware 1.13 0.73-1.76
Heart Mate 3 0.66 0.36-1.22
Other 0.68 0.30-1.52











Supplemental table 9b. Sensitivity analyses performed through additional multivariate Cox regression 
models of risk factors for all-cause death by time-updated CIED-D carrier status following LVAD 
implantation estimated by multiple imputation procedures.
Variable HR 95% CI P value
CIED-D post-LVAD 0.61 0.41-0.90 0.013
CRT-P post-LVAD 0.65 0.25-1.66 0.37
Age 1.03 1.02-1.05 <0.0001
LVAD as redo surgery 1.78 1.15-2.78 0.01
LVAD type
Heart Mate II Referent
0.35
Heart Ware 1.13 0.73-1.76
Heart Mate 3 0.66 0.36-1.22
Other 0.66 0.29-1.48
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Supplemental Table 10. Sensitivity analysis performed through an additional multivariate Cox regression 
model obtained from the stepwise selection process of risk factors for all-cause mortality, based on 
multiple imputation methods.
Variable HR 95% CI P value
CIED-D post-LVAD 0.58 0.41-0.82 0.002
Age 1.03 1.01-1.05 <0.0001
LVAD as redo surgery 1.71 1.11-2.64 0.014
Supplemental Table 11a. Multivariate Cox regression model of risk factors for all-cause mortality by time-
updated ICD carrier status following LVAD implantation, adjusted by outcome-specific variable selection
Variable HR 95% CI P value
ICD status 0.60 0.39-0.92 0.019
Age 1.03 1.01-1.05 0.001
LVAD implant as redo surgery 2.02 1.24-3.31 0.005
LVAD type
Heart Mate II Referent
0.31
Heart Ware 1.40 0.86-2.27
Heart Mate 3 0.76 0.41-1.41
Other 0.86 0.37-2.00
Number of VA episodes pre-LVAD











LVIDd pre-LVAD 0.98 0.97-1.00 0.064
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Supplemental Table 11b. Multivariate Cox regression model of risk factors for all-cause mortality by time-
updated ICD carrier status following LVAD implantation, adjusted by outcome-specific variable selection 
- sensitivity analysis based on multiple imputation.
Variable HR 95% CI P value
CIED-D post-LVAD 0.65 0.44-0.97 0.034
Age 1.03 1.02-1.05 <0.0001
LVAD as redo surgery 1.72 1.10-2.67 0.015
LVAD type
 Heart Mate II Referent
0.27
 Heart Ware 1.13 0.72-1.76
 Heart Mate 3 0.60 0.33-1.09
 Other 0.74 0.33-1.67











LVIDd at LVAD implant 0.99 0.98-1.01 0.49
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Abstract
Aims: The aim of this study was to compare early- and late-term survival and causes of 
death between patients with and without a concomitant aortic valve (AoV) procedure 
during continuous-flow left ventricular assist device (LVAD) surgery.
Methods and results: All adult primary continuous-flow LVAD patients from the 
International Society of Heart and Lung Transplantation (ISHLT) Mechanically Assisted 
Circulatory Support (IMACS) registry (n=15,267) were included in this analysis and 
stratified into patients with concomitant AoV procedure (being AoV replacement or AoV 
repair) and without AoV procedure. The primary outcome was early (≤90 days) survival 
post-LVAD surgery. Secondary outcomes were late survival, survival of patients alive 90 
days post-LVAD surgery (conditional survival) and its determinants.
Patients who underwent concomitant AoV replacement (n=457) or AoV repair (n=328) 
had a significantly reduced late survival compared with patients without an AoV 
procedure (n=14,482) (56%, 61%, 62%, respectively p=0.001), although the biggest 
difference occurred in the early postoperative period. After adjustment for other 
significant predictors, concomitant AoV replacement remained an independent 
predictor for early (HR 1.226 [1.037-1.449]) and late mortality (HR 1.477 [1.154-1.890]).
Only, in patients with moderate or severe AoV regurgitation, no significant survival 
differences were observed between patients with concomitant AoV replacement, AoV 
repair and without an AoV procedure (58%, 61%, 59%, respectively, p=0.923).
Conclusion: Concomitant AoV surgery in patients with an LVAD implantation was an 
independent predictor of worse outcome, mainly in the early postoperative period. 
Additional research is needed to determine the best AoV surgical strategy at the time 
of LVAD surgery.
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Introduction
In the recent years, more and more patients received a left ventricular assist device 
(LVAD), as treatment for end-stage HF 1. However, significant aortic valve (AoV) 
regurgitation in patients with an LVAD causes a short circulation loop, in which blood 
is pumped into the aorta by the LVAD, and flows directly back into the left ventricle 
2. This results in less unloading of the left ventricle and reduced systemic perfusion, 
indicated by an increased left ventricular end-diastolic diameter and higher levels 
of brain natriuretic peptide 3. Additionally, significant AoV regurgitation has been 
associated with increased mortality and higher hospitalization rates 3, 4. Therefore, it is 
recommended to perform a concomitant AoV procedure in patients with moderate to 
severe AoV regurgitation at the time of LVAD surgery 5. Additionally, it is recommended 
to perform a concomitant AoV procedure at the time of LVAD surgery in patients with a 
mechanical AoV 5, since mechanical AoV in LVAD patients is associated with an increased 
risk of thromboembolic events 6, 7.
Concomitant AoV replacement with a bioprosthetic valve, AoV repair, or oversewing of 
the AoV are all considered as treatment strategies, with associated risks and benefits 
8. However, conflicting results have been reported on the outcomes of concomitant 
AoV procedures, and there is limited contemporary data available on the early and late 
survival outcomes of these concomitant AoV procedures.
The aim of this study was to compare early and late survival and causes of early 
and late death between patients with and without a concomitant AoV procedure 
during continuous-flow LVAD surgery in the International Society of Heart and Lung 
Transplantation (ISHLT) Mechanically Assisted Circulatory Support (IMACS) registry.
Methods
The IMACS registry is a multinational, multicenter database, prospectively collecting 
data, as has been prescribed previously 9. In short, the aim of the IMACS registry is to 
enroll and monitor patients implanted with durable mechanical circulatory support 
devices, worldwide. The registry receives data from the Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS), European Registry for Patients 
with Mechanical Circulatory Support (EUROMACS), United Kingdom (UK) registry and 
the Japanese Mechanically Assisted Circulatory Support ( JMACS) registries as well as 
from individual hospitals worldwide.
22
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All adult patients (age ≥18 years) who underwent primary implantation of a continuous-flow 
LVAD from January 2013 through November 2017 were included in this analysis. Patients with 
a total artificial heart, isolated right ventricular assist device or with missing information on 
concomitant AoV procedure were excluded from this analysis (Supplementary Figure 1). The 
endpoint for this analysis was all-cause mortality post-LVAD surgery, device explantation 
or heart transplantation. The primary outcome was early (≤90 days post-LVAD surgery) 
survival. Secondary outcomes were late (survival during the entire follow-up period) and 
conditional survival (in patients who survived the first 90 days post-LVAD surgery), causes 
of early and late death post-LVAD surgery, device explantation and heart transplantation. 
The definitions of causes of death were defined earlier by the IMACS registry, by granular 
data on the causes of death were not available 9.
Statistical analysis
Patient characteristics are presented as mean ± standard deviation (SD) or median with 
interquartile range (IQR), depending on the distribution of continuous data and counts and 
percentages (%) for categorical data. The one-way ANOVA test or Kruskal-Wallis test was 
used to compare data for categorical variables, depending on the distribution of the data, 
and the Chi-square test was used to compare data for categorical variables. All included 
LVAD patients were stratified into those without a concomitant AoV procedure or those 
with AoV intervention (replacement or concomitant AoV repair) at the of LVAD implant. 
Additional data on which type of AoV repair technique was used was not available.
The probability of survival was analyzed using the Kaplan-Meier method and compared 
using the log-rank test. A univariable Cox proportional hazard analysis was used to 
relate preoperative parameters, such as demographics, medication, echocardiographic, 
hemodynamic and laboratory characteristics with the study outcomes (Supplementary 
Tables 1-2). Variables with a p-value <0.20 were entered in a multivariable Cox 
proportional hazard analysis, in order to adjust the prediction of AoV procedures 
for cofounders, applying the stepwise forward method, with a p<0.05 model-entry 
criterion. Data were censored at heart transplantation or device explantation due to 
recovery. The competing outcomes methodology was used to estimate the probability 
of survival, mortality, heart transplantation or device explantation over time.
Several subanalyzes have been performed, including a survival analysis in patients 
with documented moderate to severe AoV regurgitation, a survival analysis stratified 
to INTERMACS classification, device destination, presence of AoV regurgitation and a 
subanalysis without patients who proceeded towards heart transplantation.
146122_Veenis,Jesse_BNW-def .indd   460 13-11-2020   14:39
461
Concomitant aortic valve procedure and left ventricular assist device implantation
Missing data in the baseline variables were imputed, using multiple imputation. If the 
missing variables showed a monotone pattern of missing values, the monotone method 
was used, otherwise, an iterative Markov chain Monte Carlo method was used with a 
number of 10 iterations. A total of five imputations was performed, and the pooled 
data were analyzed. Variables with less than 40% missing data in the entire population 
were accepted for multiple imputation 10. The vast majority of variables had less than 
5% missing data (Supplementary Table 3). The imputed data were only used in the Cox 
proportional hazard analysis.
A two-tailed p<0.05 was considered statistically significant. All analyses were performed 
with SPSS statistical package version 25.0 (SPSS Inc., Chicago, IL, USA).
The findings herein were reviewed and approved by the IMACS Steering Committee.
Results
In total, 15,267 LVAD patients were included in this analysis and were stratified into 
those without an AoV procedure (n=14,482, 94.9%), AoV replacement (n=457, 3.0%) 
or AoV repair (n=328, 2.1%). The median follow-up period was 13.2 [5.5-25.6] months. 
The baseline characteristics are summarized in (Table 1). Overall, the median age at 
LVAD surgery was 58 years, the majority of patients were men (79.3%) and the main 
etiology of HF was non-ischemic (61.5%). In patients without an AoV procedure, 67.2% 
had no AoV regurgitation, while in 15.9% of patients with an AoV replacement and 
10.9% of the patients with an AoV repair, no AoV regurgitation prior to LVAD surgery 
was reported (p<0.001). Patients with an AoV repair were significantly older compared 
to patients without an AoV procedure or AoV replacement (p<0.001), had a lower body 
mass index (p<0.001), lower platelet counts (p=0.001), and received an LVAD more often 
as destination therapy (p=0.001). Patients who received an AoV replacement were more 
often men (p<0.001) and had a higher blood urea nitrogen level (p<0.001) compared 
with patients with an AoV procedure or AoV repair.
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Early, late and conditional survival
In the combined cohort of patients, the early survival rate (≤90 days post-LVAD surgery) 
was 90.3%, the late survival rate (up to 36 months post-LVAD surgery) was 62.1%, while 
the conditional survival rate (up to 36 months post-LVAD surgery in patients alive at 90 
days post-LVAD surgery) was 68.8%. The early survival rates were 90.4% for patients 
without an AoV procedure, 85.1% for patients with an AoV replacement and 87.4% for 
patients with an AoV repair (p<0.001), as shown in Figure 1A. Although the late survival 
rates differed significantly (Figure 1B, 62.4%, 55.5%, and 60.9%, respectively, p=0.001), 
the biggest difference occurred early post-LVAD surgery, with no additional difference 
observed in the conditional survival (Supplementary Figure 2, survival rates were 69.0%, 
65.2%, and 69.7%, respectively, p=0.268).
Patients without an AoV procedure stayed for a shorter period on the intensive care 
(7 [5-13] days), compared to patients with an AoV replacement (10 [6-17] days) and 
patients with an AoV repair (8 [5-14] days, p<0.001). Similarly, patients without an AoV 
procedure stayed for a shorter period in the hospital (19 [14-28] days) compared to 
patients with an AoV replacement (21 [16-36] days) and patients with an AoV repair (20 
[14-30] days, p<0.001). During the initial hospitalization, in 843 (5.8%) patients without 
an AoV procedure, 44 (9.6%) patients with an AoV replacement and 8 (2.4%) patients 
with an AoV repair died (p<0.001).
As shown in Supplementary Figure 3, mechanical AoV replacements (82.7%, 50.6%, 
respectively) have the worse early and late survival followed by biological AoV 
replacement (85.6%, 56.4%, respectively), AoV repair (87.4%, 60.9%, respectively), while 
no AoV procedure (90.4%, 62.4%, respectively) has the best early and late survival 
(p<0.001, p=0.001, respectively). The baseline characteristics of the patients with 
biological and mechanical AoV replacement, AoV repair and no AoV procedure are 
shown in Supplementary Table 4).
Patients with an AoV procedure and an INTERMACS class 2 or 3 had a significant worse 
survival, compared to patients without an AoV procedure, while no survival difference 
was observed in patients with an INTERMACS class 1 or 4 and higher (Supplementary 
Figure 4A-C). The causes of death are shown in Supplementary Table 5.
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Figure 1. A Early and B late survival stratified to AoV procedure post-LVAD surgery
When competing outcomes are analyzed between the patient cohorts, patients with 
an AoV replacement (29.0%) and AoV repair (29.4%) were less often transplanted at 
36 months post-LVAD surgery compared to patients without AoV procedure (36.3%) 
(Supplementary Figure 5A-C).
In patients who did not proceed towards heart transplantation, patients without an 
AoV procedure had the best survival (Supplementary Figure 6). While no significant 
difference was observed in early or medium term survival between patients who 
received the LVAD as a bridge to transplantation or as destination therapy, as shown 
in Supplementary Figure 7.
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Figure 2. A Early, B late, and C conditional survival in patients with moderate to severe AoV regurgitation 
at baseline, stratified to no AoV procedure, AoV replacement and AoV repair post-LVAD surgery.
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Survival in patients with moderate to severe AR
The baseline and clinical characteristics of 583 patients with a documented moderate 
to severe AoV regurgitation at baseline has been shown in Supplementary Table 6. As 
shown in Figure 2A-C, no significant differences in the early, late or conditional survival 
rates were observed between patients without an AoV procedure (89.4%, 58.5%, 65.4%, 
respectively), AoV replacement (90.6%, 57.5%, 63.5%, respectively) or AoV repair (86.7%, 
61.3%, 70.8%, respectively). The early, late and conditional survival of patients without 
an AoV procedure, stratified to AR at baseline is shown in Supplementary Figure 8A-C, 
while the late survival of patients without an AoV procedure, AoV replacement and AoV 
repair, stratified to AR at baseline are shown in Supplementary Figure 9A-C.
Causes of death
The causes of early and late death post-LVAD surgery are shown in Tables 2 and 
Supplementary Table 7. Multisystem organ failure was the most frequent cause of 
early death (27.7%), followed by circulatory failure (16.9%) and neurological events 
(15.9%). The most frequent cause of late death was neurological events (19.2%) 
followed by multisystem organ failure (17.5%) and circulatory failure (17.2). The 
causes of death in patients surviving the first 90 days post-LVAD surgery are shown in 
Supplementary Table 8.
Table 2. Causes of early death stratified to AoV procedure in LVAD patients post-LVAD surgery
Overall population 
(n=1,452)






Multisystem Organ Failure 402 (27.7) 368 (27.4) 22 (32.8) 12 (29.3)
Circulatory failure 246 (16.9) 230 (17.1) 7 (10.4) 9 (22.0)
Neurological events 231 (15.9) 220 (16.4) 7 (10.4) 4 (9.8)
Withdrawal of support 161 (11.1) 150 (11.2) 6 (9.0) 5 (12.2)
Major infection 110 (7.6) 101 (7.5) 4 (6.0) 5 (12.2)
RV-failure 80 (5.5) 76 (5.7) 3 (4.5) 1 (2.4)
Respiratory failure 72 (5.0) 66 (4.9) 4 (6.0) 2 (4.9)
Digestive/liver failure* 21 (1.4) 21 (1.6) 0 (0.0) 0 (0.0)
Device related 10 (0.7) 9 (0.7) 1 (1.5) 0 (0.0)
Hematologic failure 8 (0.6) 7 (0.5) 1 (1.5) 0 (0.0)
Cancer 1 (0.1) 1 (0.1) 0 (0.0) 0 (0.0)
Other 110 (7.6) 95 (7.1) 12 (17.9) 3 (7.3)
p-value for distribution between groups: 0.454
AoV, Aortic Valve; LVAD, Left Ventricular Assist Device; RV, Right Ventricular
* including hepatic dysfunction, renal dysfunction, pancreatitis
22
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Table 3. Multivariable predictors of early all-cause mortality post-LVAD surgery, stratified to AoV procedure
95% CI for HR






le No AoV procedure ref ref ref ref
AoV replacement 1.604 1.255 2.050 <0.001








No AoV procedure ref ref ref ref
AoV replacement 1.477 1.154 1.890 0.002
AoV repair 1.209 0.885 1.652 0.233
Age (years) 1.030 1.025 1.035 <0.001
Sex (men vs. women) 0.817 0.718 0.930 0.002
BMI (kg/m2) 1.019 1.011 1.028 <0.001
Creatinine (mg/dL) 1.148 0.990 1.333 0.068
BUN (mg/dL) 1.007 1.005 1.010 <0.001
AST (U/L) 1.000 1.000 1.001 0.003
Total bilirubin (mg/dL) 1.197 1.127 1.272 <0.001
Platelet (x109/L) 0.999 0.998 1.000 0.001
Albumin (g/dL) 0.728 0.663 0.800 <0.001
Hemoglobin (g/dL) 0.924 0.898 0.951 <0.001
Mean RA pressure (mmHg) 1.011 1.004 1.019 0.004
Pulmonary artery wedge pressure (mmHg) 0.990 0.983 0.996 0.002
Moderate/severe tricuspid regurgitation 1.285 1.148 1.438 <0.001
Moderate/severe mitral regurgitation 0.796 0.712 0.889 <0.001
ECMO 1.612 1.345 1.932 <0.001
LVAD strategy
BTT ref ref ref ref
BTC 0.936 0.802 1.093 0.402
DT 1.109 0.966 1.274 0.143
Rescue therapy 2.233 1.147 4.347 0.018
Bridge to recovery 2.527 1.781 3.585 <0.001
Other 1.325 0.423 4.152 0.629
LVAD, Left Ventricular Assist Device; AoV, Aortic Valve; CI, Confidence Interval; HR, Hazard Ratio; BMI, Body Mass 
Index; INTERMACS, Interagency Registry for Mechanical Assisted Circulatory Support; IABP, Intra-Aortic Balloon 
Pump; ECMO, Extra Corporeal Membrane Oxygenator; BUN, Blood Urea Nitrogen; AST, Asparate Transaminase; 
RA, Right Atrial; BTT, Bridge to Transplant; BTC, Bridge to Candidacy; DT, Destination Therapy
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Table 4. Multivariable predictors of late all-cause mortality post-LVAD surgery, stratified to AoV procedure
95% CI for HR






le No AoV procedure ref ref ref ref
AoV replacement 1.360 1.152 1.605 <0.001








No AoV procedure ref ref ref ref
AoV replacement 1.226 1.037 1.449 0.017
AoV repair 1.052 0.853 1.298 0.635
Age (years) 1.024 1.021 1.028 <0.001
BMI (kg/m2) 1.016 1.011 1.022 <0.001
Ischemic etiology 1.070 1.001 1.144 0.047
INTERMACS class (1-3 vs. 4-7) 1.101 1.005 1.207 0.040
Creatinine (mg/dL) 1.111 1.014 1.217 0.024
BUN (mg/dL) 1.006 1.004 1.007 <0.001
Total bilirubin (mg/dL) 1.085 1.042 1.129 <0.001
Platelet (x109/L) 0.999 0.999 1.000 0.016
INR 1.062 0.995 1.134 0.070
Albumin (g/dL) 0.872 0.822 0.924 <0.001
Hemoglobin (g/dL) 0.938 0.922 0.954 <0.001
Mean RA pressure (mmHg) 1.011 1.006 1.015 <0.001
Pulmonary artery wedge pressure (mmHg) 0.992 0.988 0.996 <0.001
Moderate/severe tricuspid regurgitation 1.144 1.068 1.226 <0.001
Moderate/severe mitral regurgitation 0.845 0.790 0.904 <0.001
IABP 1.074 1.000 1.154 0.050
ECMO 1.354 1.185 1.546 <0.001
LVAD strategy
BTT ref ref ref ref
BTC 0.979 0.889 1.077 0.661
DT 1.145 1.050 1.248 0.002
Rescue therapy 1.484 0.873 2.521 0.145
Bridge to recovery 1.599 1.201 2.128 0.001
Other 0.806 0.301 2.159 0.668
LVAD, Left Ventricular Assist Device; AoV, Aortic Valve; CI, Confidence Interval; HR, Hazard Ratio; BMI, Body Mass 
Index; INTERMACS, Interagency Registry for Mechanical Assisted Circulatory Support; IABP, Intra-Aortic Balloon 
Pump; ECMO, Extra Corporeal Membrane Oxygenator; BUN, Blood Urea Nitrogen; RA, Right Atrial; BTT, Bridge 
to Transplant; BTC, Bridge to Candidacy; DT, Destination Therapy
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Multivariable model
Independent risk factors for early mortality post-LVAD surgery after multivariable 
adjustment are shown in Table 3. The replacement of the AoV was significantly associated 
with an increased risk for early all-cause mortality, both unadjusted (HR 1.604 [1.255-
2.050], p<0.001) as adjusted for other significant predictors (HR 1.477 [1.154-1.890], 
p=0.002, while AoV repair was no significant predictor, compared to no AoV procedure. 
Similarly, AoV replacement was an predictor for late all-cause mortality, unadjusted (HR 
1.360 [1.152-1.605], p<0.001) and adjusted 1.226 [1.037-1.449], p=0.017) (Table 4).
Discussion
This is the largest, contemporary study investigating the outcomes after continuous-
flow LVAD implantation with and without a concomitant AoV procedure. The main 
findings from this study were decreased, mainly in the early, survival rate of patients 
with an AoV replacement or repair compared to patients without an AoV procedure. 
Following adjustment for other significant predictors, AoV replacement remained an 
independent predictor for all-cause mortality. Furthermore, the main causes of early 
death included multi organ failure, circulatory failure, and neurological events.
Untreated significant AoV regurgitation could be very hemodynamically compromising 
due to the short circulation loop, while less severe AoV regurgitation might be less 
cumbersome. Surprisingly, in up to 15% of our patients who underwent an AoV 
procedure, no AoV regurgitation was reported prior to LVAD surgery. In these patients, 
the decision for an AoV procedure could have been made based on the peri-operative 
echocardiogram, showing a significant AoV regurgitation. Additionally, these patients 
might have undergone a concomitant AoV procedure in order to replace or oversew 
the AoV due to a pre-existing mechanical AoV, as is recommended 5. However, both 
peri-operative echocardiographic data as well as replacement of a mechanical AoV 
were not collected in the IMACS database, so these hypotheses could not be tested. 
However, as our results indicate that AoV replacement is an independent predictor 
for mortality, stringent criteria for a concomitant AoV procedure at the time of LVAD 
surgery might be warranted, especially in patients with only a mild AoV regurgitation. 
Additionally, less invasive procedures for the treatment of significant AoV regurgitation 
in LVAD patients have been suggested. Only small studies have investigated the usage 
of a transcatheter aortic valve replacement (TAVR) procedure to treat significant AoV 
regurgitation in patients already on LVAD support, showing promising results 11-13. 
Using a TAVR procedure concomitant with LVAD surgery could reduce the circulatory 
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bypass time, reducing the risk of myocardial ischemia, as shown in a recent case-report 
14. However, experience and evidence with this off-label use of the TAVR procedure 
are very limited, and this technique might have additional limitations such as the 
challenging aspect of these kind of procedures in LVAD patients. Additional trials are 
highly needed in order to determine the optimal strategy for the treatment of significant 
AoV regurgitation at the time of LVAD surgery. Especially since our results demonstrated 
that in patients with a significant AoV regurgitation, the survival rates between patients 
with and without an AoV procedure was similar.
Early and late survival
Previous studies investigating the association between survival and AoV procedures 
reported conflicting results, with some studies indicating a worse survival 15-18, while 
others reported similar or better survival rates in patients with a concomitant AoV 
procedure 19-23. However, most of these studies were single-center studies and were 
limited by the lower number of patients with a concomitant AoV procedure (with only one 
of them including more than 100 patients with an AoV procedure), and some reported 
only outcomes of multiple concomitant cardiac procedures combined. The largest 
study used the INTERMACS dataset, and included 6,721 adult LVAD patients, with 125 
patients undergoing concomitant AoV closure, 95 AoV repair, and 85 AoV replacement 
between June 2006 and December 2012 15. In the INTERMACS study, patients undergoing 
a concomitant AoV procedure had significantly lower 1-year survival rates (patients with 
an AoV repair 79%, AoV replacement 72% and AoV closure 64%) compared to patients 
without an AoV procedure (81%, p=0.0003). In comparison to the INTERMACS study, 
our study reflects a more contemporary, worldwide LVAD population, a much higher 
number of LVAD patients were included, with a higher number of AoV procedures. The 
late survival rates in our study were higher compared to the INTERMACS study, most 
likely reflecting the improvement in LVAD management and survival over time. Similar 
to the INTERMACS study, our results demonstrated a lower survival rate in patients with 
an AoV procedure, although, in our study, patients with an AoV replacement had the 
lowest survival, compared to patients with an AoV closure in the INTERMACS study.
Surprisingly, in patients with moderate or severe AR no significant survival differences 
were observed between patients with and without concomitant AoV procedures. 
Additionally, in patients without a concomitant AoV procedure, no significant survival 
difference was observed between patients with and without AR. Only a trend towards 
a better survival was observed in patients with AVR and AR compared to patients 
22
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without AR. These results suggests that the increased risk of a AoV procedure, might 
out weight its benefits.
Only biological prosthesis are recommended for concomitant AoV replacement, and it 
is recommended to perform a concomitant AoV procedure at the time of LVAD surgery 
in patients with a mechanical AoV 5. Despite these recommendations, a small number of 
patients still received a concomitant mechanical AoV during LVAD surgery. Our results, 
clearly demonstrates that patients with a mechanical AoV have the worst survival, thus 
supporting the recommendations to only use biological prosthesis in LVAD patients.
Multiple closure and repair techniques have been reported in LVAD patients, each 
with their own risks and benefits 8. A variation in the used operating techniques might 
explain the observed variation in outcome after AoV repair between INTERMACS 
and IMACS study. However, this hypothesis could not be tested since both databases 
do not have sufficient data to discriminate between different operating techniques. 
Additionally, our results did not discriminate between AoV repair or closure, which might 
have contributed to the observed variation. However, in patients with an AoV closure, 
native ejection from the heart is not possible, especially during catastrophic pump 
dysfunction. A catastrophic pump dysfunction, although rare, is a severe complication 
and is in 2% of all LVAD patients the cause of death 1. Additionally, by overseewing the 
AoV, a blind pouch is created, potentially increasing the risk of thrombus formation on 
the AoV, thus increasing the risk of thromboembolic events. Therefore, the decision for 
the closure of the AoV should not be taken lightly.
Causes of death
In our combined cohort of LVAD patients, the most common causes of early death 
were multisystem organ failure, circulatory failure, and neurological events post-
LVAD surgery, similar to previous report 24. The lower survival in patients with an 
AoV replacement appears to be accompanied by an increase in multisystem organ 
failure, while patients with an AoV repair died more often due to a circulatory failure 
compared to patients without an AoV procedure. Surprisingly, fatal neurological events 
occurred frequently, and more often in patients without an AoV procedure, compared to 
patients with a concomitant AoV replacement or repair. Potentially, antithrombotic and 
antiplatelet therapy was introduced earlier in patients with an AoV procedure compared 
to patients without an AoV procedure, thus preventing fatal neurological events. 
However, detailed information on the timing of the introduction of antithrombotic and 
146122_Veenis,Jesse_BNW-def .indd   474 13-11-2020   14:39
475
Concomitant aortic valve procedure and left ventricular assist device implantation
antiplatelet therapy was lacking. Unfortunately, no granular data was available in the 
IMACS database for more specification of the causes of early and late death.
The most common causes of late death were neurological events, multi organ failure, 
and circulatory failure, which are similar as previously reported by the INTERMACS, 
EUROMACS and IMACS databases 1, 24, 25. Patients with an AoV replacement and 
repair died more often due to multisystem organ failure, and patients with an AoV 
repair died more often due to a circulatory failure compared to patients without 
an AoV procedure.
Competing outcomes
In this cohort, LVAD patients with an AoV procedure were less often transplanted 
in comparison to patients without an AoV procedure. As previously suggested, 
AoV regurgitation might be treated more aggressively in patients with an LVAD as 
destination therapy 15. However, the observed difference between those without an 
AoV procedure and replacement could not fully be explained by the difference in 
device strategy. Potentially, the significantly higher age in the patients with an AoV 
replacement might have influenced the decision not to proceed towards transplantation 
after LVAD implantation.
Limitations
This study has some limitations. First, due to the retrospective nature of this study, 
some data was missing in our study. Although, we used multiple imputation to deal 
with the missing data, this might have caused a minor bias might have been caused 
due to the missing data. Additionally, some errors might have occurred during data 
entry. Second, in order to ensure data anonymization, LVAD brand information was not 
available in the research database. Therefore, brand-specific sub-analysis could not be 
performed. Data on the presence and severity of AoV regurgitation was available for 
all patients, however, information on why surgeons decided for an AoV replacement or 
repair was not available. It is likely that this might have varied between the participating 
centers due to local experiences and preferences. Additionally, the degree of AoV 
regurgitation was graded by the local site, and not by an independent core lab, this 
might have caused some bias. Lastly, no discrimination between AoV repair or closure 
was made in the database.
22
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Conclusion
This is the largest study comparing the short- and long-term survival of concomitant 
AoV procedures in continuous-flow LVAD patients with pre-existing AoV regurgitation. 
Concomitant AoV surgery, especially replacement, is associated with lower survival rates 
compared to patients without an AoV procedure. Only in patients with moderate to 
severe AR, no survival difference was observed in patients who underwent concomitant 
AoV surgery, compared to those without AoV surgery. These results suggest that 
resolving less severe AR might not outweigh the risk of AoV surgery. Therefore, 
additional research is urgently needed to determine the optimal strategy in order to 
treat or not to treat AoV regurgitation at the time of LVAD surgery.
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Supplementary data:
Supplementary Table 1. Univariable predictors of early all-cause mortality post-LVAD surgery
95% CI for HR
Variables HR Lower Upper p-value
Demographics
Age (years) 1.030 1.025 1.035 <0.001
Sex (men vs. women) 0.914 0.808 1.034 0.153
BSA (m2) 0.936 0.790 1.110 0.448
BMI (kg/m2) 1.007 0.999 1.015 0.076
Ischemic etiology 1.317 1.188 1.459 <0.001
Atrial fibrillation 1.294 1.147 1.458 <0.001
Blood type
O ref ref ref ref
A 1.067 0.952 1.195 0.265
B 1.133 0.969 1.325 0.118
AB 1.091 0.839 1.419 0.515
INTERMACS class (1-3 vs. 4-7) 1.404 1.201 1.641 <0.001
IABP 1.337 1.201 1.489 <0.001
ECMO 2.580 2.216 3.002 <0.001
≥3 inotropic use 1.526 1.263 1.843 <0.001
Laboratory
Creatinine (mg/dL) 1.801 1.597 2.032 <0.001
BUN (mg/dL) 1.013 1.011 1.015 <0.001
AST (U/L) 1.001 1.001 1.001 <0.001
Total bilirubin (mg/dL) 1.294 1.226 1.365 <0.001
WBC (x10
9/L) 1.000 0.999 1.000 0.698
Platelets (x10
9/L) 0.997 0.996 0.998 <0.001
INR 1.296 1.192 1.411 <0.001
Albumin (g/dL) 0.552 0.509 0.600 <0.001
Hemoglobin (g/dL) 0.852 0.831 0.874 <0.001
Hemodynamic
Mean RA pressure (mmHg) 1.020 1.013 1.026 <0.001
Pulmonary artery wedge pressure (mmHg) 0.996 0.991 1.002 0.185
Systolic pulmonary artery pressure (mmHg) 0.997 0.994 1.001 0.131
Diastolic pulmonary artery pressure (mmHg) 0.993 0.987 0.999 0.015
Cardiac output (L/min) 1.028 0.985 1.073 0.201
Severe RV dysfunction 1.204 1.047 1.383 0.009
Severe LV dysfunction (<20%) 0.884 0.794 0.983 0.023
Moderate or severe tricuspid regurgitation 1.258 1.136 1.394 <0.001
Moderate or severe mitral regurgitation 0.799 0.722 0.885 <0.001
Device strategy
BTT ref ref ref ref
BTC 1.097 0.941 1.279 0.236
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Supplementary Table 1.  (continued)
95% CI for HR
Variables HR Lower Upper p-value
DT 1.598 1.401 1.823 <0.001
Rescue therapy 2.473 1.275 4.797 0.007
Bridge to recovery 4.937 3.526 6.913 <0.001
Other 1.492 0.479 4.651 0.490
LVAD, Left Ventricular Assist Device; CI, Confidence Interval; HR, Hazard Ratio; BSA, Body Surface Area; BMI, 
Body Mass Index; INTERMACS, Interagency Registry for Mechanical Assisted Circulatory Support; IABP, Intra-
Aortic Balloon Pump; ECMO, Extra Corporeal Membrane Oxygenator; BUN, Blood Urea Nitrogen; AST, Asparate 
Transaminase; WBC, White Blood Count; RA, Right Atrial; RV, Right Ventricle; LV Left Ventricle; BTT, Bridge to 
Transplant; BTC, Bridge to Candidacy; DT, Destination Therapy
Supplementary Table 2. Univariable predictors of late all-cause mortality post-LVAD surgery 
95% CI for HR
Variables HR Lower Upper p-value
Demographics
Age (years) 1.027 1.024 1.030 <0.001
Sex (men vs. women) 0.969 0.897 1.047 0.425
BSA (m2) 1.005 0.907 1.113 0.929
BMI (kg/m2) 1.006 1.001 1.010 0.020
Ischemic etiology 1.347 1.265 1.434 <0.001
Atrial fibrillation 1.164 1.079 1.255 <0.001
Blood type
O ref ref ref ref
A 1.140 1.064 1.222 <0.001
B 1.081 0.980 1.193 0.120
AB 1.121 0.951 1.321 0.174
INTERMACS class (1-3 vs. 4-7) 1.217 1.116 1.327 <0.001
IABP 1.214 1.135 1.299 <0.001
ECMO 1.707 1.517 1.921 <0.001
≥3 inotropic use 1.258 1.103 1.434 0.001
Laboratory
Creatinine (mg/dL) 1.614 1.498 1.739 <0.001
BUN (mg/dL) 1.009 1.008 1.010 <0.001
AST (U/L) 1.001 1.000 1.001 <0.001
Total bilirubin (mg/dL) 1.106 1.067 1.147 <0.001
WBC (x10
9/L) 1.000 0.999 1.000 0.393
Platelets (x10
9/L) 0.999 0.998 0.999 <0.001
INR 1.161 1.093 1.233 <0.001
Albumin (g/dL) 0.716 0.680 0.754 <0.001
Hemoglobin (g/dL) 0.897 0.883 0.910 <0.001
146122_Veenis,Jesse_BNW-def .indd   480 13-11-2020   14:39
481
Concomitant aortic valve procedure and left ventricular assist device implantation
Supplementary Table 2.  (continued)
95% CI for HR
Variables HR Lower Upper p-value
Hemodynamic
Mean RA pressure (mmHg) 1.015 1.011 1.019 <0.001
Pulmonary artery wedge pressure (mmHg) 0.997 0.994 1.001 0.122
Systolic pulmonary artery pressure (mmHg) 1.000 0.998 1.002 0.909
Diastolic pulmonary artery pressure (mmHg) 0.995 0.991 0.998 0.004
Cardiac output (L/min) 1.032 1.006 1.060 0.017
Severe RV dysfunction 1.108 1.015 1.209 0.022
Severe LV dysfunction (<20%) 0.903 0.846 0.965 0.002
Moderate or severe tricuspid regurgitation 1.117 1.049 1.189 0.001
Moderate or severe mitral regurgitation 0.829 0.779 0.883 <0.001
Device strategy
BTT ref ref ref ref
BTC 1.072 0.975 1.179 0.149
DT 1.541 1.420 1.672 <0.001
Rescue therapy 1.519 0.895 2.576 0.121
Bridge to recovery 2.335 1.763 3.091 <0.001
Other 0.743 0.278 1.984 0.553
LVAD, Left Ventricular Assist Device; CI, Confidence Interval; HR, Hazard Ratio; BSA, Body Surface Area; BMI, 
Body Mass Index; INTERMACS, Interagency Registry for Mechanical Assisted Circulatory Support; IABP, Intra-
Aortic Balloon Pump; ECMO, Extra Corporeal Membrane Oxygenator; BUN, Blood Urea Nitrogen; AST, Asparate 
Transaminase; WBC, White Blood Count; RA, Right Atrial; RV, Right Ventricle; LV Left Ventricle; BTT, Bridge to 
Transplant; BTC, Bridge to Candidacy; DT, Destination Therapy










Current smoker 604 (4.0)
Dialysis 23 (0.2)
Current ICD therapy 1,969 (12.9)
History of CABG 1,898 (12.4)
Atrial fibrillation 642 (4.2)
NYHA-classification 1,252 (8.2)
INTERMACS classification 96 (0.6)
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Supplementary Table 3.  (continued)
IABP prior to LVAD surgery 387 (2.5)
ECMO prior to LVAD surgery 389 (2.5)
Ventilator prior to LVAD surgery 38 (0.2)














RA pressure 5,460 (35.8)
PCWP 4,774 (31.3)
Systolic PAP 2,524 (16.5)
Diastolic PAP 2,665 (17.5)




Mitral valve regurgitation 1,180 (7.7)
Tricuspid valve regurgitation 1,308 (8.6)
AoV regurgitation 2,174 (14.2)
LVEDD 3,145 (20.6)
Main LVAD strategy 3 (0.0)
Concomitant procedure
Congenital surgery 0 (0.0)
Mitral valve surgery 0 (0.0)
Tricuspid valve surgery 0 (0.0)
Pulmonary valve surgery 0 (0.0)
RVAD surgery 1,750 (11.5)
Other concomitant surgery 0 (0.0)
AoV, Aortic Valve; LVAD, Left Ventricular Assist Device; BSA, Body Surface Area; BMI, Body Mass Index; CVA, 
CerebroVascular Accident; DM, Diabetes Mellitus; ICD, Implantable Cardioverter Defibrillator; CABG, Coronary 
Artery Bypass Graft; NYHA, New York Heart Association; INTERMACS, Interagency Registry for Mechanically 
Assisted Circulatory Support; IABP, Intra-Aortic Balloon Pump; ECMO, Extracorporeal Membrane Oxygenator; 
BUN, Blood Urea Nitrogen; AST, Asparate Aminotransferase; ALT, Alanine AminoTransaminase; LDH, Lactate 
DeHydrogenase; WBC, White Blood Count; RA, Right Atrial; PCWP, Pulmonary Capillary Wedge Pressure; PAP, 
Pulmonary Artery Pressure; LVEF, Left Ventricular Ejection Fraction; RVEF, Right Ventricular Ejection Fraction; 
LVEDD, Left Ventricular End Diastolic Diameter; BTT, Bridge to Transplant; BTC, Bridge to Candidacy; RVAD, Right 
Venticular Assist Device
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Supplementary Table 5. Causes of late death in different INTERMACS class patients, stratified to AoV 
procedure in LVAD patients post-LVAD surgery
Overall population 
(n=3,890)







Device related 11 (1.5) 11 (1.6) 0 (0.0) 0 (0.0)
RV-failure 31 (4.3) 30 (4.4) 1 (4.8) 0 (0.0)
Withdrawal of support 74 (10.3) 72 (10.5) 2 (2.7) 0 (0.0)
Circulatory failure 123 (17.2) 115 (16.8) 3(14.3) 5 (41.7)
Multisystem Organ Failure 160 (22.3) 156 (22.8) 2 (9.5) 2 (16.7)
Neurological events 122 (17.0) 119 (17.4) 3 (14.3) 0 (0.0)
Major infection 66 (9.2) 62 (9.1) 2 (9.5) 2 (16.7)
Respiratory failure 26 (3.6) 26 (3.8) 0 (0.0) 0 (0.0)
Digestive/liver failure 5 (0.7) 5 (0.7) 0 (0.0) 0 (0.0)
Cancer 7 (1.0) 7 (1.0) 0 (0.0) 0 (0.0)
Hematologic failure 3 (0.4) 3 (0.4) 0 (0.0) 0 (0.0)
Other 88 (12.3) 77 (11.3) 8 (38.1) 3 (25.0)
INTERMACS class 2-3
Device related 59 (2.3) 51 (2.1) 6 (6.1) 2 (3.0)
RV-failure 105 (4.1) 97 (4.1) 5 (5.1) 3 (4.5)
Withdrawal of support 297 (11.6) 283 (11.8) 7 (7.1) 7 (10.6)
Circulatory failure 440 (17.2) 417 (17.4) 6 (6.1) 17 (25.8)
Multisystem Organ Failure 426 (16.7) 388 (16.2) 24 (24.5) 14 (21.2)
Neurological events 507 (19.9) 481 (20.1) 18 (18.4) 8 (12.1)
Major infection 211 (8.3) 200 (8.4) 7 (7.1) 4 (6.1)
Respiratory failure 131 (5.1) 122 (5.1) 5 (5.1) 4 (6.1)
Digestive/liver failure 40 (1.6) 39 (1.6) 1 (1.0) 0 (0.0)
Cancer 28 (1.1) 27 (1.1) 1 (1.0) 0 (0.0)
Hematologic failure 16 (0.6) 12 (0.5) 4 (4.1) 0 (0.0)
Other 294 (11.5) 273 (11.4) 14 (14.3) 7 (10.6)
INTERMACS class 4 and higher
Device related 12 (2.0) 11 (2.0) 1 (4.5) 0 (0.0)
RV-failure 31 (5.2) 31 (5.6) 0 (0.0) 0 (0.0)
Withdrawal of support 69 (11.7) 64 (11.5) 2 (9.1) 3 (25.0)
Circulatory failure 102 (17.2) 92 (16.5) 9 (40.9) 1 (8.3)
Multisystem Organ Failure 89 (15.0) 86 (15.4) 1 (4.5) 2 (16.7)
Neurological events 117 (19.8) 111 (19.9) 4 (18.2) 2 (16.7)
Major infection 44 (7.4) 41 (7.3) 1 (4.5) 2 (16.7)
Respiratory failure 48 (8.1) 46 (8.2) 1 (4.5) 1 (8.3)
Digestive/liver failure 5 (0.8) 5 (0.9) 0 (0.0) 0 (0.0)
Cancer 7 (1.2) 7 (1.3) 0 (0.0) 0 (0.0)
Hematologic failure 5 (0.8) 5 (0.9) 0 (0.0) 0 (0.0)
Other 63 (10.6) 59 (10.6) 3 (13.6) 1 (8.3)
LVAD, Left Ventricular Assist Device; AoV, Aortic Valve; RV, Right Ventricular
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Supplementary Table 7. Causes of late death stratified to AoV procedure in LVAD patients post-LVAD surgery
Overall population 
(n=3,890)






Neurological events 748 (19.2) 713 (19.5) 25 (17.5) 10 (11.1)
Multisystem Organ Failure 681 (17.5) 635 (17.4) 28 (19.6) 18 (20.0)
Circulatory failure 688 (17.2) 627 (17.1) 18 (12.6) 23 (25.6)
Withdrawal of support 441 (11.3) 419 (11.5) 12 (8.4) 10 (11.1)
Major infection 322 (8.3) 304 (8.3) 10 (7.0) 8 (8.9)
Respiratory failure 207 (5.3) 196 (5.4) 6 (4.2) 5 (5.6)
RV-failure 171 (4.4) 162 (4.4) 6 (4.2) 3 (3.3)
Device related 82 (2.1) 73 (2.0 7 (4.9) 2 (2.2)
Digestive/liver failure* 50 (1.3) 49 (1.3) 1 (0.7) 0 (0.0)
Cancer 43 (1.1) 42 (1.1) 1 (0.7) 0 (0.0)
Hematologic failure 24 (0.6) 20 (0.5) 4 (2.8) 0 (0.0)
Other 453 (11.6) 417 (11.4) 25 (17.5) 11 (12.2)
p-value for distribution between groups: 0.028
AoV, Aortic Valve; LVAD, Left Ventricular Assist Device; RV, Right Ventricular
* including hepatic dysfunction, renal dysfunction, pancreatitis
Supplementary Table 8. Causes of death in patients alive 90 days post-LVAD surgery
Overall population 
(n=3,890)






Device related 72 (3.0) 64 (2.8) 6 (7.9) 2 (4.1)
RV-failure 91 (3.7) 86 (3.7) 3 (3.9) 2 (4.1)
Withdrawal of support 280 (11.5) 269 (11.6) 6 (7.9) 5 (10.2)
Circulatory failure 422 (17.3) 397 (17.2) 11 (14.5) 14 (28.6)
Multisystem Organ Failure 279 (11.4) 267 (11.5) 6 (7.9) 6 (12.2)
Neurological events 517 (21.2) 493 (21.3) 18 (23.7) 6 (12.2)
Major infection 212 (8.7) 203 (8.8) 6 (7.9) 3 (6.1)
Respiratory failure 135 (5.5) 130 (5.6) 2 (2.6) 3 (6.1)
Digestive/liver failure 29 (1.2) 28 (1.2) 1 (1.3) 0 (0.0)
Cancer 42 (1.7) 41 (1.8) 1 (1.3) 0 (0.0)
Hematologic failure 16 (0.7) 13 (0.6) 3 (3.9) 0 (0.0)
Other 343 (14.1) 322 (13.9) 13 (17.1) 8 (16.3)
p-value for distribution between groups: 0.081
LVAD, Left Ventricular Assist Device; AoV, Aortic Valve; RV, Right Ventricular
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Supplementary Figure 1. Inclusion flowchart
Supplementary Figure 2. Conditional survival of patients alive at 90 days post-LVAD surgery stratified 
to AoV procedure
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Supplementary Figure 3. A Early, B late, and C conditional survival stratified to no AoV procedure, bio-
logical AoV replacement, mechanical AoV replacement and AoV repair post-LVAD surgery
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Concomitant aortic valve procedure and left ventricular assist device implantation
Supplementary Figure 4. Late survival in patients with A INTERMACS class 1, B INTERMACS class 2 or 3, and 
C INTERMACS class 4 or higher at baseline, stratified to no AoV procedure, AoV replacement and AoV repair.
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Concomitant aortic valve procedure and left ventricular assist device implantation
Supplementary Figure 6. A Early, B late, and C conditional survival in patients who did not proceed to-
wards heart transplantation, stratified to no AoV procedure, AoV replacement and AoV repair.
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Supplementary Figure 7. Late survival in patients A with an LVAD as bridge to transplantation and, B an 
LVAD as destination therapy, stratified to no AoV procedure, AoV replacement and AoV repair.
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Concomitant aortic valve procedure and left ventricular assist device implantation
Supplementary Figure 8. A Early, B late, and C conditional survival in patients without a concomitant 
AoV procedure, stratified to no AR and AR at baseline.
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Supplementary Figure 9. Late survival in patients A without AoV procedure, B with AoV replacement, 
and C with AoV repair, stratified to no AR and AR at baseline.
146122_Veenis,Jesse_BNW-def .indd   500 13-11-2020   14:39
501
Concomitant aortic valve procedure and left ventricular assist device implantation
22
146122_Veenis,Jesse_BNW-def .indd   501 13-11-2020   14:39
23
146122_Veenis,Jesse_BNW-def .indd   502 13-11-2020   14:39
23
Submitted
Rate of thromboembolic and 
bleeding events in patients 
with concomitant aortic valve 
surgery and left ventricular 
assist device implantation: an 
analysis of the IMACS database
Veenis JF*, Yalcin YC*, Brugts JJ, Antonides CFJ, Veen KM, Muslem R, Bekkers JA, 
Gustafsson F, Tedford RJ, Bogers AJJC, Caliskan K 
* Equal contributions
146122_Veenis,Jesse_BNW-def .indd   503 13-11-2020   14:39
Under embargo
24
146122_Veenis,Jesse_BNW-def .indd   532 13-11-2020   14:39
24
Submitted
Prevalence of iron deficiency 
and iron administration
in LVAD and heart 
transplantation patients
Veenis JF, Radhoe SP, Roest S, Caliskan K, Constantinescu AA, Manintveld OC, Brugts JJ
146122_Veenis,Jesse_BNW-def .indd   533 13-11-2020   14:39
Under embargo
E
146122_Veenis,Jesse_BNW-def .indd   550 13-11-2020   14:39





146122_Veenis,Jesse_BNW-def .indd   551 13-11-2020   14:39
25
146122_Veenis,Jesse_BNW-def .indd   552 13-11-2020   14:39
Summary and
general discussion
146122_Veenis,Jesse_BNW-def .indd   553 13-11-2020   14:39
554
Part E | Chapter 25
Summary
Nowadays, heart failure (HF) management has become complex and includes a 
combination of various pharmacological drugs, lifestyle interventions, (remotely) 
monitoring strategies, and invasive treatment options, including valvular interventions, 
heart transplantation and left ventricular assist device (LVAD) surgery. Although HF 
care has significantly improved over the last decades, many challenges still need to 
be addressed to improve and optimize the care for the rapidly growing HF population. 
Therefore, this thesis is focused on the quality of chronic HF care in a real-world large 
contemporary study in the Netherlands as well as quality of care in advanced HF care for 
LVAD patients with the aim to improve overall HF and LVAD management. Additionally, 
we have investigated a new strategy of remote hemodynamic monitoring of chronic 
HF and LVAD patients.
Part A – Assess the current quality of heart failure care in The Nether-
lands and identify patient groups in which heart failure care could be 
optimized
In the first part of this thesis, we aimed to provide insight into the quality of HF care 
provided by the outpatient HF clinics in The Netherlands. By assessing the adherence 
to the pharmacological recommendations made in the European Society of Cardiology 
(ESC) Guidelines for the diagnosis and treatment of acute and chronic HF, a better 
understanding of the quality of care could be made. In addition, we investigated the 
quality of HF care in specific subgroups of chronic HF patients to differentiate where 
HF care needs to improve. The chronisch hartfalen ESC-richtlijn cardiologische praktijk 
kwaliteitsproject hartfalen (CHECK-HF) registry contains detailed information on patient 
characteristics, prescription rates and prescribed dosages of beta-blockers, renin-
angiotensin system (RAS) inhibitors, and mineralocorticoid receptor antagonists (MRAs), 
in 10910 Dutch chronic HF patients included from the outpatient clinics from 34 Dutch 
centers, between 2013 and 2016. Overall, 8360 patients diagnosed with HF with reduced 
ejection fraction (HFrEF) where included, while 2550 patients were diagnosed with HF with 
preserved ejection fraction (HFpEF). Several factors makes the CHECK-HF registry to an 
unique HF research project. Firstly, approximately half of all centers with an outpatient 
HF clinic in The Netherlands included patients in this registry. Additionally, data obtained 
in the registry was collected by the local HF teams and were based on recent patient visits 
and patient records. Therefore, the data in the CHECK-HF registry truly reflects the current 
status of HF care at Dutch outpatient clinics. A graphical overview of the prescription rates 
of HF medication in the different subgroups is provided in Figure 1.
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Figure 1. Summary of differences in prescription rates in A beta-blockers, B RAS-inhibitors and C MRA’s 
between subgroups at Dutch outpatient heart failure clinics 
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In Chapter 2, the age-related treatment differences in HFrEF patients are described. A 
clear relation between an increase in age and a decrease in guideline adherence was 
observed. The observed differences in guideline-adherence could not fully be explained 
by differences in baseline characteristics, such as the New York heart association (NYHA) 
classification or the presence of comorbidities. Although elderly HF patients were less 
likely to receive the guideline-recommended therapy, even the majority of the very 
elderly HFrEF patients, aged ≥80 years (octogenarian), still received two or more of 
the guideline-recommended HF drugs, but not at the recommended dose, as was 
investigated in Charter 3.
Only small differences in the treatment of chronic HF between men and women were 
observed, which partially could be explained by observed differences in baseline 
characteristics and comorbidities, as shown in Chapter 4. Additionally, the potential 
impact of implementing a hypothetical sex-specific target dose for beta-blockers and 
RAS-inhibitors for women, at 50% of the guideline-recommended target has been 
investigated. When these sex-specific target dose would be implemented, more 
women would be considered to be treated optimally. Additionally, according to these 
hypothetical sex-specific target doses, a significant proportion of the female HFrEF 
patients might be overdosed which might not result in additional treatment benefit.
In Chapters 5, 6, and 7, effects of hypertension, atrial fibrillation, and diabetes 
mellitus (all frequent comorbidities in HF patients) on the guideline-adherence have 
been described. A large proportion of the HFrEF patients included in the CHECK-HF 
registry had a systolic blood pressure of 130 mmHg or higher. Guideline-recommended 
HF drugs, as well as triple HF therapy, were more often prescribed to patients with 
lower systolic blood pressure, however, at the expense of lower prescribed dosages. In 
contrast, the guideline adherence was lower in patients with a systolic blood pressure 
of ≥130 mmHg. Atrial fibrillation was a common comorbidity at the Dutch outpatient 
HF clinics and significantly affected the prescribed HF treatment. Patients with atrial 
fibrillation were frequently treated with the guideline-recommended drugs. Small, but 
significant differences in the prescribed HF therapy was observed between diabetic 
and non-diabetic HF patients, even after adjustments for differences in baseline 
characteristics and other comorbidities. Additionally, a considerable proportion of 
this Dutch HF population would be eligible for the newly introduced sodium-glucose 
cotransporter-2 (SGLT-2) inhibitor, based on the eligibility criteria currently used in 
the clinical trials.
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The HF care at Dutch outpatient clinics has been compared to the HF care provided 
at outpatient clinics in the United States of America (USA), analyzed in the Change the 
Management of Patients with Heart Failure (CHAMP-HF) registry, in both Chapter 5 and 
7. As shown, both the prescription rate as well as the number of patients that received 
the target dose was higher in The Netherlands than in the USA HF population.
Chapter 8 highlights the differences in HF population and treatment between 
different HF outpatient clinics in The Netherlands. The observed differences in 
patient demographics could not fully explain the observed differences in prescription 
rates and prescribed dosages, which is a signal that improvements still can be made 
in guideline adherence.
A large proportion of patients in the CHECK-HF registry were diagnosed with HFpEF, 
and their clinical profile and medical management have been investigated in Chapter 9. 
Although no evidence-based treatment exists for HFpEF patients, many received drugs 
that are indicated for HFrEF patients. These drugs were most likely prescribed for the 
treatment of comorbidities, which were common in HFpEF patients. Additionally, HFrEF 
medication might have been prescribed to HFpEF patients for lack of an alternative.
In conclusion, the results from the CHECK-HF registry provide a unique insight into 
the HF management at Dutch outpatient clinics. Many HF patients received guideline-
recommended HF therapy, although the prescribed dosages were lower than 
recommended. Additionally, we have identified several specific patient categories, 
including elderly and patients with comorbidities such as hypertension, in whom the 
HF care could be optimized further.
It must be acknowledged that, due to the cross-sectional design of the CHECK-HF 
registry, no causal interference could be tested. Additionally, as clinical outcomes were 
not registered, we were unable to investigate to what extent survival in this population 
was affected by not adhering to the guideline-recommended treatment. The strengths 
of the CHECK-HF registry lies in its large scale, reflecting the real-world practice at Dutch 
outpatient clinics. These results provide new insight into the contemporary treatment 
of HF patients in a real-world setting. The findings demonstrated are very informative 
for the clinicians treating HF patients, since they provide new insight into the guideline-
adherence and identifies specific patient groups in whom guideline adherence is lower 
compared to other patient groups. 25
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Part B – Assess the impact of remote hemodynamic monitoring in chronic 
heart failure patients
In the second part of this thesis, remote monitoring strategies, specifically remote 
hemodynamic monitoring, in chronic HF patients, was investigated.
Chapter 10 provides an up-to-date overview of the currently available literature on 
remote monitoring strategies in chronic HF patients. Several non-invasive remote 
monitoring strategies, ranging from simple single variable up to very complex and 
intensive multivariable strategies, have been proposed and investigated by multiple 
large multicenter prospective studies, randomized controlled trials, and real-world 
registries over the recent decades. Overall, a modest beneficial effect on all-cause 
mortality and HF-related hospitalizations was observed in non-invasive monitoring 
strategies. The positive effect was primarily observed in more complex strategies, 
monitoring multiple variables non-invasively. Remote monitoring using implantable 
cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) devices 
failed to reduce mortality or hospitalization rates in chronic HF patients. Remote 
hemodynamic monitoring can detect a rise in cardiac filling pressures weeks before 
an episode of exacerbation of HF. The CardioMEMS device, allowing for pulmonary 
artery pressure monitoring, appears to be the most promising remote hemodynamic 
monitoring device currently available and has been proven to be safe and effective in 
preventing HF-related hospitalizations in both HFrEF and HFpEF patients.
The Dutch hemodynamic monitoring in heart failure (MONITOR HF) Trial aims to 
evaluate the improvement in quality of life, reduction of HF hospitalizations and the 
cost-effectiveness of CardioMEMS remote monitoring on top of standard care in The 
Netherlands. Chapter 11 describes the design of this randomized control trial.
The optimal time of day to monitor the pulmonary artery pressure using the 
CardioMEMS device has been described in Chapter 12. The variability of measurements 
was the lowest early in the morning, making this the most ideal moment to monitor the 
pulmonary artery pressures.
Remote hemodynamic monitoring can provide unique and additional insight in patient 
management and the effects of regular therapies. As illustrated by the case described in 
Chapter 13, the hemodynamic effects of valvular interventions, such as the MitraClip, 
can be safely and effectively monitored by the CardioMEMS system.
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In conclusion, many remote monitoring strategies in chronic HF patients have been 
investigated. Remote hemodynamic monitoring using the CardioMEMS device appears 
to be the most promising remote hemodynamic monitoring strategy in chronic HF 
patients. Additionally, the remote hemodynamic feedback has the potential to be used 
in other patient groups or indications as well.
Part C –Determine the safety and feasibility of remote hemodynamic 
monitoring in left ventricular assist device patients
In the third part of this thesis, we have investigated the safety and feasibility of remote 
hemodynamic monitoring in end-stage HF patients who transitioned towards LVAD.
A complete overview of all available literature on monitoring strategies in LVAD patients 
has been provided in Chapter 14. Several potential remote monitoring strategies have 
been proposed and assessed. Although these developments are encouraging, further 
development is necessary before they can be used for remote LVAD management. 
Combining remote hemodynamic monitoring using the CardioMEMS system with LVAD 
support could be the next step forward in remote LVAD management.
Chapter 15 describes the trends over time of the pulmonary artery pressures of 
a patient with ‘fixed’ pulmonary hypertension on LVAD support. As shown, LVAD 
support can be used to reverse so-called ‘fixed’ pulmonary artery hypertension. 
The CardioMEMS system allows for a save and adequate remote monitoring of this 
process, revealing previously unknown information of pulmonary artery pressure 
and treatment effects.
The safety and feasibility of pulmonary artery pressure guided treatment, using the 
CardioMEMS system, in patients who proceeds towards an LVAD has been tested in 
the hemodynamic guidance with CardioMEMS in patients with a left ventricular assist 
device (HEMO-VAD) pilot study, which design has been described in Chapter 16.
In Chapter 17, the short-term effects of remote hemodynamic monitoring in LVAD 
patients have been investigated. No CardioMEMS device-related safety issues occurred 
during the first three months post-LVAD surgery. Patients without the ability to 
normalize the mean pulmonary artery pressure (mPAP) shortly prior to LVAD surgery 
identifies a group of patients who were at a very high risk of all-cause mortality or 
LVAD-related complications, such as acute kidney injury or right ventricular failure. 
Additionally, the quality of life of patients without the ability to normalize their mPAPs 
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increases significantly less compared to patients who could be hemodynamically 
optimized shortly prior to LVAD surgery.
Chapter 18 highlights the long-term safety of remote hemodynamic monitoring 
using the CardioMEMS device in LVAD patients, with no occurrence of device-related 
complications or failures during the entire one-year follow-up. Additionally, all-cause 
mortality, LVAD-related adverse events, and all-cause hospitalizations occurred less 
often in patients who had normalization of their mPAP shortly prior to LVAD surgery. 
The quality of life increased in all patients post-LVAD surgery. However, the increase 
was larger and sustained better in patients who were able to normalize their mPAPs.
We conclude that remote monitoring of LVAD patients could aid clinicians in optimizing 
LVAD management. Remote hemodynamic monitoring using the CardioMEMS device can 
safely be used in LVAD patients. The additional hemodynamic feedback provided by this 
system can be used as preoperative optimization of hemodynamics, as a risk predictor 
for worse clinical outcome, and for outpatient remote monitoring and management.
Part D – Optimizing left ventricular assist device management
In the last part of this thesis we have studied these LVAD-related challenges: the 
effectiveness of a cardiac implantable electronic device with a defibrillator function 
(CIED-D, consisted of ICD and CRT with defibrillator function) therapy during LVAD 
support, the impact of age and sex on LVAD outcomes, concomitant aortic valve 
replacement during LVAD surgery, and iron deficiency.
In Chapter 19, we investigated whether carrying an active CIED-D in LVAD patients was 
associated with improved outcomes within the observational postgraduate course in 
heart failure ventricular assist device (PCHF-VAD) registry. The PCHF-VAD registry is an 
observational study, including continuous-flow LVAD patients from 12 European HF 
tertiary referral centers. An active CIED-D in patients with LVAD support was associated 
with reduced all-cause mortality. No significant differences were observed in the HF-
related hospitalization rates, the number of device-related infections requiring systemic 
antibiotics, or major bleeding events.
Chapter 20 and 21 provides detailed analyses of the age- and sex-related impact on 
LVAD outcomes and management, assessed within continuous flow LVAD patients 
included in the PCHF-VAD registry. An increase in age was independently associated 
with an increased risk of all-cause mortality. Additionally, elderly LVAD patients were 
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at a higher risk for hemocompatibility related complications and had more often new 
onset of atrial fibrillation or flutter. In contrast, elderly LVAD patients had a significantly 
lower risk of device-related infection requiring systemic antibiotics.
LVAD therapy was significantly less often utilized in women. Although women who 
underwent LVAD surgery were in a more clinical ill and unstable condition, no survival 
differences between men and women were observed. In contrast, women were more 
often weaned from LVAD support.
We have investigated the effects of concomitant aortic valve procedure during LVAD 
surgery in detail using the international society of heart and lung transplantation 
mechanically assisted circulatory support (IMACS) registry. In Chapter 22, the short- 
and long-term survival of patients with concomitant aortic valve procedures and LVAD 
surgery has been studied. In LVAD patients, concomitant aortic valve surgery was an 
independent predictor of both early and late mortality. Interestingly, the survival rates 
of patients who were diagnosed with mild aortic valve regurgitation were negatively 
impacted by concomitant aortic valve replacement. In contrast, in patients with 
moderate-to-severe aortic valve regurgitation, no survival differences were observed 
between patients with or without a concomitant aortic valve procedure.
In order to provide additional insight into the risks of concomitant aortic procedures 
in LVAD patients, the association with hemocompatibility related complications have 
been assessed in Chapter 23. No association between concomitant aortic valve 
replacement and an increased rate of thromboembolic events was observed. In 
contrast, concomitant aortic valve surgery was an independent risk factor for major 
bleeding events post-LVAD surgery.
The prevalence of iron deficiency in LVAD and heart transplantation patients has been 
described in Chapter 24. Although the guidelines recommend the regular screening of 
chronic HF patients for iron deficiency, not all advanced HF patients were screened for 
iron deficiency in the year prior to LVAD surgery or heart transplantation. The prevalence 
of iron deficiency was very high prior to LVAD surgery or heart transplantation and 
increased even further post-surgery. The majority of patients with an iron deficiency 
received iron administration.
25
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General discussion and future perspectives
Quality of heart failure care in The Netherlands; the importance of registries
Assessing the quality of care is an old concept, firstly introduced in the beginning of 
the 20th century. Since the 1980’s more universal methods and definitions have been 
introduced. 1 The degree to which the provided health care increases the likelihood of 
desired health outcomes in a manner consistent with current professional knowledge 
is a frequently used definition for the quality of care. 2 Prescribing and optimizing the 
guideline-recommended therapy in chronic heart failure (HF) patients significantly 
improves mortality, morbidity, and quality of life. 3 Therefore, the level of adherence 
to these guidelines, including the prescription rates and prescribed dosages, could be 
used as a parameter for the quality of HF care.
As shown in this thesis, many Dutch HF patients with a reduced ejection fraction (HFrEF) 
seen at the outpatient clinics received the guideline-recommended HF drugs, indicating 
that Dutch outpatient clinics provide a high quality of HF care. We believe that the 
quality of care should not only be measured by the adherence to the guidelines but 
should also be compared to other countries. The prescription rates of HF drugs in HFrEF 
patients in other Western countries are shown in Figure 2. 4-8 As shown, the prescription 
rates at Dutch outpatient HF clinics were very high, compared to counties such as Italy, 
Norway, United Kingdom and the United States of America (USA), and similar to Sweden. 
These results indicate that the quality of HF care was very high, especially compared 
to other Western countries.
Multiple factors could influence the prescription rates between countries. First of all, 
we should not underestimate the crucial role of dedicated HF nurses. Organizing the 
HF care in a specialized setting, with a coordinating role for the HF nurses, leads to 
better guideline adherence, as well as a better up-titration of the prescribed dosages. 
9-11 Additionally, the accessibility to specialized HF care might have differed. In general, 
health care insurance is universally carried in all European countries in contrast to the 
USA. This might have led to lower availability of HF care and access to prescribed HF 
medication in the USA. Finally, it has been suggested that American treating physicians 
might overemphasize the possibility and the risks of side effects of HF drugs. 12 This 
could have resulted in lower prescription rates in the USA.
146122_Veenis,Jesse_BNW-def .indd   562 13-11-2020   14:39
563
Summary and general discussion
Figure 2. Prescription rates of HF drugs in several Western countries
Areas to optimize and individualize chronic heart failure care in The 
Netherlands
Although the quality of HF care in The Netherlands is outstanding, several areas of 
HF management could be optimized further. First of all, similar to other countries, 
the prescribed dosages of HF drugs are lower than the guideline-recommended 
target dosages. 3, 13 Since all HF drugs have a dose-dependent effect on the survival, 
prescribing the target dose or maximum tolerated dose is of great importance. 14, 15 
Multiple strategies to further up-titrate HF dosages have been proposed, including 
medication up-titration protocols, regular monitoring, feedback of benchmarked clinical 
indicators, and involvement of HF nurses in the up-titration of HF drugs. 13 However, the 
ideal up-titration strategy is still up for debate, and additional research to determine 
the best approach is urgently needed.
Secondly, the HF therapy in elderly HF patients, and specifically in octogenarians, 
should be further improved. This thesis demonstrates that both the prescription 
rates and prescribed dosages decreased with an increase in age in The Netherlands. 
25
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Several age-related factors have been associated with suboptimal HF therapy, such 
as frailty, cognitive impairment, polypharmacy as well as frequent comorbidities. 16 
However, using a slow up-titrating approach, with a close monitoring and awareness of 
comorbidities and frailty could result in an optimized and individualized therapy, even 
in octogenarian HF patients. 17, 18
A clear association exists between hypertension and an increased risk of mortality and 
HF-related hospitalizations in chronic HF patients. 19, 20 Surprisingly, more than 40% of 
all HFrEF patients from the Dutch CHECK-HF registry had a systolic blood pressure of 
130mmHg or higher, potentially at an increased risk for adverse events. Even more 
strikingly, these patients did not receive the maximum HF therapy, with room for 
improvement in both the prescription rates and prescribed dosages. Treating physicians 
might be reluctant to optimize HF therapy out of fear to introduce symptomatic 
hypotension. One could argue that hypotension should not be considered a side-
effect but as a wanted effect of the therapy. Although no target blood pressure has 
been defined, and blood pressure treatment varies greatly between professionals and 
outpatient clinics, we believe that slowly up-titration combined with close monitoring 
should be used to optimize the HF therapy in every patient up to the guideline-
recommended or maximum tolerated dosage.
New developments could improve HF care in the Netherlands even further, and lead to 
a more tailored approach. Currently, a one-size-fits-all strategy is used as per the 2016 
European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of 
acute and chronic HF. 3 However, the recently published results from the BIOlogy Study 
to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study contributed to the 
discussion of whether gender-specific guidelines are indicated. 21 In this subanalysis, 
the authors demonstrated that women had the maximum reduction in mortality and 
HF-related hospitalizations at approximately 50% of the guideline-recommended target 
dose for beta-blockers and RAS-inhibitors, while the maximum risk reduction in men 
was achieved at the guideline-recommended target dose. As shown in this thesis, a 
larger proportion of women would be considered to be adequately treated, with a large 
proportion of women who might have been overdosed when these hypothetical gender-
specific target doses would be used. As these results are based on a single posthoc 
analysis, we should not directly implement them into the current clinical practice, and 
the current guideline-recommended target dose should be maintained for both men 
and women for the time being. Additional research is urgently needed, investigating 
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whether gender-specific guidelines are indicated, potentially leading to a better tailored 
approach for men and women.
Research in the new drug, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, has gained 
a lot of attention recently. Initially, this drug was tested as a new antidiabetic but also 
showed beneficial effects on cardiovascular endpoints. 22-24 Recently, the DAPA-HF trial 
demonstrated positive outcomes in chronic HF patients, regardless whether they had 
diabetes or not. 25 Currently, several other trials are investigating the effects of SGLT-2 
inhibitors in HF patients as well, and if positive, SGLT-2 inhibitors will be added as a new 
treatment option in HF management. 26, 27 Determine the potential clinical impact of new 
drugs can be very important to assess the potential impact these drugs could have on 
the clinical practice. As shown in this thesis, based on the inclusion criteria currently 
used in the clinical trials, more than 30% of the Dutch HF population would be eligible 
for SGLT-2 inhibitor treatment.
Optimal monitoring strategies in chronic heart failure
Close monitoring in chronic HF patients is considered to be a cornerstone in HF 
management. Over the last decades, technological improvements have been made to 
remote monitoring, which led to an increase in the use of remote monitoring strategies 
in cardiac care, as well as in HF management. 28 In HF care, remote monitoring strategies 
can be divided into three main categories, (1) non-invasive remote monitoring, (2) 
remote monitoring using cardiac implantable electronic devices (CIEDs, consisted of 
ICD and CRT devices), and (3) remote hemodynamic monitoring. 29 The ideal remote 
monitoring strategy is still up to debate, especially since each remote monitoring 
strategy has its own up and downsides.
Non-invasive remote monitoring usually uses one or a combination of the following 
methods, regular telephone calls, remote monitoring of blood pressure, heart rate or 
weight, and monitoring of signs and symptoms. The effectiveness of these monitoring 
strategies has been extensively investigated, with very inconsistent results. However, 
overall a small benefit of non-invasive remote monitoring in reducing mortality and 
HF-related hospitalization has been shown, especially in the more advanced non-
invasive remote monitoring strategies. 30 Due to its non-invasive character, as well as 
the relatively low costs, non-invasive remote monitoring is relatively easy to implement 
in a wide variety of chronic HF patients.
25
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Many chronic HF patients have a CIED, and many of the newer generations of these 
devices allow for remote monitoring. This could make remote monitoring of chronic HF 
patients using these implanted devices an ideal option. Unfortunately, many studies 
have shown that this strategy is not effective in improving patients outcomes. 31
Hemodynamic remote monitoring has become available with the introduction of 
implantable pressure measuring devices, such as the CardioMEMS system. Multiple 
trials and real-world data registries have shown that the CardioMEMS is safe and 
effective in preventing HF-related hospitalizations in New York heart association (NYHA) 
functional class III HF patients. 32-34 The CardioMEMS device is implanted during a right-
sided heart catheterization, making it a more invasive strategy. Additionally, the costs 
associated with the implantation are considerably higher compared to non-invasive 
remote monitoring strategies.
Based on the current evidence, we believe that all chronic HF patients should be remotely 
monitored. However, the ideal monitoring strategy is still up for debate. Based on the 
current evidence and the information on costs, we would suggest that less symptomatic 
chronic HF patients, defined as patients with an NYHA class of I or II, should be monitored 
using an extensive non-invasive remote monitoring strategy. More symptomatic HF 
patients, defined as NYHA class III, would benefit more from remote hemodynamic 
monitoring. Additional research is urgently needed to guide this discussion further. 
Information on the cost-effectiveness of remote monitoring is especially needed, as well 
as the effectivity of remote hemodynamic monitoring in less symptomatic chronic HF 
patients and its association with quality of life. Currently, trials are being conducted in 
order to provide more insight into these research questions. 35, 36
Expanding the field on remote hemodynamic monitoring
Although remote hemodynamic monitoring is currently only used to monitor chronic 
HF patients to prevent congestion and HF-related hospitalizations, we believe that this 
technique could be used in different areas as well.
In the recent CardioMEMS studies, more than half of all treatment adjustments were 
caused by changes in diuretics. 33, 34 These results suggest that the majority of medication 
changes were made to optimize the volume status, guided by the hemodynamic 
feedback. Based on the first results from the CHAMPION trial, treatment guidelines have 
been proposed. 37 These guidelines recommend to use diuretics to reach and maintain 
an optimal volume status. However, we believe that diuretics and volume correction 
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are only the first step in the remote hemodynamic monitoring of chronic HF patients. 
When a patient is in a euvolemic status, the hemodynamic feedback should be used to 
optimize the HF treatment further. Adjustments in the dose of renin-angiotensin-system 
(RAS) inhibitors, mineralocorticoid receptor antagonists (MRAs), as well as nitrates or 
other vasodilators, could be used to optimize the hemodynamic status. 38 The additional 
hemodynamic feedback can reassure and guide the treating physicians during the up-
titrating HF medication, and a normalization of the pulmonary artery pressures could 
be used as a marker for successful treatment optimization.
Left-sided valvular diseases can cause an increase in the left atrial pressure, and 
consequently the pulmonary artery pressures could rise. 39 Pulmonary artery 
hypertension is an indication for valvular intervention, as is recommended by the 2017 
ESC Guidelines for the management of valvular heart disease. 40 Therefore, regular 
echocardiographic assessment is recommended, and invasive measurements of the 
pulmonary artery pressures should be performed when pulmonary hypertension 
is suspected. 40 We hypothesize that remote hemodynamic monitoring could be 
used to monitor patients with a left-sided valvular disease remotely, and could be 
used in the decision making whether valvular intervention is indicated. Additionally, 
the hemodynamic effects of these interventions could be remotely monitored. 
Unfortunately, this strategy could be limited due to the additional costs associated 
with remote hemodynamic monitoring.
However, chronic HF patients are frequently diagnosed with a left-sided valvular 
disease. 41 In these patients, remote hemodynamic monitoring that is already used 
for the monitoring of congestion, could also be used for the remote monitoring of the 
progression of the valvular disease, and aid in the clinical decision making whether an 
intervention is indicated in the HF patient population.
Irreversible pulmonary hypertension is a contraindication for heart transplantation, 
as the right ventricle of the donor heart is not capable of overcoming the fixed high 
pulmonary vascular resistance after a period of stunning by ischemia. Therefore, 
it is recommended by the International Society of Heart and Lung Transplantation 
to regularly (preferably at 3- to 6-months intervals) perform diagnostic right-heart 
catheterizations, especially in patients with reversible pulmonary hypertension. 42 
Alternatively, we believe that remote hemodynamic monitoring could be a suitable 
alternative for the regular diagnostic right-heart catheterizations. It will reduce the 
burden on the hospital resources and limit the discomfort for the patient. Additionally, 
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remote hemodynamic monitoring allows for a daily assessment of the pulmonary 
artery pressures, which could be very dynamic. However, the reversibility of pulmonary 
hypertension cannot be tested using the currently available remote hemodynamic 
monitoring systems. Therefore, when pulmonary hypertension is diagnosed based 
on remote hemodynamic monitoring, reversibility should be tested using classic right-
heart catheterization. One could argue that remote hemodynamic monitoring would 
be too costly. However, this remotely monitoring strategy could reduce the number of 
right-heart catheterizations required, reducing the burden on hospital resources.
Patients with end-stage HF, in which the patients have become refractory to medical 
therapy, could be treated with left ventricular assist device (LVAD) support. However, 
shortly after LVAD surgery, severe complications such as right ventricular (RV) failure 
and acute kidney injury (AKI) can occur. 43, 44 Although multiple risk-scores have been 
proposed 43, 45, it remains challenging to select the right patients and determine the 
proper timing of LVAD surgery, and guidance in the optimizing of patients is lacking. All 
these factors are crucial to improve outcomes after LVAD surgery.
Remote hemodynamic monitoring could be used to determine the ideal timing of LVAD 
surgery. In patients with remote hemodynamic monitoring, no effects of treatment 
changes were observed in the period before LVAD surgery. Additionally, when the 
hemodynamic information was available for the treating physician, the time until 
the patient went for LVAD surgery was shorter. 46 These results suggest that remote 
hemodynamic feedback could aid in the proper timing of LVAD surgery.
As shown in this thesis, remote hemodynamic monitoring shortly prior to LVAD surgery 
could safely identify patients with an increased risk for LVAD-related complications. 
Furthermore, the hemodynamic feedback can also be used to optimize the patient 
status further, and the response to treatment changes can be used to determine the 
ideal LVAD implantation window.
The implementation of remote hemodynamic monitoring in end-stage HF patients who 
are eligible for heart transplantation or LVAD surgery could be considered too costly. 
However, a significant proportion of these patients deteriorated from stable NYHA 
class III HF. The evidence for remote monitoring in chronic NYHA class III HF is growing 
rapidly. We believe that more and more patients eligible for heart transplantation or 
LVAD therapy will already have a remote monitoring device. This will make it easier and 
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relatively cheaper to implement remote monitoring strategies in these end-stage HF 
patients as well.
As discussed, we believe that remote hemodynamic monitoring can be used in many 
additional areas of HF and cardiac care, then for what it is currently used. However, 
these hypotheses are based on a small number of patients, posthoc analyses, and pilot 
studies. Therefore, additional research is needed to investigate the true potential of 
remote hemodynamic monitoring.
Optimizing and individualizing left ventricular assist device therapy
The current widely used LVAD devices provide only static and calculated pump 
parameters without the option of remote monitoring. This limits LVAD management, 
and remote monitoring is currently not available. Remotely obtained hemodynamic 
feedback could be used to guide and optimize medical therapy in LVAD patients. 46 
Additionally, the pump settings could be optimized to achieve the best hemodynamic 
parameters, the number of outpatient visits might be reduced, and the quality of 
life of LVAD patients might increase further. Furthermore, adverse events, such as 
gastrointestinal bleedings, might be detected in an earlier stage by a sudden change 
in the hemodynamic feedback. 47 Earlier detection allows for a timely intervention, 
potentially preventing hospitalizations and a worse outcome. Additional research is 
currently undertaken to assess the efficacy of remote hemodynamic monitoring in 
LVAD patients on a larger scale (NCT03247829).
Besides remote monitoring, we identified several other areas in LVAD management 
that could be optimized. Ventricular arrhythmias can be a life threating condition in 
non-LVAD patients. In contrast, LVAD patients are generally not significantly affected 
by ventricular arrhythmias since the LVAD provides sufficient forward blood flow. 
48 However, ventricular arrhythmias might introduce or worsening preexisting RV 
failure with a harmful effect on the overall survival of LVAD patients. 49 Therefore, 
CIED with a defibrillation function (CIED-D) could have a beneficial effect in LVAD 
patients. However, inconsistent results have been published, with several, mostly 
single-center, retrospective studies from the USA demonstrated no beneficial effects 
of CIED-Ds. In contrast, data from European centers suggested a better survival in 
patients with CIED-D therapy. 50 Differences in implantation rates of CIED-Ds as well as 
baseline characteristics between the American and European populations might have 
contributed in a more homogenous CIED-D patient group in the European studies. 51 
These patients were more likely to have an elevated risk for ventricular arrhythmias 
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and sudden cardiac death, and were more likely to benefit more from CIED-D therapy. 
Based on the current evidence and the results from this thesis, we would recommend 
not to replace a CIED-D in patients without ventricular arrhythmias, or with many 
inappropriate shocks. Replacement or even implantation of a CIED-D should be 
considered in patients with significant ventricular arrhythmias, especially when joined 
by RV failure.
Although no strict age contraindication for heart transplantation exists in the current 
guidelines, it is recommended to very carefully select patients > 70 years of age. 3, 
42 However, no recommendations are available to guide LVAD teams in the patient 
selection based on age. Based on the results in this thesis, we believe that no strict age 
eligibility criteria should be implemented in LVAD care. Although the all-cause mortality 
rate was significantly higher in elderly LVAD patients, the overall survival was still good, 
even in patients of ≥ 65 years. However, we would recommend to carefully select 
patients ≥ 65 years, especially since these patients are also at a higher risk for major 
bleeding events, as well as hemocompatibility related adverse events. Therefore more 
vigilant monitoring of elderly LVAD recipients might be indicated. Additionally, other 
comorbidities are more frequent in elderly patients, which might limits the beneficial 
effect of LVAD implantation.
Despite women comprise approximately half of the end-stage HF population, they 
are underrepresented in clinical LVAD trials. 52, 53 Similarly, women are less frequent 
supported with an LVAD in the clinical practice. 54 Women who undergo LVAD surgery 
are more frequent instable and critical ill, indicating that women might be referred 
for LVAD surgery in a later stage. Additional research is needed to investigate why the 
utilization of LVAD therapy is lower in women.
It remains unclear whether sex-related survival differences exists. Studies investigating 
the elderly pulsatile-flow LVADs showed a worse survival in women, while in modern 
continuous-flow LVAD no difference between men and women was observed. 54, 55 
Pulsatile-flow LVADs were larger devices, while women have a smaller intrathoracic 
volume, which could have contributed to the higher mortality in women with the 
larger pulsatile-flow LVADs. Further research is warranted to assess whether the 
survival of women on LVAD support could be improved by a more timely referral and 
better implantation timing.
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Concomitant aortic valve procedures during left ventricular assist 
device therapy
A short loop circulation, with insufficient unloading of the LV and forward blood flow 
to supply all organs, can occur due to aortic valve (AoV) regurgitation during LVAD 
support. 56 The presence of AoV regurgitation in LVAD patients has been associated 
with an increased risk of mortality. 57 Therefore, concomitant AoV surgery is frequently 
used to correct the AoV regurgitation. However, this strategy is also associated with 
an increased risk of mortality, especially in patients with only mild AoV regurgitation 
preoperatively. Additionally, patients undergoing concomitant AoV surgery are at an 
increased risk for major bleeding events postoperatively. Potentially, this increased risk 
is caused by a prolongation of the cardiopulmonary bypass time, which is associated 
with an increased risk of mortality. 58
These results demonstrate that the decision to perform concomitant AoV surgery 
should not be taken lightly. Based on this thesis, we would recommend only perform 
concomitant AoV surgery in patients with at moderate-to-severe AoV regurgitation 
before LVAD surgery, as is recommended by the current guidelines. 59 In these patients, 
the gained beneficial effect of resolving the AoV regurgitation appears to outweigh 
the additional risks of the additional procedure. In patients with less severe AoV 
regurgitation, the benefits do not outweigh the risk, and concomitant AoV surgery 
should not be performed.
Iron deficiency in advanced heart failure patients
Similarly to chronic HF patients, iron deficiency is highly prevalent in LVAD patients. 60 
Iron is essential for the function of cardiomyocytes, and iron deficiency is associated 
with a decreased function of the left and right ventricle. 61, 62 Only the left ventricular is 
supported by the LVAD, and the LVAD depends on a good right ventricle function. Right 
ventricular failure is a common and severe complication in LVAD patients. 43 Therefore, 
adequately screening for and treatment of iron deficiency in LVAD patients could prevent 
severe right ventricular failure and improve the overall outcome of LVAD patients.
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Future perspectives
Over the last decades, heart failure care has developed rapidly and we expect this trend 
to continue in the upcoming years. We expect that new drugs will be developed for 
the treatment of heart failure patients, especially in patients with a preserved ejection 
fraction. Multiple heart failure registries are currently conducted. We expect that the 
insight provided from these studies will aid in the improvement of the quality of heart 
failure care. In the next decade, these insights should be used to determine the ideal 
target dose for each patient group. Additionally, an effective up-titration strategy needs 
to be developed in order to prescribe the desired target dose in each patient.
With the rapidly growing heart failure population, remote monitoring will become 
increasingly important. We expect that a standardized remote monitoring package will 
become available. Less symptomatic heart failure patients will be remotely monitored 
using non-invasive techniques, while invasive remote monitoring options will be used 
to keep a close eye on more symptomatic and ill patients. The information of all these 
patients will be processed at a central location, using the latest technologies and 
machine learning techniques. An intuitive and clear overview of this data will be provided 
for the treating physicians, clearly indicating which patients needs additional care.
Finally, we expect further development of left ventricular assist devices. We expect that 
the devices will become even smaller, allowing for less invasive implantation techniques. 
This new generation of devices could also be used to partially support the left ventricle, 
making them more useful as a bridge to recovery. Technologies for wireless charging 
will be incorporated, allowing for a completely independent device without the need 
for a driveline. Last but not least, these newer generation devices are expected to 
provide real-time hemodynamic data, as well as information on the valvular opening 
and functions, which will be able to be monitored remotely. Based on this information, 
the pump setting can be altered automatically while the patient is at home.
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Conclusion
This thesis contributes to the knowledge regarding the many challenges that still need 
to be addressed to further optimize heart failure and left ventricular assist device care. 
We demonstrated that the care for chronic heart failure patients at Dutch outpatient 
clinics is of high quality, especially compared to other Western countries. In addition, 
we identified specific areas, including the prescribed dosages, the prescription for 
the elderly, and the treatment of hypertension that could be further optimized. 
Furthermore, the potential clinical impact of new developments such as gender-specific 
target dosages and the introduction of sodium-glucose cotransporter-2 inhibitors have 
been assessed and could have a significant effect on heart failure management.
Depending on the severity of heart failure, different monitoring strategies might be 
indicated. Non-invasive remote monitoring might be indicated in less symptomatic 
heart failure patients, while more symptomatic patients might benefit more from 
remote hemodynamic monitoring. Furthermore, we have identified potential new 
areas were remote hemodynamic monitoring could be used, including the monitoring 
of valvular heart diseases, monitoring of pulmonary artery pressures in heart failure 
patients on the heart transplantation waiting list as well as monitoring of patients going 
for left ventricular assist device surgery.
We have investigated the hybrid construction of remote hemodynamic monitoring and 
left ventricular assist support for the first time prospectively, and have demonstrated 
that this strategy is safe and feasible. The hemodynamic feedback can be used to 
identify patients at very high risk for left ventricular assist device-related complication. 
Additionally, remote hemodynamic monitoring can be used to determine the ideal 
left ventricular assist device implantation window and allows for remote outpatient 
monitoring and optimization.
We have identified several challenges in left ventricular assist device management, 
which could be addressed to optimize and individualize the left ventricular assist device 
care, including iron deficiency, age- and sex-related outcomes, and the use of cardiac 
implantable devices. Our results highlight the importance of careful consideration of 
whether concomitant aortic valve surgery is indicated during left ventricular assist 
device surgery. With this thesis, we hope to address many challenges in heart failure 
care, which could be the next step towards a more optimal and a tailored approach for 
each heart failure patient.
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Samenvatting
Hartfalen zorg is tegenwoordig erg complex, en bestaat uit een combinatie van 
medicamenteuze behandeling, leefregels, monitoringstrategieën (op afstand) en 
invasieve behandelopties, waaronder klepinterventies, harttransplantatie en steunhart 
(ook wel ‘left ventricular assist device’, LVAD) implantatie. Ondanks dat de hartfalen 
behandeling de afgelopen decennia aanzienlijk is verbeterd, zijn er nog vele uitdagingen 
die moeten worden aangepakt om de zorg voor de snelgroeiende hartfalen populatie 
te verbeteren en te optimaliseren. Daarom richt dit proefschrift zich op de kwaliteit 
van de Nederlandse chronische hartfalen zorg in een grote hedendaagse ‘real-world’ 
studie en de kwaliteit van de zorg voor LVAD patiënten met het doel om de zorg voor 
deze patiënten te verbeteren. Daarnaast hebben we een nieuwe methode voor de 
monitoring van chronische hartfalen en LVAD patiënten op afstand onderzocht.
Deel A – Vaststellen van de kwaliteit van hartfalen zorg in Nederland, en 
identificatie van patiëntengroepen waarin de hartfalen behandeling zou 
kunnen worden verbeterd
Met het eerste deel van dit proefschrift hebben we inzicht willen verkrijgen in de 
huidige kwaliteit van hartfalen zorg verleend op de Nederlandse hartfalen poliklinieken. 
Dit inzicht kan worden verkregen door de naleving van de behandelrichtlijn van de 
European Society of Cardiology (ESC) voor hartfalen te onderzoeken. Tevens hebben we 
de kwaliteit van de hartfalen zorg in specifieke patiëntengroepen met chronisch hartalen 
onderzocht om zo in kaart te brengen waar de hartfalen zorg verbeterd kan worden. 
De chronisch hartfalen ESC-richtlijn cardiologische praktijk kwaliteitsproject hartfalen 
(CHECK-HF) registratie bevat gedetailleerd informatie over patiëntkarakteristieken, 
voorschrijfpercentages en voorgeschreven doseringen van bètablokkers, renine-
angiotensine-systeem (RAS) inhibitoren en mineralocorticoïde receptorantagonisten 
(MRA’s) van 10910 Nederlandse chronische hartfalen patiënten die tussen 2013 en 2016 
behandeld werden op de poliklinieken van 34 Nederlandse centra. In totaal waren 8360 
patiënten gediagnosticeerd met hartfalen met een gereduceerde ejectiefractie (HFrEF) 
en 2550 patiënten gediagnosticeerd met hartfalen met een behouden ejectiefractie 
(HFpEF) geïncludeerd. Verschillende aspecten maakt de CHECK-HF registratie tot een 
uniek onderzoeksproject. Als eerste heeft ongeveer de helft van alle Nederlandse centra 
met een hartfalen polikliniek patiënten geïncludeerd in deze registratie. Daarnaast is 
de data in de registratie verzameld door leden uit de lokale hartfalen behandelteams 
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en was die gebaseerd op de meest recente polibezoek en patiëntendossier. Hierdoor 
weerspiegelt de data uit de CHECK-HF registratie de huidige stand van zaken op 
de Nederlandse hartfalenpoliklinieken.
In Hoofdstuk 2 zijn de leeftijdsspecifieke verschillen in de behandeling van chronische 
hartfalen patiënten beschreven. Met een stijging van de leeftijd daalde de naleving van 
de richtlijnen. Het verschil in de naleving van de richtlijnen kon niet volledig worden 
verklaard door de verschillen in baseline karakteristieken zoals de New York heart 
association (NYHA) classificatie of de aanwezigheid van comorbiditeiten. Ondanks dat 
de kans kleiner was dat oudere hartfalen patiënten de door de richtlijn aanbevolen 
behandeling ontvingen, ontving de meerderheid van de tachtigjarige HFrEF patiënten, 
twee of meer van de richtlijn aanbevolen hartfalen medicatie. Echter werden deze 
medicamenten niet op de aanbevolen dosering voorgeschreven, zoals is onderzocht 
in Hoofdstuk 3.
Slechts kleine verschillen in de behandeling tussen mannen en vrouwen werden 
geobserveerd, waarvan een deel verklaard kon worden de verschillen in de baseline 
karakteristieken en comorbiditeiten, zoals Hoofdstuk 4 laat zien. Daarnaast 
hebben we de potentiele impact van het toepassen van een hypothetische geslacht-
specifieke streefdosering, met een streefdosering van 50% van de door de richtlijn 
aanbevolen dosering voor bètablokkers en RAS-inhibitors voor vrouwen, onderzocht. 
Indien deze geslacht-specifieke streefdosering toegepast zou worden, zouden meer 
vrouwen de streefdosering ontvangen. Daarnaast zou een significant deel van de 
vrouwelijke HFrEF patiënten dan een te hoge dosering ontvangen, mogelijk zonder 
extra toegevoegde behandeleffect.
In Hoofdstuk 5, 6 en 7 zijn de effecten van vaak voorkomende comorbiditeiten 
zoals hypertensie, atriumfibrilleren en diabetes mellitus op de naleving van de 
behandelrichtlijnen beschreven. Een groot deel van de HFrEF patiënten uit de CHECK-
HF registratie hadden een systolische bloeddruk van 130 mmHg of hoger. De door de 
richtlijn aanbevolen hartfalen medicatie en de combinatie van alle drie de hartfalen 
medicamenten werd vaker voorgeschreven in patiënten met een lagere systolische 
bloeddruk. Daarentegen, patiënten met een systolische bloeddruk ≥130 mmHg 
werden minder vaak volgens de richtlijn behandeld. Atriumfibrilleren was een vaak 
voorkomende comorbiditeit in de Nederlandse poliklinische hartfalen patiënten en 
beïnvloedde de voorgeschreven hartfalen behandeling significant. Patiënten met 
atriumfibrilleren ontvingen vaak de aanbevolen behandeling. Kleine maar significante 
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verschillen in de hartfalenbehandeling tussen patiënten met en zonder diabetes werden 
gevonden, ook na correctie voor verschillen in de baseline karakteristieken en overige 
comorbiditeiten. Wanneer de toelatingseisen uit de huidige klinische trials toegepast 
zouden worden zou een substantieel deel van de Nederlandse hartfalen populatie in 
aanmerking komen voor behandeling met de nieuwe sodium-glucose cotransporter-2 
(SGLT-2) inhibitors.
De hartfalen zorg verleend op de Nederlandse poliklinieken is vergeleken met de 
hartfalen zorg verleend op de poliklinieken in de Verenigde Staten van Amerika, welke 
onderzocht is in de Change the Management of Patients with Heart Failure (CHAMP-HF) 
registratie, in Hoofdstuk 5 en 7. Nederlandse hartfalen patiënten kregen vaker de in 
de richtlijn aanbevolen hartfalen medicamenten en de streefdosering voorgeschreven 
in vergelijking met de Amerikaanse hartfalen populatie.
Hoofdstuk 8 benadrukt de verschillen in hartfalen populaties en behandeling tussen 
de verschillende hartfalen poliklinieken in Nederland. Verschillen in de demografische 
patiëntengegevens konden de gevonden verschillen in aantal voorgeschreven 
medicamenten en doseringen niet volledig verklaren. Dit geeft aan dat het naleven 
van de behandelrichtlijn nog verder verbeterd zou kunnen worden.
Een groot gedeelte van de patiënten geïncludeerd in de CHECK-HF registratie 
waren gediagnostiseerd met HFpEF. Het klinische profiel en de medicamenteuze 
behandeling van deze patiënten is onderzocht in Hoofdstuk 9. Hoewel er geen 
‘evidence-based’ behandelingen beschikbaar zijn voor HFpEF patiënten, ontvingen 
veel HFpEF patiënten medicatie dat geïndiceerd is voor de behandeling van HFrEF 
patiënten. Deze medicamenten waren waarschijnlijk voorgeschreven voor de 
behandeling van veel voorkomende comorbiditeiten. Daarnaast zouden deze HFrEF 
medicijnen voorgeschreven kunnen zijn aan de HFpEF patiënten bij een gebrek aan 
een alternatieve behandeling.
Concluderend, de resultaten van de CHECK-HF registratie geven een uniek inzicht 
in de hartfalen behandeling op Nederlandse hartfalen poliklinieken. Veel hartfalen 
patiënten worden behandeld met de in de richtlijn aanbevolen hartfalen behandeling, 
echter is de voorgeschreven dosering lager dan is aanbevolen. We hebben 
verschillende patiëntencategorieën geïdentificeerd, waaronder ouderen en patiënten 
met comorbiditeiten zoals hypertensie, waarin de hartfalen behandeling verder 
geoptimaliseerd zou kunnen worden.
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Door het cross-sectionele studie design kon causaliteit niet onderzocht worden. Verder 
waren er geen klinische uitkomsten geregistreerd. Hierdoor konden we het effect van 
het minder frequent voorschrijven van in de richtlijn aanbevolen hartfalen medicatie 
op de overleving van de hartfalen populatie niet onderzoeken. De CHECK-HF registratie 
heeft een zeer groot aantal patiënten geïncludeerd, die samen een goede afspiegeling 
geven van de echte praktijk op de Nederlandse hartfalen poliklinieken. Dit is een van de 
sterke punten van deze hartfalen registratie. De resultaten van de CHECK-HF registratie 
geven nieuw inzicht in de hedendaagse behandeling van hartfalen patiënten in een 
‘real-world’ setting. Deze bevindingen zijn erg informatief voor hartfalen cardiologen 
aangezien ze nieuw inzicht geven in de naleving van de richtlijnen en er specifieke 
patiëntencategorieën zijn geïdentificeerd waarin de richtlijn naleving lager is dan in 
de overige patiëntencategorieën.
Deel B – Vaststellen van de impact van hemodynamische monitoring van 
chronische hartfalen patiënten op afstand
In het tweede deel van dit proefschrift zijn strategieën om chronische hartfalen 
patiënten op afstand te kunnen monitoren, en voornamelijk hemodynamische 
monitoring op afstand, onderzocht.
Hoofdstuk 10 geeft een up-to-date overzicht van de beschikbare literatuur over op 
afstand monitoring strategieën in chronische hartfalen patiënten. Verschillende niet 
invasieve monitoring strategieën, variërend van simpele univariabele tot erg complexe 
en intensieve multivariabele strategieën, zijn de afgelopen decennia voorgesteld en 
onderzocht door meerdere grote multicenter prospectieve studies, gerandomiseerde 
gecontroleerde onderzoeken, en ‘real-world’ registraties. Niet invasieve monitoring 
strategieën hadden een bescheiden positief effect op de overleving en hartfalen 
gerelateerde ziekenhuisopnames. Dit positieve effect werd voornamelijk waargenomen 
in de meer complexe strategieën, bestaande uit niet invasieve monitoring van meerdere 
variabelen. Het op afstand monitoren van chronische hartfalen patiënten middels 
implanteerbare cardioverter defibrillator (ICD) of cardiale resynchronisatietherapie 
(CRT) apparaten had geen effect op de overleving of het aantal ziekenhuisopnames. 
Op afstand hemodynamische monitoring kan een stijging van de vullingsdrukken in 
het hart weken voordat een episode van hartfalen exacerbatie ontstaat detecteren. 
Het CardioMEMS systeem kan de pulmonaal arterie druk monitoren en is momenteel 
de meest belovende strategie voor hemodynamische monitoring op afstand. Het 
is aangetoond dat deze strategie veilig en effectief is om hartfalen gerelateerde 
ziekenhuisopnames in zowel HFrEF als HFpEF patiënten te voorkomen.
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De Nederlandse hemodynamic monitoring in heart failure (MONITOR HF) Trial onderzoekt 
of CardioMEMS monitoring bovenop de standaard zorg kan zorgen voor een verbetering 
in de kwaliteit van leven, vermindering van het aantal hartfalen gerelateerde 
ziekenhuisopnames en onderzoekt de kosteneffectiviteit in Nederland. De opzet van 
dit gerandomiseerd gecontroleerd onderzoek is omschreven in Hoofdstuk 11.
Het ideale moment op de dag om de pulmonaal arterie druk met de CardioMEMS te 
meten is omschreven in Hoofdstuk 12. De variabiliteit tussen de metingen was het 
kleinst vroeg in de ochtend, waardoor dit het meest ideale moment is om de pulmonaal 
arterie drukken te monitoren.
Hemodynamische monitoring op afstand kan unieke informatie en extra inzicht geven 
in de patiënten management en het effect van vaak gebruikte behandeling. Zoals 
geïllustreerd is in de casus omschreven in Hoofdstuk 13, kunnen de hemodynamische 
effecten van klepinterventies zoals de MitraClip veilig en effectief worden gemonitord 
met behulp van de CardioMEMS.
Concluderend, veel verschillende strategieën voor de op afstand monitoring van 
chronische hartfalen patiënten zijn onderzocht. De CardioMEMS systeem is de meest 
belovende techniek om patiënten hemodynamisch op afstand te kunnen monitoren. 
Verder heeft hemodynamische monitoring op afstand de potentie om voor andere 
indicaties en in andere patiëntencategorieën gebruikt te kunnen worden.
Deel C – Vaststellen van de veiligheid en haalbaarheid van hemodyna-
mische monitoring op afstand in steunhart patiënten
We hebben de veiligheid en haalbaarheid van hemodynamische monitoring op afstand 
in patiënten met eindstadium hartfalen die overgingen op ondersteuning van een LVAD 
onderzocht in het derde deel van dit proefschrift.
Een overzicht van alle beschikbare literatuur van de verschillende monitoring 
strategieën in LVAD patiënten wordt gegeven in Hoofdstuk 14. Er zijn verschillende 
mogelijke strategieën voor monitoring op afstand voorgesteld en onderzocht. Deze 
ontwikkelingen zijn veelbelovend, echter is doorontwikkeling noodzakelijk voordat deze 
strategieën in de zorg voor LVAD patiënten kunnen worden toegepast. Het combineren 
van op afstand hemodynamische monitoring via de CardioMEMS met LVAD therapie 
kan de volgende stap voorwaarts zijn voor LVAD zorg op afstand.
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Hoofdstuk 15 omschrijft de pulmonaal arterie drukken over de tijd in een LVAD patiënt 
met ‘gefixeerde’ pulmonale hypertensie. LVAD ondersteuning kan gebruikt worden 
om zogenoemde ‘gefixeerde’ pulmonale hypertensie te behandelen. Het CardioMEMS 
systeem kan gebruikt worden om dit proces veilig en adequaat op afstand te monitoren. 
Hiermee wordt tot nu toe onbekende informatie over longdrukken en het effect 
van behandelingen inzichtelijk.
De veiligheid en haalbaarheid van pulmonaal arterie druk gestuurde behandeling 
middels het CardioMEMS systeem in patiënten die in aanmerking komen voor LVAD 
implantatie is onderzocht in de hemodynamic guidance with CardioMEMS in patients with 
a left ventricular assist device (HEMO-VAD) pilot studie. De opzet van deze pilot studie is 
omschreven in Hoofdstuk 16.
In Hoofdstuk 17 zijn de korte termijn effecten van op afstand hemodynamische 
monitoring van LVAD patiënten onderzocht. Gedurende de eerste drie maanden na LVAD 
implantatie deden er zich geen CardioMEMS gerelateerde veiligheidsproblemen voor. 
Patiënten waarbij voor LVAD implantatie de gemiddelde pulmonaal arterie druk (mPAP) 
niet genormaliseerd kan worden vormen een patiëntengroep die een sterk verhoogd 
risico hebben om te overlijden en LVAD gerelateerde complicaties waaronder acute 
nierschade en rechter ventrikel falen te ontwikkelen. Bovendien neemt de kwaliteit 
van leven significant minder toe in patiënten waarbij de mPAP niet genormaliseerd kan 
worden in vergelijking met patiënten waarbij dat wel lukt.
Hoofdstuk 18 benadrukt de veiligheid van hemodynamische monitoring op afstand 
middels de CardioMEMS in LVAD patiënten. Gedurende het volledige eerste jaar van 
follow-up zijn er geen device gerelateerde complicaties of storingen waargenomen. In 
de patiënten waarin de mPAP kort voor LVAD implantatie genormaliseerd kon worden 
was de sterfte en het aantal LVAD gerelateerde complicaties en ziekenhuisopnames 
lager. Na de LVAD implantatie verbeterde de kwaliteit van leven in alle patiënten. Echter, 
deze verbetering was sterker en hield langer aan in patiënten met een normalisatie van 
de mPAP voorafgaande aan de LVAD implantatie.
We concluderen dat op afstand monitoring van LVAD patiënten clinici kan helpen om de 
LVAD zorg te optimaliseren. De CardioMEMS kan veilig worden gebruikt om op afstand 
LVAD patiënten hemodynamisch te monitoren. De additionele hemodynamische 
feedback die wordt geleverd door het CardioMEMS systeem kan gebruikt worden in 
de preoperatieve optimalisatie van de hemodynamische status van de patiënt, als 
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risicovoorspeller voor slechtere klinische uitkomst en om de patiënten op afstand te 
kunnen monitoren en behandelen.
Deel D – Optimaliseren van steunhart zorg
In het laatste deel van dit proefschrift hebben we de volgende LVAD gerelateerde 
uitdagingen onderzocht: de effectiviteit van cardiaal geïmplanteerde elektronische 
apparaat met een shock functie (CIED-D, bestaande uit een ICD en CRT met een 
defibrillatie functie) tijdens LVAD ondersteuning, de impact van leeftijd en geslacht 
op LVAD uitkomsten, gelijktijdige aortaklep vervanging gedurende de LVAD 
implantatie en ijzerdeficiëntie.
In Hoofdstuk 19 hebben we in de observationele postgraduate course in heart failure 
ventricular assist device (PCHF-VAD) registratie onderzocht of een actieve CIED-D 
geassocieerd was met verbeterde uitkomsten in LVAD patiënten. De PCHF-VAD 
registratie is een observationele studie waarin LVAD patiënten werden geïncludeerd 
vanuit 12 Europese tertiaire hartfalen verwijzingscentra. Een actieve CIED-D in LVAD 
patiënten was geassocieerd met een verlaagde mortaliteit, verlaagd aantal device 
gerelateerde infecties waarvoor systemische antibiotica noodzakelijk waren en 
significante minder bloedingen.
Hoofdstuk 20 en 21 geven gedetailleerd analyses van de invloed van leeftijd en 
geslacht op LVAD uitkomsten en management in de PCHF-VAD registratie. Een toename 
in leeftijd was onafhankelijk geassocieerd met een verhoogde risico op mortaliteit. 
Verder hadden oudere LVAD patiënten een verhoogd risico op ‘hemocompatibiliteit’ 
gerelateerde complicaties en hadden vaker een nieuwe episode van atriumfibrilleren 
of flutter. Oudere LVAD patiënten hadden daarentegen een significant lager risico op 
device gerelateerde infectie waarvoor systemische antibiotica noodzakelijk waren.
LVAD therapie wordt significant minder vaak gebruikt in vrouwen. Desondanks dat 
vrouwen die een LVAD implantatie ondergaan vaker zieker en instabieler waren, werden 
er geen verschillen in overleving tussen manen en vrouwen gevonden. Daarentegen 
kon de LVAD ondersteuning in vrouwen vaker worden afgebouwd.
We hebben de effecten van het gelijktijdig vervangen van de aortaklep tijdens LVAD 
implantatie in detail onderzocht in de international society of heart and lung transplantation 
mechanically assisted circulatory support (IMACS) registratie. In Hoofdstuk 22 zijn de korte 
en lange termijn overleving onderzocht van patiënten met een gelijktijdige vervanging 
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van de aortaklep en LVAD implantatie. Gelijktijdige vervanging van de aortaklep was een 
onafhankelijke voorspeller voor vroege en late sterfte in LVAD patiënten. In patiënten 
met slechts een milde aortaklepinsufficiëntie had gelijktijdige aortaklepvervanging een 
negatief effect op de overleving van LVAD patiënten. In patiënten met een matig tot 
ernstige aortaklepinsufficiëntie daarentegen waren er geen verschillen in de overleving 
tussen patiënten met en zonder een gelijktijdige aortaklepvervanging.
Om meer inzicht in het risico van gelijktijdige aortaklepvervanging te krijgen, is de 
associatie van ‘hemocompatibiliteit’ gerelateerde complicaties onderzocht in Hoofdstuk 
23. Er werd geen associatie tussen gelijktijdige aortaklepvervanging en een verhoogd 
risico op trombo-embolische events gevonden. Gelijktijdige aortaklepvervanging 
was daarentegen een onafhankelijke riscofactor voor significante bloedingen 
na LVAD implantatie.
De prevalentie van ijzerdeficiëntie in LVAD en harttransplantatie patiënten is omschreven 
in Hoofdstuk 24. Ondanks dat de richtlijn regelmatige screening voor ijzerdeficiëntie 
in chronische hartfalen patiënten aanbeveelt, waren niet alle eindstadium hartfalen 
patiënten gescreend op ijzerdeficiëntie in het jaar voordat zij een LVAD implantatie 
of harttransplantatie ondergingen. De prevalentie van ijzerdeficiëntie was zeer hoog 
voorafgaande aan de LVAD implantatie of harttransplantatie en was zelfs hoger na 
de operatie. Het grootste gedeelte van de patiënten met een ijzerdeficiëntie werd 
behandeld met ijzersuppletie.
Toekomst perspectieven
De hartfalen zorg heeft zich de afgelopen decennia snel ontwikkeld en we verwachten 
dat deze trend zich de komende jaren zal doorzetten. We verwachten dat nieuwe 
medicamenten ontwikkeld zullen worden voor de behandeling van hartfalen, 
voornamelijk voor patiënten met een behouden ejectiefractie. Meerdere hartfalen 
registraties worden momenten uitgevoerd. We verwachten dat de informatie uit deze 
studies zullen bijdragen aan de verbetering van de hartfalen zorg. In het komende 
decennium zullen deze nieuwe inzichten gebruikt moeten worden om de ideale target 
dosis voor elke patiëntencategorie te bepalen. Daarnaast moet er een effectieve titratie 
strategie worden ontwikkeld zodat de gewenste streefdosering wordt voorgeschreven 
aan elke patiënt.
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Met de snel toenemende hartfalen populatie zal monitoring op afstand steeds 
belangrijker worden. We verwachten dat een gestandaardiseerd pakket voor monitoring 
op afstand beschikbaar zal komen. Minder symptomatische hartfalen patiënten 
zullen op afstand worden gemonitord met niet invasieve technieken, terwijl invasieve 
monitoring opties gebruikt zullen worden om meer symptomatische patiënten 
nauwlettend in de gaten te houden. Alle informatie van deze patiënten zal op een 
centrale locatie verwerkt worden, gebruikmakend van de meest recente technologie en 
‘machine learning’ technieken. De data zal op een intuïtieve en overzichtelijke manier 
worden gepresenteerd aan de behandeld arts, waarbij patiënten die extra zorg nodig 
hebben duidelijk zichtbaar zijn.
Tot slot verwachten we dat de steunharten continu verder ontwikkeld zullen worden. 
We verwachten dat de steunharten steeds kleiner zullen worden, waardoor minder 
invasieve implantatie technieken gebruikt kunnen worden. Deze nieuwe generatie 
steunharten zouden dan ook gebruikt kunnen worden voor de partiële ondersteuning 
van de linker ventrikel, waardoor ze meer geschikt worden als overbruggingsbehandeling 
tot de linker ventrikel functie is hersteld. Draadloze oplaadtechnieken zullen worden 
geïntegreerd waardoor een volledig geïmplanteerd steunhart ontwikkeld kan 
worden, zonder een driveline. Als laatste verwachten we dat deze nieuwe generatie 
steunharten ‘real-time’ informatie geven over de hemodynamica, het openen van de 
hartkleppen en de klepfunctie dat op afstand gemonitord kan worden. Gebaseerd op 
deze informatie kunnen de pompinstellingen automatisch aangepast worden terwijl 
de patiënt thuis is.
Conclusie
Dit proefschrift draagt bij aan de kennis met betrekking tot de vele uitdagingen die nog 
moeten worden aangepakt om de hartfalen en steunhart zorg verder te verbeteren. 
We hebben aangetoond dat de Nederlandse hartfalen poliklinieken een hoge kwaliteit 
van zorg aan chronische hartfalen patiënten verlenen, voornamelijk in vergelijking met 
andere westerse landen. Daarnaast hebben we specifieke gebieden in de hartfalen zorg 
geïdentificeerd, waaronder de voorgeschreven dosering, het voorschrijven bij ouderen 
en de behandeling van hypertensie, die verder geoptimaliseerd kunnen worden. Verder 
hebben we de klinische impact van nieuwe ontwikkelingen zoals geslacht specifieke 
streefdoseringen en de introductie van een sodium-glucose cotransporter-2 inhibitor 
onderzocht. Deze nieuwe ontwikkelingen kunnen een significante effect hebben op 
de hartfalen zorg.
146122_Veenis,Jesse_BNW-def .indd   590 13-11-2020   14:39
591
Dutch summary (Nederlandse samenvatting)
Afhankelijk van de ernst van het hartfalen kunnen verschillende monitoring 
strategieën geïndiceerd zijn. Niet invasieve monitoring kan gebruikt worden om 
minder symptomatische hartfalen patiënten op afstand in de gaten te houden, terwijl 
meer symptomatische patiënten meer profijt zullen hebben van hemodynamische 
monitoring op afstand. Verder hebben we potentieel nieuwe gebieden geïdentificeerd 
waar hemodynamische monitoring op afstand gebruikt zou kunnen worden, waaronder 
monitoring in patiënten met een aangedane hartklep, monitoring van pulmonaal arterie 
drukken in hartfalenpatiënten op de harttransplantatie wachtlijst en de monitoring van 
patiënten die voor steunhart implantatie gaan.
We hebben de hybride combinatie van de hemodynamische monitoring op afstand 
en steunhart ondersteuning voor de eerste keer prospectief onderzocht. We hebben 
laten zien dat deze combinatie veilig en haalbaar is. De hemodynamische informatie kan 
gebruikt worden om patiënten met een zeer hoog risico voor steunhart gerelateerde 
complicaties te identificeren. Verder kan de op afstand gemonitorde hemodynamische 
informatie gebruikt worden om de ideale steunhart implantatie moment vast te stellen. 
Verder kan deze techniek gebruikt worden om steunhart patiënten vanuit de polikliniek 
te monitoren en optimaliseren.
We hebben verschillende uitdagingen in de zorg voor patiënten met een steunhart 
geïdentificeerd welke aangepakt kunnen worden om de zorg voor patiënten met 
een steunhart te verbeteren en optimaliseren, waaronder ijzerdeficiëntie, leeftijd en 
geslacht specifieke uitkomsten en het gebruik van cardiale geïmplanteerde apparaten. 
Onze resultaten benadrukken het belang van een goede afweging of gelijktijdige 
aortaklepvervanging tijdens een steunhart implantatie geïndiceerd is. In dit proefschrift 
hebben we vele uitdagingen uit de hartfalen zorg geprobeerd aan te pakken, wat de 
volgende stap zou kunnen zijn naar een meer geoptimaliseerde en geïndividualiseerde 
aanpak voor elke hartfalen patiënt.
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